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Abstract 
 
The work herein comprises two distinct projects: the first involves the construction of 
allylic ketones IV and enones V directly from primary alcohols I, using a novel one-pot 
procedure (Scheme I). Following development of this methodology, its application to 
the synthesis of indolizidine alkaloid elaeokanidine A (VII) was investigated.  
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Scheme I: A one-pot procedure to construct unsaturated ketones IV and V from primary alcohols I 
 
The second research area concerns the development of a copper(II)-catalysed radical 
cyclisation reaction to form spirocyclic oxindoles VIII directly from linear anilides VII 
(Scheme II), along with subsequent preliminary studies towards to the synthesis of 
spirotryprostatin A (IX).  
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Scheme II: Copper-catalysed cyclisation of anilides VII to form spirocyclic oxindoles VIII
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Chapter 1 – Overview  
 
1.1 The importance of new methodologies for synthesis 
 
In order to gain access to new useful organic molecules, whether for new technologies 
and commercial application, or to develop more effective and safer medicines for 
combating disease, we require the use of organic synthesis. Despite the utility of 
already established procedures, chemists are always striving to improve synthetic 
strategies on the basis of several criteria, including: cheaper and less toxic reagents; 
broader substrate scope and structural diversity; atom economy; and ease and 
efficiency of preparation.  
 
 
1.2 One pot reactions 
 
In recent years, “one-pot” or “telescoped” procedures, in which multiple 
transformations are performed without intermediate isolation, have become popular 
tools with the organic chemist due to their inherent potential benefits such as high 
efficiency, operational simplicity, reduced costs and lower waste products. In addition, 
they allow in situ preparation and elaboration of intermediates which may be 
problematic due to their reactivity, toxicity or stability when isolated. This area has 
been reviewed recently in a book by one of the pioneers of the area, and so only a brief 
introduction will be given here.1 
 
OHTMS OTMS
TMS OEt
O
OEt
O
Ph3P
1. (COCl)2, DMSO,
CH2Cl2, 78 °C, 15 min
2. Et3N, 5 min
78 °C to 20 °C
54%
1 2
3
4
 
Scheme 1: Ireland’s Swern/Wittig reaction 
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An early illustrative example is given by Ireland and Norbeck. From alcohol 1, using 
the Swern procedure, they were able to synthesise acylsilane 2, which they believed 
polymerises rapidly and thus had been previously undocumented. Maintaining the 
reaction mixture at −78 °C, ylide 3 was added and subsequently the novel alkene 4 was 
produced in 54% yield (Scheme 1).2 
 
There are two distinct types of one-pot procedure: tandem and sequential.  A tandem 
reaction is one in which two or more chemical processes occur under the same reaction 
conditions. In the context of this thesis, tandem refers to a reaction in which all 
reagents are added to the reaction mixture from the start, whereas in a sequential 
reaction, further reagents are added to the reaction mixture once the preceding 
transformation is complete, such as in the Ireland example (Scheme 1).  
 
The advantages of a tandem one-pot synthesis are well illustrated in an example from 
the Taylor group (Scheme 2). In a two-step oxidation/Wittig reaction from (E)-3-
bromoprop-2-en-1-ol (5), poor overall yields of diene 8 were obtained. However, in a 
one-pot procedure, whereby isolation of problematic aldehyde 6 was not necessary, the 
same set of transformations was achieved in a much improved 78% yield.3 This is an 
example of a true tandem process. 
 
Br OH Br O Br
CO2Et
[O]
MnO2, 7, CH2Cl2
1030% over 2 steps
78%
5 6 8
CO2Et
Ph3P
7
 
Scheme 2: One-pot oxidation/Wittig reaction 
 
Perhaps one of the most commonly seen uses for one-pot synthesis in the York group 
involves the oxidation of primary alcohols to aldehydes,3,4 yet it has also found utility 
in a number of other protocols,5,6 such as the telescoped Intramolecular 
Michael/Olefination (TIMO) reaction developed by the Taylor group (Scheme 3).7 The 
first step involves deprotonation of the phosphonate 9 which subsequently undergoes 
intramolecular Michael addition. The intermediate 10 is not isolated and instead 
paraformaldehyde is added to the reaction mixture in order to initiate the HWE 
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reaction. Performing these reactions stepwise with intermediate isolation gave an 
overall yield of only 42% whereas this TIMO approach affords the -methylene--
butyrolactone product 11 in an improved 77% yield. 
 
O
O
O
(EtO)2P
O
O
O
O
P
O
OEtEtO
O
O
O
KOtBu a) (CH2O)n
b) aq. NH4Cl
77%
9 10 11  
Scheme 3: TIMO approach to an -methylene--butyrolactone 
 
As a representative example from another group, Lallemand et al. demonstrated the 
use of a tandem Diels‒Alder/allylation process, a sequence originally developed by 
Vaultier,8 in the preparation of 15 (Scheme 4).9 The [4+2]-cycloaddition of catechol 
boronic ester 12 and methyl acrylate (13) creates the allylating agent 15 in situ, which 
then reacts with the already present aldehyde 14 to furnish the highly functionalised 
alcohol 16 with complete relative stereocontrol of three chiral centres. 
 
OBn
O
B
O
MeO2C
O
OBn
80 °C, 16 h
B
CO2Me
OBn
O
O
CO2Me
OBn
HO
H
OBn
1 eq
12
8 eq
13
3 eq
14
15 16
33%
 
Scheme 4: Lallemand’s tandem Diels‒Alder/allylation 
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1.3 Aims 
 
There were two main aims in this research project. First, to develop a one-pot process 
for the construction of both ,- and ,- unsaturated ketones 17 and 18, and then to 
apply this methodology to the synthesis of elaeokanidine A (19) (Figure 1). This topic is 
described in Chapters 2 and 3. 
 
R
O
17 18
R
O N
O
N
H
elaeokanidine A (19)
H
H
H
 
Figure 1: Unsaturated ketones 17 and 18, and elaeokanidine A (19) 
 
The second aim was to extend a copper(II)-catalysed cyclisation methodology to the 
formation of spirocyclic oxindoles 21 directly from linear precursors 20, and then 
showcase this reaction with the synthesis of a natural product, namely 
spirotryprostatin A (22) (Figure 2). This topic is described in Chapters 4 and 5. 
 
X
N
O
N
O
R N
O
R
XN
O
n
nR1
R1
R2
R2
X = C or C=O
20 21
N
H
O
N
spirotryprostatin A (22)
N
O
O
H
O
 
Figure 2: Linear anilides 20, spirocyclic oxindoles 21 and spirotryprostatin A (22) 
 
Chapters 2‒5 describe the results in each area, and each Chapter contains a more 
detailed overview and discussion. 
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Chapter 2 – New telescoped routes to unsaturated ketones 
 
2.1 Introduction to ,- and ,-unsaturated ketones  
 
2.1.1 Unsaturated ketones in natural products 
 
The ,-unsaturated ketone motif is widespread in both natural products and synthetic 
intermediates leading to them. ,-Unsaturated ketones are frequently responsible for 
the  biological activity of natural products due to their inherent ability to act as a 
Michael acceptor to nucleophilic amino acid residues.10  
 
For example, guieranone A (23) is a naphthalene derivative with useful antifungal 
activity, originally isolated from the leaves of Guiera senegalensis.11 It has recently 
succumbed to a total synthesis by McCullock et al. who utilised an ortho-directed 
metallation process for the installation of the ,-unsaturated ketone unit in 23.12 
9-Oxo-seco-ratiferolide-5-O-(2-methylbutyrate) (24) is one of several cytotoxic 
compounds isolated from the plant Ratibida columnifera and also exhibits an 
unsaturated ketone functionality (Figure 3).13 At present, no synthesis of this 
compound has been reported.  
 
O
OMe
OMeOMe
MeO O
O
OH
O
O
O
O
23 24
MeO
HO
O O
OMe
OH
25
 
Figure 3: Natural products containing the ,-unsaturated ketone motif 
 
Curcumin (25), a constituent of the spice turmeric, has been shown to exhibit multiple 
biological responses including anti-oxidant activity, enhancement of wound healing 
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and anti-cancer effects,14 presumably due to the presence of the ,-unsaturated ketone 
functionality (Figure 3). A number of synthetic derivatives of curcumin containing the 
enone functionality have shown inhibition of angiogenesis in murine endothelial cells 
and this has important implications in cancer therapy.15     
 
Due to the activity of ,-unsaturated ketone-containing compounds, this feature can 
be exploited in synthetic drug molecules. A recent patent by Ganem et al. specifies that 
in their compounds, for example 2-crotonyloxymethylcyclohex-2-enone (26), an 
endocyclic enone was a requirement for anti-tumour activity.16  
 
O
O
O
2-Crotonyloxymethylcyclohex-2-enone (26)  
 
The structures shown above are just a few examples of the myriad of compounds that 
display the ,-unsaturated ketone motif. Nevertheless, many other natural products 
have been prepared using key intermediates containing the important ,-unsaturated 
ketone function and this demands efficient methods for its preparation.17-20 
 
For example, Jacobsen et al. used enone 27 in their total synthesis of (−)-columbiasin 
(29) as a precursor to diene 28, which then paved the way for a Diels‒Alder reaction. 
Further chemical transformations gave the natural product 29 in 8 steps from the diene 
28 (Scheme 5). 18 
 
O
O
TESO
1. CH3PPh3Br, KHMDS
2. i) KHMDS; ii) TESCl
O
O OH
H
H
27 28 ()-columbiasin (29)
8 steps
 
Scheme 5: Jacobsen’s total synthesis of (−)-columniasin (29) via enone 27 
 
On the other hand, ,-unsaturated ketones 17 are rarely seen in natural products,21-24 
due to the facile isomerisation that they can undergo to give the corresponding enones. 
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They are, however, interesting structures in their own right, as they can be useful 
building blocks for other structural motifs.25,26 For example, Jiang and co-workers used 
,-unsaturated ketones as a starting point to form isoxazolines 31 via oximes 30 by 
means of a palladium-catalysed cyclisation reaction (Scheme 6).26 
 
R
O
R
N
OH
N O
ArRAr Br
1 mol% Pd2(dba)3
2 mol% Xantphos
NaOtBu, PhMe, 105 °C
NH2OH.HCl, NaOAc
EtOH/H2O, rt
16 examples
R = aryl/alkyl
46-94% (final step)
17 30
31  
Scheme 6: Construction of isoxazolines 31 from ,-unsaturated ketones 17 
 
 
2.1.2 Previous methods for making ,- and ,-unsaturated ketones  
 
Many of the methods available for the construction of olefins can be applied to the 
synthesis of ,-unsaturated ketones. Perhaps one of the most widely used of these is 
the Wittig reaction, and those related to it, such as the Peterson olefination and the 
Horner‒Wadsworth‒Emmons reaction. For examples, Aoyagi and co-workers reacted 
ylide 32 with trifluroacetaldehyde (33) to yield enone 34 in high yield (Scheme 7).27 
 
F
+ O
O
PPh3
O
CF3F
F
Et2O
81%
32 33 34  
Scheme 7: Formation of enone 34 via a Wittig reaction 
 
One popular method available for the construction of functionalised olefins is 
metathesis, a class of reactions for which Grubbs, Schrock and Chauvin shared the 2005 
Nobel Prize in Chemistry.28 There are a number of metal-based catalysts available 
which can be used for a variety of metathesis reactions including ring-closing 
metathesis (RCM),29 enyne metathesis,30 and ring-opening metathesis polymerisation 
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(ROMP).31 For the compounds that we desire, a cross-metathesis is required, with one 
of the coupling partners already having the enone functionality in place.32,33 For 
example, the reaction between methyl vinyl ketone (35) and alkene 36 in the presence 
of Grubbs’ second generation catalyst (38) to provide functionalised enone 37 (Scheme 
8).34 
 
O
+
TBSO TBSO
O
Grubbs-II (2 mol%)
CuI (3 mol%)
Et2O, 35 °C, 3 h
98%, >20:1 E/Z
N NMes Mes
Ru
Ph
Cl
Cl PCy3
Grubbs-II (38):
35 36 37
 
Scheme 8: Cross metathesis reaction  
 
In 2002, Nicolaou et al. published a novel procedure utilising 2-iodoxybenzoic acid 
(IBX) for the one-pot oxidation of alcohols, e.g., 39, into their corresponding enones e.g., 
40 (Scheme 9).35 Although efficient, the reaction is often not regioselective. 
Furthermore, the procedure uses DMSO as solvent at elevated temperatures with long 
reaction times and these are quite harsh conditions which we aimed to avoid. 
 
OH O
IBX (4.0 eq), 80 oC
DMSO, 22 h, 76%
39 40  
Scheme 9: IBX oxidation of an alcohol to a dienone 
 
Using ,-unsaturated ketone 41 as an example, Scheme 10 illustrates some of the other 
methods available for the construction of this system. It is worth noting, however, that 
each of these approaches poses its own potential difficulties. 
 
As with other olefins, the double bond in ,-unsaturated ketones can be constructed 
by elimination of sulfur or selenium-containing compounds such as 42 (a),36 although 
synthesis of these species themselves may be cumbersome, involving several steps. 
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Friedel‒Crafts acylation (b) with 44 is only suitable for aromatic compounds such as 
benzene (43),37 and in cases where substituents on the ring are present, regioselectivity 
issues may occur. The Grignard reaction (c) illustrated below,38 where LG is a leaving 
group such that the substrate 45 is an ester or acid halide, was shown to yield only 22% 
of the desired product 41, whereas the nickel-mediated reaction of 46 with 47 (d) gave 
only 17% yield of enone 41.39 The aldol condensation (e),40 which utilises simple 
starting materials 48 and 49, is perhaps the most versatile and well established of these 
reaction processes, but yields are not always satisfactory. 
 
O
LG
O
Cl
O
O
Cl
O
PhMgBr
H
O
Br
61%
22%
52%
(2 steps)
17%
Ni
O
SePh
O
100%
(a)
(b)
(c)
(d)
(e)
(f)
74%
DABCO
H2O2, Py
41
42
43
44
45
46
47
48
49
50
 
Scheme 10: Current methods for the formation of (E)-1-phenylbut-2-en-1-one (41) 
 
On the other hand, isomerisation of ,-unsaturated ketones such as 50 (f) can also 
provide useful entry into the desired class of compound,41 and we hoped to exploit this 
method in the development of our own methodology. 
 
Routes to ,-unsaturated ketones often involve the manipulation of carboxylic acid-
derived compounds, for example the Barbier-type allylation of nitriles such as 51,42 or 
the Hosomi‒Sakurai reaction of allyl silanes of type 53 with acid chlorides 46 (Scheme 
11).43 
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Br
Zn/AlCl3
ON
HCl
Cl
OSi
InBr3
51 50 46
5352
 
Scheme 11: Barbier allylation and Hosomi‒Sakurai reaction 
 
Taguchi and co-workers have used alkene-derived acylzirconocene chlorides, e.g., 54, 
as synthons for the acyl anion, for use in a copper(I)-catalysed cross-coupling reaction 
with allyl bromide (52) to form ,-unsaturated ketones such as 55 (Scheme 12).44 
 
Ph(CH2)4 ZrCp2
O
Cl
Br
Ph(CH2)4
O
CuI (10 mol%),
DMF, 0 °C, 1 h
91%
54
52
55
 
Scheme 12: Copper-catalysed cross-coupling of an acylzirconocene chloride with allyl bromide 
 
In a procedure by Pedro and co-workers, acetal-protected mandelic acid (56) was 
subjected to alkylation with allyl bromide (52), followed by hydrolysis and oxidative 
decarboxylation with cobalt complex 59 to give allylic ketone 50 in good overall yield.45  
 
O
O
O
Ph
Ph
HO CO2H
Ph
O
KOH
EtOH
pivaldehyde,
MeCN, O2, 0 °C
59
59:
O
O
O
Ph
LDA, THF, 78 °C
Br
52%
97%
N N
OO
N N
O O
Co
NMe4
+
56
52
57 58
50
 
Scheme 13: Alkylation/hydrolysis/decarboxylation route to allylic ketone 50 
 
In contrast to these methods, we wished to use primary alcohols as starting materials. 
There are precedented routes to ,-unsaturated ketones from aldehydes,46 and 
primary alcohols using ruthenium-catalysed transfer hydrogenation/diene coupling.47 
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In addition, several groups have used allylations/oxidations in a stepwise fashion 
from aldehydes or primary alcohols to create ,-unsaturated ketones,26,48,49 whereas we 
wished to use a one-pot approach. 
 
As shown, several routes to ,- and ,-unsaturated ketones already exist in the 
literature, but we believed there was still scope for improvement and increased 
versatility for making these compounds.  
 
 
2.2 Aims of project I 
 
Having given an overview of currently existing methods for ,-unsaturated ketone 
preparation, we believed that the methodology proposed below would give an original 
starting point from which to construct these enone moieties under milder conditions 
and potentially improve on existing yields. Indeed, an excellent way to rapidly 
increase reaction efficiency and molecular complexity is to combine several discrete 
steps into a single one-pot process. 
 
Therefore, the vision for this project was to develop a methodology for a novel one-pot 
oxidation/allylation/oxidation/isomerisation procedure, in order to provide a new 
scheme for the facile construction of ,- and ,-unsaturated ketones 17 and 18 
(Scheme 14). 
 
R R
OH
R
O
R
O
R
M
cat.
OH O
H+ or B-
60 61 62
17 18
[O]
[O]
63
 
Scheme 14: Proposed one-pot oxidation/allylation/oxidation/isomerisation process 
  
Oxidation of a primary alcohol 60 to aldehyde 61 provides the substrate for allylation. 
The resulting allylic alcohol 62 could then be further oxidised in situ to ,-unsaturated 
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ketone 17 which under acidic or basic conditions should isomerise to the conjugated 
enone 18. 
 
Of the two types of one-pot procedures, tandem processes are practically easier to 
carry out than sequential reactions as the need for monitoring the reaction is reduced. 
We therefore hoped to be able to use a tandem process for this methodology. 
 
In order to ensure success in developing such a process which is both practical and 
reliable, the reagents and reaction conditions for each step must be chosen with great 
care, and a selection of the most widely used of these processes, along with a brief 
optimisation of each individual step, is next described. 
 
 
2.3 Optimisation of steps 
 
2.3.1 Primary alcohol oxidation 
 
2.3.1.1 Available methods  
 
Of the four processes we aim to combine, two of these are oxidation. A wide variety of 
oxidising agents for a range of purposes are available to the synthetic chemist.50  For 
the oxidation of alcohols to aldehydes or ketones, transition metal reagents in high 
oxidation states are frequently employed. 
 
Manganese dioxide has seen extensive use previously in the Taylor group for the 
oxidation of alcohols 60 to aldehydes 61, as illustrated earlier in Scheme 2.3 Chromates, 
such as pyridinium dichromate (PDC) and pyridinium chlorochromate (65, PCC), are 
also widely used for alcohol oxidation, partially due to their ease of handling, however, 
they have the disadvantage of being carcinogenic. The Jones reagent can also be used 
but is significantly more reactive and will fully oxidise primary alcohols 60 directly to 
carboxylic acids 64 (Scheme 15). 
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R OH
N
H CrO3Cl
-CrO3
aq. H2SO4
R OR OH
O
60 6164
65
 
Scheme 15: Chromate oxidations 
 
Using catalytic TPAP under an oxygen atmosphere, p-chlorobenzyl alcohol (60a) can be 
oxidised to aldehyde 61a in quantitative yield (Scheme 16).51 Ley et al. have since 
reported room temperature variants whereby this type of reaction can be run using 
either NMO or oxygen as co-oxidant.52,53 
 
Cl CH2OH Cl CHO
TPAP (5 mol%), O2
Toluene 70-80 °C
mol. sieves, 30 min
60a 61aquant.
 
Scheme 16: TPAP oxidation of p-chlorobenzyl alcohol 
 
A number of oxidising agents which are not metal-based have also been developed. Of 
these, perhaps the most commonly used is Dess‒Martin periodinane (DMP, 66),54 and 
its variant IBX (67),55 both based on hypervalent iodine (Figure 4). These compounds 
both contain an iodine atom in a +5 oxidation state, which is reduced to I(III) during 
alcohol oxidation. 
 
O
I
O
AcO OAc
OAc
66
O
I
O
OH
O
67
 
Figure 4: Dess‒Martin periodinane and IBX 
 
TEMPO (2,2,6,6-tetramethylpiperidin-1-oxyl) can be used catalytically as a mild 
oxidant for transforming primary and secondary alcohols into their respective 
aldehydes and ketones, with a variety of secondary oxidants available.56-58 
 
Another set of oxidising agents which avoid the use of metals are based on the 
reduction of DMSO to dimethyl sulfide with concomitant alcohol oxidation. A number 
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of variants on this method exist, dependant on the reagent used for activation of 
DMSO: The Pfitzner‒Moffatt (DCC),59 Parikh‒Doering (SO3∙py),60 Albright‒Goldman 
(Ac2O),61 and Onodera (P2O5) oxidations to name a few.62  
 
Of these DMSO-containing methods, one of the most commonly used is the Swern 
oxidation which utilises oxalyl chloride (68) for activation.63 The driving force for the 
Swern oxidation is release of CO2 and CO (Scheme 17).64  
 
R OH Cl
O
Cl
O
+ R O
CO2, CO
DMSO, Et3N
6860 61
 
Scheme 17:  Swern oxidation 
 
Whilst well documented, the Swern and related oxidations are not always practical for 
one-pot synthesis due to their multistep and multicomponent procedures as well as 
use of DMSO, the removal of which can be problematic. Simple reagents such as DMP, 
MnO2 or PCC would offer a better alternative for our methodology. 
 
 
2.3.1.2 Results 
 
As a test substrate for optimisation of the individual steps in the tandem sequence, the 
commercially available compound p-chlorobenzyl alcohol (60a) was chosen, and the 
oxidation was examined first. Of the various oxidising systems tested, including TPAP 
with O2 (Table 1, entries 1 and 2),53 or NMO as re-oxidant (entry 3),52 and Markó’s 
copper system (entry 4),65 MnO2 and DMP were found to be the most effective for this 
substrate (entries 5‒7), with the reactions proceeding well in both acetonitrile and 
dichloromethane to give quantitative conversions.66 Although no starting material was 
observed using PCC (entry 8), mass recovery was much lower than that seen with 
MnO2 or DMP. Therefore, at this point, MnO2 or DMP seemed the optimal choice for 
the tandem methodology.  
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Table 1: Conditions for oxidation to 4-chlorobenzaldehyde (61a) 
Cl
OH
Cl
O
60a 61a
[O]
 
Entry Oxidant Solvent Conversion to 61a (%)c 
1 TPAP/O2 CH2Cl2b 75 
2 TPAP/O2 10% MeCN in CH2Cl2b 96 
3 TPAP/NMO CH2Cl2 92 
4 CuCl/phen/O2a Fluorobenzene 33 
5 MnO2 MeCN 100 
6 DMP MeCN 100 
7 DMP CH2Cl2 100 
8 PCC CH2Cl2 100 
aReaction also requires the addition of di-t-butyl azodicarboxylate (DBAD) and N-
methylimidazole (NMI); b4Å mol. sieves added to the reaction mixture; cQuoted conversions are 
based on 1H NMR spectra of the unpurified reaction mixture, relative to unreacted starting 
material  
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2.3.2 Allylation 
 
2.3.2.1 Available methods  
 
The individual allylation reaction was studied next. Allylation reactions, as the name 
suggests, involve addition of an allyl group to an electrophilic centre. We were 
interested in the allylation of carbonyl compounds of type 61 to form a homoallylic 
alcohol 62. The reaction is believed to proceed via a 6-membered chair transition state 
69, as depicted in Scheme 18,67 and its modifications generally depend on the type of 
allylating agent 63 employed. 
 
 
MO MOR R
R O
R
OH
M
61
63
62
69 70  
Scheme 18: Allylation reaction proceeding via a cyclic transition state 
 
For example, the Barbier allylation utilises allyl bromide (52) and a metal such as 
magnesium, zinc or indium to form a Grignard-type reagent in situ.68 By contrast, the 
Keck allylation uses allyltributyltin (71) as the source of allyl functionality and a Lewis 
acid for aldehyde activation (Scheme 19).69 
 
R H
O
R
OH
SnBu3
Lewis acid
Br
Mg/Zn/In
Keck allylation
Barbier allylation
61 62
52
71
 
Scheme 19: Barbier and Keck allylations 
 
In 2004, Solin demonstrated the use of a palladium pincer-type catalyst 72 in 
conjunction with allyltributyltin (71) to perform allylation reactions via 1−allyl-
[J. Am. Chem. Soc., 
2004, p7026] 
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palladium intermediate 73 (Scheme 14).70 More specifically, intermediate 73 is first 
generated by means of transmetallation with stannane 71. Coordination of aldehyde 61 
then results in allylation via transition state 74 and, following ligand exchange, affords 
homoallylic alcohol 62. 
 
O O
PdPh2P PPh2
L
O O
PdPh2P PPh2
O O
PdPh2P PPh2
O
R
OH
R
SnBu3
R O
72
73 74
62
71
61
 
Scheme 14. Allylation using Solin’s pincer catalyst 
 
Owing to the cyclic nature of the transition state through which these allylic reactions 
are believed to proceed, an array of both diastereo- and enantioselective variants of this 
reaction process have been developed.71  As an example, Brown allylation uses  a chiral 
allylborane 76 which exploits the chirality of the allylating agent to control the 
stereochemistry of the resulting alcohol 77 (Scheme 16).72  
 
B
2
H
O
OH
Et2O, 100 °C
82%, 99% ee
75
76
77
 
Scheme 16. Asymmetric brown allylation of acrolein (75) 
 
An alternative allyl source is potassium allyltrifluoroborate (78), synthesized by Batey 
et al. in 1999.73 In combination with a Lewis acid, most aldehydes were shown to 
undergo allylation under very mild conditions. 
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For example, 4-nitrobenzaldehyde (61b) underwent an efficient allylation in the 
presence of potassium allyltrifluoroborate, with boron trifluoride diethyl etherate as 
Lewis acid, affording homoallylic alcohol 62b in 96% yield (Scheme 15).73 Room 
temperature variants have also been described, along with the use of montmorillonite 
K10 clay as an alternative Lewis acid.74 
 
O2N
O
O2N
OH
KF3B
CH2Cl2, 78 °C
BF3OEt2
96%
61b 62b
78
 
Scheme 15. Allylation of 4-nitrobenzaldehyde (61b) using Batey’s potassium allyltrifluoroborate salt 78 
 
In our methodology we aim to use a procedure which is both mild and facile. Use of 
allyltributyl tin (71) or potassium allyltrifluoroborate (78) in combination with a Lewis 
acid would seem the sensible choice. 
 
Initial studies in the group showed that in the allylation reaction of aldehyde 61a with  
allyltributyltin (71), a number of Brønsted and Lewis acids were found to be inefficient, 
with scandium triflate, p-nitrobenzoic acid, maleic acid and magnesium bromide all 
failing to promote the desired reaction to allylic alcohol 62a (Scheme 20).66 
 
Cl
O
Cl
OH
Bu3Sn
61a 62a
Various acids
71
 
Scheme 20: Failed allylation reactions 
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2.3.2.2 Results 
 
Pleasingly, allylation of 61a using catalytic amounts of ytterbium triflate with stannane 
71 was successful,75  giving a 68% yield of alcohol 62a following overnight reaction. 
(Scheme 21).  
 
OH
Cl
O
Cl
Yb(OTf)3 (20 mol%)
MeCN, rt, 24 h
68%
61a 62a
Bu3Sn 71
 
Scheme 21: Ytterbium triflate‒catalysed allylation of p-chlorobenzaldehyde  
 
We also wished to investigate the utility of potassium allyltrifluoroborate (78) for the 
methodology. Batey et al. have demonstrated the use of potassium allyl- and 
crotyltrifluoroborate salts in a number of allylation and crotylation reactions.73 
Potassium allyltrifluoroborate (78) was prepared according to Batey’s procedure by 
reacting allylmagnesium bromide (79) with trimethyl borate followed by acidic 
hydrolysis.76 The resultant boronic acid was converted into the corresponding 
trifluoroborate salt using potassium bifluoride to give an overall yield of 69% (lit.73 
yield 76%) (Scheme 22). 
 
MgBr BF3K
(i) B(OMe)3, THF, 78 °C, 2 h
(ii) HCl, H2O, 0 °C, 30 min
(iii) KHF2, H2O, rt, 30 min
69%
7879
 
Scheme 22: Synthesis of potassium allyltrifluoroborate (78) 
 
Potassium allyltrifluoroborate (78) was shown to perform well in the allylation reaction 
of 61a with BF3∙OEt2 catalysis, giving an excellent yield of product 62a following 
overnight reaction (Scheme 23).76 
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Cl
O
Cl
OHKF3B
61a 62aCH2Cl2, rt, 18 h
BF3OEt2 (0.5 eq)
78 (2 eq)
93%  
Scheme 23: Allylation with potassium allyltrifluoroborate 
 
 
2.3.3 Secondary alcohol oxidation 
 
2.3.3.1 Available methods 
 
The next step in our model tandem sequence would be oxidation of alcohol 62a to 
ketone 17a. Generally, most of the oxidising agents used for primary alcohol oxidation 
(vide supra, Chapter 2.3.1) can also be applied to the oxidation of secondary alcohols to 
ketones, such as the DMSO-based procedures, hypervalent iodine compounds and 
chromate compounds. For example, using PCC in CH2Cl2 at room temperature, it was 
reported that allylic alcohol 80 was converted into the corresponding ketone 50 in 98% 
yield without alkene isomerisation (Scheme 24).77 
 
OH O
PCC, AcONa, MgSO4
CH2Cl2, rt
98%80 50
 
Scheme 24: PCC oxidation of an allylic alcohol 
 
 
2.3.3.2 Results 
 
With alcohol 62a in hand, oxidation to ketone 17a was next explored (Table 2). Ideally, 
for a one-pot procedure, we wished to be able to use the same reagent for oxidation of 
both the primary alcohol 60 and the secondary alcohol 62. Surprisingly, manganese 
dioxide (entry 1) was unsuccessful in the oxidation of 62a, as was TPAP (entry 2), with 
no trace of desired product 17a observed. Only Dess‒Martin periodinane (entries 3 and 
4) and pyridinium chlorochromate (entry 5) were capable of oxidising allyl alcohol 62a 
to the corresponding ketone, although the latter provided a poor mass recovery. Thus, 
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we concluded that Dess‒Martin periodinane was the best oxidising agent for this 
methodology. 
 
Table 2: Conditions for oxidation to 17a 
Cl
OH
Cl
O
[O]
62a 17a  
Entry Oxidant Solvent Yield (%)a Conversion (%)b 
1 MnO2 MeCN 0 0 
2 TPAP/O2 CH2Cl2c 0 0 
3 DMP MeCN 98 100 
4 DMP CH2Cl2 NId 100 
5 PCC CH2Cl2 40 100 
aIsolated yields; bQuoted conversions are based on 1H NMR spectra of the unpurified reaction 
mixture; c4Å mol. sieves added to the reaction mixture; dNI = not isolated 
 
 
2.3.4 Isomerisation 
 
2.3.4.1 Available methods  
 
Following oxidation to ,-unsaturated ketone 17, the final step in the proposed one-
pot sequence is isomerisation of ketone 17 to conjugated ketone 18 (Scheme 25). 
 
R
O
R
O
17 18
 
Scheme 25: Isomerisation to the conjugated ketone 
 
This type of isomerisation is known to be effected with the use of acids such as TsOH,78 
and HCl,79 or with bases such as DBU,80 and DABCO.41 There is even literature 
precedent for using neutral media such as alumina to effect the desired isomerisation 
(Scheme 26).81,82 
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O O
Al2O3
Et2O, 2 h
90%50 41  
Scheme 26: Aluminium oxide isomerisation 
 
 
2.3.4.2 Results 
 
Initially, we investigated different reagents and conditions for the isomerisation of 17a 
to 18a (Table 3). Following migration of the double bond, a distinct change in the NMR 
signals of the compounds can be observed. The alkene peaks, previously a ddt at 
6.06 ppm and a pair of dq at 5.21 and 5.25 ppm in 17a, are shifted downfield and are 
now two doublets of quartets at 6.86 and 7.08 ppm, each integrating at 1H. The doublet 
of triplets at 3.73 ppm previously seen for the -CH2 in 17a is no longer present, and 
instead a doublet of doublets at 2.00 ppm is seen for the terminal methyl group of 18a, 
much further upfield. 
 
Table 3: Attempted isomerisations of 17a to 18a 
Cl
O
Cl
O
Conditions
17a 18a  
Entry Reagent Solvent Estimated yield (%)a 
1 Al2O3 Et2O 73b 
2 Al2O3 CH2Cl2 90 
3 Oxalic acid, BF3.OEt2 CH2Cl2 Complex mixture 
4 DBU Et2O 96 
5 DABCO IPA 81 
aBased on mass recovery and 1H NMR analysis of the unpurified reaction mixture; bPurified 
yield 
 
As anticipated from the literature precedent, stirring 17a in diethyl ether in the 
presence of alumina resulted in a reasonable yield of enone 18a (entry 1), whereas 
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reaction in CH2Cl2 resulted in high mass recovery with a small amount of an 
unidentified impurity (entry 2), which was encouraging for potential later 
incorporation into a one-pot process. On the other hand, oxalic acid,80 whether used 
stoichiometrically or catalytically in the presence of BF3∙OEt2 gave a complex mixture 
of products and the desired enone could not be identified (entry 3). Catalytic DBU 
(entry 4),80 and DABCO were both shown to perform the desired isomerisation (entry 
5),41 giving high mass recovery with only trace impurities. 
 
We also investigated the use of other reagents in the isomerisation of 17c to provide 
enone 18c (Table 4). Under basic conditions with sodium hydroxide (entry 1), or acidic 
(HCl) conditions (entry 2), a complex mixture of products was observed by TLC and 
NMR spectroscopic analysis. Testing previously successful conditions, DABCO and 
DBU both resulted in full conversion to 18c, with high mass recovery and only minor 
impurities (entries 3 and 4). Isomerisation with alumina was also successful, although 
in this case, the E-isomer of 18c was not exclusively formed (entry 5). 
 
Table 4: Attempted isomerisations of 17c to 18c 
MeO
O
MeO
O
Conditions
17c 18c
 
 
Entry Reagent Solvent Estimated yield (%)a 
1 NaOH THF Complex mixture 
2 HCl THF Complex mixture  
3 DABCO IPA 93 
4 DBU Et2O 98 
5 Al2O3 Et2O 70 (95:5 E:Z) 
aBased on mass recovery and 1H NMR analysis of the unpurified reaction mixture 
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2.4 Tandem allylation/oxidation 
 
Having investigated the individual steps of our proposed methodology, we now 
wished to combine these into a one-pot process. Initially, our aim was to effect a 
tandem allylation/oxidation reaction from p-chlorobenzaldehyde (61a) to generate the 
allyl ketone 17a (Scheme 21). By choosing to not yet involve the primary alcohol 
oxidation, this would allow easier analysis of the reaction progress. 
 
Cl
O
Cl
OM
cat.
[O]
61a 17a
Cl
OH
62a
 
Scheme 21. Tandem allylation/oxidation 
 
From previous investigations, it seemed that Dess‒Martin periodinane (66) was the 
most preferable oxidant for this methodology. In an initial attempt at a sequential 
reaction using stannane 71 in the presence of ytterbium triflate for the allylation, 
followed by DMP oxidation, pleasingly ketone 17a was successfully obtained with full 
conversion by TLC and NMR spectroscopy (Scheme 27). Interestingly, however, 
following column chromatography, using 10% KF-SiO2 to aid removal of the tin 
residues,83 the only observable product was enone 18a, obtained in a 50% isolated yield 
over the complete process. 
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Bu3Sn
Yb(OTf)3 (20 mol%)
61a 62a
Cl
O
DMP (2 eq), 3 h
17a
Cl
O
18a
Flash column chromatography
(10% KF-SiO2)
(71, 1.2 eq)
MeCN, 24 h
50%
 
Scheme 27: Sequential allylation/oxidation reaction with stannane 71 
 
Disappointingly, when these conditions were applied to a tandem process, whereby 
DMP was added to the reaction mixture at the start, predominantly starting material 
was seen after 72 h, possibly resulting from the stannane being oxidised before having 
a chance to react with the aldehyde in the slow allylation reaction (Scheme 23). 
Promotion of the allylation reaction with benzoic acid, as demonstrated by Aspinall,84 
also failed. 
 
Cl
O
Cl
O
DMP (2 eq), MeCN, 72 h
61a 17a
Bu3Sn
Yb(OTf)3 (20 mol%)
(71, 1.2 eq)
 
Scheme 23. Failed attempt at a tandem allylation/oxidation reaction with stannane 71 
 
Attention then turned to the potassium allyltrifluoroborate (78) allylation. A sequential 
reaction using literature conditions for the allylation,76 followed by 2 equivalents of 
DMP worked well to give ketone 17a with full conversion, and a 78% yield following 
purification (Scheme 28).  
 
R
ODMP (2 eq)
R
OH
R
O
KF3B
50 mol% BF3OEt2
61a 62a 17a
R = p-ClC6H4
rt, CH2Cl2, 2 h
78%
4 h
78
 
Scheme 28: Sequential allylation/oxidation with potassium allyltrifluoroborate (78) 
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In addition to the higher yield observed in the sequential reaction, the absence of tin 
by-products which can be difficult to remove, along with shorter reaction times, made 
78 a superior allyl source to 71 for this methodology. Also, ketone 17a was obtained 
without double bond isomerisation due to the simplified purification procedure. 
 
These conditions were subsequently applied to the tandem process, and in this case, a 
13:2 mixture of ketone:aldehyde was obtained (Table 5, entry 1). When the amount of 
allyl source 78 was increased, large quantities of alcohol were seen remaining (entries 2 
and 3). Given these results, it was hypothesised that excess potassium 
allyltrifluoroborate (78) was being oxidised by DMP. This would reduce the amount of 
oxidant present and result in recovered alcohol (62a). To counter this, the ratios of 
potassium allyltrifluoroborate to BF3∙OEt2 were modified as an alternative method for 
increasing the rate of allylation (entries 4 and 5). Although almost full consumption of 
both aldehyde 61a and alcohol 62a were now seen, the super-stoichoimetric BF3∙OEt2 
appeared to cause problematic side-products which could not be identified nor 
removed by chromatography. Attempts at instead altering the quantity of oxidant gave 
complex mixtures of intermediates and so this was not investigated any further. 
 
Table 5: Conditions for tandem allylation/oxidation of aldehyde 61a to ketone 17aa 
Cl
O
Cl
OKF3B
BF3OEt2
CH2Cl2
DMP
61a 17a
78
Cl
OH
62a
+
 
Entry Eq. of 78 Eq. of BF3∙OEt2 61a : 62a : 17ab Yield of 17ab,c 
1 2 0.5 2 : 0 : 13 87 
2 5 0.5 0 : 7 : 100 7 
3 2.5 0.5 0 : 5 : 3 38 
4 2 1 1 : 0 : 100 84d 
5 1.5 1.5 3 : 0 : 100 81d 
aReagents were added to one pot with 2 eq of DMP in CH2Cl2 and stirred at rt for 18 h before 
work-up; bBased on 1H NMR analysis of the unpurified reaction mixture; cEstimated percentage 
yield; dImpurities could not be removed by column chromatography 
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Due to the apparent sensitivity in the quantities of reagents added, and the problems 
this may cause with other substrates, it was decided to abandon work on the tandem 
reaction approach and concentrate on optimising the sequential reaction and 
incorporating the double bond migration. 
 
 
2.5 Sequential allylation/oxidation 
 
Focussing now on a sequential allylation/oxidation process, it was discovered that 
even with as little as 1.05 eq. of potassium allyltrifluoroborate (78) and 0.5 eq. of 
BF3∙OEt2, the allylation still went to completion within 5 minutes. The quantity of 
Dess‒Martin periodinane used could also be reduced without significant effect on the 
conversion time. Adding 1.2 eq. of DMP in a sequential manner and stirring for a 
further hour followed by standard aqueous work-up gave the ketone 17a in near 
quantitative yield, with purity as indicated by NMR spectroscopic analysis judged to 
be sufficient enough that column chromatography was not required. These conditions 
were then applied to a number of substrates, with results shown in Table 6. 
 
Good results were seen with the electron-withdrawing chloro-, bromo- and nitro- 
substrates (entries 1‒3), and a moderate yield was observed with trifluoromethyl 
substrate 61e. This lower yield could be attributed to the reported instability of ketone 
17e.48 However, the same was not the case for substrates with electron-donating 
groups. These less electrophilic aldehydes seemed not to tolerate the addition of 0.5 eq. 
BF3∙OEt2 (Entries 4‒8); immediate degradation of starting material was observed in 
these cases. Reduction to 20 mol% BF3∙OEt2 was shown to prevent degradation to an 
extent and some product was observed, but even with 1.5 eq. of potassium 
allyltrifluoroborate (78) the allylation did not go to completion. An alternative 
procedure for these substrates would therefore be required. 
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Table 6: Results of allylation/oxidation from aldehydes 61 
 
R
O
R
O (i) (ii)
R
OH
61 62 17  
 
Reagents and conditions: i) Potassium allyltrifluoroborate (78, 1.05 eq), BF3∙OEt2 (0.5 eq), CH2Cl2, 
rt, 10 min; ii) DMP (2 eq), rt, 1 h 
 
Entry R Yield of 17 (%)a 
1 
Cl  
17a 97 
2 
O2N  
17b Quantitative 
3 
Br  
17d Quantitative 
4 
F3C
 
17e 65b 
5 
MeO  
17c 0 
6 
O
 
17f 0 
7 
 
17g 0 
8 
 
17h 0 
a,-unsaturated ketones required no further purification; bPurity approx. 85% by 1H NMR 
analysis 
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2.6 Allylation/oxidation/isomerisation  
 
We now wished to try to incorporate the isomerisation into the one-pot sequence to 
directly obtain the conjugated enone 18 (Scheme 29). Unfortunately, any attempts to 
incorporate previous isomerisation methods into the one-pot process by adding 
reagents to the reaction mixture following final oxidation, resulted in either no reaction 
or a complex mixture of products. Trying to perform isomerisation reactions on 
isolated but unpurified products, in a pseudo-sequential process, proved to be 
capricious; if the substrate had not been subjected to chromatography then yields were 
severely reduced. This suggests that the products of the BF3∙OEt2 allylation/oxidation 
reaction were not as pure as analysis had originally indicated, but that a residual 
impurity was the cause of the loss in efficiency of the isomerisation reaction. 
 
R
O
R
OH
BF3K
BF3OEt2
R
O
DMP
R
O
Conditions
61a 62a
17a 18a
CH2Cl2
 
Scheme 29: Attempted incorporation of the isomerisation into a sequential reaction 
 
This prompted us to consider other isomerisation methods which might be more 
amenable to a one-pot reaction. It was thought that addition of excess BF3∙OEt2 at the 
end of the sequential reaction might generate the isomerised product (18a) as desired. 
Although this was the case, a number of other unknown products were observed and 
the desired product was not easy to isolate. Addition of water at the end of the 
sequential reaction showed no isomerisation, and only served to hydrolyse the excess 
Dess‒Martin periodinane present. In a publication by Curran it was suggested that 
similar isomerisation reactions can be performed with silica.85 In our hands, however, 
column chromatography generally resulted in only a small amount of conversion and 
no significant amount of isomerised product was observed by stirring with SiO2. 
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When allyltributyltin (71) had been used previously for the allylation, the subsequently 
formed ketone was purified by column chromatography using 10% w/w of finely 
ground KF and 90% w/w silica (KF-SiO2) in order to aid removal of the tin residues.83 
Partial or total isomerisation of the ketone was often observed in this process and it 
was thought that this was due to the KF-SiO2 itself. An attempt to incorporate this into 
the sequential reaction by adding KF-SiO2 to the unpurified reaction mixture again 
showed no isomerisation. When the ,-unsaturated ketone 17a was instead isolated 
after the allylation/oxidation sequence then re-dissolved in solvent, the attempted 
isomerisation was found to be capricious. Several attempts were made but varying 
degrees of isomerisation to the conjugated ketone 18a were observed and a close-
running impurity frequently appeared. If the KF-SiO2 mixture was not freshly made, 
the resultant reaction mixture frequently appeared to contain more impurities.  
 
 
Table 7: Results of allylation/oxidation and allylation/oxidation/isomerisation from aldehydes 61 
 
R
O
R
O
R
O (i) (iii)(ii)
R
OH
61 62 17 18  
 
Reagents and conditions: i) Potassium allyltrifluoroborate (78), BF3∙OEt2, CH2Cl2, rt, 10 min; ii) 
DMP, rt, 1 h; iii) Column chromatography on KF-SiO2 
 
Entry R Yield of 17 (%)a Yield of 18 (%)c 
1 
Cl  
17a 97 18a 38 
2 
O2N  
17b Quantitative 18b 23 
3 
Br  
17d Quantitative 18d 40 
4 
F3C
 
17e 65b 18e 0 
aIsolated yields, ,-unsaturated ketones required no further purification; bPurity approx. 85% 
by 1H NMR analysis; cPurified yields 
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In order to obtain pure samples of the ,-unsaturated ketones, the respective 
previously prepared ,-unsaturated ketones were subjected to column 
chromatography using freshly prepared KF-SiO2. A number of examples are shown in 
Table 7 but unfortunately, yields are disappointing, and in the case of with 
trifluoromethyl substrate 17e, no product or starting material were observed following 
chromatography, potentially due to the instability of these compounds.48  
 
 
2.7 Alternative allylation 
 
Given the incompatibility observed with several of the substrates under BF3∙OEt2 
allylation conditions, we next sought to tackle this problem. At this time, Batey et al. 
had recently published a report on the use of montmorillonite K10 in allylation and 
crotylation reactions.74 Montmorillonite K10 is an acidic clay catalyst, the use of which 
has precedent in a number of microwave reactions including the synthesis of 
bismaleimides and bisphthalimides.86 The efficacy of this catalyst in place of BF3∙OEt2 
for less activated aldehydes was subsequently investigated. 
 
Individual allylation reactions were performed on a number of substrates, followed by 
a sequential allylation/oxidation, results of which are summarised in Table 8. The 
literature procedure uses 20:1 CH2Cl2:H2O as the solvent,74 however, in the 
allylation/oxidation process being investigated the use of water is detrimental as it 
causes hydrolysis of the Dess‒Martin periodinane, such that even after stirring 
overnight with excess DMP (3 eq), full conversion was not seen (entry 1).  The 
allylation reaction was run under anhydrous conditions but in the absence of water, 
the reaction failed to go to completion (entry 2). 
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Table 8: Results of allylations and allylation/oxidations using montmorillonite K10 
 
R
O
R
O (i) (ii)
R
OH
61 62 17
R
O (i)
R
OH
61 62
 
Reagents and conditions: i) Potassium allyltrifluoroborate (78, 1.2 eq), montmorillonite K10, AcOH (11 eq), 
CH2Cl2, rt, 15 min; ii) DMP (1.8 eq), rt, 1 h 
 
Entry Substrate Solvent system Yield of 62 (%)a Yield of 17 (%)a 
 
1 
 
O
O  
 
CH2Cl2 
H2O 
Not run 
77b (17c) 
(+21% of 62c) b,c 
 
2 
 
O
O  
 
CH2Cl2 
36b (62c) Not run 
 
3 
 
O
O  
 
CH2Cl2 
AcOH 
85 80  
 
4 
 
O
 
 
CH2Cl2 
AcOH 
92 (62h) 57 (17h) 
aIsolated yield; bBased on 1H NMR analysis of the unpurified reaction mixture; c3 eq. of DMP 
used 
 
As an alternative proton source, acetic acid was tested in the allylation. Acetic acid is a 
by-product of the DMP oxidation and so it could be assumed that its presence would 
not cause problems in this step of the reaction. Satisfyingly, allylation of anisaldehyde 
in the presence of acetic acid (11 eq.) proceeded smoothly, and in combination with the 
DMP oxidation gave 80% of ,-unsaturated ketone after purification by flash column 
chromatography (entry 3). Cinnamaldehyde, a substrate which was not compatible 
with the previous allylation conditions, was also allylated successfully and further 
oxidised to give ketone 4h in moderate yield (entry 4).  
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2.8 Oxidation/allylation/oxidation 
 
With a general MK10-catalysed allylation/oxidation procedure for a range of aldehyde 
substrates now developed, we next wished to extend this to an 
oxidation/allylation/oxidation protocol. As acetic acid is a by-product of the DMP 
reaction, we envisioned that the acid formed in the first oxidation may be sufficient to 
aid catalysis in the allylation step. Pleasingly, this was indeed the case, and thus these 
conditions were applied to a number of primary alcohol substrates (Table 9).  
 
In order to ensure complete oxidation of the secondary alcohol, additional DMP was 
added in a sequential fashion. Different substrates exhibit differing reaction rates, 
making it not possible for a universal quantity of oxidant to be added from the start; 
too much resulted in oxidation of the allylating agent, whereas too little gave 
incomplete oxidation of the secondary alcohol. 
 
The reaction proceeded well to give a range of aromatic products in good to excellent 
yields (entries 1-5). Conditions were also applied to a range of heterocyclic systems. 
Furan-derived ketone 17f was observed by NMR analysis of the unpurified material, 
however, its apparent volatility prevented isolation of pure product (entry 6). On the 
other hand, thiophene-derived product 17j was obtained in high yield (entry 7). With 
4-pyridine methanol (60k) as substrate, a mixture of products was obtained. NMR 
analysis of the unpurified product following the reaction revealed the presence of ,-
unsaturated ketone 17k along with enone 18k in a 4:5 ratio. This phenomenon is 
presumably due to the basic nature of pyridine bringing about self-isomerisation. In 
addition, the allylic ketone 17k was shown to be unstable to silica, as attempted 
purification resulted in ,-unsaturated ketone 18k as the sole product (entry 8). 
Unfortunately, indole-derived product 17m was only obtained in low yield (entry 9), 
whereas the aliphatic compound piperidine methanol (60n) provided ketone 17n in 
moderate yield (entry 10). Pleasingly, cinnamyl alcohol (60h) and protected sugar 60o 
were converted into the corresponding ketones 17h and 17o in moderate to high yield 
(entries 11 and 12). 
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Table 9: Oxidation/allylation/oxidation reactions 
 
R
O
R
O (ii) (iii)
R
OH
61 62 17
R
OH
60
(i)
 
Reagents and conditions: i) DMP (1.5‒2.0 eq), CH2Cl2, rt, 1 h; ii) montmorillonite K10, potassium 
allyltrifluoroborate (78, 1.5‒2.0 eq), rt, 1 h; iii) DMP (2.0‒2.5 eq), rt, 1 h 
 
Entry Product Yielda Entry Product Yielda 
1 
O
Cl
17a
 
71 7 
S
O
17j
 
76 
2 
O
O2N
17b
 
96 8 
N
O
17k
N
O
18k
 
41b 
 
 
48 
3 
O
O 17c  
92 9 
N
Boc
O
17m
 
31 
4 
O
Br
17d
 
85 10 N
OBoc
17n
 
63 
5 
O
17i
 
75 11 
O
17h
 
67 
6 
O
O
17f  
24b 12 
O
O
17o
O
O
O
O
 
75 
aPercentage isolated yield; bBased on 1H NMR analysis of the unpurified reaction mixture 
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2.9 Oxidation/allylation/oxidation/isomerisation 
 
Given the problems previously encountered with incorporating the isomerisation into 
a one-pot process, it was deemed necessary to subject ,-unsaturated ketones 17 to 
purification prior to isomerisation to the related enone 18. A selection of ,-
unsaturated ketones 17, prepared using the oxidation/allylation/oxidation 
methodology outlined in Chapter 2.8, were stirred with a catalytic amount of DBU in 
diethyl ether. Results of the subsequent isomerisations were gratifying, and are 
summarised in Table 10. 
 
Table 10: DBU-catalysed isomerisations to give ,-unsaturated ketones 
 
R
O
R
ODBU (0.1 eq)
Et2O, 24 h
17 18
 
Entry Product Isolated yield (%)a 
1 
O
Cl  
18a 95 
2 
O
MeO
 
18c 96 
3 
S
O
 
18j 87 
4 
O
O
O
O
O
O
 
18o 
70 
(>20:1 E:Z) 
aE-only unless otherwise stated 
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2.10 Summary and future work 
 
Our aim was to develop a one-pot oxidation/allylation/oxidation procedure to convert 
primary alcohols directly into ,- and ,-unsaturated ketones. Following 
investigation of the individual steps, attempts were made at effecting a tandem 
allylation/oxidation reaction, but these were unsuccessful. A sequential 
allylation/oxidation protocol using BF3∙OEt2-catalysed allylation to give 
,-unsaturated ketones was demonstrated, with incorporation of a KF-SiO2 
isomerisation in a pseudo-one-pot fashion. Unfortunately, this process was not 
compatible with the poorly electrophilic aldehydes tested, and so an alternative 
approach was investigated.  
 
A one-pot oxidation/allylation/oxidation reaction from primary alcohols to 
,-unsaturated ketones was subsequently developed. Using Dess‒Martin periodinane 
as oxidant for both steps, potassium allyltrifluoroborate allylation proceeds with 
catalysis achieved by montmorillonite K10 along with acetic acid, which is present as a 
by-product of DMP oxidation. Attempts at involving isomerisation into a one-pot 
process were unsuccessful, however, DBU-catalysed isomerisation to give 
,-unsaturated ketones has been demonstrated on a selection of ,-unsaturated 
ketones following the novel one-pot reaction. 
 
Future work will revisit the isomerisation and its incorporation into the one-pot 
procedure, as well as the application of this methodology to natural product synthesis. 
Studies towards the synthesis of elaeokanidine A will follow in the next Chapter.   
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Chapter 3 – Towards the synthesis of elaeokanidine A 
 
3.1 Project aims and background 
 
The indolizidine skeleton is ubiquitous in natural products, with well over 100 
reported naturally occurring molecules containing this structural unit.87 Eleaokanidine 
A (19) (Scheme 30) is an indolizidine alkaloid isolated from Elaeocarpus kaniensis.88,89 Its 
structure and relative stereochemistry have been elucidated but its absolute 
stereochemistry has yet to be confirmed. To date, elaeokanidine A has never 
succumbed to total synthesis. It has not been tested for biological activity, although the 
activity of related alkaloids lead us to believe that it may have interesting 
pharmacological properties and obtaining larger quantities of this compound would 
allow this to be further investigated.  
 
All of these factors make elaeokanidine A an attractive target for total synthesis, and 
thus our aim was to devise a synthetic route to this compound. Our proposed 
retrosynthetic strategy is based on addition of ammonia into an enone system (Scheme 
30), which we believed could potentially be constructed using the 
oxidation/allylation/oxidation/isomerisation (O/A/O/I) methodology outlined in 
Chapter 2.  
 
N
O
N
H
elaeokanidine A (19)
N
O
N OH
81 82
H
H
H
Conjugate
addition
O/A/O/I
H
H
 
Scheme 30: Proposed retrosynthesis of elaeokanidine A (19) 
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3.1.1 Elaeocarpus indolizidine alkaloids 
 
Alkaloids are a group of nitrogenous compounds that are derived from natural 
sources. Initial studies by Johns et al. in the late 1960s and early 1970s on extracts from 
the plant genus Elaeocarpus yielded numerous indolizidine alkaloids, i.e. those which 
contain a fused 5-6 ring system with a nitrogen atom shared between the two rings.90-94 
The first of these were (±)-elaeocarpine (83) and (±)-isoelaeocarpine (84), which differ 
only in the cis/trans-relationship at the ring junction, along with (+)-isoelaeocarpicine 
(85), all of which were extracted from Elaeocarpus polydactylus (Figure 5).90,91 The 
complete relative stereochemistry of (±)-elaeocarpine (83) was obtained from an X-ray 
crystal structure of its hydrobromide salt.95 Recently, all of these compounds have been 
shown to have affinity for the human -opioid receptor, which has implications in pain 
relief.96 
 
O
N
H
H
O
O
N
3
H
H
O
83 84
HO
N
H
O
85
HO
 
Figure 5: (±)-Elaeocarpine (83), (±)-isoelaeocarpine (84) and (+)-isoeleaocarpicine (85), alkaloids from 
Elaeocarpus polydactylus 
(Structures indicate relative stereochemistry only) 
 
 
Extracts from Elaeocarpus dolichostylis yielded two new structurally related alkaloids, 
(+)-elaeocarpiline (86) and (−)-isoelaeocarpiline (87) (Figure 6).92 The relationship 
between (+)-elaeocarpiline (86) and (±)-elaeocarpine (83) was proved by reducing the 
latter with H2 over Pd/C in benzene to give (+)-elaeocarpiline (86).97 Five further 
alkaloids were isolated from Elaeocarpus sphaericus; four of these differ from 
(+)-elaeocarpiline and (−)-isoelaeocarpiline only in the stereochemical configuration at 
C-7, C-8 and C-9, whereas the fifth is isomeric in its double bond placement.98  
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86 87
 
Figure 6: (+)-Elaeocarpiline (86) and (−)-isoelaeocarpiline (87), alkaloids from Elaeocarpus dolichostylis 
 
In 2011, two more indolizidine alkaloids from Elaeocarpus sphaericus, closely related to 
elaeocarpine (83) and isoelaeocarpine (84), were discovered, namely (±)-3-
oxoisoelaeocarpine, which possesses an addition carbonyl at the 3-position of 
isoelaeocarpine, and (±)-elaeocarpine N-oxide.99  
 
In 1971, extracts from Elaeocarpus kaniensis were investigated;88,89 from these extracts, 
eight new alkaloids were isolated (Figure 7). Through a combination of spectroscopic 
studies, structures were assigned to elaeokanine A (88), elaeokanine B (89), elaeokanine 
C (90), elaeokanine D (91), elaeokanine E (92) and elaeokanidine A (19), but only the 
relative stereochemistry of these compounds was determined at this point. The 
remaining two natural products, elaeokanidine B and elaeokanidine C are 
stereoisomers of elaeokanidine A but there was insufficient data to unequivocally 
assign their structures.89 
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N
O
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N
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N
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H
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H
H
N
OH
H
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H
H
N
OH
H
N
HH
H
(+)-elaeokanine A (88) ()-elaeokanine B (89)
()-elaeokanine C (90) elaeokanine D (91)
elaeokanine E (92) elaeokanidine A (19)
 
Figure 7: Alkaloids isolated from Elaeocarpus kaniensis 
(In the cases of 91, 92, and 19, the structures shown indicate relative stereochemistry only) 
 
 
Over the years, elaeokanine A (88) has been the subject of a number of syntheses.100-109 
The majority of these have been racemic but more recently, asymmetric variants have 
also emerged.101-104 Syntheses of elaeokanine B (89),103,105,110 C (90),104-107 and E (92) have 
also been reported,111 however, to date, the synthesis of elaeokanidine A (19) has not 
been reported. The asymmetric syntheses of elaeokanines A, B and C were the ultimate 
proof of their respective structures, and enabled confirmation of their absolute 
stereochemistry. 
 
 
3.1.2 Biological activity of related alkaloids 
 
Studies in 2005 yielded two previously unknown alkaloids from the leaves of 
Elaeocarpus grandis (Figure 8), grandisine A (93) and grandisine B (94) which were 
shown to have affinity for the human -opioid receptor.112 A further five alkaloids, 
grandisine C‒G, were discovered from the same plant in 2006. Investigations into the 
bioactivity of these compounds revealed that, along with (−)-isoelaeocarpiline (87), 
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they all showed affinity for the human -opioid receptor, with IC50 values ranging from 
1.55 to 75.4 μM.113  
 
N
O
O
O
H
H
grandisine A (93) grandisine B (94)
N N
O
N
O
O
H
grandisine D (95)  
Figure 8: Grandisines A (93), B (94) and D (95), alkaloids from Elaeocarpus grandis 
 
Shortly afterwards, a novel indolizidine alkaloid, (±)-elaeocarpenine (96), along with 
three previously known compounds, was isolated from Elaeocarpus fuscoides 
(Figure 9).96 This compound showed structural similarities to the Elaeocarpus 
polydactylus alkaloids (vide supra, Figure 5) and also exhibited human -opioid receptor 
binding affinity. 
 
N
O
96
HO
 
Figure 9: (±)-Elaeocarpenine (96), an alkaloid from Elaeocarpus fuscoides 
 
In 2007, five novel pyrrolidine alkaloids were tested for biological activity. Habbemines 
A (97) and B (98) were isolated from Elaeocarpus habbemensis,114 whilst peripentonines 
A–C (99, 100 and 101, respectively) were isolated from Peripentadenia mearsii (Figure 
10).115 All of these natural products displayed a binding affinity for the human -opioid 
receptor. 
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N OH
97 R = OH
99 R = X
98 R = OH
100 R = X
R
101 R = X
N
H
O
= X
 
Figure 10: Habbemines A (97) and B (98) and peripentonines A‒C (99‒101) 
 
The biological activity of these related indolizidine and pyrrolidine alkaloids, along 
with other indolizidine alkaloids such as castanospermine is encouraging regarding 
the potential bioactivity of elaeokanidine A.116,117 
 
 
3.1.3 Structural elucidation of elaeokanidine A 
 
The structure of elaeokanidine A (19) was solved primarily through NMR 
spectroscopic studies, aided by infrared and mass spectrometry data. Comparisons to 
the spectra of firmly established alkaloids also aided the assignment of the structure.89  
 
7
N 11
O
12
H
H
N
HH
H
A
elaeokanidine A (19)  
 
The 1H NMR spectrum indicated a close structural similarity to elaeokanine D (91). As 
was reported for elaeokanine D in the same publication, on evaluation of the coupling 
constants, the authors proposed that ring A sits in a twisted conformation. The J11,12  
coupling constants (J = 7.0 and 2.0 Hz) were found to be lower than those expected for 
trans-diaxial coupling (J = 9‒13 Hz) if H-12 were to be in an axial position.118 If, 
however, H-12 was in an equatorial position, typical equatorial-equatorial or 
equatorial-axial (J = 2‒5 Hz) coupling constants of a cyclohexane ring in chair 
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conformation suggest that J11,12  (7.0 Hz) is higher than should be expected.118 Indeed, a 
twisted conformation which minimises the interaction between H-7 and the methyl 
group would explain this phenomenon (Figure 15). 
 
N
N
H
O
 
Figure 15. Three-dimensional representation of elaeokanidine A (19) 
 
 
3.1.4 Biosynthesis  
 
Alkaloids are formed from natural sources by the condensation of polyketides, the 
biosynthetic pathway of which is well established (Scheme 31). Polyketides of type 106 
arise from the Claisen-type condensation of acetyl-CoA (102) with malonyl-CoA (103) 
to form a -keto-thioester 105, which subsequently undergoes further cycles of 
condensation with malonyl-CoA (103) leading to chain elongation.119 
 
O
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105106  
Scheme 31: The biosynthesis of poly--keto thioesters 
 
Amino acids provide additional building blocks for biosynthesis. By undergoing 
several enzymatic processes, ornithine (107) can be converted into 3,4-dihydropyrrole 
(110),120 and it is postulated that this moiety provides the nitrogen atom present in the 
indolizidine alkaloids (Scheme 32).89 
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CO2H
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CO2
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phosphate
coenzyme
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NH2
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N Schiff base formation
107 108
109110  
Scheme 32: Formation of dihydropyrrole from ornithine 
 
Hart proposed a biosynthesis of the E. kaniensis alkaloids whereby an 8-carbon 
polyketide, 111, condenses with dihydropyrrole (110) to provide the indolizidine 
skeleton; further transformations led to the other alkaloids (Scheme 33).89 The 
biogenesis of elaeokanidine A (19) with its extra nitrogen atom, however, was not 
explained. 
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Scheme 33: Hart’s proposed biosynthesis of E. kaniensis alkaloids 
 
Following on from a report in which ammonia was shown to have an artefact-inducing 
effect,121 it is suggested that elaeokanidine A (19), along with grandisine B (94), is in 
fact formed on treatment with aqueous ammonia during the extraction procedure as 
opposed to being a natural product in its own right. 
Consequently, Katavic proposed a mechanism for the formation of elaeokanidine A, 
involving reaction of ammonia with the dehydrated product of 113 (Scheme 34).122 
Nucleophilic attack of ammonia on to the endocyclic enone in 81 first affords 114 and 
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an intramolecular Michael addition onto the remaining ,-unsaturated ketone of 114 
subsequently leads to elaeokanidine A (19). 
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Scheme 34: Proposed ammonia-induced formation of elaeokanidine A (19)  
 
Although elaeokanidine A may not be a natural product in itself, and merely an 
artefact, its synthesis is nevertheless interesting due to the aforementioned factors. We 
aim to exploit Katavic’s proposed synthesis by preparing 81, which may indeed be the 
true natural product derived from Elaeocarpus kaniensis, and using ammonia to install 
the nitrogen atom in the final compound. We plan to use precedented routes to 
construct the main indolizidine framework. 
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3.1.5 Previous syntheses of the indolizidine core  
 
The literature contains a wealth of different synthetic strategies towards the 
indolizidine core.87 Of these, some of the most common involve imino Diels‒Alder 
reactions, 1,3-dipolar cycloadditions, or intramolecular cyclisation of acyliminium ions. 
 
Weinreb and co-workers used compound 115 as a precursor for an imino Diels‒Alder 
reaction, whereby thermally-assisted elimination of acetic acid provided an imine 
moiety as the dienophile for cyclisation. The bicyclic system 116 was obtained in 82% 
yield following reflux in o-dichlorobenzene, and this intermediate was then taken 
forwards for the racemic synthesis of the indolizidine alkaloid slaframine (117) 
(Scheme 35).123 
 
N
O
OTBS
CO2Me
(±)-slaframine (117)
NH
O
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CO2Me
AcO
DCB, 
82%
N
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H H
NH2
115 116  
Scheme 35: Weinreb’s imino Diels‒Alder approach to the indolizidine core 
 
Wightman et al. demonstrated a 1,3-dipolar cycloaddition of N-oxide 118 and alkene 
119 to provide the bicyclic structure 120 in 44% after 4 days at reflux. Zinc-mediated 
N‒O cleavage followed by lactamisation then furnished indolizidine 121 in 83% yield, 
which was further manipulated to provide the natural product (+)-lentiginosine (122) 
(Scheme 36).124 
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Scheme 36: Wightman’s 1,3-dipolar cycloaddition approach to the indolizidine core 
 
Overman established a route to the indolizidine structure 124, by means of a 
TFA-induced acyliminium ion cyclisation of vinylsilane 123 as one of the key steps 
(Scheme 37).125 The group went on to use this intermediate in the total synthesis of both 
elaeokanine A (88) and elaeokanine B (89).  
 
N
TFA, reflux
62%
O Br
N OH
O
TMS
Br
elaeokanine A (88)
elaeokanine B (89)
123 124  
Scheme 37: Overman’s acyliminium ion cyclisation route to the indolizidine core. 
 
Similarly, Taber et al. used a Lewis acid‒mediated acyliminium cyclisation to form 
lactam 126 from 125 as a key step in the group’s route to elaeokanine A (Scheme 38).100 
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O CO2Me1. SnCl4, DCE
125 126
2. DBU, THF
27%
elaeokanine A (88)
N
O
CO2Me
OMe
 
Scheme 38: Taber’s acycliminium ion cyclisation approach to the indolizidine core 
 
In contrast, Pohmakotr et al. used a base-induced cyclisation of sulfoxide 127 to afford 
indolizidine 128 as the key step in their route to racemic tashiromine (129) (Scheme 
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39).126 Owing to the relevance of these latter two routes to our project, these will be 
discussed in more detail in a later section (vide infra, Chapters 3.2.1 and 3.2.2).  
 
N O
N
S
O
Ph
127 128
LiHMDS, THF
S
O
Ph
N OH
H
(±)-tashiromine (129)
 
Scheme 39: Pohmakotr’s base-induced cyclisation approach to the indolizidine core 
 
 
3.1.6 Retrosynthetic analysis  
 
To date, elaeokanidine A (19) has never succumbed to total synthesis. The unconfirmed 
absolute stereochemistry and the pharmacological activity of related structures make it 
an interesting target. Aside from the indolizidine core, the main structural feature of 
elaeokanidine A is the additional nitrogenous ring. As alluded to previously, this could 
in principle be formed by double Michael addition of ammonia to dienone 81 (vide 
supra, Scheme 34). Three of the stereocentres would be introduced in this final 
ammonia-trapping step.  Attack of the nucleophile onto the two enones would install 
two stereocentres, with proton quenching installing the final. At this point we hoped to 
utilise our oxidation/allylation/oxidation/isomerisation (O/A/O/I) methodology for 
the synthesis of the ,-unsaturated ketone functionality in 81 from alcohol 82 (Scheme 
40). 
 
N
O
N
H
19
N
O
N OH
81 82
H
H
H
Conjugate
addition
O/A/O/I
H
H
 
Scheme 40:  Proposed retrosynthesis of elaeokanidine A 
 
The following section will describe the results and current progress towards the 
synthesis of elaeokanidine A.  
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3.2 Results and discussion 
 
Elaeokanidine A (19) is an indolizidine alkaloid isolated from the leaves of Elaeocarpus 
kaniensis, a rainforest species found in New Guinea. It contains four stereocentres, three 
of which are at ring junctions. The absolute configuration is unknown and only the 
relative stereochemistry has been reported.88 Our proposed retrosynthesis involves the 
addition of ammonia into a dieneone system 81 (Scheme 40), to which we hope to gain 
access using the newly developed oxidation/allylation/oxidation/isomerisation 
methodology outlined in the Chapter 2, starting from alcohol 82. In the first instance 
we wished to synthesise a racemic form of alcohol 82 in order to test the viability of our 
proposed route. In order to achieve this, we looked to the literature for inspiration.   
 
 
3.2.1 Pohmakotr’s route 
 
In 2008, Pohmakotr et al. described a route to the key intermediate 82 as part of their 
synthesis of (±)-tashiromine (Scheme 41).126 
 
NH
O
N
O S
Ph
O N
S
O
Ph
N
S
O
Ph
H
N
S
O
Ph
OH
N OH
(a) (b)
(c)
(d)(e)
130 127 128
13113282
 
Reagents and conditions: (a) NaH, DMF, PhS(CH2)4Br, 0 °C to rt (75%); then NaIO4, MeOH, H2O, 
0 ºC to rt, 12 h (70%); (b) LiHMDS, THF, −78 ºC to rt, 15 h; (c) NaBH4, MeOH, 0 ºC to rt (69% 
from 127); (d) LDA, THF, (CH2O)n, −78 ºC to rt, 15 h (55%); (e) toluene, reflux, 8 h (47%) 
Scheme 41: Pohmakotr’s route to 82 
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Beginning from pyrrolidinone (130), the first step of Pohmakotr’s route was installation 
of a sulfide-containing side-chain by alkylation. Attack of the deprotonated 
pyrrolidinone displaces the bromine to install the alkyl chain, which was subsequently 
oxidised from the sulfide to give sulfoxide 127. Deprotonation at the -position of 
sulfoxide 127 with LiHMDS induced cyclisation by means of attack on to the carbonyl 
functionality, followed by elimination of water, gives indolizidine 128 (Scheme 42). 
 
N
O S
Ph
O N
S
O
Ph
N
O S
Ph
O
LiHMDS
N
SOPh
O
N
SOPh
OH2
H2O quench
H
-H2O
127 128
 
Scheme 42: Mechanism of LiHMDS-mediated cyclisation 
 
Sodium borohydride reduction of intermediate 128 gave bicycle 131, which with 
subsequent deprotonation and addition of paraformaldehyde, served to introduce the 
oxygen functionality in 132. Finally, thermal elimination of the sulfoxide afforded the 
desired alcohol, 82.126 We therefore envisaged that we could use this route, or a 
modification thereof, for our synthesis of alcohol 82. 
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3.2.1.1 Alkylation 
 
Synthetic efforts began by initially following a modification of Pohmakotr’s 
synthesis.126 Rather than pre-making the side chain for a convergent synthesis, a linear 
approach was taken due to ease and the hope of improving on existing yields. 
Alkylation of pyrrolidinone (130) with dibromobutane (133) gave bromide 134, which 
was subsequently substituted with thiophenol to afford sulfide 135. Oxidation with 
m-CPBA provided the desired sulfoxide 127, for Pohmakotr’s cyclisation with LiHMDS 
(Scheme 43 and 46). The initial alkylation, as described by Comoy,127 pleasingly 
surpassed the literature (65%) to afford the brominated compound 134 in 90% yield 
(Scheme 43). Reaction of bromide 134 with stoichiometric thiophenol in ethanolic 
potassium hydroxide gave the sulfide 135 in quantitative yield.128  
 
NH
O
N
O Br
N
O SPh
90%
quant.
130 134
135
NaH, DMF, 80 °C, 24 h
Br
Br
133
PhSH, KOH, EtOH
rt, overnight
 
Scheme 43: Alkylation and substitution steps 
 
 
3.2.1.2 Oxidation 
 
Oxidation of sulfide 135 with m-CPBA using conditions described by Barton, whereby 
isolation of the sulfoxide was achieved by filtering the reaction mixture followed by an 
aqueous work-up,129 gave sulfoxide 127 in 66% yield. An alternative method, as used 
previously in the Taylor group was also attempted. This involved slow neutralisation 
with triethylamine followed by loading on to silica gel and subsequent column 
chromatography (Scheme 44). 
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1. m-CPBA, CH2Cl2
0 °C to rt overnight
135 127127
1. m-CPBA, CH2Cl2, 15 °C, 1 h
2. Et3N, overnight, then FCC
66% 93%
2. Filtration then
aqueous work-up
 
 
Scheme 44: m-CPBA oxidation to sulfoxide 98 
 
In this case, the conditions resulted in an improved 93% yield; but, in both cases partial 
over-oxidation to the sulfone was also observed (ca. 8%). This was confirmed by 
comparison of data with an authentic sample of sulfone 136 (Scheme 45). There are two 
distinct differences in the NMR spectra of the two compounds; firstly, the aromatic 
protons of the sulfone are shifted further downfield compared to those of the sulfoxide; 
secondly the spectrum of the sulfoxide is more complex than that of the sulfone due to 
the effect of the lone pair on the chiral sulfur centre. This makes it easy to identify the 
presence of over-oxidation although unfortunately the sulfone was not easily separable 
from the sulfoxide, therefore this small impurity was carried through the synthesis. 
 
N
O SPh
135
N
O
136
S
O
Ph
O
m-CPBA (3.4 eq)
CH2Cl2
 
Scheme 45: Over-oxidation of sulfide to sulfone 
 
 
3.2.1.3 Cyclisation 
 
The first attempt at the cyclisation using Pohmakotr’s procedure went smoothly, 
giving compound 128 in 89% yield with 100% conversion by 1H NMR spectroscopy 
(Scheme 46).  
 
N
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Ph
127 128
LHMDS, THF
78 °C to rt overnight
89%
 
Scheme 46: Key cyclisation step 
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Problems arose when the cyclisation conditions were repeated; disappointingly, no 
product was observed. Subsequent attempts at this reaction had variable success, with 
differing degrees of conversion into product 128 observed. An alternative method was 
used for the synthesis of sulfoxide 127 as there were concerns that the sulfone present 
in the starting material could be having a detrimental effect. Ravikumar has shown 
that with hexafluoroisopropanol as solvent, only sulfoxide is observed from peroxide 
oxidation of the corresponding sulfide; no over-oxidation to the sulfone is seen. On our 
substrate this was indeed the case; oxidation was complete within 10 min and the pure 
sulfoxide 127 isolated in quantitative yield (Scheme 47). 130 
 
N
O SPh
N
O S
O
HFIP, rt, 10 min
30% aq. H2O2
100%135 127
Ph
 
Scheme 47:  Peroxide oxidation of sulfide 135 to sulfoxide 127 
 
Unfortunately, when this material was subjected to the cyclisation conditions, no 
product was observed.  The cyclisation was hence deemed not to be reproducible and 
the route was abandoned. Progress up until this point is summarised in Scheme 48. 
 
NH
O
N
O Br
N
O SPh
N
O SPh
O
N
S
O
Ph
(a) (b)
(c) (d)
90% 100%
93% 089%
130 134 135
127 128  
 
Reagents and conditions: (a) NaH, DMF, Br(CH2)4Br, 80 ºC, 24 h; (b) PhSH, KOH, EtOH, r, 18 h;                  
(c) (i) m-CPBA, CH2Cl2, −15 ºC, 1 h (ii) Et3N, rt, 16 h; (d) LHMDS, THF, −78 ºC to rt, 16 h 
Scheme 48: Progress made towards the synthesis of 62  
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3.2.2 Taber’s route  
 
An alternative route to compound 82 has been described by Taber’s group (Scheme 
53).100  
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Scheme 49: Taber’s synthesis of 82 
 
They reported initial deprotonation of succinimide (137) using sodium in ethanol 
wherein conjugate addition of the generated nucleophile onto acrolein (75) gave the 
aldehyde 138, which was subjected to Horner‒Wadsworth‒Emmons olefination with 
trimethyl phosphonoacetate (139) to provide E-alkene 140. Sodium borohydride 
reduction of the imide moiety resulted in a hydroxylactam 141, which underwent 
methylation with acidic methanol to provide 125. A tin-mediated cyclisation to give 
142 and subsequent elimination afforded 126. Reduction with diisobutylaluminium 
hydride of both the ester and amide functional groups then gave the desired product 
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82 in seven steps and 6% overall yield. We therefore chose to repeat this route to gain 
access to intermediate 82 for our synthesis of elaeokanidine A (19). 
 
 
3.2.2.1 Horner‒Wadsworth‒Emmons reaction and reduction 
 
In our hands, the conjugate addition proceeded smoothly with good mass recovery of 
the slightly impure aldehyde 138 following column chromatography (Scheme 50).  
 
NH
O
O
Na, acrolein, EtOH, rt
N
O
O
O>100% (slightly impure)
137 138  
Scheme 50: Conjugate addition of succinimide (137) with acrolein (75) 
  
The published HWE reaction on 100 mg scale followed by Kugelrohr distillation gave 
olefin 140 in 56% yield over 2 steps.100 In our hands, on a 3 g scale, 65% of material was 
obtained following vacuum distillation.  
 
The subsequent NaBH4 reduction of 140 to 141 posed a number of problems. The 1H 
NMR spectrum of alcohol 141 did not correspond to the data given in the literature, 
and indeed the carbon spectrum appeared to show an additional peak. On comparison 
with the data for 125, it transpired in fact that methylation had occurred during the 
acidic work up, taking 140 straight through to methoxylactam 125 (Scheme 51).  
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Scheme 51: Direct reduction/methylation of 140 
 
An additional difficulty encountered was that the reduction consistently failed to go to 
completion despite addition of up to 2 extra equivalents of sodium borohydride, thus 
resulting in a low yield of product. Due to this problem, a different approach was 
taken. It was hoped that by modifying the conditions used in the HWE reaction, 
cleaner starting material for the reduction would be obtained and this might result in a 
more reproducible reaction. Results of this optimisation are summarised in Table 11.  
 
Table 11: Optimisation of the HWE reaction 
 
Base
N
O
O
CO2Me
138 140
N
O
O
O
P
O
O
RO
O
RO
R = Me, 139
R = Et, 139a
 
Entry Base Phosphonoacetate Yielda E:Z 
1 NaH 139 65%b 100:8 
2 NaHMDS 139 70% 100:12 
3 NaHMDS 139a 52% E only 
4 K2CO3 139 97% E only 
aUnpurified yield, compounds did not require purification; bYield following distillation 
 
Using the original conditions with sodium hydride (entry 1), the product was purified 
by distillation which was time-consuming due to the very high boiling point of the 
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product; at 3 mbar pressure, temperatures of over 200 ºC were required. Using sodium 
hexamethyldisilazide instead of sodium hydride as base, the unpurified product 
resulting from the reaction was much cleaner (entry 2), but a small amount of the Z-
isomer was visible. Moving to methyl diethylphosphonoacetate 139a (entry 3) it was 
reasoned that non-bonding interactions would give exclusively the E-isomer. Although 
this was the case, the yield of 140 obtained was only moderate (52%). Finally, using a 
procedure similar to that of Cordero,131 potassium carbonate in aqueous THF was 
employed and satisfyingly gave very pure samples of 140 in near quantitative yield 
(entry 4). 
 
Pleasingly, subsequent reductions on this material saw full conversion without trouble, 
resulting in a much improved yield; on a ~5 mmol scale, an 84% yield of 125 was 
achieved and when scaled up to ~50 mmol this was almost maintained, with a 78% 
yield observed. 
 
N
O
OMe
CO2Me
N
O
O
CO2Me
i) NaBH4, MeOH, 0 °C
ii) conc. HCl, rt
7884%140 125  
Scheme 52: Reduction/methylation of 140 to give methoxylactam 125  
 
 
3.2.2.2 Cyclisation and elimination  
 
Methoxy amides such as 125 have been shown to easily form N-acyliminium ions 
under acidic or Lewis acidic conditions and undergo subsequent inter- and 
intramolecular reactions.132 As such, it is proposed that the mechanism for the tin-
mediated cyclisation of 125 proceeds via an N-acyliminium intermediate (Scheme 53). 
Lewis acid catalysed removal of the methoxy group by tin(IV) chloride would furnish 
N-acyliminium ion 143. Conjugate addition of a chloride ion onto the ,-unsaturated 
ester would result in the enolate anion 144, which as a nucleophile would then trap the 
iminium ion to afford the product, 142. 
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Scheme 53: Proposed mechanism for the tin-mediated cyclisation 
 
In our hands, the cyclisation/elimination sequence proceeded to give 26‒28% yield of 
126 over the two steps, comparable to the literature yield of 27%.100 Thus far, the 
cyclisation and elimination were the least fruitful steps in this route and therefore 
required some optimisation. A number of alternative Lewis acids were tried in the 
hope of increasing yields, including tin(IV) bromide, tin(II) bromide, zinc(II) chloride 
and tin(II) chloride dihydrate (previously been used in the Taylor group for Lewis 
acid-mediated cyclisation reactions133), but none of these served to improve the 
reaction (Scheme 54). In most cases, the only compounds observed were starting 
material or what appeared by NMR spectroscopic analysis to be nucleophilic 
displacement of the methoxy group by the anion of the Lewis acid.  
 
N
O
OMe
CO2Me
N
O CO2Me
X
SnCl22H2O, CH2Cl2, rt or
125 X = Cl (142)
X = Br (142a)
SnBr4, SnBr2 or ZnCl2, DCE, 70 °C
 
Scheme 54: Alternative Lewis acids for cyclisation 
 
We wished to investigate the use of dichloromethane as a cheaper and less toxic 
alternative to dichloroethane for the reaction solvent. Pleasingly, performing the 
cyclisation reaction in CH2Cl2 at 40 °C resulted in a comparable yield to that seen in 
DCE, albeit requiring a longer reaction time (64 h compared to 40 h). The dilution of 
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the reaction was also increased in order to reduce the possibilty of undesired 
polymerisation by means of intermolecular reaction of the reactive intermediate. Under 
these conditions, reactions on a 10‒20 mmol scale consistently gave 29‒36% yield of 126 
over the two steps (Scheme 55). 
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CO2Me
N
O CO2Me
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SnCl4, CH2Cl2 (0.050.08 M)
125 142
40 °C, 64 h
126
DBU, THF
60 °C, 24 h
2936% (2 steps)
N
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Scheme 55: SnCl4 cyclisation in CH2Cl2 followed by elimination 
 
Although a marginal improvement in the yield for the cyclisation had been achieved, 
we still wished to investigate other methods. A patent by Eli Lilly and Co. describes a 
procedure using DMSO to remove tin(IV) chloride from waste streams by forming an 
SnCl4∙2DMSO complex which is insoluble in a range of alcoholic and hydrocarbon 
solvents.134 It was hence envisioned that DMSO could be used to quench the tin salts in 
the cyclisation reaction as an alternative work-up procedure, which could improve the 
mass recovery and, consequently, the yield of the reaction. First, however, it was 
necessary to check that the complex was not soluble in dichloromethane, the reaction 
solvent. When two equivalents of DMSO were added to a solution of SnCl4 in 
dichloromethane, a white solid immediately formed which could be filtered to leave a 
clear solution. 
 
The DMSO quench was next tested in the cyclisation reaction itself, where satisfyingly, 
a large amount of white complex precipitated out of solution. Unfortunately, a slight 
solubility in the reaction solvent meant that complete removal of the complex could not 
be easily achieved, which led to problems in the following step and as such, no 
improvement in yield was seen (Scheme 56). Nevertheless, the DMSO technique avoids 
the possibility of ester hydrolysis during work-up and is more facile than the previous 
NaOH quench, making it a practical option for larger scale synthesis. 
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i) SnCl4, CH2Cl2, reflux
Cl
ii) DMSO (2 eq), filter
N
O CO2Me
DBU, THF
29% over 2 steps
125
142 126  
Scheme 56: Incorporation of the DMSO quench for the cyclisation reaction 
 
 
3.2.2.3 Aza-Baylis‒Hillman reaction 
 
Finally, we chose to investigate the aza-Baylis‒Hillman reaction as an alternative way 
to improve the cyclisation/elimination sequence. The aza-Baylis-Hillman (ABH) 
reaction generally involves addition of a catalytic quanitity of a nucleophile onto a 
Michael acceptor, 136, and subsequent coupling of the -position with an imine of type 
145 to give adducts of type 147 (Scheme 57).135,136 
 
R H
N
R
Z
Z
R
NH
R
base/nuc
145
136
147  
Scheme 57: General scheme for the Aza-Bayliss-Hilman reaction 
 
It was reasoned that it should be possible to effect this transformation with an 
acyliminium ion as the electrophile, since it should be more reactive than an imine. 
Indeed, Aggarwal and co-workers demonstrated this using ethoxylactams 148 and 151 
with TMSOTf/BF3∙OEt2 to form the acyliminium ions and dimethyl sulfide as the 
nucleophile for the aza-Baylis‒Hillman reaction. Both inter- and intramolecular 
examples were reported (Scheme 58).137 
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Scheme 58: Aggarwal’s ABH reactions of an acyliminium ion 
 
Unfortunately, when we tried this procedure with methoxylactam 125, none of the 
desired product 126 was seen (Scheme 59). 
 
N
O
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CO2Me
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O CO2Me
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BF3OEt2
SMe2
CH3CN
125 126
 
Scheme 59: Attempt at Aggarwal’s ABH reaction with methoxylactam 125 
 
According to a review by Speckamp and Hiemstra, where the alkoxylactam bears an 
acetate or mesylate as a leaving group, no catalyst is required to form the acyliminium 
ion.132 It was therefore conceived that if an acetoxylactam 154 was formed in situ, it 
might be possible to achieve the synthesis of lactam 126, without having to go through 
compound 142, by effecting an aza-Baylis‒Hillman-type reaction with acyliminium ion 
143 (Scheme 60). 
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Scheme 60: Desired Aza-Baylis‒Hillman reaction 
 
The hydroxylactam 141 could be made by acid hydrolysis of methoxylactam 125 or 
from reduction of imide 140, using a non acidic work-up. Using the latter method gave 
141 in 33% yield (Scheme 61). Although the data for this compound does not fit with 
those reported in the literature,100 our evidence strongly suggests that the correct 
compound had been formed. In addition to mass spectrometry giving the correct mass 
for the sodium adduct, 1H NMR spectroscopy showed a clear coupling (J = 8.5 Hz) 
between the alcohol proton and the proton alpha to the nitrogen. When we previously 
attempted to make 141 using the conditions reported in the literature,100 instead only 
methoxylactam 125 was observed (vide supra, Scheme 51). This suggests that 
hydroxylactam 141 may not have been formed in the original paper. 
 
N
O
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CO2Me
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NaBH4, MeOH
125 141
0 °C, 2 h
then
aq. NaHCO3
33%
 
Scheme 61: Preparation of the hydroxylactam 141 
 
On attempting mesylation of this hydroxylactam, elimination of the resulting mesylate 
was seen and so no further attempts were made to prepare this compound. In contrast, 
the acetoxy compound 154 could be easily formed by treatment of hydroxylactam 141 
with acetic anhydride in the presence of base and catalytic DMAP, leading to a near 
quantitative yield based on mass recovery and 1H NMR analysis of the unpurified 
product. This compound was isolated for characterisation, although, it was inevitably 
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prone to hydrolysis back to the starting hydroxylactam 141, thus giving a low isolated 
yield following purification (Scheme 62).  
 
N
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CO2Me
N
O
OAc
CO2Me
Et3N, DMAP, Ac2O
CH2Cl2, 1.5 h
7%141 154  
Scheme 62: Formation of acetoxylactam 154 
 
Treatment of the reaction mixture containing acetoxylactam 154 with methanol led to 
formation of the methoxylactam 125, suggesting that 154 does indeed form the 
acyliminium ion 143 under the reaction conditions (Scheme 63). 
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Scheme 63: Formation of acetoxylactam 154 and acyliminium ion 143 
 
Although a number of attempts were made to effect the desired cyclisation using 
acetate 154, none were successful. DMAP has been shown to be an effective base in 
Aza-Baylis-Hillman reactions,136 and therefore it was conceived that heating the 
reaction vessel following acylation with DMAP still present should initiate the desired 
cyclisation. In some cases, additional Et3N and PPh3 were added as an alternative 
nucleophile, and the solvent was also replaced with THF or acetonitrile. However, 
unfortunately, no product 126 was ever observed. 
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Scheme 64: Failed attempts at an ABH reaction 
 
Given these difficulties we therefore continued using 126 prepared by the 
cyclisation/elimination method previously described (Scheme 55). 
 
 
3.2.2.4 Reduction 
 
The next step of the synthesis is the reduction of ester 126 to give alcohol 82. In Taber’s 
route,100 a modest yield of 44% is quoted for this reduction using DIBAL-H. In our 
hands, using this method, despite complete consumption of starting material only a 
15% yield of product was achieved following chromatography. It was believed that 
these low yields were a result of the work-up procedure. Therefore, a simplified work-
up was employed involving quenching with methanol and water followed by filtration 
of the resultant gel,138 which served to improve the yield for this step to 76% (Scheme 
65). The NMR spectroscopic data obtained for this compound were consistent with 
those given in the literature.100 
 
N
O CO2Me
126
i) DIBAL-H, THF, 78 °C
ii) MeOH, H2O, filter
N
OH
76% 82
 
Scheme 65: Reduction of 126 to alcohol 82 
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3.2.3 Oxidation of indolizidine alcohol 82 
 
With alcohol 82 in hand, it was time to try to incorporate our 
oxidation/allylation/oxidation/isomerisation methodology. We first tested the 
Dess‒Martin periodinane oxidation of 82, where unfortunately, the desired aldehyde 
156 appeared to have been formed, but only as one of a complex mixture of products 
(Table 12, entry 1). Initial attempts a one-pot oxidation/allylation/oxidation procedure 
from alcohol 82 to avoid isolation of the aldehyde resulted in a complex mixture and 
the desired unsaturated ketones 157 and 81 could not be identified (Scheme 66). 
 
N
OH
82
N
O
157
or N
O
1. DMP, CH2Cl2
2. 78, MK10
3. DMP
81  
Scheme 66: Failed attempt at an oxidation/allylation/oxidation procedure 
 
For the oxidation of 82 to 156, the literature describes the use of the Swern procedure, 
quoting a yield of 72% following column chromatography.100 In our hands, unpurified 
yields were variable, ranging from 73‒97% (Table 12, entry 2). Furthermore, the nature 
of the aldehyde and its potential limited stability, meant that it was preferable to take 
the unpurified material through without risking decomposition during purification. 
However, the unpurified residue obtained from work-up of the Swern reaction 
invariably contained some impurities. Thus, it was decided to investigate alternative 
oxidation procedures for this substrate. Buffering the Dess‒Martin periodinane with 
sodium bicarbonate or pyridine gave little to no improvement on the previous attempt; 
whilst some aldehyde appeared to have formed, the residues obtained were of 
insufficient purity (entries 3 and 4). Manganese dioxide showed a partial reaction after 
2 hours, but on trying to force complete conversion with higher temperatures or longer 
reaction times, the product was seen to decompose to polar material (entries 5‒7). The 
same was true with CrO2 (entry 8) and TPAP (entries 9 and 10). Parikh-Doering 
oxidation appeared to go cleanly by TLC analysis however no material was isolated as 
extraction from the aqueous layer proved fruitless (entry 11).  It was hence deemed 
that Swern oxidation (entry 2) was indeed the optimum procedure. 
 
  
Chapter 3 
 
 
66 
 
Table 12: Oxidation of the indolizidine alcohol 82 
N
O
N
OH
Oxidation
82 156  
Entry Oxidant Solvent Temperature Observations/yielda 
1 DMP CH2Cl2 rt Complex mixture 
2 (COCl)2/DMSO CH2Cl2 −78 °C to rt 73‒97% 
3 DMP/NaHCO3 CH2Cl2 rt 44% 
4 DMP/Py CH2Cl2 rt Complex mixture 
5 MnO2 CH2Cl2 rt Partial reaction, decomposed 
6 MnO2 CH2Cl2 reflux Partial reaction, decomposed 
7 MnO2 PhMe reflux Partial reaction, decomposed 
8 CrO2  PhMe rt Partial reaction, decomposed 
9 TPAP/O2 CH2Cl2 rt Partial reaction, decomposed 
10 TPAP/NMO CH2Cl2 rt Partial reaction, decomposed 
11 SO3∙Py/DMSO CH2Cl2 rt No material isolated 
aUnpurified yield, based on mass recovery and 1H NMR analysis of the unpurified reaction 
mixture; bCrO2 is also known as magtrieveTM 
 
 
3.2.4 Allylation and oxidation of indolizidine aldehyde 156 
 
In order to allylate and oxidise the aldehyde, we wanted to use the conditions from our 
allylation/oxidation methodology (Scheme 67). 
 
N
O
156
N
OH
158
BF3K
N
O
157
MK10, AcOH
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78
 
Scheme 67: Desired allylation/oxidation procedure 
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Aldehyde 156 was subjected to the allylation conditions using potassium 
allyltrifluoroborate (78) and montmorillonite K10, although only 2 eq. of acetic acid 
were added due to the sensitivity of the substrate. On consumption of the starting 
material, Dess‒Martin periodinane was added to the reaction mixture and stirred for 
one hour. Reasonable mass recovery was seen following work-up, but it appeared that 
the desired product 157 had not been formed, as the alkene peaks visible in the 
1H NMR spectrum were not as expected. Further analysis revealed that in fact the ,-
unsaturated ketone 157 had isomerised to the ,-unsaturated ketone 81 under the 
reaction conditions (Scheme 68). Disappointingly, a large loss of product was seen 
following purification by column chromatography, yielding only 7% of 81 from 
aldehyde 156.  
 
N
O
N
O
MK10, AcOH (2 eq)
then DMP
7%
BF3K
156 81  
Scheme 68: Formation of dienone 81 
 
It was decided to first look at optimising the individual steps for this substrate, starting 
with the allylation. Using water instead of acetic acid with the montmorillonite K10 
clay, as per the original publication,74 a 38% yield of 158 was achieved following 
purification (Table 13, entry 1). BF3∙OEt2 allylation gave a poor yield of 16% (entry 2). 
Montmorillonite K10 with two equivalents of acetic acid gave material that was 
sufficiently pure to take on without chromatography, with a 48% unpurified yield 
(entry 3). It was thought that the relatively low mass recovery observed in each case 
may be due to the water solubility of the product and so a non-aqueous work-up was 
tested on the MK10/H2O system, whereby a simple filtration through silica was 
performed. This resulted in a slightly improved 45% yield following purification (entry 
4). 
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Table 13: Allylation of the indolizidine aldehyde 156 
N
O
156
N
OH
158
BF3K
Conditions
 
Entry Catalyst system Work-up used Yield (%)a 
1 MK10/H2O Aqueous 38 
2 BF3∙OEt2 Aqueous 16 
3 MK10/AcOH Aqueous 48b  
4 MK10/H2O Non-aqueous filtration 45 
a Isolated yield following column chromatography; b Unpurified yield 
 
This demonstrated that the allylation could be performed in either acetic acid or water, 
both giving moderate yields. Given that the allylation step on its own proceeded well 
in acetic acid, it would appear that the DMP oxidation was the problematic step in the 
allylation/oxidation procedure detailed previously in Scheme 68. Our efforts now 
turned to investigating alternative oxidation procedures which are outlined in Table 
14. 
 
Table 14: Oxidation of the indolizidine allylic alcohol 158 
N
OH
158
N
O
81
Oxidation
 
Entry Oxidation system Observations/yielda 
1 PCC Complex mixture of products 
2 MnO2 No reaction 
3 TPAP/O2  No reaction 
4 Buffered DMP Non-aqueous work-up, no product seen 
5 Swern  26% 
a Isolated yield following purification 
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Dess‒Martin periodinane buffered with sodium bicarbonate offered no improvement 
to the previous procedure. In this case, a simple filtration was employed as work-up in 
case water solubility was an issue but no product was observed in the 1H NMR 
spectrum of the unpurified material. Pyridinium chlorochromate, manganese dioxide 
and TPAP/O2 showed no reaction. The standard Swern procedure offered the best 
result, with complete conversion of starting material seen by TLC and NMR 
spectroscopic analysis. However, only a 26% yield of dienone 81 was obtained; the low 
yield of the reaction may be partly attributed to difficulties in purification of the polar 
dienone. 
 
In view of the disappointing yields observed with the oxidation/allylation/oxidation 
approach to dienone 81, other routes were investigated. 
 
 
3.2.5 Alternative routes to dienone 81 
 
As an alternative to the allylation/oxidation approach, different routes from aldehyde 
156 to enone 81 were probed (Scheme 69). 
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Scheme 69: Possible alternatives to the allylation/oxidation approach 
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Since Route B involves the same oxidation step that had caused problems with the 
previous approach, and Route A involves a very similar oxidation of 159 to 81, the 
most promising of these possibilities was Route C, which utilises Nicolaou’s IBX 
oxidation to transform elaeokanine B (89) into the desired dienone 81.35 
 
Grignard addition of propylmagnesium chloride to 156, to give 89, was achieved in a 
moderate 24% yield (Scheme 70). The subsequent IBX oxidation, however, proved 
highly problematic. Whilst the reaction appeared successful, with complete 
consumption of starting material and apparent appearance of dienone 81 observed by 
TLC analysis, extraction of the product from the DMSO was less successful. 
 
N
O
N
O
ClMg
N
OH
IBX
DMSO/fluorobenzene
80 °C, 18 h
158 8189
THF, 10 °C to rt
24%
 
Scheme 70: Attempted IBX oxidation 
 
Following the published work-up procedure,35 no product was extracted into the 
organic layer. Treatment of the aqueous layer with 4 M NaOH did not aid this, and 
further extractions with dichloromethane, chloroform and ethyl acetate also failed to 
yield any product. Extraction with butan-2-ol served only to isolate the DMSO and 
unreacted IBX. 
 
The reaction was repeated in deuterated DMSO in order to verify by NMR analysis 
whether the reaction had been successful. Once the fluorobenzene had been removed 
in vacuo, a 1H NMR spectrum of the unpurified reaction mixture was obtained but 
disappointingly, none of the desired product 81 was visible. The starting material 
appeared to have been consumed and whilst IBX was clearly present, no other 
products could be identified. 
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3.2.5.1 The Meyer‒Schuster reaction 
 
Due to the limited success with the oxidation/allylation/oxidation procedure, an 
initial investigation was made into the Meyer‒Schuster reaction as an alternative 
method for installing the enone moiety. The Meyer‒Schuster reaction is the re-
arrangement of a propargylic alcohol into an enone whereby the placement of the 
unsaturation and oxygen functionality are reversed (Scheme 71).139  
 
R1
OH
R
R2
R
R1 O
R2
160 161  
Scheme 71: General scheme for the Meyer‒Schuster rearrangement 
 
Retrosynthetically, for our desired compound 81 this would take us back to 162, which 
could in turn be synthesised by Sonogashira coupling of 163 and 164, using a vinyl 
halide or triflate 163 as an alternative handle for the indolizidine core (Scheme 72).  
 
N
OTf/X
N
HO
N
O
+
OH
81 162 163 164  
Scheme 72: Retrosynthetic analysis using the Meyer-Schuster reaction as a key step 
 
A test substrate for the Meyer‒Schuster reaction was prepared by deprotonation of 
phenylacetylene (165) with n-BuLi and subsequent addition of acetaldehyde, which 
provided propargylic alcohol 166 in 68% yield (Scheme 73).  
 
MeH
O
Me
OH
Ph
Ph
n-BuLi,
THF, 78 °C
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Scheme 73: Formation of propargylic alcohol 166 
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To our disappointment, none of the literature conditions attempted gave any 
rearrangement, including scandium triflate in either ethanol or dichloromethane,139 
sulfuric acid in aqueous acetone, 140 or p-TSA in ethanol at reflux (Scheme 74).141  
 
Me
OH
Ph
Ph
O
Me
166 167
Sc(OTf)3, EtOH or CH2Cl2, rt
or
H2SO4, aq. acetone, reflux
or
PTSA, EtOH, reflux
 
Scheme 74: Failed Meyer‒Schuster reactions 
 
 
3.2.6 Ammonia Cyclisation 
 
With a small quantity of dienone 81 in hand, obtained from the previous 
oxidation/allylation/oxidation chemistry, the final step in the synthesis was the 
ammonia cyclisation. The dienone was treated with 35% aqueous ammonia in 
methanol and allowed to stir for 16 h (Scheme 75). TLC analysis showed complete 
consumption of starting material 81 whilst 1H NMR spectroscopic analysis of the 
unpurified product revealed that both the double bonds were no longer present and 
doublets corresponding to the methyl groups were clearly visible. This evidence 
suggested that a mixture of elaeokanidine A (19) and its diastereomers 19a‒c had been 
formed; this was confirmed by HRMS ([MH]+ 209.1654) but unfortunately, no further 
information could be obtained by NMR spectroscopic analysis and attempts at 
separating the mixture by flash column chromatography were unsuccessful. Due to 
lack of material and time, this concluded the work on the racemic synthesis of 
elaeokanidine A (19). 
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Scheme 75: Ammonia cyclisation with possible products (relative stereochemistry shown) 
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3.2.7 Summary of racemic route 
 
Following optimisation of the various steps, our racemic route to the indolizidine core 
of elaeokanidine A, and subsequent completion of the synthesis to give an inseparable 
mixture of diastereoisomers, is summarised in Scheme 76. 
NH
O
O
(a)
N
O
O
O
N
OMe
O
CO2Me
N
O CO2Me
(d)
(e)
2936%
(2 steps)
(f)
76%
N
OH
N
O
O
CO2Me
97% over 2 steps
(c)
84%
N
O CO2Me
Cl
137 138
140 125
142 126 82
N
O
(g)
73-97% (crude)
156
N
OH
158
BF3K
(h)
45%
N
O
81
P
O
OO
MeO
MeO
139
N
O
N
H
H
H
(i)
26%
(b)
(j)
80%
elaeokanidine A (19) +
diastereoisomers 19ac
(racemic)
  
Reagents and conditions: (a) Na, acrolein (75), EtOH, rt, 3 h; (b) K2CO3, THF, H2O, rt, 16 h; 
(c) i) NaBH4, MeOH, 0 °C to rt, 1 h; ii) conc. HCl; (d) SnCl4, CH2Cl2, 40 °C, 64 h; (e) DBU, THF, 
60 °C, 24 h; (f) DIBAL-H, THF, −78 °C, 1 h; (g) (COCl)2, DMSO, Et3N, CH2Cl2, −78 °C to rt, 2 h; 
(h) MK10/H2O, CH2Cl2, rt, 30 min; (i) (COCl)2, DMSO, Et3N, CH2Cl2, −78 °C to rt, 30 min; 
(j) 35% aq. NH3, MeOH, 16 h. 
Scheme 76: Progress towards the synthesis of elaeokanidine A 
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3.2.8 Further work 
 
At a similar time to this work, James Cuthbertson was working on the synthesis of the 
alkaloids grandisine B (94) and grandisine D (95). As part of this project, an alkyne-
acetal cyclisation methodology to gain access to ,-unsaturated carbonyls was 
developed, the utility of which was demonstrated in the construction of an indolizidine 
framework for the synthesis of grandisines B and D.142,143 This procedure was 
subsequently applied to the asymmetric synthesis of elaeokanidine A, using proline-
derived alkyne 168 as a common intermediate.  
 
Deprotonation of the alkyne followed by quenching with S-phenyl 
benzenethiosulfonate provided thiol 169, which was then subjected to the cyclisation 
conditions. Stirring in formic acid at reflux afforded thioester 170 in 69% over the two 
steps, having formed the key indolizidine core. This was followed by a Liebeskind-
Srogl coupling with boronic acid 171 to give enantiomerically pure dienone 81 in 43% 
yield (Scheme 77). 
 
N
EtO OEt
N
EtO OEt
SPh
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O
SPh
H
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O
H
1. n-BuLi,78 °C
2. PhS-SO2Ph
HCO2H
neat, reflux
69% (2 steps)
B(OH)2
Pd2(dba)3, CuTC,
P(OEt)3, THF
69%
171
168 169
170 81
 
Scheme 77: Asymmetric route to dienone 81 
 
On treatment with aqueous ammonia, as in the racemic series, an inseparable mixture 
of compounds was formed, thought to be elaeokanidine A and its diastereoisomers. 
These are likely to include elaeokanidines B and C, whose relative stereochemistry are 
unknown. Although complete separation of the diastereoisomers could not be 
achieved by chromatography, a sample enriched in elaeokanidine A (19) was obtained, 
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the identity of which was confirmed by comparison to the isolation data and NOE 
studies (Figure 11).88  
 
N
O
N
H
H
H
H
19  
 
 
    NOE correlations 
Figure 11: Structure and NOE correlations of elaeokanidine A (19) 
 
Unfortunately the sample obtained was not of sufficient purity to obtain an optical 
rotation measurement in order to determine the absolute stereochemistry of the natural 
product. Further work to completely separate the diastereoisomers is thus required. 
The work detailed in this section was published in Cuthbertson’s PhD thesis.144  
 
 
3.3 Summary and future work 
 
N
O
N
H
19
N
O
N OH
81 82
H
H
H
H
H
 
 
Good progress was made following Pohmakotr’s route towards 82 however this was 
halted by a lack of reproducibility with the cyclisation step. Following Taber’s 
synthesis, the route to 82 has been repeated several times and each step has been 
optimised, providing an improved racemic synthesis of the indolizidine core. 
Application of the oxidation/allylation/oxidation/isomerisation methodology to this 
alcohol was not as successful as we had anticipated, however alternative conditions 
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have been investigated for the preparation of racemic 81 and the subsequent addition 
of ammonia was demonstrated.  
 
Further work by Cuthbertson successfully established a proline-derived asymmetric 
synthesis of dienone 81, making use of an alkyne-acetal cyclisation reaction. Following 
addition of ammonia to provide a mixture of diastereoisomers, a sample enriched in 
elaeokanidine A was obtained, however, the purity of the sample was not sufficient to 
record an optical rotation, thus the absolute stereochemistry of the alkaloid cannot be 
confirmed at this stage. 
 
Further studies will investigate alternative methods for separation of the isomeric 
alkaloids in order to obtain pure samples of elaeokanidine A along with its isomers for 
full characterisation. 
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Chapter 4 – Copper(II)-catalysed formation of spirooxindoles 
4.1 Introduction to oxindoles and spirooxindoles 
 
Oxindole (171) is a bicyclic aromatic heterocycle with a benzene ring fused to a 
pyrrolidinone (Figure 12), and is structurally related to the naturally occurring 
compound isatin (172).  Structurally more complex 3,3-disubstituted oxindoles 173 are 
common in nature and as a consequence, are of great interest to synthetic chemists. For 
example, many stereoselective methods for the formation of 3,3-disubstituted 
oxindoles have been developed, such as the enantioselective hydroxyamination,145,146 or 
fluorination of 3-oxindoles,147 as well as the conjugate addition of oxindoles to Michael 
acceptors,148-150 and asymmetric decarboxylative allylation.151  
 
N
H
O
N
H
O
R
R'
171 173
N
H
O
172
O
N
H
O
174
 
Figure 12: Oxindole compounds 
 
Both oxindoles 171 and spirooxindoles 174 are important motifs in organic and 
medicinal chemistry, not only because they possess a structurally interesting 
framework, but also owing to the biological activity that many of these compounds 
exhibit. As a result, over recent years, much effort has been devoted to developing 
innovative ways to synthesise these structures rapidly and efficiently.152-155    
 
Spirooxindoles 174 are a class of oxindole with a 3,3-spirocyclic junction. These 
compounds are extremely common in nature as part of natural products as well as 
many synthetic drugs.152 
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4.2 Important spirooxindole compounds 
 
Compounds containing the spirooxindole motif frequently display a range of 
interesting biological activities, whether these be naturally occurring molecules or 
medicinally relevant analogues.152 As well as several other classes of bioactive oxindole 
structures, a large number of pyrrolidine-containing spirocyclic oxindole natural 
products exist, and these have been the subject of much investigation in recent 
years.152,154 An example of such a natural product is the analgesic horsfiline (175), 
which was isolated from the plant Horsfieldia superba,156 and has already succumbed to 
a number of total syntheses.157-164 Structural relatives of horsfiline (175) such as 
coerulescine (176),165 and elacomine (177),152,166 have also been studied in great detail 
(Figure 13).  
 
N
H
O
O
N
()-horsfiline (175)
N
H
O
NH
(+)-elacomine (177)
HON
H
O
N
()-coerulescine (176)  
 
Figure 13: Horsfiline (175) and related natural products 
 
Extracts from the leaves of Alangium javanicum, collected in Malaysian Borneo, were 
found to induce Cu2+-dependent DNA strand scission,167,168 and this property was 
attributed to the indole glycoside javaniside as the active component (178). DNA 
cleavage may be an important process in the treatment of cellular disorders and 
javaniside is therefore a potentially useful lead compound in the development of novel 
drugs for the therapy of cancer and certain other diseases.167,168 
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As a further example, spirotryprostatins A and B (22 and 180) were isolated in 1996 
and have since been synthesised numerous times due to their interesting structure and 
biological profiles as mammalian cell cycle inhibitors (Figure 14).  
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Figure 14: Spirotryprostatins A (22) and B (180) 
 
In addition to natural products themselves, their analogues, as well as compounds 
inspired by natural product structures, are often developed as potential drug 
molecules. For instance, Wang and co-workers used a rational structure-based design 
in the discovery of a potent MDM2-binding compound 181 (Figure 15).169 MDM2 is 
known to interact with the tumour suppressor protein p53, and thus the nature of this 
interaction was the basis for drug design. The oxindole core of 181 closely mimics the 
indole of tryptophan, the amino acid residue of p53 identified as being the most critical 
for protein binding. Two other important residues, phenylalanine and leucine, are 
mimicked by the phenyl ring and the tert-butyl group respectively, with the 
pyrrolidine ring providing a rigid backbone for the compound. The molecular 
architecture of this drug is indeed reminiscent of the spirotryprostatin structure. 
 
A range of structurally similar compounds were prepared by Waldmann’s group, one 
of which, 182, was submitted for biological evaluation and found to interfere with 
microtubule polymerisation, ultimately leading to incomplete cell division (Figure 
15).170 It therefore has potential use in cancer therapy. The Proctor group have also 
been developing a samarium-mediated route to spirotryprostatin-inspired molecules 
(e.g., 183) which are currently undergoing biological evaluation (Figure 15).171 
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Figure 15: Potential spirooxindole drug candidates 
 
We were ourselves also interested in the spirotryprostatin natural product family and 
our work in the area will be discussed in Chapter 5. 
 
Given the evident abundance and importance of spirocyclic oxindoles, the following 
section focuses on the synthetic methods towards these structural units. 
 
4.3 Current methods for spirooxindole formation 
 
A large number of spirooxindole natural products have been isolated over the years, 
with more and more coming to light as time progresses.172 As such, interest in this field 
has grown, resulting in vast arrays of publications in recent literature for the 
construction of spirooxindole structures.154 Given recent reviews in this area, only 
publications post-2010 will be discussed. 
 
4.3.1 Isatin-derived methods 
 
Many of the methods for spirooxindole formation focus on the derivatization of isatin 
(172), a naturally occurring molecule and in recent literature, multiple procedures were 
unveiled for using isatin-type molecules to create spirooxindole scaffolds. 
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Several of these protocols involve cycloaddition reactions, such as the Diels‒Alder 
reaction,173 and dipolar cycloadditions,174,175 and frequently involve the use of 
azomethine ylides.176,177 For instance, Bhati and co-workers used isatin-derived 
molecules 184 as a starting point for making azomethine ylides 186, which then 
underwent a [3+2]-dipolar cycloaddition with alkene 187 to yield complex 
spirooxindoles 188 with very high regioselectivity (Scheme 78).178 A very similar 
procedure was used by Das et al. in the synthesis of sugar-based pyrrolidine 
spirooxindoles 190 (Scheme 78).179  
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Scheme 78: Spirocyclic oxindole formation via azomethine ylides 
 
Numerous multicomponent reactions for the synthesis of drug-like molecules have 
also been reported.180-184 For example, Perumal and co-workers developed a 
4-component synthesis of spiro-dihydropyridines 197 (Scheme 79).180 The proposed 
mechanism is that an initial reaction of amine 191 and alkyne 192 forms zwitterion 193 
and is followed by a 1,4-addition to Michael acceptor 195, formed by Knoevenagel 
condensation of isatin (172) and 194. Intramolecular cyclisation of 196 and 
tautomerization then forms the product 197. 
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Scheme 79: Perumal’s multicomponent approach to spirooxindoles 
 
Shi and co-workers have demonstrated a process using tin dichloride, whereby a 
tandem reduction/cyclisation mechanism is proposed (Scheme 80). The tin(II) first 
reduces the nitro group of 198 to an amine 199, then activates isatin (172) ready for 
attack. Cyclisation then occurs via an acetal-type mechanism to give the product 201.185 
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Scheme 80: Shi’s tin(II) dichloride reduction/cyclisation 
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A number of asymmetric isatin-derived reactions towards spirooxindoles have also 
been reported. For example, Bencivenni and co-workers performed a Pictet-Spengler 
reaction of tryptamines with isatins, using a BINOL-derived chiral phosphoric acid 
catalyst to form a range of spirooxindoles in good yields and enantioselectivities.186 
Wang and co-workers performed an asymmetric Henry reaction of isatin (172) with 
nitromethane in the presence of a chiral organocatalyst cupreine (hydroxycinchonine) 
(204) to form 3,3-disubstituted oxindole 202 which, after further manipulation, was 
cyclised to give the natural product (S)-(‒)-spirobrassinin (203) in high 
enantioselectivity following recrystallisation (Scheme 81).187  
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Scheme 81: Wang’s synthesis of (S)-(‒)-spirobrassinin 
 
 
4.3.2 Other methods from oxindoles 
 
In addition to isatin-derived methods, many methods for the formation of 
spirooxindoles involve manipulation of precursors which already contain the core 
oxindole structure, such as 3-substituted-oxindoles 205, 3-alkenyl-oxindoles 206, or 
indeed unsubstituted oxindole itself (171) (Figure 16).188 
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Figure 16: Oxindole compounds utilised for spirooxindole formation 
 
Wang and co-workers performed a double Michael addition of unfunctionalised 
oxindole 207 to a variety of symmetric dienones 208 using a cinchona-based catalyst to 
provide product 209 with good to excellent enantioselectivity (Scheme 82).189 
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Scheme 82: Wang’s asymmetric double Michael addition 
 
Daïch et al. synthesised spiro--lactam oxindoles 212 from -bromoacetamides 211 and 
methylene oxindoles 210 via an aza-Michael-initiated ring closure (Scheme 83).190 As 
such, a variety of pyrrolidinone spirooxindole products 212 were obtained in moderate 
to good yields and a range of diastereoselectivities. Wang and co-workers have also 
used a similar Michael addition/cyclisation approach with isothiocyanato imides as 
the coupling partner, forming 3,3-thiopyrrolidinyl spirooxindole compounds.191   
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Scheme 83: Daïch’s aza-Michael-initiated ring closure 
 
The Shao group have published two routes for constructing 
spirocyclopentaneoxindoles from 3-allyloxindoles 213, both using the same 
bifunctional thiourea catalyst 218 (Scheme 84).192,193  
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Scheme 84: Shao’s routes to spirocyclopentaneoxindoles 
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Route A involves an organocatalysed Michael addition of 214, followed by an 
intramolecular silyl nitronate-olefin cycloaddition/fragmentation sequence.192 Route B 
begins with a cross metathesis with 216, followed by two consecutive Michael 
additions.193 Both procedures form products 215 and 217 in very good yield with 
excellent diastereo- and enantioselectivity. Similar products have also been obtained by 
Barbas III et al. using an organocatalysed Michael/Henry cascade reaction.194 
 
Electron-poor alkenes of type 219 are also useful substrates for spirocycle formation 
and could be utilised in a number of processes.195 In this context, Shi and co-workers 
demonstrated this in the formation of spirocyclopenteneoxindoles 221 via a 
[3+2]-cycloaddition with Morita‒Baylis‒Hillman adducts of type 220 to give product in 
good yield and often excellent diastereoselectivity (Scheme 85).196  
 
N
NC
CN
O
Ph
O
N
H
O
CN
CN
PhO
·
CO2Et
N
O
CN
CNEtO2C
Ph3P
N
O
CN
CN
EtO2C
Ar
Ar
OBoc
CO2Et
PPh3 or dppb
quinidine-derived
catalyst
Bn
toluene, rttoluene, rt
74%
15 examples
69 to >99% yield
2:1 to >99:1 dr
DCE, 80 °C
N
H
NC
CN
O
11 examples
8899%
96:4 to >99:1 dr
97 to >99% ee
R R
219
220
221
222
223
224
225
226
Bn Bn
 
Scheme 85: Spirocycle formation from electron-poor alkenes 
 
Almost concomitantly, an enantioselective version of this type of reaction was shown 
by Lu,197 and Barbas III has also published a stereoselective variant using similar 
substrates.198 An alternative cycloaddition strategy was also employed by Jia and co-
workers,199 which made use of allene substrate 222 to give spirocyclopenteneoxindoles 
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223 with contrasting regiochemistry to that in products 221 (Scheme 85). Finally, Wang 
and coworkers used alkenes of type 224 as substrates for an organocatalytic double 
Michael addition protocol, giving rise to cyclohexanone products 226 with excellent 
yields, diastereoselectivity and enantioselectivity (Scheme 85).200  
 
Jørgensen and co-workers have developed an asymmetric organocatalytic Diels-Alder 
reaction of 3-alkenyl-oxindoles 227 to form cyclohexene-spirooxindoles 230 via a 
trienamine intermediate (Scheme 86).201  
 
N
O
EtO2C
Boc
N
O
Boc
CO2Et
OHC
92%, 98% ee
O
N
H OTES
Ph
Ph
N
H
N
O
Boc
CO2Et
HN
93%, 97% ee, >99:1 dr
NH HN
HN
S S
NH
Ar Ar
Ar = 3,5-(CF3)2-C4H3
(20 mol%)
o-fluorobenzoic acid (20 mol%)
CHCl3
227
228
229
230
231
232
233
 
 
Scheme 86: Organocatalytic Diels-Alder approaches to spirooxindoles 
 
A very similar protocol was utilised by Melchiorre and co-workers, employing the 
same proline-derived organocatalyst 228 but with 2-methylindole‒based substrates.202 
A Diels‒Alder approach using similar oxindole substrates (e.g., 227) has also been 
developed by Barbas III and co-workers, employing a dithiourea organocatalyst 232, 
and using 3-vinylindole (231) as the diene couple partner (Scheme 86). Not only were 
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products of type 233 obtained in high yields and enantioselectivity, but 
diastereoselectivity was excellent in all cases.203 
 
Another important and well-established method for the construction of 
spiropyrrolidine oxindoles is that of Carreira’s cyclopropane ring expansion. Using 
magnesium iodide as a bifunctional catalyst, cyclopropane oxindoles of type 234 can be 
reacted with a range of imines 235, forming products of type 236 in both high yield and 
diastereoselectivity (Scheme 87).152 This procedure was effectively utilised in the 
synthesis of indole alkaloids horsfiline,163 strychnofoline,204 and spirotryprostatin 
B.205,206 
 
N
Bn
O +
N
R
R1
N
Bn
O
N
R1
R
5598%
80:20 to 91:9 dr
MgI2 (10 mol%)
THF, 80 °C,
sealed tube
R = allyl,Bu
R1 = Et, iPr, Ph
R,R1 = [CH2]4
234 235
236
 
Scheme 87: Carreira’s cyclopropane ring expansion 
 
 
4.3.3 Methods from linear substrates 
 
Although the above procedures are undoubtedly synthetically useful, they focus on the 
functionalisation of intermediates derived from cyclic oxindoles or isatin. Whilst isatin-
derived methods make good use of a naturally occurring scaffold, one drawback is the 
lack of functionality on the aromatic ring, a feature which is desired or required for 
several natural products and drug molecules. In contrast, and of direct relevance to this 
project, is the synthesis of spirooxindoles by means of the cyclisation of linear 
precursors, and these methods are discussed in the following section. 
 
Several methods for the preparation of spirocyclic oxindoles from linear substrates 
have been developed. In 2004, Baldwin and Mao published an efficient route to 
spirooxindoles via a hetero-Claisen rearrangement, starting from a hydroxylamine 237 
and a carboxylic acid 238.  In this particular case, DCC coupling enabled access to the 
acylated carbamate 239, whereas subsequent formation of the enolate of 239 led to a 
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[3,3]-sigmatropic rearrangement as the key feature of this method. Finally, 
lactamisation yielded the spirooxindole 241 in excellent overall yield (Scheme 88).207  
 
N
MeO2C OH
+
CO2H N
MeO2C O
O
DCC, DMAP
85%
NH
MeO2C
CO2H N
OMeO2C
KHMDS, THF, 78 °C
82%
NaOAc, Ac2O, 65 °C
88%
237 238 239
240 241
 
 
Scheme 88: Baldwin’s hetero-Claisen approach to spirocyclic oxindoles 
 
More recently, Jiang and co-workers have used copper(II) as a Lewis acid catalyst in a 
tandem dearomatisation/intramolecular Friedel‒Crafts reaction of 242 for the 
formation of spirofurooxindoles 244 (Scheme 89).208  
 
N
R
O
O
Ar
HO
CuSO45H2O (1.5 eq)
N
R
O
OAr
NO
ROAr
FriedelCrafts
AcOH (0.1 eq)
toluene, 100 °C
Acid
242
243
244
 
Scheme 89: Jiang’s tandem dearomatisation/intramolecular Friedel‒Crafts reaction 
 
Several palladium-mediated processes towards spirocyclic oxindoles are also 
known,209,210 including Schönhaber and Müller’s Diels‒Alder domino cascade,211 and 
Takemoto’s intramolecular carbosilylation.212  
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4.4 Metal-mediated cyclisation reactions 
 
Of particular importance is the palladium-mediated cyclisation of linear precursors 
towards oxindoles. These methods are by far the most established means of entry to 
oxindoles.155 For example, the palladium-catalysed amination and amidation reactions 
of aryl halides, as developed by Buchwald and Hartwig, have been known for many 
years.213,214 An intramolecular variant of this reaction can be utilised for the 
construction of oxindoles, as shown in Scheme 90. Zhu and co-workers used a 4-
component Ugi reaction followed by intramolecular Buchwald‒Hartwig amidation of 
248 under microwave irradiation to rapidly access a diverse range of 3-substituted 
oxindoles 250 in good to excellent yield.215 
 
I
N
R
O
R3
H
N
O
R4
Pd(dba)2 (5 mol%)
K2CO3 (2 eq)
PhMe/MeCN (1:1)

PCy2
Me
N
R4
N R
R3
O
O
13 examples
6099%
(2 steps)
I
O
R2R
1 NH2
R2
+
R3 OH
O
+ R4 NC+
(5 mol%)
MeOH, rt
64245
246
248 249 250
247
R2
 
Scheme 90: Zhu’s Ugi/intramolecular Buchwald‒Hartwig amidation sequence to form oxindoles 
 
In 1998, Hartwig’s group demonstrated an alternative to this reaction, using the -
arylation of anilides 251 to form oxindoles of type 252.216 This procedure was later 
improved by the group with use of a different ligand (Scheme 91), including an 
asymmetric variant.217 Since then, a large number of enantioselective variants with 
chiral ligands for palladium have been reported.218 
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N
O
R
R1
N
O
R1RPd(OAc)2 (5 mol %)
PCy3 (5 mol%)
tBuONa (1.5 eq)
Br
R,R1 = H/alkyl/aryl
16 examples
1099% yield
251 252  
Scheme 91: Hartwig’s -arylation of anilides 
 
Whilst useful, these reactions have the disadvantage of requiring pre-functionalised 
anilides (e.g., aryl iodide or bromide) and often utilise expensive ligands for palladium. 
 
 
4.4.1 Copper(II)-mediated cyclisation reactions 
 
In 2009, Kündig’s group reported a new method using non-prefunctionalised aryl 
substrates 253 and enabled cyclisation mediated by copper(II) chloride instead of the 
more expensive palladium.219 The main drawbacks of this method were that the use of 
a stoichiometric amount of oxidant, a large excess of a strong base, and 
anhydrous/inert conditions were required. In addition, substrate scope was limited to 
having an aromatic group in the 3-position (Scheme 92). 
 
N
O
Ar
N
3
O
ArRCuCl2 (2.2 eq)
tBuONa (5.0 eq)
DMF, 110 °C
R = alkyl
13 examples
4297% yield
324 h253 254  
Scheme 92: Kündig’s copper-mediated cyclisation 
 
Almost concomitantly, the Taylor group reported a copper(II)-mediated cyclisation of 
unfunctionalised linear precursors 255 to form 3,3-disubstituted oxindoles,220 but in 
contrast to Kündig’s method, the reaction could now proceed without the use of excess 
base in wet solvent. An electron-withdrawing group, such as ester, nitrile or 
phosphonate was key to the success of this reaction and enabled rapid access to 
products 256 in good yield (Scheme 93).  
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N
O
EWG
R
N
O
EWGR
KOtBu (1.1 eq),
DMF, 110 °C
1 h
R = aliphatic
4 examples
7698% yield
Cu(OAc)2H2O (1.0 eq)
255 256
 
Scheme 93: Taylor’s stoichiometric copper(II) cyclisation 
 
This reaction process was subsequently much improved, negating the need for a base, 
by using just catalytic amounts of inexpensive copper(II) acetate monohydrate at 
elevated temperatures under an air atmosphere (Scheme 94).221 
 
N
R1
O
EWG
R
N
O
EWGR
R1
Cu(OAc)2H2O (5 mol%)
mesitylene, 165 °C, air
R = aliphatic
R1 = Me or Bn
14 examples
5392% yield
255a 256a  
Scheme 94: Taylor’s catalytic Cu(II) cyclisation procedure 
 
 
4.4.2 Proposed mechanism of Cu(II) cyclisation reactions 
 
It is believed that the mechanism for the copper(II)-mediated cyclisation is radical-
based,219 which was further corroborated by the use of a cyclopropane radical probe.68 
In the case of the catalytic procedure, the enolate 257 is presumably formed by a weak 
base in the form of acetate from Cu(OAc)2∙H2O, or the substrate itself (255), initiated by 
the high reaction temperature. Amide enolate oxidation takes place to form radical 258. 
It is likely that this oxidation mediated by copper(II), which is then reoxidised by 
molecular oxygen from Cu(I) back to Cu(II), but could potentially also be brought 
about by oxygen itself. Radical 258 then undergoes homolytic aromatic substitution. 
Finally, oxidation of radical 259 and rapid loss of a proton gives rise to product 256. 
This mechanism is therefore overall a formal double C‒H activation (Scheme 95). 
Unpublished studies in the Taylor group, showed that both copper and oxygen are 
required for the reaction: the reaction does not proceed with oxygen alone, even under 
an oxygen atmosphere or with air bubbled through the reaction mixture.222 However, 
the precise role of copper and oxygen in the mechanism is still unclear. It is unknown 
whether copper is required for the initial radical formation, or the oxidation to the 
carbocation 260, or both. 
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255
257 258
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260256  
Scheme 95: Proposed mechanism for the catalytic aerobic radical cyclisation 
 
4.5 Aims of project II 
 
It was envisaged that the catalytic copper(II) cyclisation methodology could be readily 
extended, simply by incorporating the electron withdrawing group in a ring in the 
form of a lactam or cyclic imide of type 20, thus allowing access to spirocyclic 
oxindoles 21 (Scheme 96). Given the abundance of the spirocyclic oxindole unit in 
natural products and drugs, we recognised that the development of this reaction 
would constitute an appealing entry to this highly prevalent building block. Our aim 
was to investigate the substrate scope of the reaction and the results which have come 
out of this study are shown in the next section. 
 
mesitylene, , air
X
N
O
N
O
R
N
O
R
XN
O
n
nR2
R2
Cu(OAc)2H2O (5 mol%)
R1
R1X = C or C=O
20 21  
Scheme 96: Proposed route to spirocyclic oxindoles 
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4.6 Results and discussion 
 
4.6.1 Synthesis of precursors 
 
The linear substrates for the copper cyclisation can be synthesised in just a few simple 
steps from the parent lactam or imide (e.g., 261, Scheme 97). In the first step, N-
protection with Boc anhydride affords N-substituted intermediate 262. Deprotonation 
of 262 and subsequent treatment with benzyl chloroformate delivers the ester 263. The 
benzyl group is cleaved by means of hydrogenolysis to give the carboxylic acid 264 
which, in order to avoid decarboxylation, is immediately subjected to amide coupling 
with the desired aniline, furnishing the cyclisation precursor 20.  
 
LiHMDS
CbzCl
H2, Pd/C
EtOAc
THF, 78 °C
Boc2O
DMAP
MeCN
or THF, rt
NH
O
N
O
Boc N
O
Boc
BnO
O
N
O
Boc
HO
O
N
O
Boc
N
O
R
ArNHR
N ClI-
Et3N, CH2Cl2
n n n
n n
n = 1, 262a, 92%
n = 2, 262b, quant.
n = 1, 263a, 63%
n = 2, 263b, 95%
n = 1, R = Me, R1 = H, 20a, 97%
n = 2, R = Me, R1 = m-OMe, 20b, 78%
n = 2, R = PMB, R1 = H, 20c, 86%
R1
(yields over 2 steps)
261
n = 1 or 2
n = 1, 264a
n = 2, 264b
 
Scheme 97: Example of precursor synthesis 
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4.6.2 Optimisation of the copper cyclisation  
 
Optimisation studies on the acyclic substrate system had identified 5 mol% copper(II) 
acetate in refluxing mesitylene under an air atmosphere as optimal conditions (vide 
supra, Scheme 94).221 
 
Applying the same conditions to substrate 20a, the reaction failed to go to completion 
(Table 15, entry 1), even after a prolonged reaction time. In addition, a large amount of 
decomposition of the linear substrate 20a was seen, resulting in the formation of aniline 
265 and Boc-protected lactam 262a (Scheme 98), which was difficult to separate from 
the desired product 21a. 
 
mesitylene
170 °C, 0.5 h
N
O
N
O
N
O
N
O
Boc
Boc
Cu(OAc)2H2O
N
O
NH
Boc+ +
0.37 : 1
(5 mol%)
20a 21a 262a265
 
Scheme 98: Product and decomposition products of the cyclisation of 20a 
 
Thus, a brief study into the optimal cyclisation conditions was carried out in the first 
instance. Pleasingly, by increasing the catalyst loading to 10 mol%, the reaction was 
complete within 30 min (Table 15, entry 2). However, some decomposition material 
was still observed. In an attempt to combat this, a number of different acetate-based 
copper sources and additives were investigated (Table 15). 
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Table 15: Optimisation of conditions for the cyclisation reaction of 20a to give 21a 
mesitylene, 170 °C, 0.5 h
N
O
N
O
N
O
N
O
Boc
Boc
Copper source
N
O
Boc+
20a 21a 262a
 
Entry Copper source 
Catalyst 
Loading 
Additive 21a:262aa 
Yield of 
21a (%)e 
1 Cu(OAc)2∙H2O 5 mol% - 0.38 : 1b 11 
2 Cu(OAc)2∙H2O 10 mol% - 2.50 : 1 58 
3 Cu(OAc)2 10 mol% - 2.56 : 1 59 
4 Cu(OAc)2∙H2O 10 mol% 4Å MS 0.24 : 1c 13 
5 Cu(OAc)2 10 mol% 4Å MS 0.62 : 1d 17 
6 CuOAc 10 mol% - 2.86 : 1 57 
7 Cu(OAc)2∙H2O 10 mol% AcOH 2.63 : 1 61 
8 Cu(OAc)2∙H2O 10 mol% Pyridine 3.13 : 1 48 
aBy 1H NMR analysis of the unpurified reaction mixture; bReaction terminated after 4.5 h 
(starting material remaining); cReaction terminated after 1.5 h (starting material remaining); 
dReaction terminated after 1 h (starting material remaining); eYields based on mass recovery 
and 1H NMR analysis of isolated material following column chromatography 
 
It was hypothesised that the decomposition may come about due to hydrolysis of the 
substrate with water, either produced in the reaction or derived from the catalyst itself. 
Anhydrous copper acetate as catalyst gave a comparable result (entry 3), but 
unexpectedly, the use of molecular sieves only served to slow down the cyclisation 
reaction, leading to an even larger proportion of decomposed material (entries 4 and 5). 
As the proposed cyclisation mechanism involves a re-oxidation of Cu(I), copper(I) 
acetate should also in principle be a suitable catalyst for the reaction. This was indeed 
the case (entry 6), with the yield of 21a being comparable to that obtained with 
copper(II) acetate. Whilst this supports the theory of copper(I) re-oxidation, it did not 
enhance the efficiency of the reaction. To investigate whether a build up of either acid 
or base in the reaction mixture could be causing the unwanted side reaction, both acetic 
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acid (entry 7) and pyridine (entry 8) were employed as additives. Unfortunately, only a 
marginal improvement in yield was observed by the addition of acetic acid, and 
therefore the use of just 10 mol% copper(II) acetate (entry 2) was settled upon as 
optimal in this case. 
 
 
4.6.2.1 Reaction times 
 
We next explored the effect of reaction time on the yield of oxindole product on 
different substrates 20b and 20c. Extended reactions times were shown to result in a 
significant amount of Boc cleavage, giving 266b‒c (Table 16, entries 1 and 3), which is 
not unusual as the reaction is carried out at 170 °C. This cleavage could be minimised 
by keeping reaction times at 30 minutes (entries 2 and 4). Boc-cleavage could be 
eliminated altogether by performing the reaction at a lower temperature in toluene, 
resulting in a slightly improved yield, but much longer reaction times were required, 
typically overnight (entry 5). 
 
 
Table 16: Different reaction times and temperatures for the cyclisation of 20b and 20c 
 
N
O
N
O
R
Boc
N
O
BocN
O
R
N
O
HN
O
R
+
X
X X
Cu(OAc)2H2O
(10 mol%)
solvent,  , time
X = OMe, R = Me, 20b
X = H, R = PMB, 20c X = OMe, R = Me, 21b
X = H, R = PMB, 21c
X = OMe, R = Me, 266b
X = H, R = PMB, 266c
 
Entry Substrate Solvent Temp /°C Time /h Yield of 21a Yield of 266a 
1 20b mesitylene 170 1 37  16 
2 20b mesitylene 170 0.5 48 - 
3 20c mesitylene 170 1 42 15 
4 20c mesitylene 170 0.5 48 7 
5 20c toluene 120 16 56 - 
aIsolated yields 
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4.6.3 Scope of the reaction 
 
In order to investigate the scope of the cyclisation, a wide range of substrates were 
prepared, with variations in ring size, protecting groups and substitution pattern 
around the aromatic ring (Figure 17). 
 
X
N
O
N
O
R
n
R1
R2
X = CH2 or C=O
n = 0, 1, 2 or 3
R/R2 = Boc, Me, Bn, PMB or Dmb
R1 = H, OMe, Cl, Br, NO2, CF3 or CN  
Figure 17: Range of substrates prepared to investigate the scope of the cyclisation reaction 
 
4.6.3.1 Ring size and type 
 
In the first instance, an investigation into the scope of the ring size of the spirocycle 
was launched and substrates ranging from 4-membered to 7-membered rings, 
including both lactams and imides were studied (Scheme 99). 
 
Boc-protection to form intermediates 262b,d,e,g,h was trivial, giving near quantitative 
yields in all cases, whereas results from the benzylcarboxylation step were variable. In 
an attempt to prepare the Boc-protected succinimide substrate from 262e, difficulties 
were encountered in the benzylcarboxylation step, thus a methyl succinimide substrate 
263f was prepared instead. Low yields were observed for this step with the imide 
substrates, and this was due to the presence of two acidic sites in the molecule, thus 
resulting in the double addition of the electrophile as the side reaction. Hydrogenolysis 
of intermediates 264b to 264h and subsequent amide coupling proceeded without 
incident, thus providing substrates 20d to 20i in good to excellent yield. 
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X
NH
O
X
N
O
R2
X
N
O
R2
BnO
O
X
N
O
R2
HO
O
X
N
O
R2
N
O
n n n
n n
n = 0, X = CH2, R
2 = Boc, 262d, 87%
n = 1, X = C=O, R2 = Boc, 262e, 91%
n = 1, X = C=O, R2 = Me, 262f
n = 2, X = CH2, R
2 = Boc, 262b, quant.
n = 2, X = C=O, R2 = Boc, 262g, 97%
n = 3, X = CH2, R
2 = Boc, 262h, 86%
n = 0, X = CH2, R
2 = Boc, 263d 54%
n = 1, X = C=O, R2 = Boc, 263e, 0%
n = 1, X = C=O, R2 = Me, 263f, 39%
n = 2, X = CH2, R
2 = Boc, 263b, 95%
n = 2, X = C=O, R2 = Boc, 263g, 39%
n = 3, X = CH2, R
2 = Boc, 263h, 41%
n = 0, X = CH2, R
2 = Boc, 264d
n = 1, X = C=O, R2 = Me, 264f
n = 2, X = CH2, R
2 = Boc, 264b
n = 2, X = C=O, R2 = Boc, 264g
n = 3, X = CH2, R
2 = Boc, 264h
n = 0, X = CH2, R
2 = Boc, 20d, 73%
n = 1, X = C=O, R2 = Me, 20f, 89%
n = 2, X = CH2, R
2 = Boc, 20i, 80%
n = 2, X = C=O, R2 = Boc, 20g, 78%
n = 3, X = CH2, R
2 = Boc, 20h, 60%
(yields over 2 steps)
n = 04
261
(a) (b)
(c) (d)
 
Reagents and conditions: a) Boc2O, DMAP, THF or MeCN, rt, 16 h; b) LiHMDS, CbzCl, THF, 
−78 °C, 1 h; c) H2, Pd/C, EtOAc, 0.5‒2 h; d) 2-chloro-1-methylpyridinium iodide, Et3N, 
PhNHMe, CH2Cl2, 0 °C to rt, 16 h 
Scheme 99: Substrates prepared with differing ring sizes 
 
 
We were also interested in the reactivity of substrate 20j. Following the procedure by 
Vanotti et al.,223 Meldrum’s acid (267) was coupled with Boc--alanine (268) and the 
resulting intermediate was heated under reflux to give lactam 262j in good yield 
(Scheme 100). Standard conditions for the benzylcarboxylation with LiHMDS as base 
led to decomposition. Nevertheless, the weaker base, K2CO3 was successful in 
providing ester 263j. Unfortunately, on attempting to form 20j, the acid resulting from 
the hydrogenolysis step was found to undergo immediate decarboxylation, reverting 
to compound 262j. Thus, the synthesis of 20j by this route was deemed fruitless. 
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O
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O
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N
O
O
O
O
O
+
BocHN OH
O
1. EDCMeI, DMAP
2. EtOAc, reflux
61%
N
O
O
Boc
K2CO3
CbzCl, EtOH
36%
Pd/C, H2
20j263j
262j267 268
 
Scheme 100: Attempted formation of substrate 20j 
 
With a range of substrates in hand, attention was next turned to spirooxindole 
formation (Table 17). Pleasingly, all of the substrates were shown to successfully 
undergo cyclisation, with methyl succinimide 20f showing the highest yield of product 
(entry 1). 5-, 6- and 7- membered lactams provided products 21a, 21i and 21h in 
moderate to good yield, showing that a range of ring size is tolerated under the 
reaction conditions (entries 2‒4). The 4-membered lactam 20d was slow to react and 
ultimately gave rise to low yield of 21d (entry 5), which is presumably due to the 
unfavourable ring strain of the planar enolate and radical intermediates, or due to the 
high reactivity of the product. 
 
Cyclisation of the Boc-protected glutarimide substrate 20g resulted in a large amount 
of Boc-cleavage (42% of free amine 266g was isolated) (entry 6). This could be easily 
minimised and hence the yield of 21g increased to 45% by performing the reaction in 
toluene for 16 h at 120 °C (Scheme 101).  
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Table 17: Cyclisation of lactam and imide substrates of differing ring size 
mesitylene, 170 °C, air, 30 minX
N
O
N
O
N
O
XN
O
n
n
R2
R2
Cu(OAc)2H2O (10 mol%)
20ag 21aj
 
Entry Product Yield (%)a Entry Product Yield (%)a 
1 
N
O
N
O
O
21f  
70 4 
N
O
N
O
Boc
21h  
64 
2 
N
O
N
O
Boc
21a
 
58c  5 
N
NO
O
Boc
21d  
26b,c 
3 
N
O
N
O
Boc
21i  
56 6 
N
O
N
O
O
Boc
21g  
17d 
aIsolated yields; bReaction terminated after 2 h; cYield extrapolated; a small amount of 
Boc-protected lactam 262 co-eluted; dReaction in PhMe gave 45% 
 
N
O
N
O
O
Boc
N
O
Boc
N
O
O
+
N
O
HN
O
O
Cu(OAc)2H2O
a) mesitylene,
30 min, 170 °C
or
b) toluene,
16 h, 120 °C
a) 17%
b) 45%
a) 42%
20g
21g 266g
 
Scheme 101: Cyclisation of 20g at different temperatures 
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4.6.3.2 Substitution on the aromatic ring 
 
We were next interested in looking at the effect of the substituents on the anilide 
aromatic ring on the cyclisation reaction. Towards this end, a range of ortho, meta and 
para-substituted compounds with electron-withdrawing and electron-donating groups 
20k‒r were prepared (Scheme 102). This was achieved in generally good yields over 2 
steps from 263b and set the stage for the copper(II)-mediated cyclisation step (Tables 
18 and 19). 
 
N
O
R
1. H2, Pd/C
2.
Ar
H
N
R
R1N
O
Boc
BnO
O
N
O
Boc
(Yields over 2 steps)
R = Me, R1 = o-NO2, 20k , 37%
R = Me, R1 = o-CN, 20l, 77%
R = Dmb, R1 = p-OMe, 20m, 74%
R = Me, R1 = p-Cl, 20n, 78%
R = Me, R1 = p-CF3, 20o, 80%
R = Me, R1 = m-OMe, 20p, 76%
R = Me, R1 = m-Br, 20q, 42%
263b
 
Scheme 102: Preparation of substrates to investigate substitution effects 
 
The aniline 270 required for the synthesis of substrate 20l was prepared by a copper-
mediated mono-methylation of 2-aminobenzonitrile (269) following the procedure of 
González (Scheme 103).224  
 
 
NH
CN
NH2
CN
1. Pyridine, dioxane, Cu(OAc)2, 15 min
2. MeB(OH)2, reflux, 4 h
41%269 270  
Scheme 103: Preparation of 2-(methylamino)benzonitrile (270) 
 
Anilines 273 and 275 were prepared by means of a reductive amination reaction, 
following procedures by Trost,158 and Teichert,225 respectively (Scheme 104). These 
were subsequently used in the synthesis of substrates 20m and 20p. 
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NH
O
O
O
NH2
O
O
O O
1. AcOH, 100 °C, 1 h
2. NaBH4, EtOH, 0 °C, 10 min
then rt, 30 min
64%
271 272
273
+
O NHO NH2
1. NaOMe,MeOH
2. (CH2O)n, MeOH, rt, 6 h
3. NaBH4, reflux, 2 h then rt, 12 h
76%
274 275
 
Scheme 104: Preparation of anilines 273 and 275 
 
Electron-withdrawing groups were not well tolerated in the cyclisation reaction (Table 
18). Nitrile-containing 20l (entry 1), and trifluoromethyl-substituted 20o (entry 2), did 
cyclise but afforded rather low yields of products 21l and 21o. In the case of the nitro-
substituted 20k (entry 3), cyclisation was halted altogether and the only observable 
products were those arising from the decomposition of precursor 20k, namely the 
aniline and Boc-protected lactam 262b.  
 
In contrast, compounds with the electron-donating methoxy- group provided better 
yields of products 21b and 21m (Table 18, entries 4 and 5). Pleasingly, chloride-
substituted 20n (entry 6) was shown to be a compatible substrate in the reaction, and 
constitutes a useful handle for further cross coupling reactions to create drug-like 
molecules. 
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Table 18: Cyclisation of substrates with ortho/para- substituents 
mesitylene, 170 °C, air
N
O
N
O
R
Cu(OAc)2H2O (10mol%)
R1
R1
N
O
Boc
N
O
Boc
20b,ko 21b,ko
 
Entry Product Yield (%)a Entry Product Yield (%)a 
1 
N
O
BocN
O
CN
21l  
19b  4 
N
O
BocN
O
O
21b
 
48b 
2 
N
O
BocN
O
F3C
21o
 
32b  5 
N
O
BocN
OO
O
O
21m
 
63 
3 
N
O
BocN
O
NO2
21k  
0c 6 
N
O
BocN
O
Cl
21n  
62 
aIsolated yields; bYield extrapolated; a small amount of Boc-protected lactam 262b co-eluted; 
cReaction in PhMe at 120 °C also failed 
 
 
As could be predicted, the cyclisation of meta-substituted substrates 20p and 20q 
resulted in the formation of two isomeric products 20pp/20qp and 20po/20qo, which 
were obtained in high overall yield (Table 19). More intriguing, was the ratio in which 
these isomeric products were formed.  
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Table 19: Cyclisation of substrates with meta-substituents 
mesitylene, 170 °C, air, 30 min
N
O
N
O
Cu(OAc)2H2O (10 mol%)
R1
N
O
Boc
N
O
Boc
R1
20pq 21pq  
Entry Products Yield of 21pa Yield of 21oa 
1 
N
O
BocN
O
O
21pp           
N
O
O NBoc
O
21po  
18 58b 
2 
N
O
BocN
O
Br
21qp           
N
O
Br NBoc
O
21qo  
25b 44 
a Percentage isolated yields; bYield extrapolated; a small amount of Boc-protected lactam 262b 
co-eluted 
 
More specifically, the major products 21po and 21qo were found to be derived from 
radical addition to the position of the benzene ring with two adjacent substituents. 
Although this observation is counter-intuitive in light of steric arguments, formation of 
major isomers 21o could be explained by electronic factors, whereby adjacent 
substitution leads to a more stable cyclohexadienyl radical 277o intermediate following 
addition to the benzene ring (Scheme 105). In order for 277p to benefit from 
stabilisation by the meta-substituent (R1), the radical is only required to be in 
conjugation with one of the two double bonds in the intermediate, therefore the second 
double bond is less likely to contribute significantly to stabilisation.  In contrast, radical 
277o has both double bonds arranged in a linear fashion between the nitrogen atom 
and the meta-substituent, allowing additional resonance stabilisation and thus a more 
stable intermediate. Similar regioselectivity in aromatic radical cyclisations has also 
been observed by others.226 
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+NBoc
O
N
O
R1
N
O
BocN
O
R1 N
O
R1 NBoc
O
(minor) (major)
NBoc
O
N
O
R1 +
N
O
BocN
O
R1 N
O
R1 NBoc
O
"steric" "electronic"
20
276
277p 277o
21p 21o
 
 
Scheme 105: Regioisomeric intermediates and products from the cyclisation of meta-substituted 
compounds 
 
 
4.6.3.3 Protecting group variation 
 
It was also important to us to establish that a range of protecting groups could be 
tolerated in the cyclisation reaction and thus broaden the synthetic utility of this 
process. Previous studies had shown that copper(II) cyclisation was ineffective in the 
case where the anilide bears a free NH, thus nitrogen protection is crucial.219 First, the 
protection of both the lactam and the anilide nitrogen atoms was explored. 
 
Boc carbamate as well as methyl, benzyl and PMB groups were chosen and precursors 
20r‒v were obtained in good to quantitative yields (Scheme 106).  
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N
O
R
N
O
R2
N
O
R2
BnO
O
N
O
R2
(Yields over 2 steps)
R2 = Me, 262r
R2 = Bn, 262s
R2 = PMB, 262t
R2 = Me, 263r, 40%
R2 = Bn, 263s, 87%
R2 = PMB, 263t, 66%
R = Me, R2 = Me, 20r, quant.
R = Me, R2 = Bn, 20s, 92%
R = Me, R2 = PMB, 20t, 81%
R = Bn, R2 = Boc, 20u, 77%
R = Boc, R2 = Boc, 20v, 61%
(a) (b)
(c)
N
O
R2
HO
O
R2 = Me, 264r
R2 = Bn, 264s
R2 = PMB, 264t
 
Reagents and conditions: (a) LiHMDS, CbzCl, THF, −78 °C, 1 h; (b) H2, Pd/C, EtOAc, 0.5‒2 h; 
(c) 2-chloro-1-methylpyridinium iodide, Et3N, PhNHR, CH2Cl2, 0 °C to rt, 16 h 
Scheme 106: Preparation of differently protected substrates 
 
Benzyl-protected lactam 262s and PMB-protected lactam 262t were both prepared by 
N-alkylation of δ-valerolactam (261b), using procedures by Cossy,227 and Winter,228 
respectively (Scheme 107). 
 
NH
O
N
O
Bn
N
O
PMB
i) n-BuLi, THF,
78 °C, 20 min
ii) BnBr, 78 °C
to rt, 16 h
33%
NaH, PMBCl,
reflux, 24 h
94%
261b262s 262t
 
Scheme 107: Preparation of benzyl- and PMB-protected lactams 262s and 262t 
 
The aniline 279 required for substrate 20v was prepared by K2CO3-mediated Boc-
protection of aniline (278), based on the procedure by Peterson (Scheme 108).229 
 
NH2
H
N
Boc
278 279
K2CO3, Boc2O
1:1 THF:H2O, rt, 7 h
94%  
Scheme 108: Boc-protection of aniline (278) 
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Each of these substrates 20r‒v was then submitted to the cyclisation reaction conditions 
and the methyl group was shown to be the best protecting group for the lactam, closely 
followed by benzyl and PMB (Table 20, entries 1‒3). The lower yield of the Boc-
protected 21i could be easily attributed to the thermal Boc cleavage under the reaction 
conditions (entry 4).  
 
Table 20: Investigation into nitrogen protecting groups 
mesitylene, 170 °C, air, 30 min
N
O
R
N
O
R
Cu(OAc)2H2O (10mol%)
N
O
R2
N
O
R2
 
Entry Product Yield (%)a Entry Product Yield (%)a 
1 
N
O
N
O
21r  
65 5 
N
O
BocN
O
Dmb
O
21m  
63 
2 
N
O
N
O
Bn
21s  
64 6 
N
O
BocN
O
Bn
21u  
51 
3 
N
O
N
O
PMB
21t  
64 7 
N
O
BocN
O
PMB
21c  
48 
4 
N
O
N
O
Boc
21i  
56 8 
N
O
BocN
O
Boc
21v  
0b 
a Isolated yields, bReaction in PhMe at 120 °C also failed 
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In terms of anilide protection, in addition to the Dmb group shown previously (Table 
20, entry 5), both the benzyl and PMB groups were shown to be compatible (entries 6 
and 7), albeit yields of products 21u and 21c were somewhat lower than in the case of 
the methyl protected substrates. Unfortunately, Boc protection of the anilide was not 
compatible under the reaction conditions (entry 8); the only observable products were 
those arising from decomposition of the linear precursor 20v. Thus, the anilide 
nitrogen atom protecting group is limited to those with electron donating character 
only. We speculate that the electron-withdrawing nature of the Boc group significantly 
reduces the ability of the anilide nitrogen atom to stabilise the intermediate radical in 
the addition step, thus shutting down the desired reaction. 
 
Pleasingly, we were able to obtain a suitable crystal of 21u, thus allowing us to 
conclusively prove the structure of this spirocyclic oxindole (Figure 18). 
N
O
BocN
O
Bn
21u  
Figure 18: Crystal structure of 21u 
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4.6.3.4 Five-membered compounds 
 
A selection of 5-membered substrates with various protecting groups and aromatic 
ring substitution were synthesised and subjected to the cyclisation conditions (Table 
21).  
 
(a) (b)
N
O
N
O
BnO
O
N
O
HO
O
N
O
R2
N
O
R
(c)
262x 263x, 47%
R = Bn, R1 = H, R2 = Boc, 20w, 64%
R = Bn, R1 = H, R2 = Me, 20x, 94%
R = PMB, R1 = H, R2 = Me, 20y, 87%
R = Me, R1 = H, R2 = Me, 20z, 74%
R = Me, R1 = Cl, R2 = Me, 20za, 67%
(yields over 2 steps)
264x
R1
N
O
Boc
HO
O
264a
(d)
 
Reagents and conditions: (a) LiHMDS, CbzCl, THF, −78 °C, 1 h; (b) H2, Pd/C, EtOAc, 2 h; 
(c) 2-chloro-1-methylpyridinium iodide, Et3N, ArNHR, CH2Cl2, 0 °C to rt, 16 h; (d) 2-chloro-1-
methylpyridinium iodide, Et3N, PhNHBn, CH2Cl2, 0 °C to rt, 16 h 
Scheme 109: Synthesis of 5-membered substrates 
 
The results of these cyclisation reactions showed similar trends to those seen in the 6-
membered series of substrates, whereby N-methyl protection showed superior yields 
to Boc/PMB groups (entry 2 vs entry 1, entry 4 vs entry 3), and that chlorine 
substitution on the aryl group gave one of the highest yielding reactions (entry 5). 
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Table 21: Cyclisation of selected 5-membered compounds 
mesitylene, 170 °C, air
N
O
N
O
R N
O
R
N
O
R2
R2
Cu(OAc)2H2O (10 mol%)
R1
R1
 
Entry Product Yield (%)a Entry Product Yield (%)a 
1 
N
Bn
O
N
O
Boc
21w
 
55 4 
N
O
N
O
21z  
58 
2 
N
Bn
O
N
O
21x  
58 5 
N
O
N
O
Cl
21za
 
66 
3 
N
PMB
O
N
O
21y  
55    
aIsolated yields 
 
4.6.4 Additional work 
 
Further work in the group, performed by Vilius Franckevičius and Pauline Drouhin, 
has addressed the problem of the unwanted side-reaction during the cyclisation 
procedure, namely the decomposition of the linear precursors. It has been shown that 
by vigorously bubbling air through the reaction mixture, rather than simply exposing 
the vessel to an air atmosphere, the rate of the cyclisation reaction relative to the 
decomposition can be increased, thus resulting in a higher yield of the desired oxindole 
product.  
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Using these conditions, the cyclisation of a number of previously synthesised 
substrates was repeated and a direct comparison of these results has been made (Table 
22). Gratifyingly, in all cases the yield of product was improved over that obtained 
with the previous protocol (Tables 17 to 21). In addition, a PMB protected oxindole 
21zb analogous to the Boc-protected glutarimide product 21g was prepared.230  The use 
of this less labile protecting group allowed a much improved yield of 91% of 21zb to be 
achieved (entry 10).  
 
To demonstrate synthetic utility, this improved cyclisation procedure was applied to a 
formal synthesis of horsfiline (175),230 intercepting intermediate 21zc from the synthesis 
of Trost and Brennan (Scheme 110).158 
 
Future work will look at the possibility of an enantioselective variant of the copper-
catalysed cyclisation reaction. 
 
N
Dmb
O
N
O
N
Dmb
O
N
O
BnO
O
N
O
N
O
N
H
O
N
(±)-horsfiline (175)
2 steps
Trost & Brennan
(a)
48%
(b),(c)
97%
d)
71%
MeO
MeO MeO
261x 262x 20zc
21zc
 
Reagents and conditions: (a) LDA, CbzCl, THF, −78 °C, 1 h; (b) H2, Pd/C, EtOAc, 2 h; (c) 2-chloro-
1-methylpyridinium iodide, Et3N, 273, CH2Cl2, 0 °C to rt, 1 h; (d) Cu(OAc)2∙H2O (10 mol%), 
mesitylene, air bubbled through, 1.5 h  
Scheme 110: Taylor’s formal synthesis of horsfiline via copper-catalysed spirooxindole formation 
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Table 22: A comparison of cyclisation reactions using both improved and previous procedures 
mesitylene, 170 °C
air bubbled through
X
N
O
N
O
R N
O
R
XN
O
n
n
R2
R2
Cu(OAc)2H2O (10 mol%)
R1
R1
 
Entry Product Yield (%)a,b Entry Product Yield (%)a,b 
1 
N
Bn
O
N
O
21x  
80 (58) 6 
N
O
BocN
O
Bn
21v  
69 (51) 
2 
N
O
N
O
Cl
21za  
76 (66) 7 
N
O
BocN
O
Cl
21n  
70 (62) 
3 
N
O
N
O
21r  
76 (65) 8 N
O
BocN
O
Dmb
O
21m
 
73 (63) 
4 
N
O
N
O
Bn
21s  
83 (64) 9 
N
O
BocN
O
O
21b  
60 (48) 
5 
N
O
N
O
PMB
21t  
73 (64) 10 
N
O
N
O
O
PMB
21zb  
91 
aIsolated yields. Reaction carried out with air vigorously bubbled through the reaction mixture, 
performed by Franckevičius or Drouhin; bNumbers in parenthesis denote previous yields. 
Reaction carried out under an air atmosphere    
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4.7 Summary of the methodological studies 
 
Following on from previous work in the Taylor group, a simple and efficient route for 
the formation of lactam and imide-based spirocyclic oxindoles has been developed. 
This procedure has shown to be compatible with a wide range of ring sizes, 
substitution patterns and protecting groups.  
 
Cyclisation of 5-, 6- and 7- membered lactam and imide substrates have been shown to 
proceed well, providing good yield of products. The 4-membered -lactam substrate 
on the other hand gave a low yield of product. 
 
A variety of protecting groups are compatible for the nitrogen of the lactam, with the 
less labile methyl, benzyl and PMB groups offering the highest yields. In terms of 
anilide protection, Me, Bn, PMB and Dmb were all shown to be compatible, although 
the more electron-withdrawing Boc group was not. 
 
A range of substrates with aromatic substituents were cyclised, with electron-donating 
groups exhibiting high yields of product. Strongly electron-withdrawing groups, 
however, resulted in only small quantities of product or indeed none at all. In the case 
of meta-substituted substrates, an interesting regioselectivity was observed, with major 
products being those arising from cyclisation on the carbon between the two aromatic 
substituents. 
 
With the simplicity of both the substrate synthesis and the cyclisation itself, it is 
possible to build up a large degree of molecular complexity in just a few synthetic steps 
in a straightforward fashion. Indeed, the ease with which oxindole products can be 
obtained with this methodology encouraged us to establish its utility in natural 
product synthesis, specifically the synthesis of spirotryprostatin A, and our work 
towards this goal is detailed in the following Chapter. 
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Chapter 5 – Towards the synthesis of spirotryprostatin A 
5.1 Introduction to the spirotryprostatins 
 
The spirotryprostatins have attracted much interest since their discovery in 1996 by 
Cui et al. (Figure 19).231,232 Spirotryprostatin A (22) and spirotryprostatin B (180) were 
isolated from the fungus Aspergillus fumigatus, and have both been shown to exhibit 
cell cycle inhibition activity, making them potential lead compounds for cancer 
treatment.  
 
N
H
O
N
N
O
O
H
O N
H
O
N
N
O
O
H
spirotryprostatin A (22) spirotryprostatin B (180)
 
Figure 19: Spirotryprostatins A and B 
 
Spirotryprostatin B is structurally the simpler variant in that it lacks a methoxy 
substituent on the aromatic ring and one of the stereogenic centres is absent due to 
additional unsaturation. Overall, both compounds bear a pentacyclic carbon skeleton 
and, most importantly, contain a spirocyclic oxindole motif.  
 
 
5.1.1 Previous syntheses of spirotryprostatin A 
 
At least three syntheses of spirotryprostatin A have been reported to date, with each 
route using a different method to construct the spirooxindole core. The first of these 
syntheses was disclosed in 1998 by Edmondson and Danishefsky (Scheme 111),233,234  
and utilised an oxidative rearrangement of a fused indole 281 to form spirocycle 283 as 
the key step. This reaction is thought to occur via bromohydrin intermediate 282, 
wherein the groups on the top () face direct bromination to the -face. Stereospecific 
ring contraction then occurs resulting in bromide displacement and leading to the 
desired stereoisomer 283 in 46% yield with the core structure successfully assembled 
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(Scheme 111). The natural product 22 was then readily accessed in four straightforward 
chemical manipulations. 
N
H
NBoc
CO2Me
SPh
MeO
N
H
MeO
O
NBoc
MeO2C
SPh
NBS, THF, H2O, AcOH
46%
N
H
NBoc
CO2Me
SPh
MeO
Br
OH
N
H
O
N
N
O
O
H
O
spirotryprostatin A (22)
4 steps
281
283
282
 
Scheme 111: Danishefsky’s approach to the spirocyclic core of spirotryprostatin A 
 
An alternative synthesis of spirotryprostatin A was reported in 2003 by Williams and 
co-workers.235,236 Similar to the strategies discussed earlier in Chapter 4.3 (vide supra, 
page 81), they used a 1,3-dipolar cycloaddition reaction for the construction of the 
spirooxindole core. More specifically, starting with 3,3-disubstituted oxindole 284, 
treatment with trifluoroacetic acid led to the in situ formation of unstable methylene 
oxindole 285 as a dipolarophile, whereas condensation of aldehyde 287 with chiral 
amine 286 formed azomethine ylide 288 as the desired dipole. Cycloaddition reaction 
between 285 and 288 afforded the desired product 289 in 44% yield and, remarkably, 
installed three new stereogenic centres with complete diastereocontrol. Subsequent 
cleavage of the chiral auxiliary, conjugation with a proline residue and double bond 
installation swiftly paved the way to spirotryprostatin A. 
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N
H
MeO
N
H
MeO
O
N
O
N
H
O Ph
Ph
O
CHO
OMe
O Ph
Ph
O
H
OMe
N
H
MeO
O
TMS
TFA
PhMe
0 °C
3 Å mol. sieves
PhMe
15 to 0 °C
44%
N
O Ph
Ph
O
OMe
284 286
285
288
289
287
 
Scheme 112: Williams’ approach to the spirocyclic core of spirotryprostatin A 
 
The synthesis of spirotryprostatin A by Horne and co-workers was published in 2004 
and focused on a stereoselective spirocyclisation strategy (Scheme 113).237 Their 
venture began with the di-functionalisation of tryptophan methyl ester (290) with NBS. 
This step displayed only moderate selectivity, thus leaving the authors with a 3:2 
mixture of regioisomeric indole bromides 291’ and 291’’ to carry forward. The key step 
involves condensation of amines 291’/291’’ with aldehyde 292 and activation of the 
resulting imine with proline-derived acyl chloride 293, thus providing an electrophilic 
N-acyliminium ion and facilitating spirocyclization to 294. TFA-assisted hydrolysis of 
the resulting haloindolenine intermediate 294 furnished a mixture of spirocyclic 
oxindoles 295, which were subjected to zinc-mediated Troc-cleavage and lactamisation. 
Regioisomeric products 296’ and 296’’ were now separable and the desired spirocycle 
296’ was obtained in an overall yield of 26%, in a highly stereocontrolled manner 
(Scheme 113).  This was then subjected to Cu-catalysed methoxylation conditions to 
furnish spirotryprostatin A (22) in 11% yield.  
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N
H
Br
N
H
O
N
Br
CO2Me
NH2
O
N
Troc
MeO2C
TFA
N
H
Br
CO2Me
NH2Br
Br
N
H
O
N
N
O H
BrN
H
O
N
N
O H
Br
+
+
(56%, 3:4)
(3:2 mixture taken forward)
Zn, MeOH,
reflux
30% 26%
N
H
CO2Me
NH2
N
Br
N
O
N
Troc
MeO2C
Br
O
1.
2.
N
Troc
O
Cl
spirotryprostatin A
(22)
2 eq. NBS
AcOHHCOOH
CuI, NaOMe
DMF
11%
290
291'
291''
292
293
294 295
296'' 296'
 
Scheme 113: Horne’s approach to the spirocyclic core of spirotryprostatin A 
 
More recently, Gong and co-workers, whilst not gaining access to spirotryprostatin A 
itself, instead synthesised two diastereomers of the natural product, 302 and 303 
(Scheme 114). The group performed an enantioselective Brønsted acid-mediated 1,3-
dipolar cycloaddition reaction of 299 with the azomethine ylide arising from 
condensation of 297 and 298, to form the pyrrolidine portion in 300 with excellent 
diastereocontrol as a single enantiomer and diastereomer in high yield. The nitro 
group was then reduced to a hydroxylamine which underwent lactamisation to form 
301 following benzyl protection.238 
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CO2Me
MeO NO2
H2N
CO2Et
CO2Et
CHO
MeO NO2
CO2Me
NH
EtO2C
CO2Et
10 mol% 304
PhMe, 3 Å mol. sieves
40 °C, 72 h
>99:1 dr
>99:1 ee
94%
MeO
NH
EtO2C
CO2Et
N
O
OBn
(i) Zn, AcOH, CH2Cl2
(ii) BnBr, Et3N, CH2Cl2
80%
+ +
304
O
O
O
O
O
PP
HO
O
OH
O
7 steps
N
H
O
N
NO
O
H
O N
H
O
N
NO
O
H
O
+
9,18-bis-epispirotryprostatin A (302) 18-epispirotryprostatin A (303)
297 298 299
300 301
 
Scheme 114: Gong’s approach to diastereomers of spirotryprostatin A 
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5.1.2 Previous syntheses of spirotryprostatin B 
 
Spirotryprostatin B (180), on the other hand, has been a more frequent target for 
chemical synthesis than spirotryprostatin A, presumably due to its simpler structure. 
Several of the total syntheses of 180 make use of methods very similar to those seen in 
spirotryprostatin A synthesis, such as Williams’ dipolar cycloaddition approach,239 and 
Horne’s Mannich-type reaction,240 a similar version of which was used by 
Danishefsky.241  Ganesan performed a biomimetic oxidative rearrangement via a 
bromohydrin,242 much like Danishefsky’s strategy for spirotryprostatin A. As 
previously mentioned, Carreira utilised the group’s cyclopropanation ring expansion 
methodology for the synthesis of spirotryprostatin B, amongst other natural products 
(vide supra, Chapter 4.3.2),205,206 whereas Overman effected cyclisation from a linear 
anilide precursor by means of an intramolecular Heck reaction.243 
 
A more distinct synthesis of spirotryprostatin B was performed by Fuji and co-workers 
(Scheme 115). Their strategy commenced with oxindole 305,244 in which the quaternary 
stereocentre had been installed in high enantiomeric excess using the group’s 
asymmetric nitro-olefination methodology. Following further manipulation to access 
allylic alcohol 306, a catalytic amount of acid in refluxing acetonitrile promoted 
cyclisation and enabled rapid entry to spirocycle 307 (Scheme 115), albeit in low yield. 
The low efficiency of this reaction was attributed to the need to halt the reaction at 50% 
conversion in order to avoid deprotection of the Boc moiety, but, importantly, an 
unwanted diastereomer 307’’ was also formed along with the desired compound 307’ 
as a 1:1 mixture.245 
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N
H
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97% ee
HN
OH
O
HN
O
BocN
CO2Me
H
HN
N
O
O
BocN
CO2Me
H
p-TSA (10 mol%)
MeCN
reflux, 25 min
6 steps
HN
N
O
O
BocN
CO2Me
H
24% 23%
+
desired undesired
305
306
307' 307''
 
Scheme 115: Fuji’s approach to spirotryprostatin B 
 
In their synthesis, Trost and Stiles used a palladium-catalysed decarboxylative 
prenylation reaction to install the quaternary oxindole stereogenic centre. Pleasingly, 
the in presence of chiral phosphine ligand 311, prenylation occurred regioselectively 
alpha- to the carbonyl of the oxindole with high stereocontrol. Following conversion of 
the prenyl side chain in 309 into allylic acetate 310, stereoselective cyclisation was 
achieved using trimethylaluminum, which acted as both a Brønsted base to form an 
aluminium amide in situ, as well as a Lewis acid to activate the allylic acetate towards 
nucleophilic attack, thus furnishing spirotryprostatin B (180) in 45% yield (Scheme 
116).246 
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HN
O
HN
O
H
HN
O
Me3Al, DCE, rt
45%
N
O
N
N
O
O
H
HN
O
H
N
O
HN
O
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O
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HN
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O
H
N
O
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NH HN
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PPh2 Ph2P
311
308 309
310 180
  
 
Scheme 116: Trost’s approach to spirotryprostatin B 
 
Despite the wealth of synthetic strategies towards the spirotryprostatins, we were now 
interested in showcasing our copper(II)-catalysed oxindole cyclisation method by 
applying it to a new synthesis of spirotryprostatin A (22). Our retrosynthetic strategy 
and preliminary results in this area are detailed in the following sections. 
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5.2 Results and discussion 
 
5.2.1 Retrosynthesis of spirotryprostatin A 
 
Retrosynthetically, an initial disconnection of the two amide bonds in spirotryprostatin 
A (22) gives a proline fragment and spirooxindole 312 (Scheme 117). We envisaged that 
the isobutylene side-chain in 312 could be introduced via selective addition of an 
appropriate nucleophile to the N-Boc-pyrrolidinone carbonyl in 313 and subsequent 
stereoselective reduction. Intermediate 313 will result from the copper(II)‐catalysed 
cyclisation of anilide 314 as the key step, which could in turn be easily synthesised 
from inexpensive (S)‐pyroglutamic acid (315). We aim to exploit the stereogenic centre 
from the chiral pool to set up two other stereocentres in the synthesis of 
spirotryprostatin A (22). 
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Scheme 117: Retrosynthesis of spirotryprostatin A (22) 
 
We identified two potential elements for consideration and optimisation in the key 
copper-mediated cyclisation step of 314 to 313: the regioselectivity of cyclisation, given 
that the methoxy substituent in anilide 314 is in the meta- position, as well as the 
diastereoselectivity of the cyclisation.  
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5.2.2 Initial steps 
 
Initial work saw the synthesis of m-methoxy anilide 320 (Scheme 118). Following 
literature procedures, the first step was esterification of (S)-pyroglutamic acid 
(315),247,248 followed by Boc-protection of the resultant ester 316 to give 317 in 86% yield 
over the two steps.249 With N-protected lactam 317 in hand, the previously established 
route towards cyclisation precursors could now be applied. In this context, 
benzylcarboxylation under standard acylation conditions was achieved in 72% yield, 
providing dicarbonyl 318 as an inconsequential 2:1 mixture of diastereoisomers. This 
was followed by hydrogenolysis and amide coupling with the previously prepared 
methoxy-substituted aniline 275, giving substrate 320 in 88% yield over the final two 
steps. 
 
NH
O
CO2H
NBoc
O
CO2Et
NH
O
CO2Et
(b)
93% 93%
NBoc
O
CO2Et
HO
O
dr 7:3
(a)
NBoc
O
CO2Et
BnO
O
dr 2:1
(c) (d)
(e)
72%
(f)
88% (2 steps) NBoc
O
CO2Et
N
O
dr 4:1
O
275
315 316 317
318 319
320  
Reagents and conditions: (a) SOCl2, EtOH, 0 °C to rt, 1 h; (b) Boc2O, DMAP, Et3N, CH2Cl2, rt, 12 h; 
(c) LiHMDS, CbzCl, THF, −78 °C, 1 h; (d) Pd/C, H2, EtOAc, rt, 2 h; (e) MeCN:H2O (99:1), reflux, 
24 h; (f) 2-chloro-1-methylpyridinium iodide, Et3N, CH2Cl2, 0 °C to rt, 16 h. 
Scheme 118: Synthesis of anilide substrate for cyclisation  
 
There were initial concerns that, under the basic conditions of the benzylcarboxylation 
step, deprotonation of the acidic chiral proton alpha- to the pendent ester in 318 may 
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occur, resulting in epimerisation of the all-important chiral centre. To determine 
whether or not this was indeed the case, a sample of carboxylic acid 319 was subjected 
to decarboxylative conditions, thus reforming Boc-protected lactam 317 (Scheme 118). 
An []D measurement of this material was obtained and compared to that of the 
original chiral material 317. Pleasingly, a close match was observed, with experimental 
measurements of −36.4 (c 0.86, CH2Cl2) and −37.5 (c 0.86, CH2Cl2) respectively, 
confirming that no epimerisation had taken place. With concerns of stereochemistry 
quelled, and the final steps of substrate synthesis completed, attention could now be 
turned to the key cyclisation reaction. 
 
It was our hope that the pre-existing stereogenic centre in 320, derived from (S)-
pyroglutamic acid, would result in substrate-controlled diastereoselectivity in the 
cyclisation reaction. Specifically, if the 5-membered lactam in product 321 adopts an 
envelope conformation, we would expect the thermodynamically more favoured 
product 321p’ to be that in which both the ester group and the bulk of the oxindole 
moiety are in pseudo-equatorial positions (Figure 20). As the cyclisation reaction is 
performed at elevated temperature, we anticipated that the thermodynamic product 
would prevail, based on the assumption that the radical addition step onto the benzene 
ring is a reversible process. 
 
H
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CO2Et
O
N O
H
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N
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O
O
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MeO
MeO
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Figure 20: Expected thermodynamic product from Cu(II) cyclisation of 320 
 
Alternatively, if the reaction proceeded under kinetic control, then the expected 
product 321p’’ would be that arising from formation of the new C‒C bond anti- to the 
bulk of the CO2Et group (Scheme 119), and provide the diastereomer with the incorrect 
stereochemical configuration at the quaternary carbon centre. We believed that due to 
the high temperature of the reaction, the kinetic control mechanism was unlikely. 
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Scheme 119: Formation of expected kinetic product 
 
In terms of regiochemistry, when the cyclisation precursor bears a meta-substituent, 
cyclisation can potentially yield two regioisomeric products: one arising from 
formation of the new bond at the carbon atom between the two substituents, and one 
resulting from radical addition to the position of the benzene ring furthest away from 
the methoxy substituent (Scheme 120). The former isomer 321o could be favoured 
based on electronic grounds as this leads to a more stabilised cyclohexadienyl radical 
intermediate 323o. On the other hand, addition ortho- to the substituent is the more 
sterically hindered position, suggesting that addition could take place para- to the 
substituent on steric grounds. We were excited to investigate which of the two isomers 
would be preferential in the spirotryprostatin A synthesis. 
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Scheme 120: Steric and electronic outcomes of the cyclisation reaction of meta-substituted substrate 320 
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In our first attempt, cyclisation of m-methoxy-substituted anilide 320 resulted in the 
formation of oxindole 321 as an inseparable mixture of four compounds, namely regio- 
and stereoisomers, in a combined yield of 49%. A careful inspection of NMR data 
allowed us to establish that, interestingly, a 3:2 mixture of regioisomers 321o and 321p 
was obtained, with the minor compound 321p representing the desired isomer. 
Furthermore, the minor isomer was formed as a 2:1 mixture of diastereoisomers, 
although it was not possible to establish which of the two diastereoisomers was 
desired.  It was clear that further investigation was essential. 
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Scheme 121: Cyclisation of m-methoxy anilide 320 
 
 
5.2.3 Stereoselectivity study 
 
In order to facilitate the ease of data interpretation, our study began by examining the 
stereoselectivity of the reaction without the additional complexity of regioselectivity. 
Hence, our starting point was the reaction of unsubstituted substrate 324. Using 
previously synthesised ester 318 (vide supra, Scheme 121), hydrogenolysis followed by 
amide coupling with N-methylaniline (265) furnished 324 in 83% yield over the two 
steps. 
 
  
Chapter 5 
 
 
129 
 
NBoc
O
CO2Et
N
O
83% (2 steps)
dr 4:1NBoc
O
CO2Et
BnO
O
(a), (b)
318 324  
Reagents and conditions: (a) Pd/C, H2, EtOAc, rt, 2 h; (b) 2-chloro-1-methylpyridinium iodide, 
Et3N, 265, CH2Cl2, 0 °C to rt, 16 h. 
Scheme 122: Synthesis of unsubstituted substrate 324 
 
Cyclisation of 324 under standard conditions (mesitylene, 170 °C, 30 min) provided a 
5:3 mixture of diastereoisomers in 44% overall yield. At this point we were unable to 
ascertain which diastereoisomer was the major product, as the isomer mixture was 
inseparable and therefore NOE experiments were inconclusive. Nevertheless, 
irradiation of HC showed a small enhancement of HA in the minor diastereoisomer 
325’’ (Scheme 123), suggesting that the desired stereoisomer 325’, with HA and the ester 
group on the same face, could indeed be the major product. 
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Scheme 123: Cyclisation of unsubstituted anilide 324 
 
To investigate the effect of temperature, the cyclisation reaction was repeated in 
toluene at 120 °C, whereby only a slight change to both the yield and the 
diastereomeric ratio of products 325’ and 325’’ was observed (Scheme 123). 
 
As the size of the pendent side-chain on the pyrrolidone ring (ethyl ester in 324) could 
also affect the stereoselectivity of cyclisation, we next sought to prepare a substrate 
with a larger side-chain and focused on tert-butyldiphenylsilyl (TBDPS)-protected 
primary alcohol 332 (Scheme 124). 
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Thus, following literature precedent, ester 326 was obtained by esterification of (S)-
pyroglutamic acid (315),247,248 which was then reduced with sodium borohydride.250 
The resulting pyroglutamol (327),251 was protected as a silyl ether 328 and further N-
Boc protection provided lactam 329,251 ready for benzylcarboxylation. Following 
treatment of 329 with LiHMDS and CbzCl under standard conditions, 330 was 
obtained as an inconsequential 10:1 mixture of diastereoisomers. Finally, 
hydrogenolysis followed by amide coupling of 331 with N-methylaniline (265) cleanly 
gave trans-anilide 332 (Scheme 124).  
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Reagents and conditions: (a) SOCl2, MeOH, −20 °C to rt, 1 h; (b) NaBH4, EtOH, 0 °C, 2h;  
(c) TBDPSCl, imidazole, DMF, rt, 16 h; (d) Boc2O, DMAP, MeCN, rt, 20 h; (e) LiHMDS, CbzCl, 
THF, −78 °C, 1 h; (f) ) Pd/C, H2, EtOAc, rt, 2 h; (g) 2-chloro-1-methylpyridinium iodide, 265, 
Et3N, CH2Cl2, 0 °C to rt, 16 h. 
Scheme 124: Second generation model substrate synthesis 
 
To our surprise, the cyclisation reaction of substrate 332 resulted in a completely non-
selective reaction to provide a 1:1 mixture of diastereoisomers (Scheme 125), although 
these could now be separated and assigned by NOE studies. 
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Scheme 125: Cyclisation of TBDPS-protected substrate 
 
5.2.4 Regioselectivity study 
 
Having had little success with improving the stereoselectivity of the reaction, we 
turned our attention to examining the regioselectivity control elements in the 
cyclisation. We wished to explore whether, by altering steric and electronic properties 
of the substrates, the regioselectivity of the cyclisation could be improved. In order to 
investigate this effect without the additional complication of stereoselectivity, a range 
of m-hydroxy anilide cyclisation precursors (20aa‒ad) were prepared, masked with a 
variety of oxygen protecting groups. 
 
HO NH2 RO NHBn
NBoc
O
N
O
Bn
RO
264b
R = TBS, 336b, 51%
R = H, 337e, quant.
R = Ac, 338c, 74%
(b)
(c)
R = TBS, 20ab, 74%
R = H, 20ae, 87%
R = Piv, 20ad, 90%
(e)
(f)
(d)
R = TBDPS, 335a, 31%
R = Ac, 20ac, 77%
(a)
334
R = TBDPS, 20aa, 82%
 
Reagents and conditions: (a) i) TBSCl or TBDPSCl, imidazole, DMF, rt, 4 h; ii) benzaldehyde, 
AcOH, MeOH, rt, 3h then NaBH4, rt, 1 h; (b) TBAF, THF, rt, 3 h; (c) NaH, THF, 0 °C, 10 min, 
then Ac2O, rt, 1 h; (d) 2-chloro-1-methylpyridinium iodide, Et3N, CH2Cl2, 0 °C to rt, 16 h, yields 
over 2 steps from 263b; (e) TBAF, THF, rt, 1.5 h; (f) DMAP, Et3N, PivCl, CH2Cl2, rt, 3 h 
Scheme 126: Synthesis of substrates for regioselectivity study 
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Specifically, silyl protection of 3-aminophenol (334) followed by reductive amination 
with benzaldehyde gave the benzyl protected anilines 335a and 335b.252 To access the 
acetoxy-protected phenol 336c, 336b was treated with tetrabutylammonium fluoride 
(TBAF) to remove the TBS moiety and then acylated. Amide coupling of 335a‒c with 
acid 264b gave rise to substrates 20aa to 20ac in good yields. Desilylation of 20ab 
followed by treatment with pivaloyl chloride then swiftly furnished 20d. With these 
meta-substituted precursors in hand, investigation into the regioselectivity of the 
cyclisation commenced and the results of this study, together with a direct comparison 
to methoxy-substituted precursor 20p, are shown in Table 23. 
 
Initial investigation showed that by placing an electron withdrawing acetate group on 
the aromatic ring (Table 23, entry 2), the regioselectivity of the cyclisation is diminished 
in comparison to that of the electron-donating methoxy substrate (entry 1), thereby 
shifting the ratio towards the desired regioisomer 21p.  
 
Table 23: Results of cyclisation for regioselectivity study 
+NBoc
O
N
O
P
RO
N
O
BocN
O
P
RO N
O
P
OR NBoc
O
20p,aaad
21p 21o
 
Entry R P 21p:21oa Yield of 21p b Yield of 21o b 
1 Me Me 1 : 3 18 58c 
2 Ac Bn 1 : 1.6 15 24 
3 Piv Bn 1 : 1.7 15 25c 
4 TBS Bn 1 : 1.3 19c 26 
5 TBDPS Bn 1.3 : 1 30 19 
aDetermined by 1H NMR analysis of the unpurified product mixture; bIsolated yields; cYields 
extrapolated; a small amount of Boc-protected lactam 262b co-eluted with products during 
chromatography 
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Increasing the size of the protecting group to a pivaloyl, but maintaining its electron 
withdrawing nature, had little effect on the selectivity (entry 3). Unfortunately, in both 
cases, the use of acetate or pivaloyl electron-withdrawing groups resulted in a marked 
decrease in the yield of the reaction, an observation that had already been seen in 
previous studies (vide supra, Table 18). 
 
In the case of the electron-donating silyl groups, the yields were moderate.  TBS-
protected substrate 20ab gave nearly a 1:1 ratio of regioisomers (entry 4), and 
pleasingly, the use of bulky TBDPS group resulted in the desired isomer 20aa being the 
major product (entry 5). Overall, we were able to override the electronic effects by 
making use of a large protecting group, thus giving rise to the desired regioisomer as 
the major product, although the selectivity and the yield were both still disappointing. 
 
 
5.2.5 Continuation of synthesis 
 
At this stage, we were interested in examining the cyclisation of a substrate containing 
both a TBDPS-protected meta-hydroxy aniline and a TBDPS-protected pendent primary 
alcohol functionality on the pyrrolidinone ring. Thus, cyclisation precursor 336 was 
prepared from ester 330 (Scheme 127). Cyclisation of this substrate afforded a complex 
mixture of stereo- and regioisomers (Scheme 127). One of these products was separated 
by chromatography and identified by NOE experiments as undesired diastereoisomer 
337p”. In addition to 16% of isomer 337p”, an inseparable mixture of at least three 
further compounds was isolated (approx. 28% mass recovery). We had anticipated this 
mixture to potentially comprise of the remaining three isomers 337p’, 337o’ and 337o’’, 
however, due to the complexity of the NMR data, this conclusion was only tentative 
and the identities of the individual constituents of the mixture could not be 
conclusively established at this point. 
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Scheme 127: Synthesis and cyclisation of bis-OTBDPS substrate 336 
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5.3 Future work 
 
The cyclisation step of this synthesis is evidently in need of further optimisation and 
this will be investigated in due course. If the efficiency and selectivity can be improved, 
spirotryprostatin A will be accessed via a synthetic plan as proposed in Scheme 128. 
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Scheme 128: Proposed forward synthesis of spirotryprostatin A 
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In this context, the carbonyl functionality of the pyrrolidinone amide in 337p’ should 
possess increased electrophilicity compared to the amide in the oxindole unit due to 
the electron-withdrawing nature of the Boc group. This bias should enable addition of 
a nucleophile, such as a Grignard reagent, to install the isobutene side-chain. 
 
Literature precedent shows that a nucleophilic addition/deoxygenation sequence can 
be used to convert N-Boc lactams into -substituted N-Boc pyrrolidines respectively, 
via an N-acyliminium ion intermediate, with high stereselectivity.253,254 We envisage 
using this nucleophilic addition/reductive deoxygenation sequence to convert 339 into 
340, with reduction occurring from the opposite face to the bulky OTBDPS side chain 
and installing the new stereogenic centre in 340 with the correct stereochemical 
configuration. Following this, N-Boc deprotection will allow coupling with N-Boc 
proline to form 341 (Scheme 128). 
 
Selective primary TBDPS deprotection in the presence of a phenolic TBDPS function 
with carbon tetrabromide in refluxing methanol will provide 342 following Boc 
cleavage (Scheme 128).255 Jones oxidation should then result in lactamisation directly 
from 342 to give 343. In the final stages of the synthesis, desilylation and methylation 
will reveal the methoxy substituent, whereas single-electron reductive cleavage of the 
benzyl group157,163 will provide the target natural product, spirotryprostatin A (22). 
 
5.4 Summary  
 
Preliminary studies towards the synthesis of spirotryprostatin A (22) via a copper(II)-
catalysed radical cyclisation have been conducted. The stereochemistry of the 
cyclisation was investigated and it was found to be poor to moderate with the 
substrates utilised. Studies into the regioselectivity of the cyclisation showed that the 
ratio of regioisomeric products could be shifted towards the desired isomer by the use 
of a bulky silyl group, however both selectivity and yield were still disappointing and 
further optimisation of the cyclisation reaction is required. 
 
Future work in the group will focus on continued optimisation of the copper(II) 
cyclisation reaction, followed by investigation into the subsequent steps of the 
proposed synthesis towards spirotryprostatin A (22). 
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Chapter 6 - Final conclusions and future work 
6.1 Unsaturated ketones and elaeokanidine A 
 
The aim of project I was to develop a telescoped procedure for the synthesis of ,- and 
,-unsaturated ketones 17 and 18 directly from primary alcohols 60. A one-pot route 
to ,-unsaturated ketones was subsequently developed, utilising an 
oxidation/allylation/oxidation procedure, and has been demonstrated on a range of 
aromatic and aliphatic substrates. Allylic ketones 17 could then be easily transformed 
into the corresponding conjugated systems 18 by means of DBU-catalysed 
isomerisation (Scheme 129).  
 
R
O
R
O (ii) (iii)
R
OH
61 62 17
R
OH
60
(i)
R
O
18
(iv)
Reagents and conditions: i) DMP (1.5‒2.0 eq), CH2Cl2, rt, 1 h; ii) montmorillonite K10, potassium 
allyltrifluoroborate (78, 1.5‒2.0 eq), rt, 1 h; iii) DMP (2.0‒2.5 eq), rt, 1 h; iv) DBU (0.1 eq), Et2O, 
24 h 
Scheme 129: Synthesis of ,- and ,-unsaturated ketones 17 and 18 directly from primary alcohols 60 
 
Future work in this area will address the inclusion of this isomerisation into the one-
pot procedure, in addition to the application of this methodology to natural product 
synthesis. 
 
We next sought to apply this methodology to the synthesis of elaeokanidine A (19), 
using alcohol 82 and dienone 81 as key intermediates. Following optimisation of the 
synthetic route, the construction of the indolizidine core was achieved, leading to the 
synthesis of alcohol 82. Application of the O/A/O/I methodology was not as 
successful as anticipated, nevertheless access was gained to racemic 81 and the 
subsequent addition of ammonia was demonstrated, resulting in an inseparable 
mixture of diastereoisomers. An asymmetric route to 81 was developed by 
Cuthbertson by means of the cyclisation of acetal 169, from which a sample enriched in 
elaeokanidine A (19) was obtained (Scheme 130).  
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Scheme 130: Synthetic routes to dienone 81 and elaeokanidine A (19) 
 
Future work will investigate the separation of the diastereoisomers resulting from 
ammonia addition, in order to obtain pure samples of elaeokanidine A (19). 
 
6.2 Spirooxindoles and spirotryprostatin A 
 
Building on previous work in the Taylor group concerning the synthesis of oxindoles, a 
simple and efficient route for the formation of lactam and imide-based spirocyclic 
oxindoles 21 has been developed. The key step in this process is the radical cyclisation 
of linear anilide precursors 20, a reaction which is performed using just catalytic 
amounts of copper(II) under an air atmosphere (Scheme 131). 
 
mesitylene, 170 °C,
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Scheme 131: Copper-catalysed cyclisation of linear anilides 20 to form spirooxindoles 21 
 
The cyclisation has been demonstrated on a wide range of substrates with varying ring 
size, aromatic substituents and protecting groups, thus exemplifying the broad scope 
of this reaction. It was later found, by Franckevičius and Drouhin, that the cyclisation 
could be further improved by vigorously bubbling air through the reaction mixture, 
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and the utility of the reaction was demonstrated in a formal synthesis of the alkaloid 
horsfiline. Future work will look at the possibility of an enantioselective variant of the 
copper-catalysed cyclisation. 
 
Preliminary studies towards the synthesis of spirotryprostatin A (22) have been 
launched, specifically investigating the stereo- and regioselectivity of the cyclisation of 
anilides 344 to give isomeric spirooxindoles 345 (Scheme 132). 
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Scheme 132: Stereo- and regioselectivity studies on the cyclisation reaction 
 
Altering the steric bulk of R1 had little effect on the stereoselectivity of the cyclisation 
reaction. The regioselectivity of the reaction initially favoured products 345o, where the 
new bond is formed ortho to the aromatic substituent, presumably due to favourable 
electronics. With the use of a bulky TBDPS protecting group on the oxygen, the ratio of 
regioisomeric products arising from cyclisation was shifted to the desired isomer 345p. 
 
A route for the remainder of the synthesis of spirotryprostatin A (22) from spirocyclic 
oxindole 337p’ has been proposed (Scheme 133). Future work will include optimisation 
of the cyclisation reaction and completion of the natural product synthesis.  
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Scheme 133: Substrate 337p’ for the proposed synthesis of spirotryprostatin A (22) 
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Chapter 7 – Experimental 
 
7.1 General Experimental 
 
Except where specified, all reagents were purchased from commercial sources and 
were used without further purification. All procedures were carried out under an 
argon atmosphere, unless otherwise stated. Dichloromethane (CH2Cl2) and diethyl 
ether (Et2O) were dried using an Mbraun MPS solvent purification system. 
Tetrahydrofuran (THF) was distilled over sodium benzophenone ketyl immediately 
before use. Petroleum ether (PE) refers to light petroleum ether, bp 40-60 °C. NH3 
refers to 35% aqueous ammonia. Et2O* was prepared by shaking anhydrous diethyl 
ether with a quarter volume of 9:1 pH 10 carbonate buffer:diethylamine solution; the 
solvent was dried over Na2SO4. All aqueous solutions are saturated unless otherwise 
stated. Dess‒Martin periodinane was synthesised using the procedures by Frigerio55 
(IBX) and Böckmann.256 Flash column chromatography was performed using Fluka 
silica gel 60, 220‒440 mesh at a medium positive pressure, unless otherwise stated. 
KF-SiO2 refers to 10% w/w of finely ground KF and 90% w/w silica. Analytical thin 
layer chromatography was performed on aluminium sheets pre-coated with Merck 
silica gel F254 and visualised with ultraviolet light (254 nm), and staining with aqueous 
potassium permanganate or alcoholic anisaldehyde solutions as appropriate. Rf values 
are quoted to the nearest 0.05. Preparative thin layer chromatography was performed 
on glass sheets pre-coated with Analtech silica gel GF254 and visualised with ultraviolet 
light (254 nm). Proton nuclear magnetic resonance (1H NMR) spectra were recorded at 
400 MHz on a JEOL ECX 400 spectrometer or a JEOL ECS 400 spectrometer and are 
reported as follows: chemical shift δ (ppm) (number of protons, multiplicity, coupling 
constant J (Hz), assignment). The letters a and b following assignment indicates 
diastereotopic protons. Couplings are expressed as: s, singlet; d, doublet; t, triplet; q, 
quartet; quint., quintet; m, multiplet; br, broad; or combinations of these. Coupling 
constants are quoted to the nearest 0.5 Hz and are reported as measured splittings on 
each individual resonance. Where coincident coupling constants have been observed in 
the NMR spectrum, the apparent multiplicity of the proton resonance concerned is 
reported. The residual protic solvent CHCl3 (δH = 7.26 ppm), MeCN (δH = 1.94 ppm, 
quint.) or DMSO (δH = 2.50 ppm, quint.)  was used as the internal reference. 13C NMR 
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spectra were recorded on the same spectrometer at 100 MHz, using the central 
resonance of CDCl3 (δC = 77.0 ppm) as the internal reference. 19F NMR spectra were 
recorded at 300 MHz on a JEOL ECX 400 spectrometer. DEPT-135 and two-
dimensional (COSY, HSQC, HMBC) NMR spectroscopy were used as appropriate to 
aid in the assignment of 1H and 13C NMR spectra. Chemical shifts are reported in parts 
per million (ppm) to the nearest 0.01 ppm for 1H and the nearest 0.1 ppm for 13C and 
19F. The atom numbering on the structures below is for assignment purposes and is 
independent of IUPAC nomenclature. Melting points were measured on a Gallenkamp 
melting point apparatus and are uncorrected. Infrared spectra were carried out on a 
ThermoNicolet IR100 spectrometer and are recorded as thin film between NaCl disks.  
Absorption maxima are reported in wavenumbers (cm-1) and only selected 
absorbencies are reported. Accurate mass data were recorded using a Bruker 
MicroTOF spectrometer. Elemental analysis was conducted on an Exeter Analytical, 
Inc. CE-440 Elemental Analyser with samples weighed using a Sartorius analytical 
balance. Crystallographic data was obtained using a SuperNova, Single source at 
offset, Eos diffractometer. References following compound names refer to literature 
procedures. 
 
 
7.2 Unsaturated ketones 
 
Potassium allyltrifluoroborate (78)76 
 
1
2
3
BF3K
 
 
To a solution of trimethylborate (5.57 mL, 50.0 mmol, 1.0 eq) in Et2O (75 mL) cooled to 
−78 °C was added allylmagnesium bromide (1 M in Et2O, 50.0 mL, 50.0 mmol, 1.0 eq) 
over 40 min via syringe pump. The reaction was stirred at –78 °C for 2 h then poured 
immediately onto 10% aq. HCl (50 mL) and the mixture was stirred vigorously at room 
temperature for 30 min. The layers were separated and the aqueous layer was 
extracted with Et2O (3 × 75 mL). The combined organic extracts were concentrated in 
vacuo, and a solution of KHF2 (3.5 M, 50.0 mL H2O, 175 mmol) in water was added. The 
mixture was stirred at room temperature for 30 min before storing at 4 °C overnight. 
The resultant white solid was filtered, washed with Et2O (50 mL) and dried in vacuo to 
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afford 78 (5.14 g, 69%) as a colourless powder, mp 259 °C – decomposition; 
δH (400 MHz, CD3CN) 5.92 (1H, ddt, J = 17.5, 10.0, 8.0, H-2), 4.69 (1H, d, J = 17.5, H-1a), 
4.61 (1H, d, J = 10.0, H-1b), 1.10‒1.00 (2H, m, H-3); δF (300 MHz, CD3CN) −140.0 (q, 
J = 58.0). Data consistent with the literature values.76 
 
 
1-(4-Chlorophenyl)but-3-en-1-ol (62a)76 
 
2
1
4
3 5
6
OH
Cl
7
8
 
 
To a suspension of 4-chlorobenzaldehyde (60 mg, 0.43 mmol, 1.0 eq) and potassium 
allyltrifluoroborate (126 mg, 0.86 mmol, 2.0 eq) in CH2Cl2 (5 mL) was added boron 
trifluoride diethyl etherate (26 μL, 0.21 mmol, 0.5 eq). The reaction was stirred at room 
temperature overnight then quenched with aq. NaHCO3 (5 mL). The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 × 5 mL). The combined 
organic extracts were dried (Na2SO4), and concentrated in vacuo to afford 62a (73 mg, 
0.40 mmol, 93%) as a colourless oil. Rf (1:4 EtOAc:Hexane) = 0.20; δH (400 MHz, CDCl3) 
7.34‒7.28 (4H, m, H-2, H-3), 5.78 (1H, dddd, J = 11.0, 9.5, 7.5, 6.5, H-7), 5.19‒5.14 (2H, m, 
H-8), 4.73 (1H, ddd, J = 8.0, 5.0, 3.0, H-5), 2.57‒2.40 (2H, m, H-6), 2.06 (1H, d, J = 3.0, 
OH); δC (100 MHz, CDCl3) 142.2 (C-1), 133.9 (C-7), 133.1 (C-4), 128.5 (C-2), 127.2 (C-3), 
119.0 (C-8), 72.5 (C-5), 43.9 (C-6). Data consistent with the literature values.257 
 
 
1-(4-Methoxyphenyl)but-3-en-1-ol (62c) 
 
2
1
4
3 5
6
OH
O
7
8
9
 
 
To a suspension of p-anisaldehyde (31 μL, 0.25 mmol, 1.0 eq), potassium 
allyltrifluoroborate (44 mg, 0.30 mmol, 1.2 eq) and montmorillonite K10 (50 mg) in 
CH2Cl2 (2 mL) was added acetic acid (159 μL, 2.8 mmol, 11.0 eq). The reaction mixture 
was stirred at room temperature for 15 min at which point the reaction was quenched 
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with aq. NaHCO3 and stirred for 10 min. The mixture was filtered then diluted with 
CH2Cl2 (5 mL) and brine (5 mL). The layers were separated and the aqueous layer was 
further extracted with CH2Cl2 (2 x 5 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated in vacuo to afford 62c (38 mg, 0.21 mmol, 85%) as a 
colourless oil. Rf (1:9 EtOAc:PE) = 0.10; δH (400 MHz, CDCl3) 7.28 (2H, d, J = 8.5, H-2), 
6.89 (2H, d, J = 8.5, H-3), 5.80 (1H, ddt, J = 17.0, 10.0, 7.0, H-7), 5.18‒5.11 (2H, m, H-8), 
4.69 (1H, t, J = 6.5, H-5), 2.96 (3H, s, H-9), 2.52‒2.48 (2H, m, H-6), 2.01 (1H, br s, OH); 
δC (100 MHz, CDCl3) 159.0 (C-1), 136.0 (C-4), 134.6 (C-7), 127.0 (C-3), 118.2 (C-8), 113.7 
(C-2), 72.9 (C-5), 55.3 (C-9), 43.7 (C-6). Data consistent with the literature values.257 
 
 
(1E)-1-Phenylhexa-1,5-dien-3-ol (62h) 
 
2
1
4
3 5
6
7
8
OH
9
10
 
 
To a suspension of cinnamaldehyde (31 μL, 0.25 mmol, 1.0 eq), potassium 
allyltrifluoroborate (44 mg, 0.30 mmol, 1.2 eq) and montmorillonite K10 (50 mg) in 
CH2Cl2 (2 mL) was added acetic acid (159 μL, 2.8 mmol, 11.0 eq). The reaction mixture 
was stirred at room temperature for 15 min at which point the reaction was quenched 
with aq. NaHCO3 and stirred for 10 min. The mixture was filtered then diluted with 
CH2Cl2 (5 mL) and brine (5 mL). The layers were separated and the aqueous layer was 
further extracted with CH2Cl2 (2 x 5 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated in vacuo to afford 62h (40 mg, 0.23 mmol, 92%) as a 
colourless oil. Rf (1:9 EtOAc:PE) = 0.10;  δH (400 MHz, CDCl3) 7.38 (2H, d, J = 7.0, H-3), 
7.32 (2H, t, J = 7.0, H-2), 7.24 (1H, t, J = 7.0, H-1), 6.61 (1H, d, J = 16.0, H-5), 6.24 (1H, dd, 
J = 16.0, 6.0, H-6), 5.91‒5.81 (1H, m, H-9), 5.22‒5.17 (1H, m, H-10a), 5.17‒5.14 (1H, m, 
H-10b), 4.39‒4.33 (1H, m, H-7), 2.49‒2.34 (2H, m, H-8), δC (100 MHz, CDCl3) 136.6 (C-4), 
134.0 (C-9), 131.5 (C-6), 130.4 (C-5), 128.6 (C-2), 127.7 (C-1), 126.5 (C-3), 118.6 (C-10), 
71.7 (C-7), 42.0 (C-8). Data consistent with the literature values.258 
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1-(4-Trifluoromethylphenyl)but-3-en-1-one (17e) 
 
2
1
4
3
5
6
O
F3C
7
8
 
 
To a suspension of 4-(trifluoromethyl)benzaldehyde (34 μL, 0.25 mmol) and potassium 
allyltrifluoroborate  (39 mg, 0.26 mmol, 1.05 eq) in CH2Cl2 (2 mL) was added boron 
trifluoride diethyl etherate (15 μL, 0.13 mmol, 0.5 eq) and the mixture was stirred at 
room temperature for 10 min. Dess‒Martin periodinane (127 mg, 0.30 mmol, 1.2 eq) 
was added and the mixture stirred for a further hour. The reaction was quenched with 
aq. NaHCO3 (5 mL) and aq. Na2S2O3 (5 mL) and stirred for 10 min before diluting with 
CH2Cl2 (5 mL) and brine (5 mL). The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (2 x 5 ml). The combined organic extracts then dried (Na2SO4) 
and concentrated in vacuo to afford 17e (35 mg, 0.16 mmol, 65%) as an off-white waxy 
solid, which was used without further purification. Rf (1:9 EtOAc:PE) = 0.50; 
δH (400 MHz, CDCl3) 8.07 (2H, d, J = 8.0) and 7.73 (2H, d, J = 8.0) (H-2, H-3), 6.07 (1H, 
ddt, J = 17.0, 10.5, 6.5, H-7), 5.27 (1H, dq, J = 10.5, 1.5, H-8a), 5.23 (1H, J = 17.0, 1.5, 
H-8b), 3.78 (2H, dt, J = 6.5, 1.5, H-6). Data consistent with the literature values.48 
 
 
(2E)-1-(4-Nitrophenyl)but-2-en-1-one (18b) 
 
2
1
4
3
5
6
O
O2N
7
8
 
 
To a suspsension of 4-nitrobenzaldehyde (38 mg, 0.25 mmol, 1.0 eq) and potassium 
allyltrifluoroborate (78, 39 mg, 0.26 mmol, 1.05 eq) in CH2Cl2 (2 mL) was added boron 
trifluoride diethyl etherate (15 μL, 0.13 mmol, 0.5 eq) and the mixture was stirred at 
room temperature for 10 min. Dess‒Martin periodinane (127 mg, 0.30 mmol, 1.2 eq) 
was added and the mixture stirred for a further hour. The reaction was quenched with 
aq. NaHCO3 (5 mL) and aq. Na2S2O3 (5 mL) and stirred for 10 min before diluting with 
CH2Cl2 (5 mL) and brine (5 mL). The layers were separated and the aqueous layer was 
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extracted with CH2Cl2 (2 x 5 mL). The combined organic extracts were dried (Na2SO4) 
and concentrated in vacuo to afford 17b. Flash column chromatography [KF-SiO2, 1:9 
EtOAc:PE] afforded 18b as an off-white powdery solid (11 mg, 23%). Rf (1:9 EtOAc:PE) 
= 0.10; mp 68‒71 ºC (lit259 44 ºC, MeOH-H2O); max/cm-1 (thin film) 1674, 1628, 1601, 
1518, 1346; δH (400 MHz, CDCl3) 8.32 (2H, d, J = 9.0, H-2), 8.05 (2H, d, J = 9.0, H-3), 7.14 
(1H, dq, J = 15.0, 7.0, H-7), 6.86 (1H, dq, J = 15.0, 1.5, H-6), 2.05 (3H, dd, J = 7.0, 1.5, H-8); 
δC (100 MHz, CDCl3) 189.2 (C-5), 150.0 (C-1), 147.5 (C-7), 142.8 (C-4), 129.4 (C-2), 127.2 
(C-6), 123.7 (C-3), 18.8 (C-8); m/z (ESI) 192 [MH]+; [HRMS (ESI): calcd for C10H10NO3, 
192.0655. Found: [MH]+, 192.0648 (3.6 ppm error)]. NMR and MS data consistent with 
the literature values.260 
 
 
7.2.1 General procedure A ‒ oxidation/allylation/oxidation of primary alcohols 60 
to ,-unsaturated ketones 17 
 
R
O
R
O (ii) (iii)
R
OH
61 62 17
R
OH
60
(i)
 
Reagents and conditions: i) DMP (1.5‒2.0 eq), CH2Cl2, rt, 1 h; ii) montmorillonite K10, potassium 
allyltrifluoroborate (78, 1.5‒2.0 eq), rt, 1 h; iii) Dess‒Martin  (2.0‒2.5 eq), rt, 1 h 
 
To the primary alcohol (0.25 mmol) in CH2Cl2 (5 mL) at room temperature was added 
Dess‒Martin periodinane (1.5‒2.0 eq, 0.25‒0.50 mmol) and the mixture stirred for 1 h. 
Montmorillonite K10 (50 mg) was then added followed by potassium 
allyltrifluoroborate (73 mg, 0.49 mmol) and the mixture stirred for 1 h before adding a 
further portion of Dess‒Martin periodinane (2.0‒2.5 eq, 0.5‒0.75 mmol). After 1 h, the 
reaction was quenched with aq. NaHCO3 (5 mL) and aq. Na2S2O3 (5 mL) and allowed 
to stir for 1h before diluting with brine (10 mL) and CH2Cl2 (10 mL).  The mixture was 
filtered then the layers separated. The aqueous portion was further extracted with 
CH2Cl2 (2 x 5 mL) and the combined organic extracts were dried (Na2SO4) and 
concentrated in vacuo. The crude residue was purified on silica to afford the title 
compound. 
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1-(4-Chlorophenyl)but-3-en-1-one  (17a) 
 
2
1
4
3
5
6
O
Cl
7
8
 
 
4-Chlorobenzyl alcohol (35 mg, 0.25 mmol), Dess‒Martin periodinane (161 mg and 
280 mg, 0.38 mmol and 0.66 mmol), potassium allyltrifluoroborate (78, 73 mg, 
0.49 mmol) and montmorillonite K10 (50 mg) in CH2Cl2 (5 mL) were reacted according 
to general procedure A. Flash column chromatography [1:9 EtOAc:Hexane] afforded 
17a (32 mg, 71%) as a white solid, mp 43‒45 °C; Rf (1:4 EtOAc:Hexane) = 0.40; 
δH (400 MHz, CDCl3) 7.91 (2H, d, J = 9.0), 7.44 (2H, d, J = 9.0) (H-2, H-3), 6.06 (1H, ddt, 
J = 17.0, 10.0, 6.5, H-7), 5.25 (1H, dq, J = 10.0, 1.5, H-8a), 5.21 (1H, dq, J = 17.0, 1.5, H-8b), 
3.73 (2H, dt, J = 6.5, 1.5, H-6). Data consistent with the literature values.261 
 
 
1-(4-Methoxyphenyl)but-3-en-1-one (17c) 
 
2
1
4
3
5
6
O
O
7
8
9
 
 
4-Methoxybenzyl alcohol (35 mg, 0.25 mmol), Dess‒Martin periodinane (160 mg and 
230 mg, 0.38 mmol and 0.54 mmol), potassium allyltrifluoroborate (78, 73 mg, 
0.49 mmol) and montmorillonite K10 (50 mg) in CH2Cl2 (5 mL) were reacted according 
to general procedure A. Flash column chromatography [1:9 EtOAc:Hexane] afforded 
17c (41 mg, 92%) as a white solid,  mp 42‒44 °C (lit262 41 °C); Rf (1:9 EtOAc:PE) = 0.20; 
δH (400 MHz, CDCl3) 7.95 (2H, d, J = 9.0, H-3), 6.93 (2H, d, J = 9.0, H-2), 6.07 (1H, ddt, 
J = 17.0, 10.5, 6.5, H-7), 5.21 (1H, dq, J = 10.5, 1.5, H-8a), 5.19 (1H, dq, J = 17.0, 1.5, H-8b), 
3.87 (3H, s, H-9), 3.70 (2H, dt, J = 6.5, 1.5, H-6). Data consistent with the literature 
values.262,263 
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1-(4-Nitrophenyl)but-3-en-1-one (17b) 
 
2
1
4
3
5
6
O
O2N
7
8
 
 
4-Nitrobenzyl alcohol (39 mg, 0.25 mmol), Dess‒Martin periodinane (160 mg and 
270 mg, 0.38 mmol and 0.64 mmol), potassium allyltrifluoroborate (78, 73 mg, 
0.49 mmol) and montmorillonite K10 (50 mg) in CH2Cl2 (5 mL) were reacted according 
to general procedure A. Flash column chromatography [1:9 EtOAc:Hexane] afforded 
17b (46 mg, 96%) as a white solid, mp 51‒53 °C; Rf (1:9 EtOAc:PE) = 0.30; δH (400 MHz, 
CDCl3) 8.32 (2H, d, J = 9.0, H-2), 8.12 (2H, d, J = 9.0, H-3), 6.07 (1H, ddt, J = 17.0, 10.5, 
6.5, H-7), 5.29 (1H, dq, J = 10.5, 1.5, H-8a), 5.25 (1H, dq, J = 17.0, 1.5, H-8b), 3.81 (2H, dt, 
J = 6.5, 1.5, H-6). Data consistent with the literature values.261 
 
 
1-(4-Bromophenyl)but-3-en-1-one (17d) 
 
2
1
4
3
5
6
O
Br
7
8
 
 
4-Bromobenzyl alcohol (47 mg, 0.25 mmol), Dess‒Martin periodinane (160 mg and 
270 mg, 0.38 mmol and 0.64 mmol), potassium allyltrifluoroborate (78, 73 mg, 
0.49 mmol) and montmorillonite K10 (50 mg) in CH2Cl2 5 mL) were reacted according 
to general procedure A. Flash column chromatography [1:9 EtOAc:Hexane] afforded 
17d (48 mg, 85%) as a white solid, mp 39‒41 °C; Rf (1:9 EtOAc:PE) = 0.60; δH (400 MHz, 
CDCl3) 7.82 (2H, d, J = 8.5), 7.60 (2H, d, J = 8.5) (H-2, H-3), 6.05 (1H, ddt, J = 17.0, 10.0, 
6.5, H-7), 5.24 (1H, dq, J = 10.0, 1.5, H-8a), 5.21 (1H, dq, J = 17.0, 1.5, H-8b), 3.72 (2H, dt, 
J = 6.5, 1.5, H-6). Data consistent with the literature values.264 
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1-(Naphthalen-2-yl)but-3-en-1-one (17i) 
 
6
5
4
3
8
7
2
1
10
9
11
12
O
13
14
 
 
(2-Naphthyl)methanol (40 mg, 0.25 mmol), Dess‒Martin periodinane (160 mg and 
230 mg, 0.38 and 0.54 mmol), potassium allyltrifluoroborate (78, 73 mg, 0.49 mmol) and 
montmorillonite K10 (50 mg) in CH2Cl2 (5 mL) were reacted according to general 
procedure A. Flash column chromatography [1:9 EtOAc:Hexane] afforded 17i (37 mg, 
75%) as a colourless oil. Rf (1:9 EtOAc:Hex) = 0.20; δH (400 MHz, CDCl3) 8.49 (1H, m, 
H-9), 8.04 (1H, dd, J = 8.5, 2.0, H-1), 7.98‒7.96 (1H, m H-4), 7.90 (1H, d, J = 8.5, H-2), 7.88 
(1H, d, J = 8.0, H-7), 7.61 (1H, ddd, J = 8.0, 7.0, 1.5, H-6), 7.56 (1H, ddd, J = 8.0, 7.0, 1.5, 
H-5),  6.16 (1H, ddt, J = 16.5, 10.0, 6.5, H-13), 5.30‒5.24 (2H, m, H-14), 3.90 (2H, dt, 
J = 6.5, 1.5, H-12); δC (100 MHz, CDCl3) 198.0 (C-11), 135.6, 133.8 and 132.5 (C-3, C-8, 
C-10), 131.1 (C-13), 130.0 (C-9), 129.5 (C-4), 128.5 (C-2), 128.4 (C-6), 127.7 (C-7), 126.8 
(C-5), 123.9 (C-1), 118.7 (C-14), 43.5 (C-12). 
 
 
1-(Furan-3-yl)but-3-en-1-one (17f) 
 
4
5
6
3
2
O 1
O
7
8
 
 
Furan-3-methanol (24 mg, 0.25 mmol), Dess‒Martin periodinane (215 mg and 215 mg, 
0.51 and 0.51 mmol), potassium allyltrifluoroborate (78, 73 mg, 0.49 mmol) and 
montmorillonite K10 (50 mg) in CH2Cl2 (2.5 mL) were reacted according to general 
procedure A. The title compound 17f was visible by crude 1H NMR spectrum, but was 
not isolated as a pure product. δH (400 MHz, CDCl3) 8.06 (1H, dd, J = 1.5, 1.0, H-1), 7.44 
(1H, dd, J = 2.0, 1.5, H-2), 6.78 (1H, dd, J = 2.0, 1.0, H-3), 6.03 (1H, ddt, J = 17.0, 10.5, 7.0, 
H-7), 5.25‒5.18 (2H, m, H-8), 3.53 (2H, dt, J = 7.0, 1.5, H-6). 
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1-(Thiophen-3-yl)but-3-en-1-one (17j) 
 
4
5
6
3
2
S 1
O
7
8
 
 
3-Thiophenemethanol (28 mg, 0.25 mmol), Dess‒Martin periodinane (160 mg and 
230 mg, 0.38 and 0.54 mmol), potassium allyltrifluoroborate (78, 73 mg, 0.49 mmol) and 
montmorillonite K10 (50 mg) in CH2Cl2 (5 mL) were reacted according to general 
procedure A. Flash column chromatography [1:9 EtOAc:Hexane] afforded 17j (29 mg, 
76%) as a colourless oil. Rf (1:9 EA: Hexane) = 0.20; δH (400 MHz, CDCl3) 8.08 (1H, dd, 
J = 3.0, 1.0, H-1), 7.56 (1H, dd, J = 5.0, 1.0, H-2), 7.32 (1H, dd, J = 5.0, 3.0, H-3), 6.06 (1H, 
ddt, J = 17.0, 10.5, 7.0 H-7), 5.23 (1H, dq, J = 10.5, 1.5, H-8a), 5.21 (1H, dq, J = 17.0, 1.5, 
H-8b), 3.67 (2H, dt, J = 7.0, 1.5, H-6); δC (100 MHz, CDCl3) 192.2 (C-5), 141.8 (C-4), 132.3 
(C-1), 130.9 (C-7), 127.0 (C-2), 126.4 (C-3), 118.8 (C-8), 44.8 (C-6). Data consistent with 
the literature values.49 
 
 
1-(Pyridin-4-yl)but-3-en-1-one (17k) and (2E)-1-(pyridin-4-yl)but-2-en-1-one (18k) 
 
 
N
1
3
2
4
5
O
6
7
17k
  
N
1
3
2
4
5
O
6
7
18k
 
 
3-Pyridylcarbinol (27 mg, 0.25 mmol), Dess‒Martin periodinane (215 mg and 215 mg, 
0.51 and 0.51 mmol), potassium allyltrifluoroborate (78, 73 mg, 0.49 mmol) and 
montmorillonite K10 (50 mg) in CH2Cl2 (5 mL) were reacted according to general 
procedure A to afford 4:5 mixture of 17k and 18k (34 mg, corresponding to 15% of 17k, 
41%). Flash column chromatography [1:9 Acetone:CH2Cl2] afforded 18k (17.5 mg, 76%) 
as a colourless oil. 17k: The title compound was visible by crude 1H NMR spectrum, 
but could not be isolated as a pure product as isomerisation occurs on silica. 
Rf (1:9 Acetone:CH2Cl2) = 0.40; δH (400 MHz, CDCl3) 8.83 (2H, dd, J = 4.5, 1.5, H-1), 7.75 
(2H, dd, J = 4.5, 1.5, H-2), 6.05 (1H, ddt, J = 17.0, 10.0, 6.5, H-6), 5.30‒5.21 (2H, m, H-7), 
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3.76 (2H, dt, J = 6.5, 1.5, H-5); 18k: Rf (1:9 Acetone:CH2Cl2) = 0.30; δH (400 MHz, CDCl3) 
8.79 (2H, dd, J = 4.5, 1.5, H-1), 7.67 (2H, dd, J = 4.5, 1.5, H-2), 7.12 (1H, dq, J = 15.5, 7.0, 
H-6), 6.82 (1H, dq, J = 15.5, 1.5, H-5), 2.03 (3H, dd, J = 7.0, 1.5, H-7); δC (100 MHz, 
CDCl3) 190.0 (C-4), 150.6 (C-1), 147.7 (C-6), 144.2 (C-3), 127.1 (C-5), 121.6 (C-2), 18.8 
(C-7). Data consistent with the literature values.265 
 
 
tert-Butyl 3-(hydroxymethyl)-1H-indole-1-carboxylate (60m) 
 
3
4
5
6
1
2
N
10
11
12
7
HO
O
O
8
9
 
 
To a solution of indole-3-methanol (212 mg, 1.44 mmol) and 4-dimethylaminopyridine 
(194 mg, 1.58 mmol, 1.1 eq) in THF (10 mL) was added tert-butyldimethylsilyl chloride 
(238 mg, 1.58 mmol, 1.1 eq) and the reaction stirred for 2 h at room temperature. 
Di-tert-butyl dicarbonate (471 mg, 2.16 mmol, 1.5 eq) was added and the reaction 
stirred at room temperature for 16 h. Tetrabutylammonium fluoride (1 M solution in 
THF, 4.48 mL, 4.48 mmol) and 3 Å molecular sieves (200 mg) were added and the 
reaction stirred for 5.5 h at room temperature before removing the solvent in vacuo. 
Flash column chromatography [0‒10% Acetone/CH2Cl2] afforded 60m (211 mg, 59%) 
as a yellow oil. δH (400 MHz, CDCl3) 8.14 (1H, br d, J = 7.5, H-5), 7.67‒7.64 (1H, m, H-2), 
7.59 (1H, br s, H-10), 7.34 (1H, ddd, J = 8.5, 7.5, 1.5, H-4), 7.27 (1H, ddd, J = 8.5, 7.5, 1.5, 
H-3), 4.85 (2H, s, H-12), 1.67 (9H, s, H-9); δC (100 MHz, CDCl3) 149.7 (C-7), 135.8 (C-6), 
129.1 (C-1), 124.7 (C-4), 123.7 (C-10), 122.7 (C-3), 120.4 (C-11), 119.3 (C-2), 115.3 (C-5), 
83.8 (C-8), 57.2 (C-12), 28.2 (C-9). Data consistent with the literature values.266 
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tert-Butyl 3-but-3-enoyl-1H-indole-1-carboxylate (17m) 
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tert-Butyl 3-(hydroxymethyl)-1H-indole-1-carboxylate (60m, 63 mg, 0.25 mmol), 
Dess‒Martin periodinane (160 mg and 280 mg, 0.38 mmol and 0.66 mmol), potassium 
allyltrifluoroborate (78, 73 mg, 0.59 mmol) and montmorillonite K10 (50 mg) in CH2Cl2 
(5 mL) were reacted according to general procedure A. Flash column chromatography 
[0‒67% CH2Cl2:Hexane] afforded 17m (21 mg, 31%) as a colourless solid, mp 99‒101 °C; 
Rf (CH2Cl2) = 0.30; max/cm-1 (neat) 2978, 2921, 1743, 1664, 1607, 1550; δH (400 MHz, 
CDCl3) 8.39‒8.36 (1H, m, H-4), 8.28 (1H, s, H-10), 8.11 (1H, dd, J = 7.0, 1.5, H-5), 
7.40‒7.32 (2H, m, H-2, H-3), 6.17‒6.06 (1H, m, H-14), 5.29‒5.23 (2H, m, H-15), 3.69 (2H, 
dt, J = 7.0, 1.5, H-13), 1.72 (9H, s, H-9); δC (100 MHz, CDCl3) 194.0 (C-12), 149.1 (C-7), 
135.5 (C-6), 132.1 (C-10), 131.3 (C-14), 127.5 (C-1), 125.5 (C-2), 124.4 (C-3), 122.7 (C-4), 
119.8 (C-11), 118.6 (C-15), 114.9 (C-5), 85.5 (C-8), 45.0 (C-13), 28.1 (C-9); m/z (ESI) 308 
[MNa]+; [HRMS (ESI): calcd for C17H19NNaO3, 308.1257. Found: [MNa]+, 308.1252 
(1.9 ppm error)]. 1H NMR data consistent with the literature values.26  
 
 
tert-Butyl 2-(hydroxymethyl)piperidine-1-carboxylate (60n) 
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To a solution of 2-piperidine methanol (150 mg, 1.28 mmol) in CH2Cl2 (5 mL) was 
added triethylamine (0.73 mL, 4.56 mmol, 3.5 eq) and di-tert-butyl dicarbonate (360 mg, 
1.56 mmol, 1.2 eq) and the reaction stirred at room temperature for 16 h. H2O (3 mL) 
was added and the layers separated. The aqueous layer was extracted with CH2Cl2 
(5 mL) and the combined organic extracts were washed with H2O (2 x 3 mL) and brine 
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(3 mL), then dried (Na2SO4) and concentrated in vacuo. Flash column chromatography 
[1:9 Acetone:CH2Cl2] afforded 60n (228 mg, 83%) as a colourless solid. Several peaks in 
the 1H NMR experienced broadening as a result of the presence of rotamers associated 
with the carbamate. Rf (1:9 Acetone:CH2Cl2) = 0.30; δH (400 MHz, CDCl3) 4.32‒4.25 (1H, 
m, H-5), 3.93 (1H, br d, J = 12.0, H-1a), 3.81 (1H, ddd, J = 11.0, 9.0, 6.0, H-6a), 3.60 (1H, 
dt, J = 11.0, 6.0, H-6b), 2.86 (1H, br t, J = 12.0, H-1b), 1.71‒1.51 (4H, m H-3, H-4), 
1.50‒1.36 (2H, m, H-2), 1.45 (9H, s, H-9). Data consistent with the literature values.267 
 
 
tert-Butyl 2-but-3-enoylpiperidine-1-carboxylate (17n) 
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tert-Butyl 2-(hydroxymethyl)piperidine-1-carboxylate (60n, 54 mg, 0.25 mmol), 
Dess‒Martin periodinane (160 mg and 280 mg, 0.38 mmol and 0.66 mmol), potassium 
allyltrifluoroborate (78, 73 mg, 0.49 mmol) and montmorillonite K10 (50 mg) in CH2Cl2 
(5 mL) were reacted according to general procedure A. Flash column chromatography 
[1:9 EtOAc:Hexane] afforded 17n (40 mg, 63%) as a colourless oil. Several peaks in the 
1H NMR experienced broadening as a result of the presence of rotamers associated 
with the carbamate. Rf (1:9 EtOAc:Hexane) = 0.30; max/cm-1 (neat) 2976, 2939, 2864, 
1720, 1691, 1642; δH (400 MHz, CDCl3) 5.92 (1H, ddt, J = 17.0, 10.0, 7.0, H-8), 5.18 (1H, br 
d, J = 10.0, H-9a), 5.13 (1H, dd, J = 17.0, 1.0, H-9b), 4.78 and 4.62 (1H, br s, H-5), 4.05 and 
3.93 (1H, br s, H-1a), 3.24‒3.20 (2H, m, H-7), 2.94‒2.74 (1H, m, H-1b), 2.24‒2.14 (1H, m, 
H-3a), 1.66‒1.52 (3H, m, H-4a, H-3b, H-2a), 1.49 (9H, s, Boc), 1.42‒1.32 (1H, m, H-2b), 
1.32‒1.22 (1H, m, H-4b); δC (100 MHz, CDCl3) 207.8 (C-6), 155.7 and 155.1 (C-10), 130.4 
(C-8), 118.7 (C-9), 80.1 (C-11), 61.0 and 59.9 (C-5), 43.8 (C-7), 42.8 and 41.7 (C-1), 28.3 
(C-12), 25.0 (C-3), 24.9 (C-2), 20.5 (C-4); m/z (ESI) 276 [MNa]+; [HRMS (ESI): calcd for 
C14H23NNaO3, 276.1570. Found: [MNa]+, 276.1573 (−0.4 ppm error)]. 
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(1E)-1-Phenylhexa-1,5-dien-3-one  (17h)  
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Cinnamyl alcohol (34 mg, 0.25 mmol), Dess‒Martin periodinane (160 mg and 220 mg, 
0.38 mmol and 0.52 mmol), potassium allyltrifluoroborate (78, 73 mg, 0.49 mmol) and 
montmorillonite K10 (50 mg) in CH2Cl2 (5 mL) were reacted according to general 
procedure A. Flash column chromatography [1:9 EtOAc:Hexane] afforded 17h (29 mg, 
67%) as a colourless oil. Rf (1:9 EtOAc:PE) = 0.30; δH (400 MHz, CDCl3) 7.59 (1H, d, 
J = 16.0, H-5), 7.56‒7.53 (2H, m) and 7.40‒7.37 (3H, m) (H-1, H-2, H-3), 6.77 (1H, d, 
J = 16.0, H-6), 6.02 (1H, ddt, J = 17.0, 10.0, 7.0, H-9), 5.25‒5.18 (2H, m, H-10), 3.44 (2H, 
dt, J = 7.0, 1.5, H-8). δC (100 MHz, CDCl3) 197.8 (C-7), 143.2 (C-5), 134.4 (C-4), 130.9 
(C-9), 130.6 (C-1), 128.9, 128.3 (C-2, C-3), 125.4 (C-6), 118.9 (C-10), 45.9 (C-8). Data 
consistent with the literature values.26 
 
 
1-((3aR,5S,5aR,8aS,8bR)-2,2,7,7-Tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-
d]pyran-5-yl)but-3-en-1-one (17o) 
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1,2:3,4-Di-O-isopropylidene-D-galactopyranose (64 mg, 0.25 mmol), Dess‒Martin 
periodinane (200 mg and 260 mg, 0.47 mmol and 0.61 mmol), potassium 
allyltrifluoroborate (78, 73 mg, 0.49 mmol) and montmorillonite K10 (50 mg) in CH2Cl2 
(2 mL) were reacted according to general procedure A. Flash column chromatography 
[0‒5% Acetone:CH2Cl2] afforded 17o (55 mg, 75%) as a colourless solid, mp 47‒49 °C; 
Rf (CH2Cl2) = 0.15; max/cm-1 (neat) 2988, 2936, 1723 (C=O), 1383; []D20 ‒144 (c 0.405, 
CH2Cl2); δH (400 MHz, CDCl3) 5.97 (1H, ddt, J = 17.0, 10.5, 7.0, H-8), 5.64 (1H, d, J = 5.0, 
H-1), 5.20‒5.08 (2H, m, H-9), 4.63 (1H, dd, J = 8.0, 2.5, H-3), 4.56 (1H, dd, J = 8.0, 2.0, 
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H-4), 4.35 (1H, dd, J = 5.0, 2.5, H-2), 4.22 (1H, d, J = 2.0, H-5), 3.50 (1H, ddt, J = 18.5, 7.0, 
1.5, H-7a), 3.33 (1H, ddt, J = 18.5, 7.0, 1.5, H-7b), 1.49 (3H, s), 1.44 (3H, s), 1.33 (3H, s) 
and 1.30 (3H, s) (H-11, H-12, H-14, H-15); δC (100 MHz, CDCl3) 207.2 (C-6), 130.0 (C-8), 
118.7 (C-9), 109.6, 109.0 (C-10, C-13), 96.4 (C-1), 73.5 (C-5), 72.3 (C-4), 70.6 (C-3), 70.4 
(C-2), 44.6 (C-7), 25.9, 25.8, 24.8, 24.2 (C-11, C-12, C-14, C-15); [HRMS (ESI): calcd for 
C15H22NaO6, 321.1309. Found: [MNa]+, 321.1317 (−2.7 ppm error)]; [Found C, 60.35%; 
H, 7.35%. C15H22O6 requires C, 60.39%; H, 7.43%]. 
 
 
7.2.2 General procedure B ‒ isomerisation of ,-unsaturated ketones 17 to 
,-unsaturated ketones 18 
 
R
O
R
ODBU (0.1 eq.)
Et
2
O, 24 h
17 18
 
 
To the ,-unsaturated ketone 17 in Et2O was added 1,8-diazabicyclo[5.4.0]undec-7-ene 
(0.1 eq) and the mixture stirred for 24 h at room temperature. The solvent was removed 
in vacuo and the residue purified on silica to afford the conjugated ketone 18. 
 
 
(2E)-1-(4-Chlorophenyl)but-2-en-1-one (18a) 
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1-(4-Chlorophenyl)but-3-en-1-one  (17a, 15.0 mg, 0.08 mmol) and 
1,8-diazabicyclo[5.4.0]undec-7-ene (1.25 μL, 0.008 mmol) in Et2O (2 mL) were reacted 
according to general procedure B. Flash column chromatography 
[0−20% EtOAc/Hexane] afforded 18a (14.2 mg, 95%) as a colourless solid, 
mp 39‒41 °C; Rf (1:4 EtOAc:Hexane) = 0.30; max/cm-1 (neat) 2968, 1671, 1622, 1587; 
δH (400 MHz, CDCl3) 7.86 (2H, d, J = 8.5) and 7.43 (2H, d, J = 8.5) (H-2, H-3), 7.08 (1H, 
dq, J = 15.0, 7.0, H-7), 6.86 (1H, dq, J = 15.0, 1.5, H-6), 2.00 (3H, dd, J = 7.0, 1.5, H-8); 
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δC (100 MHz, CDCl3) 189.4 (C-5), 145.6 (C-7), 139.0, 136.2 (C-1, C-4), 129.9, 128.9 (C-2, 
C-3), 127.0 (C-6), 18.6 (C-8); m/z (ESI) 181, 183 [MH]+; [HRMS (ESI): calcd for 
C10H1035ClO, 181.0415. Found: [MH]+, 181.0416 (‒0.5 ppm error)]. Compound 
previously reported, but no spectral data was provided.268 
 
 
(2E)-1-(4-Methoxyphenyl)but-2-en-1-one (18c) 
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1-(4-Methoxyphenyl)but-3-en-1-one  (17c, 15.0 mg, 0.09 mmol) and 
1,8-diazabicyclo[5.4.0]undec-7-ene (1.25 μL, 0.008 mmol) in Et2O (2 mL) were reacted 
according to general procedure B. Flash column chromatography 
[0−20% EtOAc/Hexane] afforded 18c (14.4 mg, 96%) as a colourless solid. 
δH (400 MHz, CDCl3) 7.95 (2H, d, J = 9.0, H-3), 7.06 (1H, dq, J = 15.0, 6.5, H-7), 6.95 (2H, 
d, J = 9.0, H-2), 6.92 (1H, dd, J = 15.0, 1.5, H-6), 3.87 (3H, s, H-9), 1.99 (3H, dd, J = 6.5, 
1.5, H-8). Data consistent with the literature values.269 
 
 
(2E)-1-(Thiophen-3-yl)but-2-en-1-one (18j) 
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1-(Thiophen-3-yl)but-3-en-1-one (17j, 23 mg, 0.15 mmol) and 
1,8-diazabicyclo[5.4.0]undec-7-ene (2 μL, 0.013 mmol) in Et2O (2 mL) were reacted 
according to general procedure B. Flash column chromatography [1:9 EtOAc:Hexane] 
afforded 18j (20 mg, 87%) as a colourless solid, mp 41‒43 °C; Rf (1:9 EtOAc:Hexane) = 
0.20; max/cm-1 (neat) 3106, 3085, 3015, 2969, 1661, 1617, 1510; δH (400 MHz, CDCl3) 8.05 
(1H, dd, J = 3.0, 1.0, H-1), 7.59 (1H, dd, J = 5.0, 1.0, H-2), 7.33 (1H, dd, J = 5.0, 3.0, H-3), 
7.09 (1H, dq, J = 15.0, 7.0, H-7), 6.80 (1H, dq, J = 15.0, 1.5, H-6), 1.98 (3H, dd, J = 7.0, 1.5, 
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H-78); δC (100 MHz, CDCl3) 184.0 (C-5), 144.2 (C-7), 142.7 (C-4), 131.9 (C-1), 128.0 (C-6), 
127.4 (C-2), 126.3 (C-3), 18.5 (C-8); m/z (ESI) 153 [MH]+, 175 [MNa]+; [HRMS (ESI): calcd 
for C8H9OS, 153.0369. Found: [MH]+, 153.0370 (‒0.8 ppm error)]. 
 
 
(2E)-1-((3aR,5S,5aR,8aS,8bR)-2,2,7,7-Tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-
b:4',5'-d]pyran-5-yl)but-2-en-1-one (18o) 
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1-((3aR,5S,5aR,8aS,8bR)-2,2,7,7-Tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-
d]pyran-5-yl)but-3-en-1-one (17o, 25 mg, 0.08 mmol) and 1,8-diazabicyclo[5.4.0]undec-
7-ene (1.25 μL, 0.008 mmol) in Et2O (2 mL) were reacted according to general 
procedure B. Flash column chromatography [1:9 EtOAc:Hexane] afforded 18o 
(17.6 mg, 70%, >20:1 E:Z) as a colourless solid, mp 101‒103 °C; Rf (CH2Cl2) = 0.40; 
max/cm-1 (neat) 2987, 2935, 1694, 1627; []D20 ‒120 (c 0.45, CH2Cl2); δH (400 MHz, 
CDCl3) 7.04 (1H, dq, J = 15.5, 7.0, H-8), 6.64 (1H, dq, J = 15.5, 1.5, H-7), 5.67 (1H, d, 
J = 5.0, H-1), 4.64 (2H, t, J = 2.0, H-3 and 4), 4.37 (1H, dd, J = 5.0, 2.0, H-2), 4.31 (1H, d, 
J = 1.5, H-5), 1.91 (3H, dd, J = 7.0, 1.5, H-9), 1.51 (3H, s, H-11 or 12), 1.43 (3H, s, H-14 or 
15), 1.34 (3H, s, H-11 or 12), 1.31 (3H, s, H-14 or 15); δC (100 MHz, CDCl3) 196.3 (C-6), 
144.4 (C-8), 126.8 (C-7), 109.7 (C-13), 108.9 (C-10), 96.5 (C-1), 73.1 (C-5), 72.4, 70.6 (C-3, 
C-4), 70.4 (C-2), 26.0 (C-11 or 12,), 25.8 (C-14 or 15), 24.8 (C-11 or 12), 24.3 (C-14 or 15), 
18.5 (C-9); m/z (ESI) 299 [MH]+, 321 [MNa]+; [HRMS (ESI): calcd for C15H22NaO6, 
321.1309. Found: [MNa]+, 321.1317 (‒2.5 ppm error)]. 
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7.3 Towards the synthesis of elaeokanidine A 
 
7.3.1 Pohmakotr’s route 
 
1-(4-Bromobutyl)pyrrolidin-2-one (134)127 
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To a stirred suspension of sodium hydride (60% dispersion in mineral oil, 660 mg, 
16.5 mmol, 1.1 eq) in DMF (5 mL) was added dropwise a solution of pyrrolidinone 
(1.14 mL, 15.0 mmol, 1.0 eq) in DMF (15 mL) and the mixture stirred for 15 min. A 
solution of 1,4-dibromobutane (3.60 mL, 30.0 mmol, 2.0 eq) in DMF (5 mL) was added 
and the mixture was heated to 80 ºC for 24 h. The reaction was cooled to room 
temperature and quenched with water (20 mL). The product was extracted with 
CH2Cl2 (3 × 20 mL), dried (Na2SO4) and concentrated in vacuo. Flash column 
chromatography [Et2O] afforded 134 (2.981 g, 90%) as a colourless oil. Rf (Et2O) = 0.10; 
δH (400 MHz, CDCl3) 3.43 (2H, t, J = 6.5, H-8), 3.37 (2H, t, J = 7.0, H-4), 3.30 (2H, t, 
J = 7.0, H-5), 2.37 (2H, t, J = 8.0, H-2), 2.02 (2H, tt, J = 8.0, 7.0, H-3), 1.87‒1.80 (2H, m), 
1.71-1.64 (2H, m) (H-6, H-7); δC (100 MHz, CDCl3) 175.0 (C-1), 46.9 (C-4), 41.3 (C-5), 33.3 
(C-8), 31.0 (C-2), 29.7, 25.7 (C-6, C-7), 17.8 (C-3). Data consistent with the literature 
values.127 
 
 
1-(4-(Phenylthio)butyl)pyrrolidin-2-one (135) 
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To a solution of benzenethiol (103 μL, 1.0 mmol, 1.0 eq) and potassium hydroxide 
(56 mg, 1.0 mmol, 1.0 eq) in ethanol (6 mL) at room temperature was added dropwise 
1-(4-bromobutyl)pyrrolidin-2-one (134, 221 mg, 1.0 mmol, 1.0 eq) as a solution in 
ethanol (2 mL). The reaction mixture was stirred for 18 h then the precipitate was 
removed via filtration and the filtrate was concentrated in vacuo to afford 135 (249 mg, 
quant.) as a yellow oil. Rf (EtOAc) = 0.20; δH (400 MHz, CDCl3) 7.32‒7.25 (4H, m, H-10, 
H-11), 7.19‒7.14 (1H, m, H-12), 3.33 (2H, t, J = 7.0, H-4), 3.27 (2H, t, J = 7.0, H-5), 2.94 
(2H, t, J = 7.0, H-8), 2.35 (2H, t, J = 8.0, H-2), 2.01‒1.92 (2H, m, H-3), 1.70‒1.88 (4H, m, 
H-6, H-7); δC (100 MHz, CDCl3) 175.0 (C-1), 136.2 (C-9), 129.0, 128.8 (C-10, C-11), 125.8 
(C-12), 46.9 (C-4), 41.7 (C-5), 33.0 (C-8), 30.9 (C-2), 26.0, 25.9 (C-6, C-7), 17.7 (C-3). Data 
consistent with the literature values.126 
 
 
1-(4-(Phenylsulfinyl)butyl)pyrrolidin-2-one (127)130 
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Method 1: A solution of 1-(4-(phenylthio)butyl)pyrrolidin-2-one (135, 249 mg, 
1.0 mmol, 1.0 eq) in CH2Cl2 (10 mL) was cooled to –15 ºC. A solution of m-CPBA 
(181 mg, 1.05 mmol, 1.05 eq) in CH2Cl2 (1 mL) was added dropwise and the reaction 
was stirred at this temperature for 1 h. Triethylamine (167 μL, 1.2 mmol, 1.2 eq) was 
added and the mixture stirred at room temperature for 16 h before pre-adsorbing onto 
silica. Flash column chromatography [1:9 MeOH:EtOAc] afforded 127 (248 mg, 93%) as 
a colourless oil; Method 2:130 To a solution of sulfide 135 (100 mg, 0.40 mmol, 1.0 eq) in 
HFIP (0.5 mL) at room temperature was added aq. H2O2 (30%, 90 μL, 0.80 mmol, 2.0 eq) 
and stirred for 10 min. The reaction was quenched with aq. Na2SO3 (0.4 mL) and the 
layers were separated. The aqueous layer was extracted with CH2Cl2 (1 mL) and the 
combined organic extracts were dried (Na2SO4) and concentrated in vacuo to afford 127 
(106 mg, quant.) as a colourless oil. Rf (1:9 MeOH:EtOAc) = 0.10; δH (400 MHz, CDCl3) 
7.61 (2H, dd, J = 8.0, 1.5, H-10), 7.54‒7.48 (3H, m, H-11, H-12), 3.33 (1H, m, H-4), 3.27 
(2H, t, J = 7.0, H-5), 2.90‒2.76 (2H, m, H-8), 2.37‒2.31 (2H, m, H-2), 2.04‒1.94 (2H, m, 
H-3), 1.81‒1.56 (4H, m, H-6, H-7); δC (100 MHz, CDCl3) 175.2 (C-1), 143.4 (C-9), 131.0 
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(C-12), 129.2 (C-11), 123.9 (C-10), 56.1 (C-8), 47.0 (C-4), 41.5 (C-5), 30.9 (C-2), 26.0, 19.2 
(C-6, C-7), 17.8 (C-3); m/z (ESI) 266 [MH]+; [HRMS (ESI): calc for C14H20NO2S, 266.1209. 
Found: [MH]+, 266.1204 (1.8 ppm error)]. Data consistent with the literature values.126 
 
 
1-(4-(Phenylsulfonyl)butyl)pyrrolidin-2-one (136) 
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To a solution of 1-(4-(phenylthio)butyl)pyrrolidin-2-one (135, 106 mg, 0.43 mmol, 
1.0 eq) in CH2Cl2 (4 mL) at 0 ºC was added m-CPBA (255 mg, 1.48 mmol, 3.4 eq) and 
the mixture stirred for 16 h. Triethylamine (237 μL, 1.7 mmol, 4.0 eq) was added and 
the mixture stirred at room temperature for 1 h before pre-absorbing onto silica. Flash 
column chromatography [1:9 MeOH:EtOAc] afforded 136 (52 mg, 43%) as a colourless 
oil. Rf (1:9 MeOH:EtOAc) = 0.30; max/cm-1 (neat) 2940, 1665, 1304, 1149; δH (400 MHz, 
CDCl3) 7.89 (2H, d, J = 7.0, H-10), 7.67‒7.62 (1H, m, H-12), 7.56 (2H, dd, J = 8.0, 7.0, 
H-11), 3.32 (2H, t, J = 7.0, H-4), 3.24 (2H, t, J = 7.0, H-5), 3.12 (2H, t, J = 7.5, H-8), 2.35 
(2H, t, J = 8.0, H-2), 1.98 (2H, tt, J = 8.0, 7.0, H-3), 1.75‒1.59 (4H, m, H-6, H-7); 
δC (100 MHz, CDCl3) 175.5 (C-1), 139.1 (C-9), 133.8 (C-12), 129.4 (C-11), 128.1 (C-10), 
55.5 (C-8), 47.2 (C-4), 41.5 (C-5), 30.9 (C-2), 25.8 (C-7), 19.9 (C-6), 17.9 (C-3); m/z (ESI) 282 
[MH]+; [HRMS (ESI): calc for C14H20NO3S, 282.1158. Found: [MH]+, 282.1161 (‒1.0 ppm 
error)]. 
 
 
8-(Phenylsulfinyl)-1,2,3,5,6,7-hexahydroindolizine (128)126 
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To a solution of hexamethyldisilazide (212 μL, 1.02 mmol, 1.6 eq) in THF (8 mL) at 
−78 ºC was added n-BuLi (1.7 M in hexanes, 0.56 mL, 0.96 mmol, 1.5 eq) and the 
mixture stirred for 30 min. To this LiHMDS solution was added dropwise a solution of 
1-(4-(phenylsulfinyl)butyl)pyrrolidin-2-one (127, 169 mg, 0.64 mmol, 1.0 eq) in THF 
and the resulting mixture allowed to slowly warm to room temperature over 16 h. The 
reaction was quenched with water (5 mL) and extracted with EtOAc (3 × 20 mL). The 
combined organic extracts were washed with water (5 mL) and brine (5 mL) then dried 
(Na2SO4) and concentrated in vacuo to afford 128 (141 mg, 89%) as a colourless oil, 
Rf (1:9 MeOH:EtOAc) = 0.20; δH (400 MHz, CDCl3) 7.57‒7.53 (2H, m, H-10), 7.46‒7.41 
(2H, m, H-11), 7.38‒7.34 (1H, m, H-12), 3.37‒3.27 (2H, m) and 3.21‒3.10 (2H, m) (H-1, 
H-5), 3.06 (1H, ddd, J = 12.0, 8.0, 4.0, H-3a), 2.93 (1H, m, H-3b), 2.30 (1H, m, H-7a), 
2.04‒1.97 (2H, m, H-2), 1.89‒1.71 (2H, m, H-6), 1.60‒1.51 (1H, m, H-7b). Data consistent 
with the literature values.270 
 
 
7.3.2 Taber’s route 
 
3-(2,5-Dioxopyrrolidin-1-yl)propanal (138)100  
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To a solution of sodium (50 mg, 2.15 mmol, 0.009 eq) in ethanol (50 mL) was added 
succinimide (137, 25 g, 253 mmol, 1.0 eq) to give a white suspension. Acrolein          
(16.9 mL, 253 mmol, 1.0 eq) was added via syringe pump over 2 h and the reaction was 
stirred for a further 3 h at room temperature. Glacial acetic acid (1 mL) was added and 
the mixture was concentrated in vacuo to give an oil which was pre-adsorbed onto 
silica. Flash column chromatography [5‒20% acetone/CHCl3] afforded the slightly 
impure aldehyde 138 (39.7 g) as a pale yellow viscous oil. Rf (1:9 MeOH:EtOAc) = 0.40; 
δH (400 MHz, CDCl3) 9.72 (1H, t, J = 1.5, C-7), 3.81 (2H, t, J = 7.0, H-5), 2.73 (2H, td, 
J = 7.0, 1.5, H-6), 2.69 (4H, s, H-2, H-3); δC (100 MHz, CDCl3) 199.4 (C-7), 176.9 (C-1, 
C-4), 41.3 (C-5), 32.3 (C-6), 28.0 (C-2, C-3). Data consistent with the literature values.100  
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Methyl (2E)-5-(2,5-dioxopyrrolidin-1-yl)pent-2-enoate (140) 
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To a solution of K2CO3 (9.18g, 66.5 mmol, 1.02 eq) in H2O (50 mL) at 0 ºC was added 
trimethyl phosphonoacetate (139, 11 mL, 68.0 mmol, 1.05 eq) and the mixture stirred at 
this temperature for 30 min. 3-(2,5-Dioxopyrrolidin-1-yl)propanal (138, 10.1 g, 
64.1 mmol, 1.0 eq) was added as a solution in THF (50 mL) and the reaction was stirred 
at room temperature overnight (16 h). The mixture was diluted with water (10 mL) and 
extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with 
water (20 mL) and brine (20 mL), dried (Na2SO4) and concentrated in vacuo to the 
afford 140 (13.2 g, 97% from 137) as colourless needles. Rf (1:9 MeOH:EtOAc) = 0.60; 
mp 60‒63 ºC (lit100 64‒65 ºC); δH (400 MHz, CDCl3) 6.83 (1H, dt, J = 16.0, 7.0, H-7), 5.84 
(1H, dt, J = 16.0, 1.5, H-8), 3.70 (3H, s, Me), 3.63 (2H, t, J = 7.0, H-5), 2.70 (4H, s, H-2, 
H-3), 2.48 (2H, qd, J = 7.0, 1.5, H-6). Data consistent with the literature values.100  
 
 
Methyl (2E)-5-(2-methoxy-5-oxopyrrolidin-1-yl)pent-2-enoate (125) 
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To a solution of methyl (2E)-5-(2,5-dioxopyrrolidin-1-yl)pent-2-enoate (140, 1.19 g, 
5.62 mmol, 1.0 eq) in MeOH (15 mL) at 0 ºC was added sodium borohydride (452 mg, 
11.9 mmol, 2.2 eq) and the mixture was stirred at room temperature for 6 h. The 
reaction was quenched with aq. HCl (conc., 4.12 mL), diluted with H2O (16.5 mL) and 
extracted with CH2Cl2 (3 × 15 mL). The combined organic extracts were washed with 
brine (15 mL), dried (Na2SO4) and concentrated in vacuo to afford 125 (1.07 mg, 84%) as 
a colourless oil. Rf (1:9 MeOH:EtOAc) = 0.50; δH (400 MHz, CDCl3) 6.90 (1H, dt, J = 16.0, 
7.0, H-7), 5.87 (1H, dt, J = 16.0, 1.5, H-8), 4.89 (1H, dd, J = 6.0, 1.5, H-4), 3.71, (3H, s, 
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H-10), 3.61‒3.53 (1H, m, H-5a), 3.31‒3.23 (1H, m, H-5b), 3.25 (3H, s, H-11), 2.58‒2.38 
(3H, m, H-2a, H-6), 2.34‒2.25 (1H, m, H-2b), 2.15‒1.94 (2H, m, H-3); δC (100 MHz, 
CDCl3) 175.1 (C-1), 166.6 (C-9), 145.5 (C-7), 122.7 (C-8), 90.3 (C-4), 52.7 (C-11), 51.5 
(C-10), 30.6 (C-5), 29.2 (C-6), 28.8 (C-2), 23.6 (C-3). Data consistent with the literature 
values.100  
 
 
Methyl 3-oxo-1,2,3,5,6,8a-hexahydroindolizine-8-carboxylate (126) 
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To a solution of methyl (2E)-5-(2-methoxy-5-oxopyrrolidin-1-yl)pent-2-enoate (125, 
2.28 g, 10.0 mmol, 1.0 eq) in CH2Cl2 (200 mL) at 0 ºC was added dropwise SnCl4 
(2.93 mL, 25.0 mmol, 2.5 eq). The mixture was stirred at 0 ºC for 30 min then heated to 
reflux and stirred at this temperature for 64 h. The reaction was then quenched with aq. 
NaOH (2 M, 80 mL) and extracted with CH2Cl2 (3 × 50 mL). The combined organic 
extracts were washed with brine (25 mL), dried (Na2SO4) and concentrated in vacuo to 
afford crude methyl 7-chloro-3-oxooctahydroindolizine-8-carboxylate (142, 1.75 g) as a 
yellow oil which was used directly without further purification. To a solution of crude 
methyl 7-chloro-3-oxooctahydroindolizine-8-carboxylate (142, 1.75 g) in THF (30 mL) at 
room temperature was added DBU (1.47 mL, 9.83 mmol). The reaction was warmed to 
60 ºC and stirred at this temperature for 24 h. The mixture was cooled to room 
temperature and diluted with CH2Cl2 (20 mL). The organic phase was washed with 
aq. HCl (10%, 20 mL) and H2O (20 mL) then back-extracted with CH2Cl2 (2 × 20 mL). 
The combined organic extracts were washed with brine (20 mL), dried (Na2SO4) and 
concentrated in vacuo. Flash column chromatography [1:9 acetone:CH2Cl2] afforded 126 
(696 mg, 36% from 125) as a colourless oil, Rf (1:9 acetone:CH2Cl2) = 0.25; δH (400 MHz, 
CDCl3) 7.06 (1H, m, H-7), 4.44‒4.36 (1H, m, H-4), 4.27 (1H, dd, J = 13.0, 6.5, H-5a), 3.77 
(3H, s, H-10), 2.78‒2.69 (1H, m, H-5b), 2.63 (1H, dddd, J = 12.5, 8.5, 7.0, 1.5, H-3a), 
2.52‒2.46 (1H, m, H-2a), 2.40 (1H, td, J = 9.5, 1.5, H-2b), 2.37-2.24 (2H, m, H-6) 1.60 (1H, 
ddt, J = 12.5, 11.0, 9.5, H-3b); δC (100 MHz, CDCl3) 173.3 (C-1), 165.3 (C-9), 137.8 (C-7), 
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131.9 (C-8), 54.6 (C-4), 51.7 (C-10), 35.1 (C-5), 31.5 (C-2), 26.7 (C-3), 25.2 (C-6). Data 
consistent with the literature values.100  
 
 
Methyl (2E)-5-(2-hydroxy-5-oxopyrrolidin-1-yl)pent-2-enoate (141) 
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To a solution of methyl (2E)-5-(2,5-dioxopyrrolidin-1-yl)pent-2-enoate (140, 91 mg,            
0.43 mmol, 1.0 eq) in MeOH (2 mL) cooled to 0 ºC was added sodium borohydride         
(48 mg, 1.29 mmol, 3.0 eq) and the reaction was stirred at 0 ºC for 2 h. The suspension 
was poured into a mixture of aq. NaHCO3 (20 mL) and CH2Cl2 (10 mL). Once 
effervescence had ceased, the layers were separated and the aqueous layer further 
extracted with CH2Cl2 (3 × 5 mL). The combined organic extracts were dried (Na2SO4) 
and concentrated in vacuo. Flash column chromatography [1:4 Acetone:CH2Cl2] 
afforded 141 (30 mg, 33%) as a microcrystalline solid, Rf (1:9 Acetone:CH2Cl2) = 0.10; 
max/cm-1 (thin film) 3175, 3003, 2933, 1722, 1657; mp 83‒85 ºC; δH (400 MHz, CDCl3) 
6.90 (1H, dt, J = 15.5, 7.0, H-7), 5.88 (1H, dt, J = 15.5, 1.5, H-8), 5.20 (1H, ddd, J = 8.5, 6.0, 
2.0, H-4), 3.72 (3H, s, H-10), 3.57 (1H, dt, J = 14.0, 7.0, H-5a), 3.36 (1H, dt, J = 14.0, 7.0, 
H-5b), 3.29 (1H, d, J = 8.5, OH), 2.58‒2.45 (3H, m, H-2a, H-6), 2.40‒2.27 (2H, m, H-2b, 
H-3a), 1.93‒1.84 (1H, m, H-3b); δC (100 MHz, CDCl3) 174.9 (C-1), 166.9 (C-9), 145.8 
(C-7), 122.7 (C-8), 83.5 (C-4), 51.6 (C-10), 38.7 (C-5), 30.7 (C-6), 28.8 (C-2), 28.3 (C-3); 
[MNa]+; [HRMS (ESI): calc for C10H15NNaO4, 236.0893 Found: [MNa]+, 236.0895 
(−0.6 ppm error)]. Data inconsistent with the literature values; this is discussed in 
Chapter 3.2.2.3).100  
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Methyl (2E)-5-(2-oxo-5-(prop-1-en-2-yloxy)pyrrolidin-1-yl)pent-2-enoate (154) 
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To a solution of methyl (2E)-5-(2-hydroxy-5-oxopyrrolidin-1-yl)pent-2-enoate (141, 
72 mg, 0.34 mmol, 1.0 eq) and DMAP (4 mg, 0.03 mmol, 0.1 eq) in CH2Cl2 (4 mL) was 
added Et3N (62 µL, 0.44 mmol, 1.3 eq) and acetic anhydride (36 µL, 0.38 mmol, 1.1 eq). 
The reaction was stirred at room temperature for 90 min then concentrated in vacuo. 
Flash column chromatography [1:9 Acetone:CH2Cl2] afforded 154 (6 mg, 0.02 mmol, 
7%) as a colourless oil. Rf (1:9 Acetone:CH2Cl2) = 0.40; max/cm-1 (thin film) 2952, 1713, 
1660; δH (400 MHz, CDCl3) 6.88 (1H, dt, J = 15.5, 7.0, H-7), 6.19 (1H, d, J = 5.5, H-4), 5.88 
(1H, dt, J = 15.5, 1.5, H-8), 3.72 (3H, s, H-10), 3.62 (1H, dd,  J = 14.0, 7.5, H-5a), 3.21 (1H, 
ddd, J = 14.0, 7.5, 6.0, H-5b), 2.62‒2.41 (3H, m, H-2a, H-6), 2.39‒2.26 (2H, m, H-3), 2.08 
(3H, s, H-12), 2.05‒1.98 (1H, m, H-2b); δC (100 MHz, CDCl3) 175.8 (C-1), 170.8 (C-11), 
166.5 (C-9), 144.9 (C-7), 123.0 (C-8), 84.7 (C-4), 51.5 (C-10), 39.6 (C-5), 30.5 (C-6), 28.2 
(C-3), 26.0 (C-2), 21.1 (C-12); 154 was found to be unstable to ESI MS, resulting in 
elimination of acetate to give the acyliminium ion 143. [M+]; [HRMS (ESI): calc for 
C10H14NO3+, 196.0968 Found: [M+], 196.0965 (1.5 ppm error)]. 
 
 
(1,2,3,5,6,8a-Hexahydroindolizin-8-yl)methanol (82)  
 
4
N
5
6
7
8
32
1
9
OH
 
 
To a solution of methyl 3-oxo-1,2,3,5,6,8a-hexahydroindolizine-8-carboxylate (126, 
86 mg, 0.44 mmol, 1.0 eq) in THF (2 mL) at –78 ºC was added dropwise DIBAL-H (1 M 
in hexanes, 2.42 mL, 2.42 mmol, 5.5 eq) over 20 min. The reaction was stirred at −78 ºC 
for 1 h then quenched with MeOH (4 mL) and H2O (4 mL). After 10 min the resultant 
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gel was filtered through Celite, washed with EtOAc (5 mL) and acetone (5 mL) and the 
filtrate concentrated in vacuo. Flash column chromatography [Et2O*] afforded 82 
(51 mg, 76%) as a brown oil, Rf (Et2O*) = 0.15; δH (400 MHz, CDCl3) 5.71‒5.67 (1H, m, 
H-7), 4.07 (2H, s, H-9), 3.19‒3.12 (1H, m, H-4), 2.93 (1H, ddd, J = 10.0, 8.5, 4.0, H-1a), 
2.83, (1H, dt, J = 11.0, 5.5, H-5a), 2.64 (1H, ddd, J = 10.0, 8.5, 7.5, H-1b), 2.54 (1H, ddd, 
J = 11.0, 7.0, 5.5, H-5b), 2.31‒2.13 (2H, m, H-6), 2.08‒1.99 (1H, m, H-3a), 1.96‒1.84 (1H, 
m, H-2a), 1.81‒1.70 (1H, m, H-2b), 1.60-1.50 (1H, dtd, J = 12.0, 10.5, 7.5, H-3b); 
δC (100 MHz, CDCl3) 139.7 (C-8), 120.7 (C-7), 64.7 (C-9), 60.3 (C-4), 52.9 (C-1), 46.5 (C-5), 
28.0 (C-3), 24.9 (C-6), 22.1 (C-2). Data consistent with the literature values.100  
 
 
7.3.3 Continuation of synthesis 
 
1,2,3,5,6,8a-Hexahydroindolizine-8-carbaldehyde (156) 
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To a solution of oxalyl chloride (206 µL, 2.43 mmol, 1.2 eq) in CH2Cl2 (2 mL) at −78 ºC 
was added dropwise DMSO (345 µL, 4.86 mmol, 2.4 eq) and the colourless mixture 
stirred at this temperature for 30 min. A solution of (1,2,3,5,6,8a-hexahydroindolizin-8-
yl)methanol (82, 310 mg, 2.03 mmol, 1.0 eq) in CH2Cl2 (2 mL) cooled to –78 ºC was 
added dropwise via cannula and the resultant solution was stirred at –78 ºC for 30 min. 
Et3N (1.41 mL, 10.1 mmol, 5.0 eq) was added and the reaction stirred at –78 ºC for a 
further 30 min. The mixture was allowed to warm to room temperature and the 
reaction was stirred at this temperature for 2 h, then poured into aq. NaHCO3 (15 mL) 
and extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated in vacuo to afford 156 (224 mg, 73%) as a brown oil which 
was used in the next step without further purification. Rf (1:9:90 NH3:MeOH:CH2Cl2) = 
0.30; δH (400 MHz, CDCl3) 9.41 (1H, s, H-9), 6.84 (1H, td, J = 4.0, 1.5, H-7), 3.43‒3.36 (1H, 
m, H-4), 2.97‒2.87 (2H, m, H-1a, H-5a), 2.72 (1H, ddd, J = 10.0, 8.5, 7.0, H-1b), 2.66‒2.60 
(1H, m, H-5b), 2.56‒2.51 (1H, m, H-6a), 2.47‒2.32 (2H, m, H-3a, H-6b), 1.92‒1.75 (2H, m, 
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H-2), 1.50‒1.39 (1H, m H-3b); δC (100 MHz, CDCl3) 192.9 (C-9), 148.5 (C-7), 143.9 (C-8), 
57.6 (C-4), 52.1 (C-1), 45.4 (C-5), 28.8 (C-3), 25.8 (C-6), 22.6 (C-2). Data consistent with 
the literature values.100 
 
 
1-(1,2,3,5,6,8a-Hexahydroindolizin-8-yl)but-3-en-1-ol (158) 
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To a solution of 1,2,3,5,6,8a-hexahydroindolizine-8-carbaldehyde (156, 126 mg,           
0.83 mmol, 1.0 eq) in CH2Cl2 (2 mL) was added montmorillonite K10 (150 mg), 
potassium allyltrifluoroborate (148 mg, 1.00 mmol, 1.2 eq) and water (75 μL, 
4.15 mmol, 5.0 eq).  The reaction was stirred at room temperature for 30 min then 
filtered through a pad of Celite, washed with CH2Cl2 and the filtrate was concentrated 
in vacuo. Flash column chromatography [1:9:50 NH3:MeOH:CH2Cl2] afforded 158 
(72 mg, 45%, 1:1 mixture of diastereoisomers) as an orange oil, Rf (1:9:50 
NH3:MeOH:CH2Cl2) = 0.20; max/cm-1 (thin film) 3368, 2912; δH (400 MHz, CDCl3) 
5.87‒5.75 (1H, m, H-11), 5.76‒5.73 (1H, m, H-7), 5.17‒5.09 (2H, m, H-12), 4.17‒4.13 (m) 
and 4.07 (dd, J = 8.0, 5.5) (1H, H-9), 3.22‒3.15 (m) and 3.15‒3.08 (m) (1H, H-4), 2.96 (1H, 
ddd, J = 10.5, 8.5, 3.5, H-1a), 2.86 (1H, dtd, J = 11.0, 5.5, 2.5, H-5a), 2.74‒2.67 (1H, m, 
H-1b), 2.55 (1H, dddd, J = 11.0, 7.0, 5.5, 3.0, H-5b), 2.45‒2.31 (2H, m, H-10), 2.30‒2.20 
(2H, m, H-6), 2.17‒2.01 (1H, m, H-3a), 1.99‒1.87 (1H, m, H-2a), 1.85‒1.74 (1H, m, H-2b), 
1.70‒1.55 (1H, m, H-3b); δC (100 MHz, CDCl3) 140.9 and 140.8 (C-8), 135.0 and 134.7 
(C-7), 121.7 and 119.1 (C-11), 117.9 and 117.7 (C-12), 73.0 and 71.7 (C-9), 60.9 and 60.5 
(C-4), 52.8 (C-1), 46.6 (C-5), 41.0 and 40.0 (C-10), 28.8 and 28.4 (C-3), 25.2 and 24.9 (C-6), 
22.0 (C-2); [HRMS (ESI): calcd for C12H20NO, 194.1539. Found: [MH]+, 194.1542 
(−1.2 ppm error)]. 
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(2E)-1-(1,2,3,5,6,8a-Hexahydroindolizin-8-yl)but-2-en-1-one (81) 
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To a solution of oxalyl chloride (17 μL, 0.19 mmol, 1.2 eq) in CH2Cl2 (1 mL) at –78 ºC 
was added dropwise DMSO (27 μL, 0.38 mmol, 2.4 eq) and the mixture stirred at this 
temperature for 30 min. A solution of 1-(1,2,3,5,6,8a-hexahydroindolizin-8-yl)but-3-en-
1-ol (158, 31 mg, 0.16 mmol, 1.0 eq) in CH2Cl2 (1 mL) cooled to –78 ºC was added 
dropwise via cannula and the resultant solution was stirred at –78 ºC for 30 min. Et3N 
(112 µL, 0.80 mmol, 5.0 eq) was added and the reaction mixture stirred at –78 ºC for a 
further 30 min. The mixture was allowed to warm to room temperature and the 
reaction was stirred at this temperature for 2 h then poured into aq. NaHCO3 (5 mL) 
and extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated in vacuo. Preparative TLC [500 μm, 1:9 MeOH:CH2Cl2] 
afforded 81 (8 mg, 26%) as a yellow oil, Rf (1:9 MeOH:CH2Cl2) = 0.30; max/cm-1 (thin 
film) 2958, 2878, 2810, 1662, 1616; δH (400 MHz, CDCl3) 6.87 (1H, dq, J = 15.0, 7.0, H-11), 
6.83 (1H, td, J = 4.0, 1.5, H-7), 6.59 (1H, dq, J = 15.0, 1.5, H-10), 3.57‒3.51 (1H, m, H-4), 
2.96‒2.86 (2H, m, H-1a, H-5a), 2.74 (1H, dt, J = 10.0, 8.0, H-1b), 2.64‒2.57 (1H, m, H-5b), 
2.54‒2.44 (1H, m, H-6a), 2.40‒2.27 (2H, m, H-3a, H-6b), 1.90 (3H, dd, J = 7.0, 1.5, H-12), 
1.87‒1.74 (2H, m, H-2), 1.44‒1.33 (1H, m, H-3b); δC (100 MHz, CDCl3) 190.6 (C-9), 142.8 
(C-7), 142.2 (C-8), 136.9 (C-11), 126.9 (C-10), 58.9 (C-4), 52.5 (C-1), 45.3 (C-5), 29.1 (C-3), 
25.4 (C-6), 22.3 (C-2), 18.4 (C-12); [HRMS (ESI): calcd for C12H18NO, 192.1383 Found: 
[MH]+, 192.1386 (−1.4 ppm error)]. 
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1-(1,2,3,5,6,8a-Hexahydroindolizin-8-yl)butan-1-ol (elaeokanine B, 89) 
 
4
N
5
6
7
8
32
1 9
OH
10
11
12  
 
To a solution of 1,2,3,5,6,8a-hexahydroindolizine-8-carbaldehyde (156, 222 mg,            
1.47 mmol, 1.0 eq) in THF (5 mL) at −10 ºC was added propylmagnesium chloride (2 M 
in Et2O, 1.47 mL, 2.94 mmol, 2 eq). The resultant mixture was stirred for 10 min at this 
temperature then allowed to warm to room temperature. The reaction was stirred at 
this temperature for a further 4 h, then quenched with H2O (5 mL) and extracted with 
Et2O (3 x 5 mL). The combined organic extracts were washed with brine (5mL), dried 
(Na2SO4) and concentrated in vacuo. Flash column chromatography [1:9:90 
NH3:MeOH:CH2Cl2] afforded 89 (70 mg, 24%, 1:1 mixture of diastereoisomers) as an 
orange oil, Rf (1:9:90 NH3:MeOH:CH2Cl2) = 0.10; δH (400 MHz, CDCl3) 5.73‒5.69 (1H, m, 
H-7), 4.13‒4.08 (m) and 4.04 (t, J = 7.0) (1H, H-9), 3.08‒3.02 (m) and 3.02‒2.95 (m) (1H, 
H-4), 2.96 (1H, ddd, J = 10.0, 8.5, 3.5, H-1a), 2.86 (1H, m, H-5a), 2.59 (1H, q, J = 9.0, 
H-1b), 2.47 (1H, m, H-5b), 2.30‒1.24 (10H, m, H-2, H-3, H-6, H-10, H-11), 0.93 (3H, td, 
J = 7.0, 2.0, H-12); δC (100 MHz, CDCl3) 142.4 and 141.8 (C-8), 121.8 and 118.7 (C-7), 74.4 
and 72.8 (C-9), 60.9 and 60.7 (C-4), 53.0 and 52.9 (C-1), 46.9 and 46.8 (C-5), 38.8 and 37.5, 
29.0 and 28.5, 25.6 and 25.4, 22.2 and 22.1, 19.4 and 19.0 (C-2, C-3, C-6, C-10, C-11), 14.1 
(C-12); [HRMS (ESI): calc for C12H22NO, 196.1696 Found: [MH]+, 196.1699 (−1.8 ppm 
error)]. Data consistent with the literature values.103 
 
 
4-Phenylbut-3-yn-2-ol (166)271 
 
2
1
4
3
5
6
7
8
OH
 
 
To a solution of phenylacetylene (165, 70 mg, 0.69 mmol, 1.0 eq) in Et2O (5 mL) at 
−78 ºC was added dropwise n-BuLi (1.6 M in hexanes, 0.42 mL, 0.69 mmol, 1.0 eq). The 
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resultant mixture was stirred at −78 ºC for 15 min then allowed to warm to 0 ºC. 
Acetaldehyde (42 μL, 0.75 mmol, 1.1 eq) was added dropwise and the reaction stirred 
at 0 ºC for 2 h then quenched with aq. NH4Cl (5 mL) and extracted with EtOAc 
(3 x 10 mL). The combined organic extracts were washed with brine (5 mL), dried 
(Na2SO4) and concentrated in vacuo to afford 166 (68 mg, 68%) as a pale yellow oil. 
Rf (1:4 EtOAc:PE) = 0.30; δH (400 MHz, DMSO-d6) 7.39‒7.31 (5H, m, H-1, H-2, H-3), 5.44 
(1H, d, J = 5.5, OH), 4.55 (1H, qd, J = 6.5, 5.5, H-7), 1.34 (1H, d, J = 6.5, H-8); 
δH (400 MHz, CDCl3) 7.44‒7.40 (2H, m), 7.32‒7.28 (3H, m) (H-1, H-2, H-3), 4.76 (1H, dq, 
J = 6.5, 5.5, H-7), 1.88 (1H, d, J = 5.5, OH), 1.55 (3H, d, J = 6.5, H-8); δC (100 MHz, CDCl3) 
131.6 (C-2 or C-3), 128.4 (C-1), 128.3 (C-2 or C-3), 122.6 (C-4), 90.0 (C-6), 84.0 (C-5), 58.8 
(C-7), 24.4 (C-8). Data consistent with the literature values.271 
 
 
3-Methyldecahydropyrrolo[2,1-f][1,6]naphthyridin-1(10bH)-one (elaeokanidine A, 
19, and 19a, 19b, 19c) 
 
4
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To a solution of (2E)-1-(1,2,3,5,6,8a-hexahydroindolizin-8-yl)but-2-en-1-one (4 mg, 
0.02 mmol) in MeOH (0.2 mL) was added NH3 (0.2 mL) and the reaction stirred at 
room temperature for 16 h. The solvent was removed in vacuo to afford 19, 19a, 19b and 
19c (3.5 mg, 80%, 10:7:8:11 mixture of diastereoisomers) as a brown oil. δH (400 MHz, 
CDCl3) 3.83‒1.25 (16H, m, H-1, H-2, H-3, H-4, H-5, H-6, H-7, H-8, H-10, H-11), 1.22 (d, 
J = 6.0), 1.21 (d, J = 6.0), 1.16 (d, J = 7.0) and 1.15 (d, J = 7.0) (3H, H-12); [HRMS (ESI): 
calc for C12H21N2O, 209.1648 Found: [MH]+, 209.1654 (−2.5 ppm error)]. Data consistent 
with the literature values.89 
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7.4 Spirooxindoles 
 
7.4.1 General procedure C ‒ Boc protection of lactams and imides 
261  
 
Boc2O
DMAP
THF, rt
X
NH
O
X
N
O
Boc
n n
262261  
 
To a solution of the amide/imide 261 (1.0 eq) in THF was added 
N,N-dimethylaminopyridine (0.1‒1.1 eq) and di-tert-butyl dicarbonate (1.1‒1.5 eq) and 
the mixture stirred at room temperature for 16 h before removing the solvent in vacuo. 
The residue was loaded onto a silica column and eluted with a petrol/ethyl acetate 
mixture to yield the Boc-protected amide/imide 262. NB. Deviations from this 
procedure are noted. 
 
 
tert-Butyl 2-oxopyrrolidine-1-carboxylate (262a)272 
 
3 4
N
1
2
5
O
O
6
7O
 
 
The title compound was prepared according to the procedure by Hara.272 To a solution 
of pyrrolidinone (2.13 g, 25.0 mmol) in MeCN (12 mL) at 0 °C was added a solution of  
di-tert-butyl dicarbonate (5.73 g, 26.25 mmol) in MeCN (8 mL) followed by 
N,N-dimethylaminopyridine (305 mg, 2.50 mmol). The reaction was stirred at room 
temperature for 2.5 h then the solvent removed in vacuo and water (75 mL) added. The 
mixture was acidified to pH6‒7 with 10% HCl followed by extraction with EtOAc 
(3 x 75 mL). The combined organic extracts were dried (Na2SO4) and concentrated in 
vacuo to give the crude compound. Flash column chromatography [50‒100% 
EtOAc/PE] afforded 262a (4.27 g, 92%) as a colourless oil. Rf (1:1 EtOAc:PE) = 0.40; 
δH (400 MHz, CDCl3) 3.75‒3.71 (2H, m, H-4), 2.51‒2.47 (2H, m, H-2), 2.02‒1.94 (2H, m, 
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H-3), 1.51 (9H, s, H-7); δC (100 MHz, CDCl3) 174.3 (C-1), 150.2 (C-5), 82.7 (C-6), 46.4 
(C-4), 32.9 (C-2), 28.0 (C-7), 17.3 (C-3). Data consistent with the literature values.272,273  
 
 
tert-Butyl 2-oxopiperidine-1-carboxylate (262b) 
 
2
3
4
5
N1
O
6 O
O
7
8
 
 
δ-Valerolactam (1.96 g, 19.8 mmol), di-tert-butyl dicarbonate (5.06 mg, 23.2 mmol) and 
N,N-dimethylaminopyridine (497 mg, 4.1 mmol) in THF (30 mL) were reacted 
according to general procedure C. Flash column chromatography [1:1 EtOAc:PE] 
afforded 262b (3.93 mg, quant.) as a pale yellow oil. Rf (1:4 EtOAc:PE) = 0.10; 
δH (400 MHz, CDCl3) 3.65‒3.62 (2H, m, H-5), 2.51‒2.47 (2H, m, H-2), 1.83‒1.77 (4H, m, 
H-3, H-4), 1.51 (9H, s, H-8); δC (100 MHz, CDCl3) 171.3 (C-1), 152.7 (C-6), 82.8 (C-7), 46.3 
(C-5), 34.9 (C-2), 28.0 (C-8), 22.8 (C-3 or 4), 20.5 (C-3 or 4). Data consistent with the 
literature values.273  
 
 
tert-Butyl 2-oxoazetidine-1-carboxylate (262d) 
 
1
2
3
N
O
4
O
O
5
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Azetidin-2-one (452 mg, 6.37 mmol), di-tert-butyl dicarbonate (2.08 g, 9.55 mmol) and 
N,N-dimethylaminopyridine (78 mg, 0.64 mmol) in THF (10 mL) were reacted 
according to general procedure C. Flash column chromatography [20‒33% EtOAc/PE] 
afforded 262d (956 mg, 87%) as a colourless oil, Rf (1:4 EtOAc:PE) = 0.20; δH (400 MHz, 
CDCl3) 3.55 (2H, t, J = 5.0, H-3), 2.97 (2H, t, J = 5.0, H-2), 1.51 (9H, s, H-6); δC (100 MHz, 
CDCl3) 164.6 (C-1), 148.0 (C-4), 83.2 (C-5), 37.7 (C-3), 36.1 (C-2), 28.0 (C-6); m/z (ESI) 194 
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[MNa]+; [HRMS (ESI): calcd for C8H13NNaO3, 194.0788. Found: [MNa]+, 194.0789 
(−0.6 ppm error)]. Data consistent with the literature values.274  
 
 
tert-Butyl 2,5-dioxopyrrolidine-1-carboxylate (262e) 
 
2
1
N
1
2
3
O
O
O
O
4 5
 
 
Succinimide (396 mg, 4.0 mmol), di-tert-butyl dicarbonate (960 mg, 4.4 mmol) and 
N,N-dimethylaminopyridine (49 mg, 0.4 mmol) in THF (10 mL) were reacted according 
to general procedure C. Flash column chromatography [1:1 EtOAc:PE] afforded 262e 
(723 mg, 91%) as a colourless microcrystalline solid, Rf (1:1 EtOAc:PE) = 0.40; 
mp 88‒90 °C (lit275 86 °C) ; max/cm-1 (neat) 2988, 2977, 2943, 1804, 1764, 1710; 
δH (400 MHz, CDCl3) 2.77 (4H, s, H-2), 1.57 (9H, s, H-5); δC (100 MHz, CDCl3) 172.8 
(C-1), 146.5 (C-3), 86.3 (C-4), 28.5 (C-2), 27.7 (C-5); m/z (ESI) 222 [MNa]+; [HRMS (ESI): 
calcd for C9H13NNaO4, 222.0737. Found: [MNa]+, 222.0736 (0.6 ppm error)]. Data 
consistent with the literature values.275 
 
 
tert-Butyl 2,6-dioxopiperidine-1-carboxylate (262g) 
 
2
3
2
1
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O
O
4 O
O
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Piperidine-2,6-dione (452 mg, 4.0 mmol), di-tert-butyl dicarbonate (960 mg, 4.4 mmol) 
and N,N-dimethylaminopyridine (49 mg, 0.4 mmol) in THF (10 mL) were reacted 
according to general procedure C. Flash column chromatography [1:1 EtOAc:PE] 
afforded 262g (829 mg, 97%) as an off-white amorphous solid, mp 102‒103 °C; 
Rf (1:1 EtOAc:PE) = 0.60; max/cm-1 (neat) 2986, 2941, 2902, 1776, 1726, 1691, 1461; 
δH (400 MHz, CDCl3) 2.64 (4H, m, H-2), 2.00 (2H, m, H-3), 1.58 (9H, s, H-6); 
δC (100 MHz, CDCl3) 170.1 (C-1), 148.9 (C-4), 86.3 (C-5), 31.8 (C-2), 27.4 (C-6), 17.1 (C-3); 
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m/z (ESI) 236 [MNa]+; [HRMS (ESI): calcd for C10H15NNaO4, 236.0893. Found: [MNa]+, 
236.0891 (1.0 ppm error)]. Compound is known,276 but no data is provided in the 
literature. 
 
 
tert-Butyl 2-oxoazepane-1-carboxylate (262h) 
 
2
3
4 5
6
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O
7 O
O
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-Caprolactam (453 mg, 4.0 mmol), di-tert-butyl dicarbonate (960 mg, 4.4 mmol) and 
N,N-dimethylaminopyridine (538 mg, 4.4 mmol) in THF (10 mL) were reacted 
according to general procedure C. Flash column chromatography [1:1 EtOAc:PE] 
afforded 262h (732 mg, 86%) as a colourless oil, Rf (1:1 EtOAc:PE) = 0.60; δH (400 MHz, 
CDCl3) 3.77‒3.74 (2H, m, H-6), 2.65‒2.62 (2H, m, H-2), 1.79‒1.70 (6H, m, H-3, H-4, H-5), 
1.51 (9H, s, H-9); δC (100 MHz, CDCl3) 175.7 (C-1), 152.9 (C-7), 82.7 (C-8), 46.1 (C-6), 
39.5 (C-2), 29.2 (C-3 or 5), 28.6 (C-3 or 5), 28.0 (C-9), 23.5 (C-4). Data consistent with the 
literature values.273 
 
 
tert-Butyl 2,4-dioxopiperidine-1-carboxylate (262j)223 
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The title compound was prepared according to the procedure by Vanotti.223 To a 
solution of boc--alanine (2.50 g, 13.2 mmol), 2,2-dimethyl-1,3-dioxane-4,6-dione 
(2.09 g, 14.5 mmol) and N,N-dimethylaminopyridine (2.42 g, 19.8 mmol) in CH2Cl2 
(70 mL) at 0 °C was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
methiodide (4.70 g, 15.8 mmol) and the resultant mixture stirred at room temperature 
for 18 h. The reaction mixture was then washed with 5% KHSO4 (4 x 50 mL), the 
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organic layer dried (Na2SO4) and concentrated in vacuo to give 4.24 g of a colourless 
solid. The solid was redissolved in EtOAc (60 mL) and heated to reflux for 7 h after 
which time the volume was reduced to approx. 15 mL and allowed to crystallize 
overnight. The solid was filtered and washed with cold EtOAc to afford 262j (676 mg, 
24%) as microcrystals. The filtrate was concentrated in vacuo and triturated with cold 
EtOAc to yield a further crop of the title compound, 262j (1.05 g, 37%, total 61%) as an 
amorphous colourless solid, mp 104‒106 °C; δH (400 MHz, CDCl3) 4.09 (2H, t, J = 6.0, 
H-5), 3.50 (2H, s, H-2), 2.61 (2H, t, J = 6.0, H-4), 1.54 (9H, s, H-8); δC (100 MHz, CDCl3) 
202.1 (C-3), 165.3 (C-1), 151.2 (C-6), 84.2 (C-7), 52.2 (C-2), 40.6 (C-5), 38.2 (C-4), 27.9 (C-
8). Data consistent with the literature values.277  
 
 
1-Benzylpiperidin-2-one (262s)227 
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The title compound was prepared according to the procedure by Cossy.227 To a stirred 
solution of n-butyllithium (1.6 M in hexanes, 6.5 mL, 10.45 mmol) in THF (30 mL) at 
−78 °C was added a solution of δ-valerolactam (942 mg, 9.50 mmol) in THF (10 mL) via 
cannula.  After stirring for 20 min at −78 °C, benzyl bromide (1.13 mL, 9.50 mmol) was 
added and the solution slowly warmed to room temperature overnight (16 h). The 
reaction was quenched with aq. NH4Cl (10 mL) and extracted with Et2O (3 x 50 mL). 
The combined organic extracts were dried (Na2SO4) and concentrated in vacuo. Flash 
column chromatography [50‒100% EtOAc/PE] afforded 262s (585 mg, 33%) as a 
colourless oil, Rf (1:1 EtOAc:PE) = 0.15; δH (400 MHz, CDCl3) 7.34‒7.23 (5H, m, H-8, 
H-9, H-10), 4.60 (2H, s, H-6), 3.21‒3.17 (2H, m H-5), 2.47 (2H, t, J = 6.5, H-2), 1.84‒1.72 
(4H, m, H-3 and 4); δC (100 MHz, CDCl3) 169.8 (C-1), 137.3 (C-7), 128.5 (C-8), 128.0 
(C-9), 127.3 (C-10), 50.0 (C-6), 47.2 (C-5), 32.4 (C-2), 23.2 (C-3 or 4), 21.4 (C-3 or 4). Data 
consistent with the literature values.227 
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1-(4-Methoxybenzyl)piperidin-2-one (262t)228 
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The title compound was prepared according to the procedure by Winter.228 To a 
solution of δ-valerolactam (630 mg, 6.36 mL) in THF (30 mL) at 0 °C was added 
4-methoxybenzylchloride (1.12 mL, 8.26 mmol) and sodium hydride (60% dispersion in 
mineral oil, 330 mg, 8.26 mmol) and the mixture heated to reflux for 24 h. After cooling, 
the reaction was quenched with H2O (20 mL) and extracted with EtOAc (3 x 100 mL). 
The combined organic extracts were dried (Na2SO4) and concentrated in vacuo. Flash 
column chromatography [50‒100% EtOAc/PE] afforded 262t (1.31g, 94%) as a 
colourless oil, Rf (1:1 EtOAc:PE) = 0.20; δH (400 MHz, CDCl3) 7.18 (2H, d, J = 8.5, H-8), 
6.84 (2H, d, J = 8.5, H-9), 4.52 (2H, s, H-6), 3.78 (3H, s, H-11), 3.18‒3.15 (2H, m, H-5), 
2.44 (2H, t, J = 6.5, H-2), 1.81‒1.70 (4H, m, H-3, H-4); δC (100 MHz, CDCl3) 169.7 (C-1), 
158.9 (C-10), 129.4 (C-8), 113.9 (C-9), 55.2 (C-11), 49.4 (C-6), 47.0 (C-5), 32.4 (C-2), 23.1 
(C-3 or 4), 21.3 (C-3 or 4), C-7 not visible due to broadening; m/z (ESI) 220 [MH]+, 242 
[MNa]+; [HRMS (ESI): calcd for C13H18NO2, 220.1332. Found: [MH]+, 220.1338 (−2.9 
ppm error)]. Data consistent with the literature values.228,278  
 
 
7.4.2 General procedure D ‒ Benzylcarboxylation of N-protected 
lactams and imides 262  
 
LiHMDS
CbzCl
THF, 78 °C
X
N
O
R2
X
N
O
R2
BnO
O
n n
262 263  
 
Based on the procedure by Bogle.279 To a solution of amide/imide 262 in THF at −78 °C 
was added dropwise a solution of LiHMDS (2.1 eq, 1.0 M in THF) and the mixture 
stirred at −78 °C for 10 min. Benzylchloroformate (1.0 eq) was then added dropwise 
and the resulting mixture stirred at −78 °C for 1 h. The reaction was quenched at 
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−78 °C with aq. NH4Cl (10 mL) and allowed to warm to room temperature. The 
aqueous layer was extracted with EtOAc (3 x 25 mL), the combined organic extracts 
washed with brine (10 mL), dried (Na2SO4) and concentrated in vacuo. The crude 
mixture was loaded onto a silica column and eluted with an EtOAC/PE mixture to 
yield the ester 263. NB. Deviations from this procedure are noted. 
 
 
3-Benzyl 1-tert-butyl 2-oxopyrrolidine-1,3-dicarboxylate (263a) 
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tert-Butyl 2,5-dioxopyrrolidine-1-carboxylate (262a, 558 mg, 3.0 mmol), LiHMDS (1 M 
in THF, 6.3 mL, 6.3 mmol) and benzylchloroformate (0.43 mL, 3.0 mmol) in THF (3 mL) 
were reacted according to general procedure D. Flash column chromatography 
[1:2 EtOAc:PE] afforded 263a (602 mg, 63%) as a colourless solid, mp 74‒76 °C; 
Rf (1:1 EtOAc:PE) = 0.40; max/cm-1 (thin film) 3066, 3034, 2980, 2935, 1787, 1756, 1729, 
1498, 1478, 1455; δH (400 MHz, CDCl3) 7.41‒7.31 (5H, m, H-1, H-2, H-3), 5.21 (2H, s, 
H-5), 3.88 (1H, ddd, J = 11.0, 8.5, 5.0, H-9a), 3.70 (1H, ddd, J = 11.0, 8.0, 7.0, H-9b), 3.59 
(1H, dd, J = 9.0, 7.5, H-7), 2.44‒2.35 (1H, m, H-8a), 2.23 (1H, dddd, J = 13.0, 9.0, 8.0, 5.0, 
H-8b), 1.53 (9H, s, H-13); δC (100 MHz, CDCl3) 168.6, 168.5 (C-6, C-10), 149.9 (C-11), 
135.2 (C-4), 128.6 (C-2), 128.4 (C-1), 128.2 (C-3), 83.5 (C-12), 67.5 (C-5), 50.2 (C-7), 44.4 
(C-9), 28.0 (C-13), 21.5 (C-8); m/z (ESI) 342 [MNa]+; [HRMS (ESI): calcd for 
C17H21NNaO5, 342.1312. Found: [MNa]+, 342.1318 (−1.8 ppm error)]. Previously 
reported,280 but no data is provided in the literature. 
 
 
3-Benzyl 1-tert-butyl 2-oxopiperidine-1,3-dicarboxylate (263b) 
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tert-Butyl 2-oxopiperidine-1-carboxylate (262b, 2.97 g, 14.9 mmol), LiHMDS (1 M in 
THF, 31.4 mL, 31.4 mmol) and benzylchloroformate (2.13 mL, 14.9 mmol) in THF 
(15 mL) were reacted according to general procedure D. Flash column chromatography 
[1:2 EtOAc:PE] afforded 263b (4.71 g, 95%) as a colourless oil, Rf (1:4 EtOAc:PE) = 0.20; 
max/cm-1 (neat) 3065, 3034, 2979, 2941, 1771, 1741, 1721, 1498, 1479, 1456; δH (400 MHz, 
CDCl3) 7.37‒7.29 (5H, m, H-1, H-2, H-3), 5.22 (1H, d, J = 12.5, H-5a), 5.18 (1H, d, 
J = 12.5, H-5b), 3.68‒3.64 (2H, m, H-10), 3.56 (1H, dd, J = 8.5, 7.0, H-7), 2.23‒2.03 (2H, m, 
H-8), 1.98‒1.89 (1H, m, H-9a), 1.85‒1.75 (1H, m, H-9b), 1.52 (9H, s, H-14); δC (100 MHz, 
CDCl3) 169.7 (C-6), 167.2 (C-11), 152.5 (C-12), 135.4 (C-4), 128.5 (C-3), 128.2 (C-1), 128.1 
(C-2), 83.3 (C-13), 67.1 (C-5), 51.4 (C-7), 45.7 (C-10), 27.9 (C-14), 24.2 (C-8), 20.9 (C-9); 
m/z (ESI) 356 [MNa]+; [HRMS (ESI): calcd for C18H23NNaO5, 356.1468. Found: [MNa]+, 
356.1469 (−0.2 ppm error)]; [Found C, 64.71%; H, 6.90%; N, 4.14%. C18H23NO5 requires 
C, 64.85%; H, 6.95%; N, 4.20%]. 
 
 
3-Benzyl 1-tert-butyl 2-oxoazetidine-1,3-dicarboxylate (263d) 
 
1
2
3
N
O
4
O
O
5
6
7
O
O
8
9
12 11
10
 
 
tert-Butyl 2-oxoazetidine-1-carboxylate (262d, 90 mg, 0.53 mmol), LiHMDS (1 M in 
THF, 1.11 mL, 1.11 mmol) and benzylchloroformate (0.075 mL, 0.53 mmol) in THF 
(2 mL) were reacted according to general procedure C. Flash column chromatography 
[1:4 EtOAc:PE] afforded 263d (86 mg, 54%) as a colourless oil, Rf (1:1 EtOAc:PE) = 0.60; 
max/cm-1 (thin film) 3066, 3034, 2981, 2936, 1810, 1731, 1498, 1474, 1456; δH (400 MHz, 
CDCl3) 7.39‒7.34 (5H, m, H-10, H-11, H-12), 5.53 (2H, d, J = 1.0, H-8), 4.10 (1H, dd, 
J = 6.5, 3.5, H-2), 3.89 (1H, dd, J = 7.0, 3.5, H-3a), 3.71 (1H, dd, J = 7.0, 6.5, H-3b), 1.52 
(9H, s, H-6); δC (100 MHz, CDCl3) 165.7 (C-7), 158.8 (C-1), 147.6 (C-4), 134.9 (C-9), 128.6 
(C-11), 128.6 (C-12), 128.3 (C-10), 84.0 (C-5), 67.8 (C-8), 53.1 (C-2), 41.1 (C-3), 27.9 (C-6); 
m/z (ESI) 328 [MNa]+; [HRMS (ESI): calcd for C16H19NNaO5, 328.1155. Found: [MNa]+, 
328.1158 (−0.9 ppm error)]. 
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Benzyl 1-methyl-2,5-dioxopyrrolidine-3-carboxylate (263f) 
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1-Methylpyrrolidine-2,5-dione (1.13 g, 10.0 mmol), LiHMDS (1 M in THF, 21.0 mL, 
21.0 mmol) and benzylchloroformate (1.43 mL, 10.0 mmol) in THF (40 mL) were 
reacted according to general procedure D. Flash column chromatography 
[1:2 EtOAc:PE] afforded 263f (959 mg, 39%) as a colourless microcrystalline solid, 
mp 61‒63 °C; Rf (1:1 EtOAc:PE) = 0.40; max/cm-1 (thin film) 3065, 3034, 2951, 1783, 1736, 
1704, 1498; δH (400 MHz, CDCl3) 7.38‒7.30 (5H, m, H-1, H-2, H-3), 5.22 (2H, s, H-5), 3.80 
(1H, dd, J = 9.5, 4.5, H-7), 3.08 (1H, dd, J = 18.0, 4.5, H-8a), 2.99 (3H, s, H-10), 2.87 (1H, 
dd, J = 18.0, 9.5, H-8b); δC (100 MHz, CDCl3) 175.0, 172.0 (C-9, C-11), 167.3 (C-6), 134.7 
(C-4), 128.6 (C-2), 128.5 (C-1), 128.2 (C-3), 68.0 (C-5), 46.3 (C-7), 32.0 (C-8), 25.3 (C-10); 
m/z (ESI) 270 [MNa]+; [HRMS (ESI): calcd for C13H13NNaO4, 270.0737. Found: [MNa]+, 
270.0738 (−0.3 ppm error)]. 
 
 
3-Benzyl 1-tert-butyl 2,6-dioxopiperidine-1,3-dicarboxylate (263g) 
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tert-Butyl 2,6-dioxopiperidine-1-carboxylate (262g, 638 mg, 2.99 mmol), LiHMDS (1 M 
in THF, 6.3 mL, 6.3 mmol) and benzylchloroformate (0.43 mL, 2.99 mmol) in THF 
(3 mL) were reacted according to general procedure D. Flash column chromatography 
[1:2 EtOAc:PE] afforded 263g (394 mg, 38%) as a colourless oil, Rf (1:4 EtOAc:PE) = 
0.10; max/cm-1 (neat) 3065, 3034, 2982, 2939, 1784, 1737, 1699, 1498, 1457; δH (400 MHz, 
CDCl3) 7.38‒7.33 (5H, m, C-1, C-2, C-3), 5.25 (1H, d, J = 12.0, H-5a), 5.21 (1H, d, J = 12.0, 
H-5b), 3.70 (1H, dd, J = 8.0, 5.0, H-7), 2.72 (1H, ddd, J = 18.0, 8.0, 5.0, H-9a), 2.66‒2.57 
(1H, m, H-9b), 2.40‒2.31 (1H, m, H-8a), 2.24‒2.15 (1H, m, H-8b), 1.57 (9H, s, H-14); 
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δC (100 MHz, CDCl3) 169.1 (C-10), 167.6 (C-6), 166.2 (C-11), 148.2 (C-12), 135.0 (C-4), 
128.8 (C-2), 128.7 (C-1), 128.3 (C-3), 86.9 (C-13), 68.0 (C-5), 48.4 (C-7), 29.8 (C-9), 27.5 
(boc), 20.7 (C-8); m/z (ESI) 370 [MNa]+; [HRMS (ESI): calcd for C18H21NNaO6, 370.1261. 
Found: [MNa]+, 370.1259 (0.6 ppm error)] 
 
 
3-Benzyl 1-tert-butyl 2-oxoazepane-1,3-dicarboxylate (263h) 
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tert-Butyl 2-oxoazepane-1-carboxylate (262h, 568 mg, 2.66 mmol), LiHMDS (1 M in 
THF, 5.6 mL, 5.59 mmol) and benzylchloroformate (0.38 mL, 2.66 mmol) in THF (3 mL) 
were reacted according to general procedure D. Flash column chromatography 
[1:2 EtOAc:PE] afforded 263h (377 mg, 41%) as a colourless oil, Rf (1:4 EtOAc:PE) = 
0.20; max/cm-1 (neat) 3065, 3034, 2979, 2935, 2867, 1767, 1747, 1715, 1498, 1456; 
δH (400 MHz, CDCl3) 7.39‒7.30 (5H, m, H-1, H-2, H-3), 5.23 (1H, d, J = 12.5, H-5a), 5.19 
(1H, d, J = 12.5, H-5b), 4.13‒4.06 (1H, m, H-11a), 3.78 (1H, dd, J = 10.5, 2.5, H-7), 3.36 
(1H, dd, J = 15.5, 10.0, H-11b), 2.18-2.10 (1H, m, H-8a), 2.02‒1.81 (3H, m, H-8b, H-9a, 
H-10a), 1.61‒1.53 (2H, m, H-9b, H-10b), 1.51 (9H, s, H-15); δC (100 MHz, CDCl3) 171.5 
(C-12), 169.6 (C-6), 152.7 (C-13), 135.5 (C-4), 128.5, 128.4 (C-2, C-3), 128.3 (C-1), 83.4 
(C-14), 67.1 (C-5), 54.4 (C-7), 45.5 (C-11), 27.9 (C-15), 27.9, 27.3 (C-9, C-10), 26.1 (C-8); 
m/z (ESI) 370 [MNa]+; [HRMS (ESI): calcd for C19H25NNaO5, 370.1625. Found: [MNa]+, 
370.1624 (0.3 ppm error)]. 
 
 
3-Benzyl 1-tert-butyl 2,4-dioxopiperidine-1,3-dicarboxylate (263j) 
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Based on the procedure by Asahi.281 To a solution of tert-butyl 2,4-dioxopiperidine-1-
carboxylate (262j, 675 mg, 3.17 mmol) in ethanol (25 mL) at 0 °C was added potassium 
carbonate (1.09 g, 7.92 mmol) and benzylchloroformate (0.48 mL, 5.33 mmol) and the 
mixture stirred at room temperature for 2.5 h. The reaction was quenched with 
10% HCl (20 mL), extracted with CH2Cl2 (3 x 50 mL), dried (Na2SO4) and concentrated 
in vacuo. Flash column chromatography [20‒50% EtOAc/PE] afforded 263j (391 mg, 
36%) as a colourless oil which crystallised on standing, mp 70‒71 °C; Rf (1:1 EtOAc:PE) 
= 0.60; max/cm-1 (thin film) 3112, 3065, 3051, 3012, 2981, 2968, 2931, 2915, 1768, 1712, 
1695, 1682, 1652, 1590, 1501, 1464; δH (400 MHz, CDCl3) 7.41‒7.37 (5H, m, H-1, H-2, 
H-3), 6.00 (1H, t, J = 1.0, H-7), 5.23 (2H, s, H-5), 3.91 (2H, t, J = 6.5, H-10a), 2.64 (2H, td, 
J = 6.5, 1.0, H-9a), 1.53 (9H, s, H-14); δC (100 MHz, CDCl3) 164.0 (C-11), 162.7 (C-8), 
152.2 (C-12), 150.8 (C-6), 134.0 (C-4), 129.1 (C-1), 128.8 (C-3), 128.6 (C-2), 111.2 (C-7), 
83.2 (C-13), 70.9 (C-5), 42.4 (C-10), 28.0 (C-14), 27.2 (C-9); m/z (ESI) 370 [MNa]+; [HRMS 
(ESI): calcd for C18H21NNaO6, 370.1261. Found: [MNa]+, 370.1246 (4.1 ppm error)]. 
 
 
Benzyl 1-methyl-2-oxopiperidine-3-carboxylate (263r) 
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1-Methylpiperidin-2-one (544 mg, 4.81 mmol), LiHMDS (1 M in THF, 10.1 mL, 
10.1 mmol) and benzylchloroformate (0.69 mL, 4.81 mmol) in THF (5 mL) were reacted 
according to general procedure D. Flash column chromatography [50‒100% 
EtOAc/PE] afforded 263r (475 mg, 40%) as a colourless oil, Rf (EtOAc) = 0.50; max/cm-1 
(thin film) 3063, 3033, 2945, 2872, 1737, 1644, 1500, 1454; δH (400 MHz, CDCl3) 7.39‒7.28 
(5H, m, H-1, H-2, H-3), 5.22 (1H, d, J = 12.5, H-5a), 5.17 (1H, d, J = 12.5, H-5b), 3.46 (1H, 
dd, J = 7.5, 6.5, H-7), 3.36 (1H, ddd, J = 12.0, 8.0, 5.0, H-10a),  3.27 (1H, dt, J = 12.0, 5.5, 
H-10b), 2.97 (3H, s, H-12), 2.18-2.01 (2H, m, H-8), 1.99‒1.90 (1H, m, H-9a), 1.82‒1.72 
(1H, m, H-9b); δC (100 MHz, CDCl3) 171.0 (C-6), 165.6 (C-11), 135.7 (C-4), 128.5 (C-2), 
128.2 (C-1), 128.1 (C-3), 66.9 (C-5), 49.7 (C-10), 49.1 (C-7), 35.0 (C-12), 25.3 (C-8), 20.9 
(C-9); m/z (ESI) 270 [MNa]+; [HRMS (ESI): calcd for C14H17NNaO3, 270.1101. Found: 
[MNa]+, 270.1111 (−3.7 ppm error)]. 
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Benzyl 1-benzyl-2-oxopiperidine-3-carboxylate (263s) 
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1-Benzylpiperidin-2-one (262s, 585 mg, 3.09 mmol), LiHMDS (1 M in THF, 6.49 mL, 
6.49 mmol) and benzylchloroformate (0.44 mL, 3.9 mmol) in THF (3 mL) were reacted 
according to general procedure D. Flash column chromatography [1:2 EtOAc] afforded 
263s (872 mg, 87%) as a colourless oil, Rf (1:1 EtOAc:PE) = 0.60; max/cm-1 (thin film) 
3062, 3031, 2945, 2870, 1739, 1644, 1587, 1494, 1464, 1453; δH (400 MHz, CDCl3) 7.40‒7.22 
(10H, m, H-1, H-2, H-3, H-14, H-15, H-16), 5.22 (2H, s, H-5), 4.77 (1H, d, J = 14.5, 
H-12a), 4.47 (1H, d, J = 14.5, H-12b), 3.56 (1H, dd, J = 7.0, 7.0, H-7), 3.28‒3.16 (2H, m, 
H-10), 2.19‒2.03 (2H, m, H-8), 1.93‒1.84 (1H, m, H-9a), 1.77‒1.67 (1H, m, H-9b); 
δC (100 MHz, CDCl3) 171.0 (C-6), 165.7 (C-11), 136.7, 135.6 (C-4, C-13), 128.6, 128.5 (C-2, 
C-3, C-14 or C-15), 128.2 (C-1 or C-16), 128.1, 127.9 (C-2, C-3, C-14 or C-15), 127.4 (C-1 
or C-16), 67.0 (C-5), 50.2 (C-12), 49.2 (C-7), 46.9 (C-10), 25.2 (C-8), 20.8 (C-9); m/z (ESI) 
346 [MNa]+; [HRMS (ESI): calcd for C20H21NNaO3, 346.1414. Found: [MNa]+, 346.1417 
(−1.0 ppm error)]. 
 
 
Benzyl 1-(4-methoxybenzyl)-2-oxopiperidine-3-carboxylate (263t) 
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1-(4-Methoxybenzyl)piperidin-2-one  (262t, 738 mg, 3.37 mmol), LiHMDS (1 M in THF, 
7.07 mL, 7.07 mmol) and benzylchloroformate (0.48 mL, 3.37 mmol) in THF (3.5 mL) 
were reacted according to general procedure D. Flash column chromatography [2:1 
PE:EtOAc] afforded 263t (790 mg, 66%) as a colourless oil, Rf (1:1 EtOAc:PE) = 0.40; 
max/cm-1 (thin film) 3064, 3033, 2941, 2870, 2837, 1736, 1642, 1585, 1512, 1493, 1463; 
δH (400 MHz, CDCl3) 7.39-7.30 (5H, m, H-1, H-2, H-3), 7.17 (2H, d, J = 8.5, H-14), 6.79 
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2H, d, J = 98.5, H-15), 5.22 (2H, s, H-5), 4.69 (1H, d, J = 14.5, H-12a), 4.40 (1H, d, J = 14.5, 
H-12b), 3.80 (3H, s, H-17), 3.56-3.52 (1H, m, H-7), 3.26-3.14 (2H, m, H-10), 2.18-2.02 (2H, 
m, H-8), 1.92-1.82 (1H, m, H-9a), 1.76-1.65 (1H, m, H-9b); δC (100 MHz, CDCl3) 171.0 
(C-6), 165.6 (C-11), 158.9 (C-16), 135.7 (C-4), 129.4 (C-14), 128.8 (C-13), 128.5 (C-2), 128.2 
(C-1), 128.1 (C-3), 113.9 (C-15), 67.0 (C-5), 55.2 (C-17), 49.7 (C-12), 49.3 (C-7), 46.7 (C-10), 
25.2 (C-8), 20.9 (C-9); m/z (ESI) 376 [MNa]+; [HRMS (ESI): calcd for C21H23NNaO4, 
376.1519. Found: [MNa]+, 376.1508 (3.1 ppm error)]. 
 
 
Benzyl 1-methyl-2-oxopyrrolidine-3-carboxylate (263x) 
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1-Methylpyrrolidin-2-one (1.04 g, 10.5 mmol), LiHMDS (1 M in THF, 22.0 mL, 
22.0 mmol) and benzylchloroformate (1.49 mL, 10.5 mmol) in THF (10 mL) were 
reacted according to general procedure D. Flash column chromatography [50‒100% 
EtOAc/PE] afforded 263x (1.25 g, 47%) as a pale yellow oil, Rf (EtOAc) = 0.50; max/cm-1 
(thin film) 3064, 3033, 2953, 2885, 1736, 1687, 1499, 1455; δH (400 MHz, CDCl3) 7.40‒7.28 
(5H, m, H-1, H-2, H-3), 5.20 (2H, s, H-5), 3.52‒3.45 (2H, m, H-7, H-9a), 3.34 (1H, ddd, 
J = 9.5, 8.5, 6.0, H-9b), 2.87 (3H, s, H-11), 2.40 (1H, dddd, J = 13.0, 8.5, 6.5, 6.0, H-8a), 2.26 
(1H, dddd, J = 13.0, 9.5, 8.5, 5.0, H-8b); δC (100 MHz, CDCl3) 170.2, 169.5 (C-6, C-10), 
135.5 (C-4), 128.5 (C-2), 128.2 (C-1), 128.0 (C-3), 67.1 (C-5), 48.2 (C-7), 47.8 (C-9), 30.0 
(C-9), 22.2 (C-8); m/z (ESI) 256 [MNa]+; [HRMS (ESI): calcd for C13H15NNaO3, 256.0944. 
Found: [MNa]+, 256.0946 (−0.8 ppm error)]. 
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7.4.3 General procedure E ‒ Hydrogenolysis and amide coupling of 
esters 263 
 
H2, Pd/C
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HO
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A solution of ester 263 in EtOAc in the presence of Pd/C was stirred under an 
atmosphere of H2 (balloon) for 0.5‒2 h. The mixture was filtered through celite, washed 
with EtOAc and concentrated in vacuo to afford the crude acid 264 which was used 
immediately in the next step. To a solution of the acid (1.0 eq) in CH2Cl2 at 0 °C was 
added the aniline (1.1 eq) and 2-chloro-1-methylpyridinium iodide (1.5 eq), followed 
by dropwise addition of triethylamine (5.0 eq) and the mixture stirred at room 
temperature for 16 h. The reaction was quenched with aq. HCl (10%, 5 mL) and 
extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts were washed with 
brine (10 mL), dried (Na2SO4) and concentrated in vacuo. The crude mixture was loaded 
onto a silica column and eluted with am EtOAc/PE mixture to yield the anilide 20. NB. 
Deviations from this procedure are noted. 
 
 
1-(tert-Butoxycarbonyl)-2-oxopyrrolidine-3-carboxylic acid (264a) 
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A solution of 3-benzyl 1-tert-butyl 2-oxopyrrolidine-1,3-dicarboxylate (263a, 576 mg, 
1.81 mmol) in EtOAc (15 mL) was hydrogenolysed in the presence of 10% Pd/C 
(80 mg) for 2 h according to general procedure E to afford the crude title compound 
(412 mg) as a colourless amorphous solid, Rf (1:1 EtOAc:PE) = 0.10; δH (400 MHz, 
CDCl3) 3.91 (1H, ddd, J = 11.5, 8.5, 3.5, H-4a), 3.70 (1H, ddd, J = 11.0, 9.0, 7.5, H-4b), 3.57 
(1H, t, J = 10.0, H-2), 2.46‒2.30 (2H, m, H-3), 1.54 (9H, s, H-8). 
 
 
1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b) 
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A solution of 3-benzyl 1-tert-butyl 2-oxopiperidine-1,3-dicarboxylate (263b, 2.40 g, 
7.22 mmol) in EtOAc (60 mL) was hydrogenolysed in the presence of 10% Pd/C 
(320 mg) for 2 h according to general procedure E to afford the crude title compound 
(1.74 g) as a colourless amorphous solid, Rf (1:1 EtOAc:PE) = 0.10; δH (400 MHz, CDCl3) 
3.70 (2H, m, H-5), 3.42 (1H, dd, J = 9.5, 7.0, H-2), 2.31‒2.21 (1H, m), 2.16‒2.05 (1H, m), 
2.02‒1.93 (1H, m), 1.91‒1.78 (1H, m) (H-3, H-4), 1.52 (9H, s, H-9). 
 
 
1-(tert-Butoxycarbonyl)-2-oxoazetidine-3-carboxylic acid (264d) 
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A solution of 3-benzyl 1-tert-butyl 2-oxoazetidine-1,3-dicarboxylate (263d, 359 mg, 
1.18 mmol) in EtOAc (30 mL) was hydrogenolysed in the presence of 5% Pd/C 
(164 mg) for 1.5 h according to general procedure E to afford the crude title compound 
(244 mg). δH (400 MHz, CDCl3) 8.20 (1H, br s, OH), 4.11 (1H, dd, J = 6.5, 3.5, H-2), 3.88 
(1H, dd, J = 7.0, 3.5, H-3a), 3.74 (1H, dd, J = 7.0, 6.5, H-3b), 1.51 (9H, s, H-6). 
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1-Methyl-2,5-dioxopyrrolidine-3-carboxylic acid (264f) 
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A solution of benzyl 1-methyl-2,5-dioxopyrrolidine-3-carboxylate (263f, 494 mg, 
2.00 mmol) in EtOAc (20 mL) was hydrogenolysed in the presence of 5% Pd/C 
(426 mg) for 30 min according to general procedure E to afford the crude title 
compound (312 mg) as a colourless oil. δH (400 MHz, CDCl3) 7.82 (1H, br s, OH), 3.82 
(1H, dd, J = 9.5, 5.0, H-2), 3.12 (1H, dd, J = 18.5, 5.0, H-3a), 3.01 (3H, s, H-6), 2.94 (1H, 
dd, J = 18.5, 9.5, H-3b). 
 
 
1-(tert-Butoxycarbonyl)-2,6-dioxopiperidine-3-carboxylic acid (264g) 
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A solution of 3-benzyl 1-tert-butyl 2,6-dioxopiperidine-1,3-dicarboxylate (263g, 381 mg, 
1.10 mmol) in EtOAc (10 mL) was hydrogenolysed in the presence of 10% Pd/C 
(50 mg) for 2 h according to general procedure E to afford the crude title compound 
(310 mg) as a colourless amorphous solid, Rf (1:1 EtOAc:PE) = 0.10; δH (400 MHz, 
CDCl3) 3.63 (1H, dd, J = 8.0, 6.5, H-2), 2.86 (1H, dt, J = 18.0, 6.0, H-4a), 2.68 (1H, ddd, 
J = 18.0, 8.5, 6.0, H-4b), 2.37‒2.31 (2H, m, H-3), 1.57 (9H, s, H-9). 
 
 
1-(tert-Butoxycarbonyl)-2-oxoazepane-3-carboxylic acid (264h) 
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A solution of 3-benzyl 1-tert-butyl 2-oxoazepane-1,3-dicarboxylate (263h, 377 mg, 
1.09 mmol) in  EtOAc (10 mL) was hydrogenolysed in the presence of 10% Pd/C 
(50 mg) for 2 h according to general procedure E to afford the crude title compound 
(235 mg) as a colourless oil, Rf (1:1 EtOAc:PE) = 0.10; δH (400 MHz, CDCl3) 4.20 (1H, dd, 
J = 15.5, 6.0, H-6a), 3.63 (1H, dd, J = 10.5, 2.0, H-2), 3.41 (1H, dd, J = 15.5, 10.5, H-6b), 
2.39‒2.32 (1H, m, H-3a), 2.08‒1.51 (5H, m, H-3b, H-4, H-5), 1.54 (9H, s, H-10). 
 
 
1-Methyl-2-oxopiperidine-3-carboxylic acid (264r) 
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A solution of benzyl 1-methyl-2-oxopiperidine-3-carboxylate (263r, 467 mg, 1.89 mmol) 
in EtOAc (20 mL) was hydrogenolysed in the presence of 10% Pd/C (90 mg) for 1 h 
according to general procedure E to afford the crude title compound (313 mg) as a 
colourless powder. δH (400 MHz, CDCl3) 3.46‒3.33 (2H, m, H-5), 3.20 (1H, dd, J = 10.5, 
6.0, H-2), 3.03 (3H, s, H-7), 2.45‒2.37 (1H, m, H-3 or 4), 2.07‒1.96 (2H, m, H-3 and/or 4), 
1.93‒1.80 (1H, m, H-3 or 4). Previously reported, but no NMR data is provided in the 
literature.282 
 
 
1-Benzyl-2-oxopiperidine-3-carboxylic acid (264s) 
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A solution of benzyl 1-benzyl-2-oxopiperidine-3-carboxylate (263s, 841 mg, 2.60 mmol) 
in EtOAc (25 mL) was hydrogenolysed in the presence of 10% Pd/C (115 mg) for 2 h 
according to general procedure E to afford the crude title compound (580 mg), 
Rf (1:1 EtOAc:PE) = 0.20; δH (400 MHz, CDCl3) 7.38‒7.22 (5H, m, H-9, H-10, H-11), 4.70 
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(1H, d, J = 14.5, H-7a), 4.57 (1H, d, J = 14.5, H-7b), 3.34‒3.27 (3H, m, H-2, H-5), 2.34‒2.35 
(1H, m), 2.08‒1.91 (2H, m), 1.86‒1.74 (1H, m) (H-3, H-4). 
 
 
1-(4-Methoxybenzyl)-2-oxopiperidine-3-carboxylic acid (264t) 
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A solution of benzyl 1-(4-methoxybenzyl)-2-oxopiperidine-3-carboxylate  (263t, 
760 mg, 2.15 mmol) in EtOAc (20 mL) was hydrogenolysed in the presence of 
10% Pd/C (95 mg) for 1.5 h according to general procedure E to afford the crude title 
compound (474 mg). δH (400 MHz, CDCl3) 7.19 (2H, d, J = 8.5, H-9), 6.88 (2H, d, J = 8.5, 
H-10), 4.62 (1H, d, J = 14.5, H-7a), 4.51 (1H, d, J = 14.5, H-7b), 3.81 (3H, s, H-12), 
3.32‒3.24 (3H, m, H-2, H-5), 2.42‒2.34 (1H, m), 2.06‒1.89 (2H, m), 1.84‒1.71 (1H, m) 
(H-3, H-4). 
 
 
1-Methyl-2-oxopyrrolidine-3-carboxylic acid (264x) 
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A solution of benzyl 1-methyl-2-oxopyrrolidine-3-carboxylate (263x, 1.23 g, 5.28 mmol) 
in EtOAc (55 mL) was hydrogenolysed in the presence of 5% Pd/C (450 mg) for 2 h 
according to general procedure E to afford the crude title compound (729 mg). 
δH (400 MHz, CDCl3) 9.77 (1H, br s, OH), 3.47-3.41 (3H, m, H-2, H-4), 2.91 (3H, s, H-6), 
2.42-2.33 (2H, m, H-3). 
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tert-Butyl 3-(methyl(phenyl)carbamoyl)-2-oxopyrrolidine-1-carboxylate (20a) 
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1-(tert-Butoxycarbonyl)-2-oxopyrrolidine-3-carboxylic acid (264a, 412 mg), 
N-methylaniline (0.21 mL, 1.98 mmol), 2-chloro-1-methylpyridinium iodide (689 mg, 
2.70 mmol) and triethylamine (1.25 mL, 8.99 mmol) in CH2Cl2 (15 mL) were reacted 
according to general procedure E. Flash column chromatography [1:1 EtOAc:PE] 
afforded 20a (556 mg, 97% over 2 steps) as a colourless foamy solid, mp 84‒85 °C; 
Rf (1:1 EtOAc:PE) = 0.30; max/cm-1 (neat) 3062, 2980, 2933, 1782, 1746, 1717, 1657, 1595, 
1496, 1477, 1455; δH (400 MHz, CDCl3) 7.45‒7.33 (5H, m, H-1, H-2, H-3), 3.91 (1H, ddd, 
J = 10.5, 9.0, 4.0, H-9a), 3.56 (1H, t, J = 9.0, H-7), 3.52 (1H, dt, J = 10.5, 8.0, H-9b), 3.32 
(3H, s, H-5), 2.47 (1H, ddd, J = 17.0, 13.0, 9.0, H-8a), 1.96 (1H, dddd, J = 13.0, 9.0, 8.0, 4.0, 
H-8b), 1.50 (9H, s, H-13); δC (100 MHz, CDCl3) 170.3 (C-6), 168.7 (C-10), 149.9 (C-11), 
143.3 (C-4), 129.8 (C-2), 128.1 (C-1), 127.6 (C-3), 83.0 (C-12), 47.4 (C-7), 44.9 (C-9), 37.8 
(C-5), 27.9 (C-13), 22.2 (C-8); m/z (ESI) 341 [MNa]+; [HRMS (ESI): calcd for 
C17H22N2NaO4, 341.1472. Found: [MNa]+, 341.1475 (−1.0 ppm error)];  [Found C, 
64.14%; H, 6.95%; N, 8.72%. C17H22N2O4 requires C, 64.13%; H, 6.97%; N, 8.80%]. 
 
 
tert-Butyl 3-((2-methoxyphenyl)(methyl)carbamoyl)-2-oxopiperidine-1-carboxylate 
(20b) 
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1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 421 mg), N-(2-
methoxypheny)-N-methylamine (261 mg, 1.91 mmol), 2-chloro-1-methylpyridinium 
iodide (663 mg, 2.60 mmol) and triethylamine (1.21 mL, 8.66 mmol) in CH2Cl2 (10 mL) 
were reacted according to general procedure E. Flash column chromatography [20‒50% 
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EtOAc/PE] afforded 20b (492 mg, 78% over 2 steps) as a colourless amorphous solid, 
mp 140‒142 °C; Rf (1:1 EtOAc:PE) = 0.40; max/cm-1 (neat) 3066, 2940, 1768, 1716, 1657, 
1597, 1501, 1460; δH (400 MHz, CDCl3) 7.48 (1H, dd, J = 7.5, 1.5, H-6), 7.31 (1H, ddd, 
J = 8.0, 7.5, 1.5, H-4), 6.97 (1H, dd, J = 7.5, 1.5, H-5), 6.93 (1H, dd, J = 8.0, 1.5, H-3), 3.81 
(3H, s, H-1), 3.65‒3.53 (2H, m, H-13), 3.34 (1H, dd, J = 10.0, 7.0, H-10), 3.20 (3H, s, H-8), 
2.14 (1H, dddd, J = 13.5, 11.5, 10.0, 4.0, H-11a), 1.96 (1H, ddt, J = 13.5, 9.5, 4.5, H-12a), 
1.84‒1.75 (1H, m, H-11b), 1.60‒1.50 (1H, m, H-12b), 1.48 (9H, s, H-17); δC (100 MHz, 
CDCl3) 170.6 (C-9), 168.2 (C-14), 154.9 (C-2), 152.5 (C-15), 132.1 (C-7), 130.1 (C-6), 129.5 
(C-4), 121.4 (C-5), 111.5 (C-3), 82.9 (C-16), 55.4 (C-1), 48.4 (C-10), 46.5 (C-13), 36.2 (C-8), 
27.9 (C-17), 25.1 (C-11), 21.5 (C-12); m/z (ESI) 385 [MNa]+; [HRMS (ESI): calcd for 
C19H26N2NaO5, 385.1734. Found: [MNa]+, 385.1722 (3.1 ppm error)]; [Found C, 62.94%; 
H, 7.15%; N, 7.56%. C19H26N2O5 requires C, 62.97%; H, 7.23%; N, 7.73%]. 
 
 
tert-Butyl 3-((4-methoxybenzyl)(phenyl)carbamoyl)-2-oxopiperidine-1-carboxylate 
(20c) 
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1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 402 mg), N-(4-
methoxybenzyl)aniline (388 mg, 1.82 mmol), 2-chloro-1-methylpyridinium iodide 
(633 mg, 2.48 mmol) and triethylamine (1.15 mL, 8.27 mmol) in CH2Cl2 (10 mL) were 
reacted according to general procedure E. Flash column chromatography [20‒50% 
EtOAc/PE] afforded 20c (629 mg, 86% over 2 steps) as a colourless oil, 
Rf (1:1 EtOAc:PE) = 0.60; max/cm-1 (neat) 3063, 2977, 2936, 2838, 1768, 1716, 1655, 1613, 
1594, 1513, 1494, 1457; δH (400 MHz, CDCl3) 7.31‒7.27 (3H, m, H-1, H-2 and/or H-3), 
7.14 (2H, d, J = 9.0, H-7), 6.79 (2H, d, J = 9.0, H-8), 4.94 (1H, d, J = 14.5, H-5a), 4.78 (1H, 
d, J = 14.5, H-5b), 3.77 (3H, s, H-10), 3.62‒3.58 (2H, m, H-15), 3.39 (1H, dd, J = 10.5, 7.0, 
H-12), 2.19 (1H, dddd, J = 13.5, 11.5, 10.5, 4.0, H-13a), 2.01‒1.92 (1H, m, H-14a), 
1.90‒1.81 (1H, m, H-13b), 1.62‒1.53 (1H, m, H-14b), 1.50 (9H, s, H-19), some aromatic 
peaks not visible due to broadening; δC (100 MHz, CDCl3) 170.1 (C-11), 168.2 (C-16), 
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158.8 (C-9), 152.2 (C-17), 142.0 (C-4), 130.0 (C-7), 129.5 (C-2 or 3), 129.2 (C-6), 128.2 (C-1), 
113.7 (C-8), 83.0 (C-18), 55.2 (C-10), 52.5 (C-5), 48.9 (C-12), 46.6 (C-15), 27.9 (C-19), 25.4 
(C-13), 21.6 (C-14), some aromatic peaks not visible due to broadening; m/z (ESI) 461 
[MNa]+; [HRMS (ESI): calcd for C25H30N2NaO5, 461.2047. Found: [MNa]+, 461.2036 
(2.4 ppm error)]. 
 
 
tert-Butyl 3-(methyl(phenyl)carbamoyl)-2-oxoazetidine-1-carboxylate (20d) 
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1-(tert-Butoxycarbonyl)-2-oxoazetidine-3-carboxylic acid (264d, 244 mg), 
N-methylaniline (0.14 mL, 1.29 mmol), 2-chloro-1-methylpyridinium iodide (450 mg, 
1.77 mmol) and triethylamine (0.82 mL, 5.89 mmol) in CH2Cl2 (5 mL) were reacted 
according to general procedure E. Flash column chromatography [20‒50% EtOAc/PE] 
afforded 20d (260 mg, 73% over 2 steps) as a colourless foam, Rf (1:2 EtOAc:PE) = 0.40; 
max/cm-1 (thin film) 3063, 2979, 2935, 1805, 1724, 1656, 1595, 1497, 1474, 1457; 
δH (400 MHz, CDCl3) 7.46‒7.33 (5H, m, H-10, H-11, H-12), 4.01 (1H, dd, J = 6.0, 3.5, 
H-3a), 3.98 (1H, dd, J = 6.0, 3.5, H-2), 3.45 (1H, t, J = 6.0, H-3b), 3.33 (3H, s, H-8), 1.49 
(9H, s, H-6); δC (100 MHz, CDCl3) 164.6 (C-7), 160.8 (C-1), 147.7 (C-4), 142.4 (C-9), 129.9 
(C-11), 128.3 (C-12), 127.5 (C-10), 83.5 (C-5), 51.6 (C-2), 41.7 (C-3), 37.7 (C-8), 27.9 (C-6); 
m/z (ESI) 327 [MNa]+; [HRMS (ESI): calcd for C16H20N2NaO4, 327.1315. Found: [MNa]+, 
327.1314 (0.3 ppm error)]. 
 
 
N,1-Dimethyl-2,5-dioxo-N-phenylpyrrolidine-3-carboxamide (20f) 
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1-Methyl-2,5-dioxopyrrolidine-3-carboxylic acid (264f, 312 mg), N-methylaniline 
(0.24 mL, 2.20 mmol), 2-chloro-1-methylpyridinium iodide (765 mg, 3.00 mmol) and 
triethylamine (1.4 mL, 10.0 mmol) in CH2Cl2 (20 mL) were reacted according to general 
procedure E. Flash column chromatography [1:1 EtOAc:PE] afforded 20f (437 mg, 89% 
over 2 steps) as a colourless amorphous solid, mp 99‒101 °C; Rf (1:1 EtOAc:PE) = 0.30; 
max/cm-1 (thin film) 2946, 1778, 1703, 1654, 1496; δH (400 MHz, CDCl3) 7.49‒7.36 (5H, 
m, H-1, H-2, H-3), 3.78 (1H, dd, J = 9.0, 5.0, H-7), 3.35 (3H, s, H-5), 3.10 (1H, dd, J = 18.0, 
5.0, H-8a), 2.96 (3H, s, H-10), 2.63 (1H, dd, J = 18.0, 9.0, H-8b); δC (100 MHz, CDCl3) 
175.9 (C-11), 174.2 (C-9), 167.5 (C-6), 142.9 (C-4), 130.0 (C-2), 128.5 (C-1), 127.7 (C-3), 
43.8 (C-7), 38.0 (C-5), 33.3 (C-8), 25.2 (C-10); m/z (ESI) 269 [MNa]+; [HRMS (ESI): calcd 
for C13H14N2NaO3, 269.0897. Found: [MNa]+, 269.0896 (0.1 ppm error)]. 
 
 
tert-Butyl 3-(methyl(phenyl)carbamoyl)-2,6-dioxopiperidine-1-carboxylate (20g) 
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1-(tert-Butoxycarbonyl)-2,6-dioxopiperidine-3-carboxylic acid (264g, 304 mg), 
N-methylaniline (0.14 mL, 1.30 mmol), 2-chloro-1-methylpyridinium iodide (452 mg, 
1.77 mmol) and triethylamine (0.82 mL, 5.90 mmol) in CH2Cl2 (10 mL) were reacted 
according to general procedure E. Flash column chromatography [1:1 EtOAc:PE] 
afforded 20g (295 mg, 78% over 2 steps) as a sticky colourless oil, Rf (1:1 EtOAc:PE) = 
0.40; max/cm-1 (neat) 3061, 2982, 2937, 1782, 1734, 1698, 1659, 1595, 1496, 1457; 
δH (400 MHz, CDCl3) 7.47‒7.28 (5H, m, H-1, H-2, H-3), 3.53 (1H, dd, J = 9.5, 5.5, H-7), 
3.33 (3H, s, H-5), 2.90‒2.84 (1H, m, H-9a), 2.45‒2.30 (2H, m, H-8a, H-9b), 1.97‒1.91 (1H, 
m, H-8b), 1.54 (9H, s, H-14); δC (100 MHz, CDCl3) 169.4 (C-10), 167.7 (C-6), 167.5 (C-11), 
148.4 (C-12), 143.1 (C-4), 130.2 (C-2), 128.6 (C-1), 127.2 (C-3), 86.5 (C-13), 45.4 (C-7), 37.7 
(C-5), 30.1 (C-9), 27.3 (C-14), 21.0 (C-8); m/z (ESI) 369 [MNa]+; [HRMS (ESI): calcd for 
C18H22N2NaO5, 369.1421. Found: [MNa]+, 369.1420 (0.3 ppm error)]. 
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tert-Butyl 3-(methyl(phenyl)carbamoyl)-2-oxoazepane-1-carboxylate (20h) 
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1-(tert-Butoxycarbonyl)-2-oxoazepane-3-carboxylic acid (264h, 235 mg), 
N-methylaniline (0.11 mL, 1.00 mmol), 2-chloro-1-methylpyridinium iodide (348 mg, 
1.37 mmol) and triethylamine (0.63 mL, 4.55 mmol) in CH2Cl2 (10 mL) were reacted 
according to general procedure E. Flash column chromatography [1:1 EtOAc:PE] 
afforded 20h (225 mg, 60% over 2 steps) as a colourless amorphous solid, mp 70‒71 °C; 
Rf (1:1 EtOAc:PE) = 0.30; max/cm-1 (neat) 3061, 2934, 2869, 1766, 1714, 1688, 1596, 1495, 
1455; δH (400 MHz, CDCl3) 7.40‒7.29 (3H, m), 7.22‒7.19 (2H, m) (H-1, H-2, H-3), 4.00 
(1H, dd, J = 15.5, 6.5, H-11a), 3.48 (1H, dd, J = 10.5, 2.0, H-7), 3.29 (3H, s, H-5), 2.55 (1H, 
dd, J = 15.5, 10.5, H-11b), 2.11‒2.05 (1H, m, H-8a), 1.90‒1.69 (3H, m, H-8b, H-9a, H-10a), 
1.50 (9H, s, H-15), 1.42‒1.27 (2H, m, H-9b, H-10b); δC (100 MHz, CDCl3) 172.5, 169.1 
(C-6, C-12), 153.0 (C-13), 143.3 (C-4), 129.7 (C-2), 128.1 (C-1), 127.7 (C-3), 83.0 (C-14), 
51.8 (C-7), 45.0 (C-11), 37.5 (C-5), 28.0 (C-15), 27.8, 27.6 (C-9, C-10), 26.8 (C-8); m/z (ESI) 
369 [MNa]+; [HRMS (ESI): calcd for C19H26N2NaO4, 369.1785. Found: [MNa]+, 369.1775 
(2.8 ppm error)]. 
 
 
tert-Butyl 3-(methyl(phenyl)carbamoyl)-2-oxopiperidine-1-carboxylate (20i) 
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1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 485 mg), 
N-methylaniline (0.24 mL, 2.20 mmol), 2-chloro-1-methylpyridinium iodide (765 mg, 
3.00 mmol) and triethylamine (1.4 mL, 10.0 mmol) in CH2Cl2 (20 mL) were reacted 
according to general procedure E. Flash column chromatography [33‒50% EtOAc/PE] 
afforded 20i (529 mg, 80% over 2 steps) as a colourless oil, Rf (1:1 EtOAc:PE) = 0.30; 
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max/cm-1 (neat) 3061, 2979, 2968, 1768, 1716, 1658, 1595, 1496, 1478, 1457; δH (400 MHz, 
CDCl3) 7.41‒7.29 (5H, m, H-1, H-2, H-3), 3.59‒3.55 (2H, m, H-10), 3.42 (1H, dd, J = 10.5, 
7.0, H-7), 3.28 (3H, s, H-5), 2.18-2.08 (1H, m, H-8a), 1.98‒1.90 (1H, m, H-9a), 1.87‒1.79 
(1H, m, H-8b), 1.59‒1.50 (1H, m, H-9b), 1.47 (9H, s, H-14); δC (100 MHz, CDCl3) 170.0 
(C-6), 168.2 (C-11), 152.4 (C-12), 143.7 (C-4), 129.8 (C-2), 128.0 (C-1), 127.3 (C-3), 83.0 
(C-13), 48.5 (C-7), 46.4 (C-10), 37.5 (C-5), 27.8 (C-14), 25.3 (C-8), 21.5 (C-9); m/z (ESI) 333 
[MH]+, 355 [MNa]+; [HRMS (ESI): calcd for C18H25N2O4, 333.1809. Found: [MH]+, 
333.1811 (−0.7 ppm error)]. 
 
 
tert-Butyl 3-(methyl(2-nitrophenyl)carbamoyl)-2-oxopiperidine-1-carboxylate (20k) 
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1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 494 mg), 2-nitro-N-
methylaniline (340 mg, 2.24 mmol), 2-chloro-1-methylpyridinium iodide (778 mg, 
3.05 mmol) and triethylamine (1.41 mL, 10.2 mmol) in CH2Cl2 (10 mL) were reacted 
according to general procedure E. Flash column chromatography [20‒50% EtOAc/PE] 
afforded 20k (296 mg, 37% over 2 steps) as an orange powder, mp 140‒142 °C; 
Rf (1:1 EtOAc:PE) = 0.50; max/cm-1 (neat) 3071, 2978, 2936, 1767, 1718, 1665, 1603, 1530, 
1485, 1458; δH (400 MHz, CDCl3) 7.93 (1H, dd, J = 8.0, 1.5, H-3), 7.87‒7.84 (1H, m, H-6), 
7.68 (1H, ddd, J = 8.0, 7.5, 1.5, H-5), 7.54 (1H, ddd, J = 8.0, 7.5, 1.5, H-4), 3.60 (2H, dd, 
J = 9.5, 4.0, H-13), 3.22 (1H, dd, J = 10.0, 6.5, H-10), 3.22 (3H, s, H-8), 2.29‒2.18 (1H, m, 
H-11a), 2.03‒1.92 (2H, m, H-11b, H-12a), 1.65‒1.52 (1H, m, H-12b), 1.48 (9H, s, H-17); 
δC (100 MHz, CDCl3) 169.7 (C-9), 168.0 (C-14), 151.9 (C-15), 146.6 (C-2), 136.6 (C-7), 
134.5 (C-5), 132.5 (C-6), 129.6 (C-4), 124.9 (C-3), 83.2 (C-16), 49.1 (C-10), 46.8 (C-13), 37.3 
(C-8), 27.9 (C-17), 24.9, 21.5; m/z (ESI) 400 [MNa]+; [HRMS (ESI): calcd for 
C18H23N3NaO4, 400.1479. Found: [MNa]+, 400.1477 (1.4 ppm error)]. 
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tert-Butyl 3-((2-cyanophenyl)(methyl)carbamoyl)-2-oxopiperidine-1-carboxylate (20l) 
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1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 220 mg), 
2-(methylamino)benzonitrile (131 mg, 1.00 mmol), 2-chloro-1-methylpyridinium iodide 
(346 mg, 1.36 mmol) and triethylamine (0.63 mL, 4.53 mmol) in CH2Cl2 (12 mL) were 
reacted according to general procedure E. Flash column chromatography 
[1:1 EtOAc:PE] afforded 20l (258 mg, 77% over 2 steps) as a colourless amorphous 
solid, mp 134‒136 °C; Rf (1:1 EtOAc:PE) = 0.20; max/cm-1 (thin film) 3071, 2978, 2938, 
2230, 1767, 1717, 1663, 1595, 1489, 1454; δH (400 MHz, CDCl3) 7.77 (1H, dd, J = 8.0, 1.0, 
H-6), 7.73 (1H, dd, J = 7.5, 1.5, H-3), 7.68 (1H, td, J = 8.0, 1.5, H-5), 7.48 (1H, td, J = 7.5, 
1.0, H-4), 3.62‒3.58 (2H, m, H-13), 3.34 (3H, s, H-8), 3.20 (1H, dd, J = 10.0, 6.5, H-10), 
2.30‒2.20 (1H, m, H-11a), 2.05‒1.96 (2H, m, H-11b, H-12a), 1.64‒1.53 (1H, m, H-12b), 
1.48 (9H, s, H-17); δC (100 MHz, CDCl3) 169.6 (C-9), 167.7 (C-14), 151.9 (C-15), 146.3 
(C-7), 134.8 (C-5), 133.6 (C-3), 130.6 (C-6), 128.9 (C-4), 115.8 (C-1), 112.1 (C-2), 83.2 
(C-16), 48.8 (C-10), 46.7 (C-13), 37.2 (C-8), 27.9 (C-17), 25.3 (C-11), 21.4 (C-12); m/z (ESI) 
380 [MNa]+; [HRMS (ESI): calcd for C19H23N3NaO4, 380.1581. Found: [MNa]+, 380.1568 
(3.4 ppm error)]. 
 
 
N-(2,4-Dimethoxybenzyl)-4-methoxyaniline (273) 
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The title compound was prepared by Johannes Klein, based on the procedure by 
Trost.158 To 4-methoxyaniline (2.46 g, 20.0 mmol) and 2,4-dimethoxybenzaldehyde 
(3.33 g, 20.0 mmol) was added glacial acetic acid (10 mL) and the mixture heated to 
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100 °C for 1 h. The solvent was removed under reduced pressure, the residue 
re-dissolved in EtOH (20 mL), cooled to 0 °C and NaBH4 (1.29 g, 34.0 mmol) was added 
portionwise. The reaction was stirred for 30 min at 0 °C and 30 min at room 
temperature before quenching with 2M NaOH (50 mL) and extracting with CH2Cl2 
(2 x 50 mL). The combined organic extracts were dried (Na2SO4) and concentrated 
in vacuo. Recrystallisation from EtOH afforded 273 (3.53 g, 64%) as pale brown needles, 
mp 72‒74 °C (lit283 72-73 °C); δH (400 MHz, CDCl3) 7.20 (1H, d, J = 8.0, H-7), 6.78 (2H, d, 
J = 9.0, H-2), 6.64 (2H, d, J = 9.0, H-3), 6.49 (1H, d, J = 2.5, H-10), 6.44 (1H, dd, J = 8.0, 
2.5, H-8), 4.22 (2H, s, H-5), 3.84 (3H, s, H-14), 3.80 (3H, s, H-13), 3.75 (3H, s, H-12); 
δC (100 MHz, CDCl3) 160.1 (C-9), 158.4 (C-11), 152.0 (C-1), 142.7 (C-4), 129.7 (C-7), 119.9 
(C-6), 114.7 (C-2), 114.4 (C-3), 103.7 (C-8), 98.5 (C-10), 55.7 (C-12), 55.3, 55.3 (C-13, C-14), 
44.1 (C-5). Data consistent with the literature values.158,283 
 
 
tert-Butyl 3-((2,4-dimethoxybenzyl)(4-methoxyphenyl)carbamoyl)-2-oxopiperidine-
1-carboxylate (20m) 
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1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 479 mg), N-(2,4-
dimethoxybenzyl)-4-methoxyaniline (273, 592 mg, 2.17 mmol), 2-chloro-1-
methylpyridinium iodide (754 mg, 2.96 mmol) and triethylamine (1.37 mL, 9.86 mmol) 
in CH2Cl2 (10 mL) were reacted according to general procedure E. Flash column 
chromatography [20‒50% EtOAc/PE] afforded 20m (761 mg, 74% over 2 steps) as an 
off-white sticky foam, Rf (1:1 EtOAc:PE) = 0.50; max/cm-1 (neat) 3056, 2938, 2837, 1767, 
1716, 1654, 1614, 1589, 1511, 1458; δH (400 MHz, CDCl3) 7.30 (1H, d, J = 8.5, H-7), 
6.78‒6.74 (2H, m, H-2), 6.43 (1H, dd, J = 8.5, 2.5, H-8), 6.31 (1H, d, J = 2.5, H-10), 4.94 
(1H, d, J = 14.5, H-5a), 4.79 (1H, d, J = 14.5, H-5b), 3.77 (3H, s), 3.76 (3H, s) (H-21, H-22), 
3.61 (2H, dd, J = 8.0, 4.5, H-16), 3.57 (3H, s, H-23), 3.44 (1H, dd, J = 10.0, 7.0, H-13), 
2.23‒2.12 (1H, m, H-14a), 2.00‒1.93 (1H, m, H-15a), 1.90‒1.81 (1H, m, H-14b), 1.63‒1.53 
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(1H, m, H-15b), 1.50 (9H, s, H-20), H-3 not visible due to broadening; δC (100 MHz, 
CDCl3) 170.3 (C-12), 168.4 (C-17), 160.0 (C-9), 158.8 (C-1), 158.3 (C-11), 152.2 (C-18), 
135.0 (C-4), 130.8 (C-7), 117.6 (C-6), 114.2 (C-2), 104.1 (C-8), 98.1 (C-10), 82.9 (C-19), 55.3 
(C-22), 55.2 (C-21), 55.1 (C-23), 48.8 (C-13), 47.2 (C-5), 46.6 (C-16), 27.9 (C-20), 25.4 
(C-14), 21.6 (C-15), C-3 not visible due to broadening; m/z (ESI) 499 [MH]+; [HRMS 
(ESI): calcd for C27H35N2O7, 499.2439. Found: [MH]+, 499.2423 (3.4 ppm error)]. 
 
 
tert-Butyl 3-((4-chlorophenyl)(methyl)carbamoyl)-2-oxopiperidine-1-carboxylate 
(20n) 
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1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 541 mg), 4-chloro-N-
methylaniline (0.30 mL, 2.45 mmol), 2-chloro-1-methylpyridinium iodide (852 mg, 
3.34 mmol) and triethylamine (1.55 mL, 11.1 mmol) in CH2Cl2 (15 mL) were reacted 
according to general procedure E. Flash column chromatography [1:1 EtOAc:PE] 
afforded 20n (618 mg, 78% over 2 steps) as a colourless microcrystalline solid, 
mp 103‒104 °C; Rf (1:1 EtOAc:PE) = 0.30; max/cm-1 (thin film) 3091, 3064, 2978, 2937, 
1768, 1716, 1659, 1592, 1490, 1457; δH (400 MHz, CDCl3) 7.39‒7.28 (4H, m, H-2, H-3), 
3.61 (2H, dd, J = 8.0, 4.5, H-10), 3.41 (1H, dd, J = 10.5, 7.0, H-7), 3.27 (3H, s, H-5), 2.16 
(1H, dddd, J = 13.5, 11.5, 10.5, 4.0, H-8a), 2.01‒1.93 (1H, m, H-9a), 1.88‒1.80 (1H, m, 
H-8b), 1.65‒1.52 (1H, m, H-9b), 1.49 (9H, s, H-14); δC (100 MHz, CDCl3) 169.9 (C-6), 
168.1 (C-11), 152.3 (C-12), 142.3 (C-4), 134.0 (C-1), 130.0 (C-2), 128.9 (C-3), 83.2 (C-13), 
48.5 (C-7), 46.5 (C-10), 37.6 (C-5), 27.9 (C-14), 25.3 (C-8), 21.5 (C-9); m/z (ESI) 389 
[MNa]+; [HRMS (ESI): calcd for C18H2335ClN2NaO4, 389.1239. Found: [MNa]+, 389.1239 
(‒0.1 ppm error)]. 
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2-(Methylamino)benzonitrile (270)224  
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The title compound was prepared according to the procedure by González.224 To a 
solution of 2-aminobenzonitrile (288 mg, 2.44 mmol) and pyridine (0.68 mL, 
8.48 mmol) in dioxane (30 mL) at room temperature was added copper(II) acetate 
(1.10 g, 6.06 mmol). The mixture was stirred at room temperature for 15 min then 
methylboronic acid (362 mg, 6.06 mmol) added and the reaction heated to reflux for 
4 h. After cooling, the mixture was filtered through a pad of celite and the solvent 
removed in vacuo. Flash column chromatography [0‒15% EtOAc/PE] afforded 270 
(131 mg, 41%) as a colourless microcrystalline solid, mp 61‒62 °C (lit284 62‒64 °C); 
Rf (1:4 EtOAc:PE) = 0.40;  δH (400 MHz, CDCl3) 7.41 (1H, ddd, J = 8.5, 7.5, 1.5, H-5), 7.38 
(1H, ddd, J = 7.5, 1.5, 0.5, H-3), 6.67 (1H, td, J = 7.5, 1.0, H-4), 6.65 (1H, br d, J = 8.5, H-6), 
4.64 (1H, br s, NH), 2.92 (3H, s, H-8); δC (100 MHz, CDCl3) 151.1 (C-7), 134.3 (C-5), 132.6 
(C-3), 118.0 (C-1), 116.3 (C-4), 110.0 (C-6), 95.5 (C-2), 30.0 (C-8). Data consistent with the 
literature values.224,284  
 
 
tert-Butyl 3-(methyl(4-(trifluoromethyl)phenyl)carbamoyl)-2-oxopiperidine-1-
carboxylate (20o) 
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1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 456 mg), 
4-(trifluoromethyl)-N-methylaniline (0.29 mL, 2.06 mmol), 2-chloro-1-
methylpyridinium iodide (718 mg, 2.81 mmol) and triethylamine (1.31 mL, 9.38 mmol) 
in CH2Cl2 (15 mL) were reacted according to general procedure E. Flash column 
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chromatography [1:1 EtOAc:PE] afforded 20o (622 mg, 80% over 2 steps) as a colourless 
powder, mp 103‒105 °C; Rf (1:1 EtOAc:PE) = 0.30; max/cm-1 (thin film) 3073, 2979, 2938, 
1768, 1718, 1662, 1612, 1517, 1477, 1459; δH (400 MHz, CDCl3) 7.68 (2H, d, J = 8.0, H-2), 
7.52 (2H, d, J = 8.0, H-3), 3.62 (2H, dd, J = 7.5, 4.5, H-10), 3.40 (1H, dd, J = 10.0, 7.0, H-7), 
3.32 (3H, s, H-5), 2.25‒2.13 (1H, m, H-8a), 2.02‒1.94 (1H, m, H-9a), 1.91‒1.80 (1H, m, 
H-8b), 1.66‒1.54 (1H, m, H-9b), 1.50 (9H, s, H-14); δC (100 MHz, CDCl3) 169.7 (C-6), 
168.0 (C-11), 152.2 (C-12), 146.9 (C-4), 130.0 (q, J = 33.0, C-1), 127.9 (C-3), 127.0 (C-2), 
123.5 (q, J = 272.5, C-15), 83.2 (C-13), 48.6 (C-7), 46.5 (C-10), 37.6 (C-5), 27.9 (C-14), 25.3 
(C-8), 21.4 (C-9); δF (376 MHz, CDCl3) −62.5 (3F); m/z (ESI) 423 [MNa]+; [HRMS (ESI): 
calcd for C19H23F3N2NaO4, 423.1502. Found: [MNa]+, 423.1509 (−1.5 ppm error)]. 
 
 
3-Methoxy-N-methylaniline (275)225 
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The title compound was prepared according to the procedure by Teichert.225 To a 
suspension of NaOMe (2.18 g, 40.6 mmol) in MeOH (12 mL) at room temperature was 
added 3-methoxyaniline (0.91 mL, 8.12 mmol). The resulting brown suspension was 
poured into a suspension of paraformaldehyde (340 mg, 11.4 mmol) in MeOH (8 mL). 
The mixture was stirred at room temperature for 6 h. Sodium borohydride (306 mg, 
8.12 mmol) was added slowly and the reaction heated to reflux for 2 h then stirred at 
room temperatre for 12 h. The reaction was quenched with aq. NaOH (2 M, 10 mL) and 
H2O (10 mL), and extracted with Et2O (3 x 25 mL). The combined organic extracts were 
dried (Na2SO4) and concentrated in vacuo. Flash column chromatography 
[1:4 EtOAc:PE] afforded 275 (707 mg, 76%) as a brown liquid, Rf (1:4 EtOAc:PE) = 0.50; 
max/cm-1 (thin film) 3411, 2991, 2934, 2904, 2834, 2810, 1616, 1512, 1499, 1463; 
δH (400 MHz, CDCl3) 7.10 (1H, t, J = 8.0, H-4), 6.29 (1H, ddd, J = 8.0, 2.5, 0.5, H-3), 6.24 
(1H, ddd, J = 8.0, 2.5, 0.5, H-5), 6.17 (1H, t, J = 2.5, H-7), 3.79 (3H, s, H-1), 2.83 (3H, s, 
H-8); δC (100 MHz, CDCl3) 160.8 (C-2), 150.7 (C-6), 129.9 (C-4), 105.7 (C-5), 102.3 (C-3), 
98.3 (C-7), 55.1 (C-1), 30.7 (C-8); m/z (ESI) 138 [MH]+; [HRMS (ESI): calcd for C8H12NO, 
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138.0913. Found: [MH]+, 138.0916 (−2.1 ppm error)]. NMR data consistent with the 
literature values.285  
 
 
tert-Butyl 3-((3-methoxyphenyl)(methyl)carbamoyl)-2-oxopiperidine-1-carboxylate 
(20p) 
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1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 456 mg), 3-methoxy-
N-methylaniline (290 mg, 2.12 mmol), 2-chloro-1-methylpyridinium iodide (737 mg, 
2.89 mmol) and triethylamine (1.34 mL, 9.63 mmol) in CH2Cl2 (15 mL) were reacted 
according to general procedure E. Flash column chromatography [1:1 EtOAc:PE] 
afforded 20p (532 mg, 76% over 2 steps) as an off-white sticky oil, Rf (1:1 EtOAc:PE) = 
0.40; max/cm-1 (thin film) 3065, 2977, 2939, 2839, 1768, 1717, 1657, 1600, 1489, 1458; 
δH (400 MHz, CDCl3) 7.29 (1H, t, J = 8.0, H-4), 6.94‒6.86 (3H, m, H-3, H-5, H-7), 3.80 
(3H, s, H-1), 3.63-3.58 (2H, m, H-13), 3.48 (1H, dd, J = 10.5, 7.0, H-10), 3.29 (3H, s, H-8), 
2.21‒2.11 (1H, m, H-11a), 2.00‒1.92 (1H, m, H-12a), 1.91‒1.80 (1H, m, H-11b), 1.65‒1.52 
(1H, m, H-12b), 1.49 (9H, s, H-17); δC (100 MHz, CDCl3) 170.0 (C-9), 168.3 (C-14), 160.5 
(C-2), 152.6 (C-15), 144.9 (C-6), 130.5 (C-4), 119.3 (C-5), 114.1 (C-3), 112.7 (C-7), 83.0 
(C-16), 55.4 (C-1), 48.7 (C-10), 46.5 (C-13), 37.5 (C-8), 27.9 (C-17), 25.5 (C-11), 21.6 (C-12); 
m/z (ESI) 385 [MNa]+; [HRMS (ESI): calcd for C19H26N2NaO5, 385.1734. Found: [MNa]+, 
385.1735 (−0.4 ppm error)]. 
 
 
tert-Butyl 3-((3-bromophenyl)(methyl)carbamoyl)-2-oxopiperidine-1-carboxylate 
(20q) 
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1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 416 mg), N-methyl-3-
bromoaniline (350 mg, 1.88 mmol), 2-chloro-1-methylpyridinium iodide (655 mg, 
2.57 mmol) and triethylamine (1.19 mL, 8.56 mmol) in CH2Cl2 (10 mL) were reacted 
according to general procedure E. Flash column chromatography [20‒50% EtOAc/PE] 
afforded 20q (296 mg, 42% over 2 steps) as a colourless amorphous solid, 
mp 113‒115 °C; Rf (1:1 EtOAc:PE) = 0.50; max/cm-1 (neat) 3062, 2977, 2934, 1768, 1717, 
1660, 1587, 1569, 1476; δH (400 MHz, CDCl3) 7.52‒7.48 (2H, m, H-1, H-16), 7.35 (1H, br s, 
H-3), 7.31‒7.28 (1H, m, H-15), 3.62 (2H, dd, J = 7.5, 4.5, H-10), 3.42 (1H, dd, J = 10.5, 7.0, 
H-7), 3.29 (3H, s, H-5), 2.23‒2.12 (1H, m, H-8a), 2.02‒1.94 (1H, m, H-9a), 1.92‒1.83 (1H, 
m, H-8b), 1.67‒1.59 (1H, m, H-9b), 1.51 (9H, s, H-14); δC (100 MHz, CDCl3) 169.8 (C-6), 
168.1 (C-11), 152.4 (C-12), 145.0 (C-4), 131.4 (C-15), 131.1, 130.5 (C-1, C-16), 126.4 (C-3), 
123.0 (C-2), 83.2 (C-13), 48.6 (C-7), 46.5 (C-10), 37.7 (C-5), 27.9 (C-14), 25.4 (C-8), 21.5 
(C-9); m/z (ESI) 433, 435 [MNa]+; [HRMS (ESI): calcd for C18H2379BrN2NaO4, 433.0733. 
Found: [MNa]+, 433.0724 (2.2 ppm error)]; [Found C, 52.27%; H, 5.57%; N, 6.60%. 
C18H23BrN2O4 requires C, 52.56%; H, 5.64%; N, 6.81%]. 
 
 
N,1-dimethyl-2-oxo-N-phenylpiperidine-3-carboxamide (20r) 
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1-Methyl-2-oxopiperidine-3-carboxylic acid (264r, 291 mg), N-methylaniline (0.22 mL, 
2.04 mmol), 2-chloro-1-methylpyridinium iodide (708 mg, 2.78 mmol) and 
triethylamine (1.29 mL, 9.25 mmol) in CH2Cl2 (15 mL) were reacted according to 
general procedure E. Flash column chromatography [0‒10% MeOH/EtOAc] afforded 
20r (472 mg, quant. over 2 steps) as an off-white microcrystalline solid, mp 113‒115 °C; 
Rf (EtOAc) = 0.10; max/cm-1 (thin film) 3058, 2942, 2871, 1654, 1634, 1594, 1496; 
δH (400 MHz, CDCl3) 7.41‒7.25 (5H, m, H-1, H-2, H-3), 3.40‒3.32 (2H, m, H-7, H-10a), 
3.28 (3H, s, H-5), 3.13 (1H, dddd, J = 12.0, 5.0, 4.0, 1.5, H-10b), 2.89 (3H, s, H-12), 2.11 
(1H, dddd, J = 13.0, 12.0, 10.0, 3.0, H-8a), 1.98‒1.90 (1H, m, H-9a), 1.84‒1.76 (1H, m, 
H-8b), 1.60‒1.48 (1H, m, H-9b); δC (100 MHz, CDCl3) 171.1 (C-6), 167.0 (C-11), 144.1 
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(C-4), 129.7 (C-2), 127.7 (C-1), 127.5 (C-3), 49.7 (C-10), 45.9 (C-7), 37.5 (C-5), 34.8 (C-12), 
25.7 (C-8), 21.3 (C-9); m/z (ESI) 269 [MNa]+; [HRMS (ESI): calcd for C14H18N2NaO2, 
269.1260. Found: [MNa]+, 269.1258 (0.9 ppm error)]. 
 
 
1-Benzyl-N-methyl-2-oxo-N-phenylpiperidine-3-carboxamide (20s) 
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1-Benzyl-2-oxopiperidine-3-carboxylic acid (264s, 580 mg), N-methylaniline (0.30 mL, 
2.74 mmol), 2-chloro-1-methylpyridinium iodide (952 mg, 3.73 mmol) and 
triethylamine (1.73 mL, 12.45 mmol) in CH2Cl2 (20 mL) were reacted according to 
general procedure E. Flash column chromatography [50‒75% EtOAc/PE] afforded 20s 
(770 mg, 92% over 2 steps) as a pale yellow oil which crystallised on standing, 
mp 84‒86 °C;  Rf (1:1 EtOAc:PE) = 0.20; max/cm-1 (thin film) 3064, 3037, 2963, 2935, 
2874, 1735, 1632, 1595, 1494; δH (400 MHz, CDCl3) 7.46‒7.21 (10H, m, H-1, H-2, H-3, 
H-14, H-15, H-16), 4.63 (1H, d, J = 15.0, H-12a), 4.54 (1H, d, J = 15.0, H-12b), 3.47 (1H, 
dd, J = 9.0, 6.5, H-7), 3.34 (3H, s, H-5), 3.28 (1H, ddd, J = 12.0, 10.0, 4.5, H-10a), 3.12‒3.06 
(1H, m, H-10b), 2.12 (1H, dddd, J = 12.5, 11.5, 9.0, 3.0, H-8a), 1.99‒1.91 (1H, m, H-9a), 
1.84 (1H, dddd, J = 12.5, 6.5, 3.0, 1.0, H-8b), 1.58‒1.47 (1H, m, H-9b); δC (100 MHz, 
CDCl3) 171.3 (C-6), 167.3 (C-11), 144.1 (C-4), 136.8 (C-13), 129.8, 128.6, 127.8, 127.8, 
127.6, 127.2 (C-1, C-2, C-3, C-14, C-15, C-16), 50.3 (C-12), 47.1 (C-10), 46.0 (C-7), 37.6 
(C-5), 25.9 (C-8), 21.3 (C-9); m/z (ESI) 345 [MNa]+; [HRMS (ESI): calcd for 
C20H22N2NaO2, 345.1573. Found: [MNa]+, 345.1576 (‒0.7 ppm error)]. 
 
 
1-(4-Methoxybenzyl)-N-methyl-2-oxo-N-phenylpiperidine-3-carboxamide (20t) 
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1-(4-Methoxybenzyl)-2-oxopiperidine-3-carboxylic acid (264t, 474 mg), N-methylaniline 
(0.21 mL, 1.98 mmol), 2-chloro-1-methylpyridinium iodide (689 mg, 2.70 mmol) and 
triethylamine (1.25 mL, 9.00 mmol) in CH2Cl2 (15 mL) were reacted according to 
general procedure E. Flash column chromatography [50‒75% EtOAc/PE] afforded 20t 
(578 mg, 81% over 2 steps) as an off-white crystalline solid, mp 141‒143 °C; 
Rf (1:1 EtOAc:PE) = 0.10; max/cm-1 (thin film) 3059, 3035, 2936, 2868, 2836, 1656, 1635, 
1595, 1512, 1495, 1463; δH (400 MHz, CDCl3) 7.45‒7.32 (5H, m, H-1, H-2, H-3), 7.17 (2H, 
d, J = 8.5, H-14), 6.83 (2H, d, J = 8.5, H-15), 4.56 (1H, d, J = 14.5, H-12a), 4.46 (1H, d, 
J = 14.5, H-12b), 3.77 (3H, s, H-17), 3.45 (1H, dd, J = 9.0, 6.5, H-7), 3.33 (3H, s, H-5), 3.24 
(1H, ddd, J = 12.0, 10.0, 4.5, H-10a), 3.10‒3.03 (1H, m, H-10b), 2.09 (1H, dddd, J = 12.5, 
11.5, 9.0, 3.0, H-8a), 1.97‒1.88 (1H, m, H-9a), 1.85‒1.77 (1H, m, H-8b), 1.55‒1.44 (1H, m, 
H-9b); δC (100 MHz, CDCl3) 171.4 (C-6), 167.1 (C-11), 158.8 (C-16), 144.1 (C-4), 129.8 
(C-2), 129.2 (C-14), 128.9 (C-13), 127.8 (C-1), 127.5 (C-3), 113.9 (C-15), 55.2 (C-17), 49.7 
(C-12), 46.8 (C-10), 46.0 (C-7), 37.6 (C-5), 25.8 (C-8), 21.3 (C-9); m/z (ESI) 353 [MH]+; 
[HRMS (ESI): calcd for C21H25N2O3, 353.1860. Found: [MH]+, 353.1859 (0.3 ppm error)]. 
 
 
tert-Butyl 3-(benzyl(phenyl)carbamoyl)-2-oxopiperidine-1-carboxylate (20u) 
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1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 483 mg), N-benzyl-N-
phenylamine (401 mg, 2.19 mmol), 2-chloro-1-methylpyridinium iodide (760 mg, 
2.98 mmol) and triethylamine (1.38 mL, 9.94 mmol) in CH2Cl2 (10 mL) were reacted 
according to general procedure E. Flash column chromatography [20‒50% EtOAc/PE] 
afforded 20u (647 mg, 77% over 2 steps) as a colourless oil which crystallised on 
standing, mp 95‒97 °C; Rf (1:1 EtOAc:PE) = 0.60; max/cm-1 (neat) 3062, 3031, 2979, 2936, 
1768, 1714, 1659, 1595, 1495, 1480, 1455; δH (400 MHz, CDCl3) 7.38‒7.19 (10H, m, H-1, 
H-2, H-3, H-7, H-8, H-9), 5.01 (1H, d, J = 14.5, H-5a), 4.85 (1H, d, J = 14.5, H-5b), 3.61 
(2H, dd, J = 8.5, 4.5, H-15), 3.42 (1H, dd, J = 10.5, 7.0, H-12), 2.20 (1H, dddd, J = 13.5, 
11.5, 10.5, 4.0, H-13a), 2.01‒1.93 (1H, m, H-14a), 1.92‒1.84 (1H, m, H-13b), 1.63‒1.52 (1H, 
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m, H-14b), 1.50 (9H, s, H-19); δC (100 MHz, CDCl3) 170.2 (C-11), 168.2 (C-16), 152.2 
(C-17), 142.0 (C-4), 136.9 (C-6), 129.6, 128.5, 128.3, 128.2, 127.2 (five of C-1, C-2, C-3, C-7, 
C-8, C-9), 83.0 (C-18), 53.2 (C-5), 48.8 (C-12), 46.5 (C-15), 27.9 (C-19), 25.4 (C-13), 21.5 
(C-14), one aromatic peak not visible due to broadening; m/z (ESI) 431 [MNa]+; [HRMS 
(ESI): calcd for C24H22N2NaO4, 431.1941. Found: [MNa]+, 431.1935 (2.5 ppm error)]. 
 
 
tert-Butyl phenylcarbamate (279)229 
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The title compound was prepared based on the procedure by Peterson.229 To a 
suspension of aniline (1.0 mL, 11.0 mmol) and potassium carbonate (3.07 g, 22.2 mmol) 
in THF:H2O (1:1, 50 mL) was added di-tert-butyl dicarbonate (2.87, 13.2 mmol) and the 
mixture stirred at room temperature for 7 h. The mixture was separated and the 
aqueous phase extracted with EtOAc (3 x 25 mL). The combined organic extracts were 
dried (Na2SO4) and concentrated in vacuo. Flash column chromatography [10‒20% 
EtOAc/hexane] afforded 279 (1.98, 94%) as a colourless microcrystalline solid, 
mp 132‒134 °C (lit286 132‒133 °C); Rf (1:4 EtOAc:PE) = 0.50; δH (400 MHz, CDCl3) 
7.38‒7.26 (4H, m, H-2, H-3), 7.05‒7.00 (1H, m, H-1), 1.51 (9H, s, H-7); δC (100 MHz, 
CDCl3) 152.7 (C-5), 138.3 (C-4), 129.0 (C-2), 123.0 (C-1), 118.5 (C-3), 80.5 (C-6), 28.3 (C-7). 
Data consistent with the literature values.286,287 
 
 
tert-Butyl 3-(tert-butoxycarbonyl(phenyl)carbamoyl)-2-oxopiperidine-1-carboxylate 
(20v) 
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1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 369 mg), tert-butyl 
phenylcarbamate (279, 322 mg, 1.67 mmol), 2-chloro-1-methylpyridinium iodide 
(581 mg, 2.28 mmol) and triethylamine (1.06 mL, 7.59 mmol) in CH2Cl2 (10 mL) were 
reacted according to general procedure E. Flash column chromatography [33‒50% 
EtOAc/PE afforded 20v (390 mg, 61% over 2 steps) as a colourless oil, 
Rf (1:1 EtOAc:PE) = 0.60; max/cm-1 (neat) 3064, 3040, 2978, 2937, 1771, 1729, 1723, 1717, 
1597, 1492, 1476, 1457; δH (400 MHz, CDCl3) 7.40‒7.35 (2H, m, H-2), 7.33‒7.28 (1H, m, 
H-1), 7.20‒7.16 (2H, m, H-3), 4.63 (1H, dd, J = 11.0, 7.0, H-7), 3.79 (1H, ddd, J = 13.5, 9.0, 
4.5, H-10a), 3.74‒3.65 (1H, m, H-10b), 2.33‒2.10 (2H, m, H-8), 2.04‒1.78 (2H, m, H-9), 
1.52 (9H, s, H-14), 1.33 (9H, s, H-16); δC (100 MHz, CDCl3) 172.5 (C-6), 168.5 (C-11), 
152.9 (C-5), 152.4 (C-12), 138.8 (C-4), 128.8 (C-2), 128.2 (C-3), 127.7 (C-1), 83.4, 83.0 (C-13, 
C-15), 52.4 (C-7), 45.9 (C-10), 28.0 (C-14), 27.7 (C-16), 24.2 (C-8), 21.6 (C-9); m/z (ESI) 441 
[MNa]+; [HRMS (ESI): calcd for C22H30N2NaO6, 441.1996. Found: [MNa]+, 441.1996 
(0.1 ppm error)]. 
 
 
tert-Butyl 3-(benzyl(phenyl)carbamoyl)-2-oxopyrrolidine-1-carboxylate (20w) 
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1-(tert-Butoxycarbonyl)-2-oxopyrrolidine-3-carboxylic acid (264a, 344 mg), 
N-benzylaniline (302 mg, 1.65 mmol), 2-chloro-1-methylpyridinium iodide (574 mg, 
2.25 mmol) and triethylamine (1.05 mL, 7.50 mmol) in CH2Cl2 (15 mL) were reacted 
according to general procedure E. Flash column chromatography [1:2 EtOAc:PE] 
afforded 20w (379 mg, 64% over 2 steps) as a sticky yellow oil, Rf (1:1 EtOAc:PE) = 0.50; 
max/cm-1 (thin film) 3063, 3031, 2933, 1782, 1746, 1717, 1657, 1595, 1495, 1454; 
δH (400 MHz, CDCl3) 7.34‒7.19 (10H, m, H-1, H-2, H-3, H-15, H-16, H-17), 5.07 (1H, d, 
J = 14.5, H-5a), 4.81 (1H, d, J = 14.5, H-5b), 3.92 (1H, ddd, J = 10.5, 9.0, 4.0, H-9a), 3.53 
(1H, t, J = 9.0, H-7), 3.52 (1H, dt, J = 10.5, 8.0, H-9b), 2.51 (1H, dtd, J = 13.0, 9.0, 8.0, 
H-8a), 1.98 (1H, dddd, J= 13.0, 9.0, 8.0, 4.0, H-8b), 1.50 (9H, s, H-13); δC (100 MHz, 
CDCl3) 170.3 (C-10), 168.8 (C-6), 149.8 (C-11), 141.5 (C-4), 136.6 (C-14), 129.6, 128.5, 
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128.4 (three of C-2, C-3, C-15, C-16), 128.3, 127.3 (C-1, C-17), 83.0 (C-12), 53.4 (C-5), 47.6 
(C-7), 44.9 (C-9), 27.9 (C-13), 22.1 (C-8), one aromatic peak not visible due to 
broadening; m/z (ESI) 417 [MNa]+; [HRMS (ESI): calcd for C23H26N2NaO4, 417.1785. 
Found: [MNa]+, 414.1786 (−0.4 ppm error)]. 
 
 
N-Benzyl-1-methyl-2-oxo-N-phenylpyrrolidine-3-carboxamide (20x) 
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1-Methyl-2-oxopyrrolidine-3-carboxylic acid (264x, 226 mg), N-benzylaniline (319 mg, 
1.74 mmol), 2-chloro-1-methylpyridinium iodide (605 mg, 2.37 mmol) and 
triethylamine (1.01 mL, 7.90 mmol) in CH2Cl2 (15 mL) were reacted according to 
general procedure E. Flash column chromatography [50‒100% EtOAc/PE] afforded 20x 
(472 mg, 94% over 2 steps) as an off-white microcrystalline solid, mp 176‒178 °C; 
Rf (EtOAc) = 0.40; max/cm-1 (thin film) 3062, 3033, 3007, 2988, 2959, 2931, 2879, 1686, 
1650, 1593, 1560, 1496, 1455; δH (400 MHz, CDCl3) 7.34‒7.18 (10H, m, H-1, H-2, H-3, 
H-13, H-14, H-15), 5.03 (1H, d, J = 14.5, H-5a), 4.85 (1H, d, J = 14.5, H-5b), 3.50 (1H, td, 
J = 9.0, 4.0, H-9a), 3.43 (1h, dd, J = 9.0, 4.0, H-7), 3.22 (1H, ddd, J = 9.0, 8.5, 7.0, H-9b), 
2.82 (4H, s, H-11), 2.53‒2.44 (1H, m, H-8a), 2.00 (1H, dddd, J = 12.5, 9.0, 8.5, 4.0, H-8b); 
δC (100 MHz, CDCl3) 171.2 (C-10), 170.5 (C-6), 141.9 (C-4), 137.0 (C-12), 129.4, 128.5, 
128.4 (three of C-2, C-3, C-13, C-14), 128.0, 127.3 (C-1, C-15), 53.4 (C-5), 47.9 (C-9), 45.6 
(C-7), 29.9 (C-11), 23.0 (C-8), one aromatic peak not visible due to broadening; m/z (ESI) 
309 [MH]+, 331 [MNa]+; [HRMS (ESI): calcd for C19H21N2O2, 309.1598. Found: [MH]+, 
309.1590 (2.3 ppm error)]. 
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N-(4-Methoxybenzyl)-1-methyl-2-oxo-N-phenylpyrrolidine-3-carboxamide (20y) 
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1-Methyl-2-oxopyrrolidine-3-carboxylic acid (264x, 226 mg), N-(4-
methoxybenzyl)aniline (370 mg, 1.74 mmol), 2-chloro-1-methylpyridinium iodide 
(605 mg, 2.37 mmol) and triethylamine (1.01 mL, 7.90 mmol) in CH2Cl2 (15 mL) were 
reacted according to general procedure E. Flash column chromatography [50‒100% 
EtOAc/PE] afforded 20y (480 mg, 87% over 2 steps) as an off-white powder, 
mp 126‒128 °C; Rf (EtOAc) = 0.20; max/cm-1 (thin film) 3060, 3037, 2997, 2932, 2885, 
2836, 1690, 1649, 1613, 1594, 1512, 1495, 1454; δH (400 MHz, CDCl3) 7.35‒7.10 (5H, m, 
H-1, H-2, H-3), 7.13 (2H, d, J = 8.5, H-13), 6.78 (2H, d, J = 8.5, H-14), 4.96 (1H, d, J = 14.5, 
H-5a), 4.79 (1H, d, J = 14.5), 3.75 (3H, s, H-16), 3.48 (1H, td, J = 9.0, 4.0, H-9a), 3.39 (1H, 
dd, J = 9.0, 7.0, H-7), 3.21 (1H, ddd J = 9.0, 8.5, 7.0, H-9b), 2.82 (3H, s, H-11), 2.47 (1H, 
ddt, J = 13.0, 9.0, 7.0, H-8a), 1.99 (1H, dddd, J = 13.0, 9.0, 8.5, 4.0, H-8b); δC (100 MHz, 
CDCl3) 171.2 (C-10), 170.3 (C-6), 158.8 (C-15), 141.8 (C-4), 129.9 (C-13), 129.4 (C-2), 129.1 
(C-12), 128.8, 128.0 (C-1, C-3), 113.7 (C-14), 55.1 (C-16), 52.7 (C-5), 47.9 (C-9), 45.6 (C-7), 
29.8 (C-11), 23.0 (C-8); m/z (ESI) 339 [MH]+, 361 [MNa]+; [HRMS (ESI): calcd for 
C20H23N2O3, 339.1703. Found: [MH]+, 339.1701 (0.7 ppm error)]. 
 
 
N,1-Dimethyl-2-oxo-N-phenylpyrrolidine-3-carboxamide (20z) 
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1-Methyl-2-oxopyrrolidine-3-carboxylic acid (264x, 646 mg), N-methylaniline (0.55 mL, 
5.04 mmol), 2-chloro-1-methylpyridinium iodide (1.79 g, 7.00 mmol) and triethylamine 
(3.29 mL, 23.6 mmol) in CH2Cl2 (100 mL) were reacted according to general procedure 
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E. Flash column chromatography [49:1 EtOAc:MeOH] afforded 20z (810 mg, 74% over 
2 steps) as an off-white microcrystalline solid, mp 120‒122 °C; Rf (EtOAc) = 0.20; 
max/cm-1 (thin film) 2988, 2941, 2889, 1686, 1638, 1592, 1497, 1450; δH (400 MHz, CDCl3) 
7.44‒7.30 (5H, m, H-1, H-2, H-3), 3.52‒3.43 (2H, m, H-7, H-9a), 3.32 (3H, s, H-5), 
3.25‒3.18 (1H, m, H-9b), 2.82 (3H, s, H-11), 2.45 (1H, dq, J = 13.5, 7.0, H-8a), 2.04‒1.94 
(1H, m, H-8b); δC (100 MHz, CDCl3) 171.3 (C-10), 170.4 (C-6), 143.6 (C-4), 129.7 (C-2), 
127.9 (C-1), 127.7 (C-3), 47.9 (C-9), 45.3 (C-7), 37.7 (C-5), 29.8 (C-11), 23.1 (C-8); m/z (ESI) 
255 [MNa]+; [HRMS (ESI): calcd for C13H16N2NaO2, 255.1104. Found: [MNa]+, 255.1101 
(1.1 ppm error)]. 
 
 
N-(4-Chlorophenyl)-N,1-dimethyl-2-oxopyrrolidine-3-carboxamide (20za) 
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1-Methyl-2-oxopyrrolidine-3-carboxylic acid (264x, 235 mg), 4-chloro-N-methylaniline 
(0.14 mL, 1.81 mmol), 2-chloro-1-methylpyridinium iodide (629 mg, 2.47 mmol) and 
triethylamine (1.14 mL, 8.22 mmol) in CH2Cl2 (15 mL) were reacted according to 
general procedure E. Flash column chromatography [50‒100% EtOAc/PE] afforded 
20za (303 mg, 67% over 2 steps) as an off-white amorphous solid, mp 96‒98 °C; 
Rf (EtOAc) = 0.30; max/cm-1 (thin film) 3055, 2949, 2884, 1686, 1654, 1591, 1491, 1453; 
δH (400 MHz, CDCl3) 7.42‒7.34 (4H, m, H-2, H-3), 3.47 (1H, td, J =  9.0, 4.0, H-9a), 3.42 
(1H, dd, J = 9.0, 7.0, H-7), 3.27 (3H, s, H-5), 3.22 (1H, ddd, J = 9.0, 8.5, 7.0, H-9b), 2.80 
(3H, s, H-11), 2.44 (1H, ddt, J = 13.0, 9.0, 7.0, H-8a), 1.97 (1H, dddd, J = 13.0, 9.0, 8.5, 4.0, 
H-8b); δC (100 MHz, CDCl3) 171.0 (C-10), 170.1 (C-6), 142.0 (C-4), 133.7 (C-1), 129.8, 
129.1 (C-2, C-3), 47.9 (C-9), 45.2 (C-7), 37.7 (C-5), 29.8 (C-11), 22.9 (C-8); m/z (ESI) 267, 
269 [MH]+, 289, 291 [MNa]+; [HRMS (ESI): calcd for C13H1635ClN2O2, 267.0895. Found: 
[MH]+, 267.0899 (−1.4 ppm error)]. 
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7.4.4 General procedure F ‒ Cyclisation of anilides 20 
 
mesitylene, 170 °C,
air, 0.52 hX
N
O
N
O
R
N
O
R
XN
O
n
nR2
R2
Cu(OAc)2H2O (10 mol%)
R1
R1X = C or C=O
20 21  
 
To the linear amide 20 (1.0 eq) was added Cu(OAc)2∙H2O (0.1 eq) and mesitylene. A 
reflux condenser was fitted and the reaction carried out under an air atmosphere. The 
flask was lowered into an oil bath, pre-heated to 170 °C, and the reaction stirred at 
170 °C for 0.5‒2 h. After allowing to cool to room temperature, the solvent was 
removed in vacuo. The residue was loaded onto a silica column and eluted with an 
EtOAc/PE mixture to yield the spirooxindole 21. 
 
 
tert-Butyl 1-methyl-2,2'-dioxospiro[indoline-3,3'-pyrrolidine]-1'-carboxylate (21a) 
 
3
4
5
6
1
2
N
8
9
O
10
11N
12
O
7
13
O
O
14
15
 
 
tert-Butyl 3-(methyl(phenyl)carbamoyl)-2-oxopyrrolidine-1-carboxylate (20a, 127 mg, 
0.40 mmol) and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in mesitylene (8 mL) 
were reacted for 30 min according to general procedure F. Flash column 
chromatography [1:3 EtOAc:PE] afforded a mixture of spirocycle 21a and lactam 262a 
(83 mg, corresponding to 73 mg of pure 21a, 58%) as a colourless amorphous solid. A 
small sample of pure 21a was isolated for full characterisation, mp 150‒152 °C; 
Rf (1:1 EtOAc:PE) = 0.50; max/cm-1 (thin film) 3058, 2980, 2935, 1783, 1750, 1716, 1613, 
1494, 1472; δH (400 MHz, CDCl3) 7.33 (1H, td, J = 8.0, 1.0, H-4), 7.17 (1H, d, J = 7.5, 1.0, 
H-2), 7.08 (1H, td, J = 7.5, 1.0, H-3), 6.86 (1H, br d, J = 8.0, H-5), 4.18 (1H, ddd, J = 10.5, 
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8.0, 7.0, H-11a), 3.98 (1H, ddd, J = 10.5, 8.5, 4.5, H-11b), 3.20 (3H, s, H-7), 2.62 (1H, ddd, 
J = 13.0, 8.0, 4.5, H-10a), 2.36 (1H, ddd, J = 13.0, 8.5, 7.0, H-10b), 1.53 (9H, s, H-15); 
δC (100 MHz, CDCl3) 174.2 (C-8), 169.3 (C-12), 150.0 (C-13), 144.3 (C-6), 129.4 (C-4), 
128.6 (C-1), 123.2, 123.1 (C-2, C-3), 108.6 (C-5), 83.6 (C-14), 59.4 (C-9), 44.1 (C-11), 28.1 
(C-10), 27.9 (C-15), 26.5 (C-7); m/z (ESI) 339 [MNa]+; [HRMS (ESI): calcd for 
C17H20N2NaO4, 339.1315. Found: [MNa]+, 339.1318 (−0.9 ppm error)]. 
 
 
tert-Butyl 7-methoxy-1-methyl-2,2'-dioxospiro[indoline-3,3'-piperidine]-1'-
carboxylate (21b) 
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tert-Butyl 3-((2-methoxyphenyl)(methyl)carbamoyl)-2-oxopiperidine-1-carboxylate 
(20b, 139 mg, 0.38 mmol) and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in 
mesitylene (8 mL) were reacted for 30 min according to general procedure F. Flash 
column chromatography [20‒30% EtOAc/PE] afforded a mixture of spirocycle 21b and 
lactam 262b (71 mg, corresponding to 67 mg of 21b, 48%) as an off-white amorphous 
solid. A small sample of pure 21b was isolated for full characterisation, mp 104‒106 °C; 
Rf (1:4 EtOAc:PE) = 0.10; max/cm-1 (neat) 2977, 2939, 1768, 1718, 1613, 1598, 1493, 1473; 
δH (400 MHz, CDCl3) 7.00 (1H, dd, J = 8.0, 7.5, H-3), 6.90‒6.86 (2H, m, H-2, H-4), 
3.89‒3.83 (2H, m, H-12), 3.84 (3H, s, H-17), 3.49 (3H, s, H-7), 2.42‒2.27 (2H, m, H-10a, 
H-11a), 2.14‒1.96 (2H, m, H-10b, H-11b), 1.47 (9H, s, H-16); δC (100 MHz, CDCl3) 175.5 
(C-8), 167.5 (C-13), 153.3 (C-14), 145.5 (C-5), 133.2 (C-1), 131.8 (C-6), 123.4 (C-3), 115.8 
(C-2), 112.8 (C-4), 83.4 (C-15), 58.2 (C-9), 55.9 (C-17), 47.1 (C-12), 32.3 (C-10), 29.9 (C-7), 
27.9 (C-16), 19.4 (C-11); m/z (ESI) 383 [MNa]+; [HRMS (ESI): calcd for C19H24N2NaO5, 
383.1577. Found: [MNa]+, 383.1569 (2.8 ppm error)]. 
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7-Methoxy-1-methylspiro[indoline-3,3'-piperidine]-2,2'-dione (266b) 
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tert-Butyl 3-((2-methoxyphenyl)(methyl)carbamoyl)-2-oxopiperidine-1-carboxylate 
(20b, 143 mg, 0.40 mmol) and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in 
mesitylene (8 mL) were reacted for 1 h according to general procedure F. Flash column 
chromatography [1:4 EtOAc:PE → 1:9 MeOH:EtOAc] afforded 266b (17 mg, 16%) as a 
pale brown amorphous solid, mp 184‒188 °C; Rf (EtOAc) = 0.20; max/cm-1 (neat) 3299, 
3072, 2943, 1707, 1665, 1614, 1597, 1491, 1465 ; δH (400 MHz, CDCl3) 7.00 (1H, dd, J = 8.0, 
7.5, H-3), 6.91‒6.86 (2H, m, H-2, H-4), 6.65 (1H, br s, NH), 3.84 (2H, s, H-14), 3.60‒3.50 
(2H, m, H-12), 3.50 (3H, s, H-7), 2.39‒2.24 (2H, m, H-10a, H-11a), 2.08‒1.94 (2H, m, 
H-10b, H-11b); δC (100 MHz, CDCl3) 176.1 (C-8), 168.6 (C-13), 145.4 (C-5), 133.4 (C-1), 
132.0 (C-6), 123.3 (C-3), 115.6 (C-2), 112.7 (C-4), 55.9 (C-14), 55.5 (C-9), 42.7 (C-12), 31.7 
(C-10), 29.9 (C-7), 18.6 (C-11); m/z (ESI) 283 [MNa]+; [HRMS (ESI): calcd for 
C14H16N2NaO3, 283.1053. Found: [MNa]+, 293.1054 (−0.0 ppm error)]. 
 
 
tert-Butyl 1-(4-methoxybenzyl)-2,2'-dioxospiro[indoline-3,3'-piperidine]-1'-
carboxylate (21c) 
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tert-Butyl 3-((4-methoxybenzyl)(phenyl)carbamoyl)-2-oxopiperidine-1-carboxylate (20c, 
169 mg, 0.39 mmol) and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in 
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mesitylene (8 mL) were reacted for 30 min according to general procedure F. Flash 
column chromatography [20‒30% EtOAc/PE] gave a mixture of spirocycle 21c and 
lactam 262b (88 mg, corresponding to 81 mg of 21c, 48%) as an off-white powder. A 
small sample of pure 21c was isolated for full characterisation, mp 164‒166 °C; 
Rf (1:4 EtOAc:PE) = 0.20; max/cm-1 (neat) 3057, 2978, 2934, 1767, 1719, 1610, 1513, 1488, 
1466; δH (400 MHz, CDCl3) 7.30 (1H, ddd, J = 7.5, 1.0, 0.5, H-2), 7.24 (2H, d, J = 9.0, H-9), 
7.18 (1H, td, J = 7.5, 1.0, H-4), 7.01 (1H, td, J = 7.5, 1.0, H-3), 6.84 (2H, d, J = 9.0, H-10), 
6.71 (1H, ddd, J = 7.5, 1.0, 0.5, H-5), 4.87 (2H, d, J = 3.0, H-7), 3.93‒3.89 (2H, m, H-17), 
3.76 (3H, s, H-12), 2.46‒2.33 (2H, m, H-15a, H-16a), 2.22‒2.11 (1H, m, H-16b), 2.09‒2.02 
(1H, m, H-15b), 1.50 (9H, s, H-21); δC (100 MHz, CDCl3) 175.6 (C-13), 167.5 (C-18), 159.0 
(C-11), 152.9 (C-19), 143.0 (C-6), 131.9 (C-1), 128.8 (C-4), 128.4 (C-9), 127.3 (C-8), 123.1 
(C-2), 122.8 (C-3), 114.2 (C-10), 109.8 (C-5), 83.5 (C-20), 58.2 (C-14), 55.2 (C-12), 47.2 
(C-17), 43.3 (C-7), 32.1 (C-15), 27.9 (C-21), 19.5 (C-16); m/z (ESI) 459 [MNa]+; [HRMS 
(ESI): calcd for C25H28N2NaO5, 459.1890. Found: [MNa]+, 459.1896 (−1.4 ppm error)]. 
 
 
1-(4-Methoxybenzyl)spiro[indoline-3,3'-piperidine]-2,2'-dione (266c) 
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tert-Butyl 3-((4-methoxybenzyl)(phenyl)carbamoyl)-2-oxopiperidine-1-carboxylate (20c, 
169 mg, 0.39 mmol) and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in 
mesitylene (8 mL) were reacted for 1 h according to general procedure F. Flash column 
chromatography [1:4 EtOAc:PE → 1:9 MeOH:EtOAc] afforded 266c (20 mg, 15%) as an 
off-white amorphous solid, mp 221‒223 °C; Rf (1:1 EtOAc:PE) = 0.10; max/cm-1 (neat) 
3301, 3061, 2935, 1712, 1664, 1610, 1513, 1488, 1465; δH (400 MHz, CDCl3) 7.30 (1H, dd, J 
= 7.5, 1.0, H-2), 7.25 (2H, d, J = 9.0, H-9), 7.18 (1H, td, J = 7.5, 1.0, H-4), 7.01 (1H, td, J = 
7.5, 1.0, H-3), 6.84 (2H, d, J = 9.0, H-10), 6.72 (1H, d, J = 7.5, H-5), 6.64 (1H, br s, NH), 
4.89 (2H, s, H-7), 3.76 (3H, s, H-12),  3.63‒3.50 (2H, m, H-17), 2.42‒2.30 (2H, m, H-15a, 
H-16a), 2.15‒2.01 (2H, m, H-15b, H-16b); δC (100 MHz, CDCl3) 176.2 (C-13), 168.4 (C-
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18), 158.9 (C-11), 143.2 (C-6), 132.2 (C-1), 128.6 (C-4), 128.3 (C-9), 127.5 (C-8), 122.9 (C-2), 
122.7 (C-3), 114.1 (C-10), 109.6 (C-5), 55.5 (C-14), 55.2 (C-12), 43.2 (C-7), 42.8 (C-17), 31.4 
(C-15), 18.8 (C-16); m/z (ESI) 359 [MNa]+; [HRMS (ESI): calcd for C20H20N2NaO3, 
359.1366. Found: [MNa]+, 359.1356 (2.9 ppm error)]. 
 
 
tert-Butyl 1'-methyl-2,2'-dioxospiro[azetidine-3,3'-indoline]-1-carboxylate (21d) 
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tert-Butyl 3-(methyl(phenyl)carbamoyl)-2-oxoazetidine-1-carboxylate (20d, 88 mg, 
0.29 mmol) and copper(II) acetate monohydrate (6 mg, 0.03 mmol) in mesitylene (6 mL) 
were reacted for 2 h according to general procedure F. Flash column chromatography 
[1:4 EtOAc:PE] afforded a mixture of spirocycle 21d and lactam 262d (25 mg, 
corresponding to 23 mg of pure 21d, 26%) as a  colourless oil, Rf (1:2 EtOAc:PE) = 0.50;  
max/cm-1 (thin film) 3061, 2979, 2937, 1810, 1721, 1657, 1614, 1484, 1471; δH (400 MHz, 
CDCl3) 7.37 (1H, td, J = 8.0, 1.0, H-4), 7.34 (1H, ddd, J = 7.5, 1.0, 0.5, H-2), 7.11 (1H, td, 
J = 7.5, 1.0, H-3), 6.87 (1H, br d, J = 8.0, H-5), 4.11 (1H, d, J = 6.5, H-10a), 3.86 (1H, d, 
J = 6.5, H-10b), 3.23 (3H, s, H-7), 1.57 (9H, s, H-14); δC (100 MHz, CDCl3) 170.9 (C-8), 
160.5 (C-11), 147.5 (C-12), 144.4 (C-6), 130.1 (C-4), 129.9 (C-1), 123.4, 123.2 (C-2, C-3), 
108.9 (C-5), 84.4 (C-13), 63.1 (C-9), 47.8 (C-10), 28.0 (C-14), 26.7 (C-7); m/z (ESI) 325 
[MNa]+; [HRMS (ESI): calcd for C16H18N2NaO4, 325.1159. Found: [MNa]+, 325.1155 
(1.2 ppm error)]. 
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1,1'-Dimethylspiro[indoline-3,3'-pyrrolidine]-2,2',5'-trione (21f) 
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N,1-Dimethyl-2,5-dioxo-N-phenylpyrrolidine-3-carboxamide (20f, 98 mg, 0.40 mmol) 
and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in mesitylene (8 mL) were 
reacted for 1.5 h according to general procedure F. Flash column chromatography 
[20‒33% EtOAc/PE] afforded 21f (68 mg, 70%) as an off-white amorphous solid, 
mp 156‒159 °C; Rf (1:1 EtOAc:PE) = 0.40; max/cm-1 (thin film) 2939, 1783, 1703, 1613, 
1494, 1471; δH (400 MHz, CDCl3) 7.39 (1H, ddd, J = 8.0, 6.0, 3.0, H-4), 7.13‒7.10 (1H, m, 
H-2, H-3), 6.93 (1H, br d, J = 8.0, H-5), 3.32 (1H, d, J = 18.0, H-10a), 3.27 (3H, s, H-7), 3.11 
(3H, s, H-13), 2.97 (1H, d, J = 18.0, H-10b); δC (100 MHz, CDCl3) 174.8, 173.4 (C-11, 
C-12), 173.2 (C-8), 144.5 (C-6), 130.0 (C-4), 127.4 (C-1), 123.6, 122.6 (C-2, C-3), 109.1 
(C-5), 56.4 (C-9), 38.6 (C-10), 27.0 (C-7), 26.0 (C-13); m/z (ESI) 267 [MNa]+; [HRMS (ESI): 
calcd for C13H12N2NaO3, 267.0740. Found: [MNa]+, 267.0738 (0.9 ppm error)]. 
 
 
tert-Butyl 1-methyl-2,2',6'-trioxospiro[indoline-3,3'-piperidine]-1'-carboxylate (21g) 
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tert-Butyl 3-(methyl(phenyl)carbamoyl)-2,6-dioxopiperidine-1-carboxylate (20g, 
114 mg, 0.33 mmol) and copper(II) acetate monohydrate (7 mg, 0.035 mmol) in toluene 
(7 mL) were heated to 120 °C for 12 h. After cooling to room temperature, the solvent 
was removed in vacuo. Flash column chromatography [20‒33% EtOAc/PE] afforded 
21g (51 mg, 45%) as an off-white amorphous solid, mp 122‒123 °C; Rf (1:1 EtOAc:PE) = 
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0.50; max/cm-1 (thin film) 3061, 2982, 2938, 1781, 1735, 1693, 1613, 1495, 1472; 
δH (400 MHz, CDCl3) 7.39 (1H, td, J = 8.0, 1.0, H-4), 7.24 (1H, dd, J = 7.5, H-2), 7.13 (1H, 
td, J = 7.5, 1.0, H-3), 6.92 (1H, br d, J = 8.0, H-5), 3.40 (1H, ddd, J = 18.0, 9.0, 6.5, H-11a), 
3.25 (3H, s, H-7), 2.87 (1H, dt, J = 18.0, 6.0, H-11b), 2.36‒2.31 (2H, m, H-10), 1.54 (9H, s, 
H-16); δC (100 MHz, CDCl3) 172.5 (C-8), 169.3 (C-12), 166.8 (C-13), 148.2 (C-14), 143.8 
(C-6), 129.9 (C-4), 127.8 (C-1), 123.6 (C-2), 123.4 (C-3), 109.1 (H-5), 86.8 (C-15), 54.8 (C-9), 
27.8 (C-11), 27.4 (C-16), 26.7 (C-7), 26.6 (C-10); m/z (ESI) 367 [MNa]+; [HRMS (ESI): calcd 
for C18H20N2NaO5, 367.1264. Found: [MNa]+, 367.1262 (0.6 ppm error)]. 
 
 
1-Methylspiro[indoline-3,3'-piperidine]-2,2',6'-trione (266g) 
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tert-Butyl 3-(methyl(phenyl)carbamoyl)-2-oxopiperidine-1-carboxylate (20g, 132 mg, 
0.40 mmol) and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in mesitylene (8 mL) 
were reacted for 1 h according to general procedure F. Flash column chromatography 
[1:2 EtOAc:PE → 3:17 MeOH:EtOAc]  afforded 266g (39 mg, 42%) as a pale brown 
amorphous solid, mp 220 °C - decomposition; Rf (1:1 EtOAc:PE) = 0.20; max/cm-1 (thin 
film) 3211, 3097, 1725, 1697, 1611, 1495, 1471, 1451; δH (400 MHz, CDCl3) 8.05 (1H, br s, 
NH), 7.40 (1H, td, J = 8.0, 1.0, H-4), 7.21 (1H, dd, J = 7.5, 1.0, H-2), 7.13 (1H, td, J = 7.5, 
1.0, H-3), 6.93 (1H, br d, J = 8.0, H-5), 3.34 (1H, ddd, J = 18.0, 9.5, 6.0, H-11a), 3.26 (3H, s, 
H-7), 2.83 (1H, dt, J = 18.0, 6.0, H-10b), 2.42‒2.28 (2H, m, H-10); δC (100 MHz, CDCl3) 
172.9 (C-8), 171.5 (C-12), 168.7 (C-13), 143.9 (C-6), 129.8 (C-4), 128.1 (C-1), 123.4, 123.4 
(C-2, C-3), 109.1 (C-5), 54.9 (C-9), 27.7 (C-11), 27.5 (C-10), 26.7 (C-7); m/z (ESI) 267 
[MNa]+; [HRMS (ESI): calcd for C13H12N2NaO3, 267.0740. Found: [MNa]+, 267.0740 
(−0.1 ppm error)]. 
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tert-Butyl 1'-methyl-2,2'-dioxospiro[azepane-3,3'-indoline]-1-carboxylate (21h) 
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tert-Butyl 3-(methyl(phenyl)carbamoyl)-2-oxoazepane-1-carboxylate (20h, 99 mg, 
0.29 mmol) and copper(II) acetate monohydrate (6 mg, 0.03 mmol) in mesitylene (6 mL) 
were reacted for 30 min according to general procedure F. Flash column 
chromatography [20‒33% EtOAc/PE] afforded 21h (63 mg, 64%) as an off-white 
amorphous solid, mp 139‒141 °C; Rf (1:4 EtOAc:PE) = 0.10; max/cm-1 (neat) 3056, 2977, 
2935, 1762, 1710, 1610, 1494, 1472; δH (400 MHz, CDCl3) 7.30 (1H, td, J = 8.0, 1.0, H-4), 
7.26‒7.23 (1H, m, H-2), 7.07 (1H, td, J = 7.5, 1.0, H-3), 6.84 (1H, d, J = 8.0, H-5), 4.23 (1H, 
ddd, J = 14.5, 9.0, 2.5, H-13a), 3.93 (1H, ddd, J = 14.5, 7.0, 2.5, H-13b), 3.22 (3H, s, H-7), 
2.25‒1.80 (6H, m, H-10, H-11, H-12), 1.45 (9H, s, H-17); δC (100 MHz, CDCl3) 174.7 
(C-8), 173.4 (C-14), 153.3 (C-15), 143.0 (C-6), 133.1 (C-1), 128.6 (C-4), 123.4 (C-2), 122.9 
(C-3), 108.5 (C-5), 82.6 (C-16), 62.5 (C-9), 43.0 (C-13), 33.1 (C-10), 27.9 (C-17), 26.5 (C-7), 
26.4 (C-11), 21.8 (C-12); m/z (ESI) 367 [MNa]+; [HRMS (ESI): calcd for C19H24N2NaO4, 
367.1628. Found: [MNa]+, 367.1631 (−0.7 ppm error)]; [Found C, 66.12%; H, 7.05%; N, 
7.92%. C19H24N2O4 requires C, 66.26%; H, 7.02%; N, 8.13%]. 
 
 
tert-Butyl 1-methyl-2,2'-dioxospiro[indoline-3,3'-piperidine]-1'-carboxylate (21i) 
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tert-Butyl 3-(methyl(phenyl)carbamoyl)-2-oxopiperidine-1-carboxylate (20i, 132 mg, 
0.40 mmol) and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in mesitylene (8 mL) 
were reacted for 30 min according to general procedure F. Flash column 
chromatography [20‒33% EtOAc/PE] afforded 20i (74 mg, 56%) as an off-white 
powder, mp 132‒134 °C; Rf (1:1 EtOAc:PE) = 0.50; max/cm-1 (thin film) 3058, 2979, 2937, 
1768, 1720, 1610, 1494, 1471; δH (400 MHz, CDCl3) 7.30‒7.25 (2H, m, H-4, H-2), 7.03 (1H, 
td, J = 7.5, 1.0, H-3), 6.83 (1H, br d, J = 8.0, H-5), 3.89‒3.80 (2H, m, H-12), 3.18 (3H, s, 
H-7), 2.37‒2.27 (2H, m, H-10a, H-11a), 2.15‒2.06 (1H, m, H-11b), 2.02‒1.95 (1H, m, 
H-10b), 1.44 (9H, s, H-16); δC (100 MHz, CDCl3) 175.3 (C-8), 167.4 (C-13), 153.0 (C-14), 
143.8 (C-6), 131.7 (C-1), 128.8 (C-4), 123.0 (C-2), 122.7 (C-3), 108.6 (C-5), 83.3 (C-15), 58.1 
(C-9), 47.0 (C-12), 31.9 (C-10), 27.8 (C-16), 26.4 (C-7), 19.3 (C-11); m/z (ESI) 353 [MNa]+; 
[HRMS (ESI): calcd for C18H22N2NaO4, 353.1472. Found: [MNa]+, 353.1475 (−0.9 ppm 
error)]. 
 
 
tert-Butyl 7-cyano-1-methyl-2,2'-dioxospiro[indoline-3,3'-piperidine]-1'-carboxylate 
(21l) 
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tert-Butyl 3-((2-cyanophenyl)(methyl)carbamoyl)-2-oxopiperidine-1-carboxylate (20l, 
86 mg, 0.24 mmol) and copper(II) acetate monohydrate (5 mg, 0.025 mmol) in 
mesitylene (5 mL) were reacted for 30 min according to general procedure F. Flash 
column chromatography [20‒30% EtOAc/PE] afforded a mixture of spirocycle 21l and 
lactam 262b (20 mg, corresponding to 16 mg of pure 21l, 19%) as off-white dendrites. A 
small sample of pure 21l was isolated for full characterisation, mp 155‒157 °C; 
Rf (1:1 EtOAc:PE) = 0.40; max/cm-1 (thin film) 2979, 2941, 2226, 1768, 1725, 1598, 1475; 
δH (400 MHz, CDCl3) 7.52 (1H, dd, J = 8.0, 1.0, H-4), 7.45 (1H, dd, J = 7.5, 1.0, H-2), 7.11 
(1H, dd, J = 8.0, 7.5, H-3), 3.97‒3.84 (2H, m, H-12), 3.59 (3H, s, H-7), 2.53‒2.28 (2H, m, 
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H-10a, H-11a), 2.12‒2.00 (2H, m, H-10b, H-11b), 1.48 (9H, s, H-16); δC (100 MHz, CDCl3) 
175.1 (C-8), 166.3 (C-13), 152.8 (C-14), 145.8 (C-6), 133.4 (C-1), 133.3 (C-4), 127.2 (C-2), 
122.9 (C-3), 116.7 (C-17), 93.9 (C-5), 84.0 (C-15), 57.0 (C-9), 47.0 (C-12), 32.0 (C-10), 28.3 
(C-7), 27.9 (C-16), 19.3 (C-11); m/z (ESI) 378 [MNa]+; [HRMS (ESI): calcd for 
C19H21N3NaO4, 378.1424. Found: [MNa]+, 378.1406 (4.9 ppm error)]. 
 
 
tert-Butyl 1-(2,4-dimethoxybenzyl)-5-methoxy-2,2'-dioxospiro[indoline-3,3'-
piperidine]-1'-carboxylate (21m) 
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tert-Butyl 3-((2,4-dimethoxybenzyl)(4-methoxyphenyl)carbamoyl)-2-oxopiperidine-1-
carboxylate (20m, 175 mg, 0.35 mmol) and copper(II) acetate monohydrate (7 mg, 
0.035 mmol) in mesitylene (7 mL) were reacted for 30 min according to general 
procedure F. Flash column chromatography [20‒50% EtOAc/PE] afforded 21m 
(110 mg, 63%) as a pale yellow oil, Rf (1:1 EtOAc:PE) = 0.60; max/cm-1 (thin film) 3079, 
2975, 2938, 2837, 1768, 1718, 1614, 1592, 1508, 1497, 1458; δH (400 MHz, CDCl3) 7.09 (1H, 
d, J = 8.5, H-16), 6.88 (1H, dd, J = 2.5, 0.5, H-2), 6.70 (1H, dd, J = 8.5, 2.5, H-5), 6.66 (1H, 
dd, J = 8.5, 0.5, H-6), 6.44 (1H, d, J = 2.5, H-12), 6.39 (1H, dd, J = 8.5, 2.5, H-15), 4.84 (2H, 
s, H-8), 3.90 (2H, t, J = 6.0, H-21), 3.84 (3H, s, H-11), 3.75 (3H, s, H-14), 3.74 (3H, s, H-4), 
2.44‒2.35 (2H, m, H-19a, H-20a), 2.16‒2.01 (2H, m, H-19b, H-20b), 1.48 (9H, s, H-25); 
δC (100 MHz, CDCl3) 175.3 (C-17), 167.5 (C-22), 160.2 (C-13), 157.9 (C-10), 155.8 (C-3), 
152.9 (C-23), 136.7 (C-7), 133.0 (C-1), 128.9 (C-16), 115.7 (C-9), 112.7 (C-5), 110.9 (C-2), 
110.0 (C-6), 104.3 (C-15), 98.3 (C-12), 83.4 (C-24), 58.6 (C-18), 55.8 (C-4), 55.3, 55.3 (C-11, 
C-14), 47.2 (C-21), 38.3 (C-8), 32.2 (C-19), 27.9 (C-25), 19.5 (C-20); m/z (ESI) 519 [MNa]+; 
[HRMS (ESI): calcd for C27H32N2NaO7, 519.2102. Found: [MNa]+, 519.2091 (2.0 ppm 
error)]. 
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tert-Butyl 5-chloro-1-methyl-2,2'-dioxospiro[indoline-3,3'-piperidine]-1'-carboxylate 
(21n) 
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tert-Butyl 3-((4-chlorophenyl)(methyl)carbamoyl)-2-oxopiperidine-1-carboxylate (20n, 
149 mg, 0.40 mmol) and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in 
mesitylene (8 mL) were reacted for 30 min according to general procedure F. Flash 
column chromatography [1:1 EtOAc:PE] afforded 21n (92 mg, 62%) as a colourless 
microcrystalline solid, mp 133‒135 °C; Rf (1:1 EtOAc:PE) = 0.45; max/cm-1 (thin film) 
3068, 2978, 2937, 1768, 1721, 1608, 1491; δH (400 MHz, CDCl3) 7.28 (1H, dd, J = 8.0, 2.0, 
H-4), 7.26 (1H, d, J = 2.0, H-2), 6.78 (1H, d, J = 8.0, H-5), 3.90‒3.86 (2H, m, H-12), 3.20 
(3H, s, H-7), 2.44‒2.29 (2H, m, H-10a, H-11a), 2.14‒1.97 (2H, m, H-10b, H-11b), 1.48 (9H, 
s, H-16); δC (100 MHz, CDCl3) 174.9 (C-8), 166.8 (C-13), 152.9 (C-14), 142.5 (C-6), 133.2 
(C-1), 128.8 (C-4), 128.0 (C-3), 123.7 (C-2), 109.5 (C-5), 83.7 (C-15), 58.2 (C-9), 47.0 (C-12), 
31.9 (C-10), 27.9 (C-16), 26.7 (C-7), 19.4 (C-11); m/z (ESI) 387, 389 [MNa]+; [HRMS (ESI): 
calcd for C18H2135ClN2NaO4, 387.1082. Found: [MNa]+, 387.1066 (4.1 ppm error)]. 
 
 
tert-Butyl 1-methyl-2,2'-dioxo-5-(trifluoromethyl)spiro[indoline-3,3'-piperidine]-1'-
carboxylate (21o) 
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tert-Butyl 3-(methyl(4-(trifluoromethyl)phenyl)carbamoyl)-2-oxopiperidine-1-
carboxylate (20o, 160 mg, 0.40 mmol) and copper(II) acetate monohydrate (8 mg, 
0.04 mmol) in mesitylene (8 mL) were reacted for 30 min according to general 
procedure F. Flash column chromatography [20‒30% EtOAc/PE] afforded a mixture of 
spirocycle 21o and lactam 262b (59 mg, corresponding to 51 mg of pure 21o, 32%) as 
off-white dentrites. A small sample of pure 21o was isolated for full characterisation, 
mp 142‒144 °C; Rf (1:1 EtOAc:PE) = 0.40;  max/cm-1 (thin film) 3077, 2980, 2939, 1770, 
1723, 1621, 1507, 1476, 1451; δH (400 MHz, CDCl3) 7.60 (1H, br d, J = 8.0, H-4), 7.50‒7.49 
(1H, m, H-2), 6.93 (1H, d, J = 8.0, H-5), 3.91 (2H, t, J = 6.0, H-12), 3.25 (3H, s, H-7), 
2.49‒2.30 (2H, m, H-10a, H-11a), 2.15‒2.02 (2H, m, H-10b, H-11b), 1.48 (9H, s, H-16); 
δC (100 MHz, CDCl3) 175.3 (C-8), 166.7 (C-13), 152.8 (C-14), 147.0 (C-6), 132.3 (C-1), 
126.8 (q, J = 4.0, C-4), 125.1 (q, J = 33.0, C-3), 124.2 (q, J = 271.5, C-17), 120.2 (q, J = 4.0, 
C-2), 108.4 (C-5), 83.8 (C-15), 58.0 (C-9), 47.0 (C-12), 31.9 (C-10), 27.9 (C-16), 26.8 (C-7), 
19.5 (C-11); δF (376 MHz, CDCl3) −61.3 (3F); m/z (ESI) 421 [MNa]+; [HRMS (ESI): calcd 
for C19H21F3N2NaO4, 421.1346. Found: [MNa]+, 421.1356 (−2.5 ppm error)]. 
 
 
tert-Butyl 6-methoxy-1-methyl-2,2'-dioxospiro[indoline-3,3'-piperidine]-1'-
carboxylate (21pp) and tert-butyl 4-methoxy-1-methyl-2,2'-dioxospiro[indoline-3,3'-
piperidine]-1'-carboxylate (21po) 
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tert-Butyl 3-((3-methoxyphenyl)(methyl)carbamoyl)-2-oxopiperidine-1-carboxylate 
(20p, 143 mg, 0.40 mmol) and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in 
mesitylene (8 mL) were reacted for 30 min according to general procedure F. Flash 
column chromatography [20‒30% EtOAc/PE] afforded 21pp (26 mg, 18%) as an 
off-white amorphous solid, as well as a mixture of spirocycle 21po and lactam 262b 
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(89 mg, corresponding to 82.5 mg of pure 21po, 58%; a small sample of pure 21po was 
isolated for full characterisation) as an off-white amorphous solid. 21pp: 
mp 145‒147 °C; Rf (1:1 EtOAc:PE) = 0.40; max/cm-1 (thin film) 3075, 2977, 2938, 2840, 
1768, 1723, 1623, 1507, 1473, 1457; δH (400 MHz, CDCl3) 7.19 (1H, d, J = 8.5, H-2), 6.55 
(1H, dd, J = 8.5, 2.5, H-3), 6.44 (1H, d, J = 2.5, H-5), 3.93‒3.82 (2H, m, H-12), 3.82 (3H, s, 
H-17), 3.20 (3H, s, H-7), 2.37‒2.29 (2H, m, H-10a, H-11a), 2.18‒2.06 (1H, m, H-11b), 
2.00‒1.93 (1H, m, H-10b), 1.47 (9H, s, H-16); δC (100 MHz, CDCl3) 175.9 (C-8), 167.9 
(C-13), 160.7 (C-4), 153.3 (C-14), 145.3 (C-6), 123.9 (C-1), 123.8 (C-2), 106.5 (C-3), 96.7 
(C-5), 83.4 (C-15), 57.8 (C-9), 55.6 (C-17), 47.1 (C-12), 32.1 (C-10), 27.9 (C-16), 26.6 (C-7), 
19.5 (C-11); m/z (ESI) 383 [MNa]+; [HRMS (ESI): calcd for C19H24N2NaO5, 383.1577. 
Found: [MNa]+, 383.1569 (2.3 ppm error)]; 21po; mp 117‒119 °C; Rf (1:1 EtOAc:PE) = 
0.50; max/cm-1 (thin film) 2976, 2938, 1768, 1716, 1610, 1476; δH (400 MHz, CDCl3) 7.25 
(1H, dd, J = 8.5, 8.0, H-4), 6.61 (1H, d, J = 8.5, H-5), 6.49 (1H, dd, J = 8.0, 0.5, H-3), 4.03 
(1H, dtd, J = 12.5, 4.5, 2.0, H-12a), 3.82 (3H, s, H-17), 3.71 (1H, ddd, J = 12.5, 11.0, 3.5, 
H-12b), 3.17 (3H, s, H-7), 2.58‒2.47 (1H, m, H-11a), 2.43‒2.36 (1H, m, H-10a), 2.07‒1.94 
(2H, m, H-10b, H-11b), 1.49 (9H, s, H-16); δC (100 MHz, CDCl3) 175.9 (C-8), 167.1 (C-13), 
154.6 (C-2), 153.3 (C-14), 145.2 (C-6), 130.1 (C-4), 118.1 (C-1), 106.3 (C-5), 101.8 (C-3), 
83.1 (C-15), 57.2 (C-9), 55.6 (C-17), 47.1 (C-12), 30.0 (C-10), 28.0 (C-16), 26.7 (C-7), 19.9 
(C-11); m/z (ESI) 383 [MNa]+; [HRMS (ESI): calcd for C19H24N2NaO5, 383.1577. Found: 
[MNa]+, 383.1566 (3.0 ppm error)]. 
 
 
tert-Butyl 6-bromo-1-methyl-2,2'-dioxospiro[indoline-3,3'-piperidine]-1'-carboxylate 
(21qp) and tert-butyl 4-bromo-1-methyl-2,2'-dioxospiro[indoline-3,3'-piperidine]-1'-
carboxylate (21qo) 
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tert-Butyl 3-((3-bromophenyl)(methyl)carbamoyl)-2-oxopiperidine-1-carboxylate (20q, 
69 mg, 0.17 mmol) and copper(II) acetate monohydrate (3.4 mg, 0.017 mmol) in 
mesitylene (3.4 mL) were reacted for 30 min according to general procedure F. Flash 
column chromatography [20‒30% EtOAc/PE] afforded a mixture of spirocycle 21qp 
and lactam 262b (19 mg, corresponding to 18 mg of pure 21qp, 25%; a small sample of 
pure 21qp was isolated for full characterisation) as an off-white powder, as well as 21qo 
(30 mg, 44%) as off-white crystals (dendrites). 21qp: mp 171‒173 °C; Rf (1:4 EtOAc:PE) = 
0.20; max/cm-1 (thin film) 3068, 2978, 2937, 1768, 1722, 1603, 1493; δH (400 MHz, CDCl3) 
7.20 (1H, dd, J = 8.0, 1.5, H-3), 7.15 (1H, d, J =8.0, H-2), 7.01 (1H, d, J = 1.5, H-5), 
3.90‒3.86 (2H, m, H-12), 3.21 (3H, s, H-7), 2.43‒2.29 (2H, m, H-10a, H-11a), 2.16‒1.96 
(2H, m, H-10b, H-11b), 1.48 (9H, s, H-16);  δC (100 MHz, CDCl3) 175.2 (C-8), 167.0 (C-
13), 153.0 (C-14), 145.3 (C-6), 130.6 (C-1), 125.6 (C-3), 124.4 (C-2), 122.6 (C-4), 112.2 (C-5), 
83.7 (C-15), 57.9 (C-9), 47.1 (C-12), 31.9 (C-10), 28.0, 27.9 (C-16), 26.7 (C-7), 19.4 (C-11); 
m/z (ESI) 431, 433 [MNa]+; [HRMS (ESI): calcd for C18H2179BrN2NaO4, 431.0577. Found: 
[MNa]+, 431.0579 (−0.4 ppm error)]; 21qo: mp 144‒146 °C; Rf (1:4 EtOAc:PE) = 0.10; 
max/cm-1 (thin film) 3070, 2978, 2935, 1769, 1720, 1605, 1457; δH (400 MHz, CDCl3) 
7.19‒7.13 (2H, m, H-3, H-4), 6.77 (1H, dd, J = 6.5, 2.5, H-5), 4.14‒4.08 (1H, m, H-12a), 
3.78‒3.70 (1H, m, H-12b), 3.18 (3H, s, H-7), 2.74‒5.59 (2H, m, H-10a, H-11a), 2.02‒1.95 
(2H, m, H-10b, H-11b), 1.50 (9H, s, H-16); δC (100 MHz, CDCl3) 174.9 (C-10), 165.5 
(C-13), 153.0 (C-14), 145.7 (C-6), 130.8 (C-1), 130.2 (C-4), 126.6 (C-3), 118.3 (C-2), 107.4 
(C-5), 83.5 (C-15), 59.0 (C-9), 46.7 (C-12), 29.2 (C-10), 27.9 (C-16), 26.7 (C-7), 19.5 (C-11); 
m/z (ESI) 431, 433 [MNa]+; [HRMS (ESI): calcd for C18H2179BrN2NaO4, 431.0577. Found: 
[MNa]+, 431.0586 (−2.1 ppm error)]. 
 
 
1,1'-Dimethylspiro[indoline-3,3'-piperidine]-2,2'-dione (21r) 
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N,1-Dimethyl-2-oxo-N-phenylpiperidine-3-carboxamide (20r, 99 mg, 0.40 mmol) and 
copper(II) acetate monohydrate (8 mg, 0.04 mmol) in mesitylene (8 mL) were reacted 
for 30 min according to general procedure F. Flash column chromatography [EtOAc] 
afforded 21r (64 mg, 65%) as an off-white amorphous solid, mp 198‒200 °C; Rf (EtOAc) 
= 0.10; max/cm-1 (thin film) 3042, 2948, 2923, 2885, 2861, 1710, 1634, 1607, 1493, 1468, 
1454; δH (400 MHz, CDCl3) 7.29 (1H, td, J = 7.5, 1.0, H-4), 7.25 (1H, ddd, J = 7.5, 1.0, 0.5, 
H-2), 7.03 (1H, td, J = 7.5, 1.0, H-3), 6.86‒6.83 (1H, m, H-5), 3.61‒3.48 (2H, m, H-12), 3.23 
(3H, s, H-7),  3.01 (3H, s, H-14), 2.40‒2.30 (2H, m, H-10a, H-11a), 2.19‒2.09 (1H, m, 
H-11b), 2.04‒1.96 (1H, m, H-10b); δC (100 MHz, CDCl3) 176.3 (C-8), 166.3 (C-13), 144.1 
(C-6), 132.5 (C-1), 128.6 (C-4), 122.8 (C-2), 122.6 (C-3), 108.5 (C-5), 55.7 (C-9), 50.2 (C-12), 
35.6 (C-14), 31.6 (C-10), 26.5 (C-7), 19.1 (C-11); m/z (ESI) 267 [MNa]+; [HRMS (ESI): calcd 
for C14H16N2NaO2, 267.1104. Found: [MNa]+, 267.1101 (1.3 ppm error)]. 
 
 
1'-Benzyl-1-methylspiro[indoline-3,3'-piperidine]-2,2'-dione (21s) 
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1-Benzyl-N-methyl-2-oxo-N-phenylpiperidine-3-carboxamide (21s, 124 mg, 0.39 mmol) 
and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in mesitylene (8 mL) were 
reacted for 30 min according to general procedure F. Flash column chromatography 
[1:1 EtOAc:PE] afforded 21s (79 mg, 64%) as an off-white amorphous solid, 
mp 134‒136 °C; Rf (1:1 EtOAc:PE) = 0.25; max/cm-1 (thin film) 3058, 3029, 2939, 2864, 
1714, 1640, 1610, 1492, 1469; δH (400 MHz, CDCl3) 7.37‒7.27 (6H, m, H-4, H-16, H-17, 
H-18), 7.26 (1H, ddd, J = 7.5, 1.0, 0.5, H-2), 7.06 (1H, td, J = 7.5, 1.0, H-3), 6.89‒6.86 (1H, 
m, H-5), 4.77 (1H, d, J = 14.5, H-14a), 4.51 (1H, d, J = 14.5, H-14b), 3.51‒3.40 (2H, m, 
H-12), 3.26 (3H, s, H-7), 2.40‒2.26 (2H, m, H-10a, H-11a), 2.12‒1.97 (2H, m, H-10b, 
H-11b); δC (100 MHz, CDCl3) 176.3 (C-8), 166.5 (C-13), 144.2 (C-6), 136.8 (C-15), 132.7 
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(C-1), 128.7 (C-4, C-17), 128.0 (C-16), 127.4 (C-18), 122.7, 122.6 (C-2, C-3), 108.5 (C-5), 
55.8 (C-9), 50.7 (C-14), 47.4 (C-12), 31.6 (C-10), 26.5 (C-7), 19.1 (C-11); m/z (ESI) 343 
[MNa]+; [HRMS (ESI): calcd for C20H20N2NaO2, 343.1417. Found: [MNa]+, 343.1408 
(2.7 ppm error)]. 
 
 
1'-(4-Methoxybenzyl)-1-methylspiro[indoline-3,3'-piperidine]-2,2'-dione (21t) 
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1-(4-Methoxybenzyl)-N-methyl-2-oxo-N-phenylpiperidine-3-carboxamide (21t, 127 mg, 
0.36 mmol) and copper(II) acetate monohydrate (7 mg, 0.035 mmol) in mesitylene 
(8 mL) were reacted for 30 min according to general procedure F. Flash column 
chromatography [1:1 EtOAc:PE] afforded 21t (81 mg, 64%) as an off-white amorphous 
solid, mp 133‒135 °C; Rf (1:1 EtOAc:PE) = 0.20; max/cm-1 (thin film) 3056, 2937, 2863, 
2837, 1713, 1638, 1611, 1512, 1492, 1467; δH (400 MHz, CDCl3) 7.31 (1H, td, J = 7.5, 1.0, 
H-4), 7.24‒7.19 (3H, m, H-2, H-16), 7.05 (1H, td, J = 7.5, 1.0, H-3), 6.89‒6.85 (3H, m, H-5, 
H-17), 4.71 (1H, d, J = 14.5, H-14a), 4.43 (1H, d, J = 14.5, H-14b), 3.80 (3H, s, H-19), 
3.49‒3.39 (2H, m, H-12), 3.25 (3H, s, H-7), 2.38‒2.24 (2H, m, H-10a, H-11a), 2.10‒1.95 
(2H, m, H-10b, H-11b); δC (100 MHz, CDCl3) 176.4 (C-8), 166.3 (C-13), 159.0 (C-18), 
144.2 (C-6), 132.8 (C-1), 129.4 (C-16), 129.0 (C-15), 128.6 (C-4), 122.7, 122.6 (C-2, C-3), 
114.0 (C-17), 108.5 (C-5), 55.8 (C-9), 55.2 (C-19), 50.1 (C-14), 47.1 (C-12), 31.6 (C-10), 26.5 
(C-7), 19.1 (C-11); m/z (ESI) 373 [MNa]+; [HRMS (ESI): calcd for C21H22N2NaO3, 
373.1523. Found: [MNa]+, 373.1505 (4.7 ppm error)]. 
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tert-Butyl 1-benzyl-2,2'-dioxospiro[indoline-3,3'-piperidine]-1'-carboxylate (21u) 
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tert-Butyl 3-(benzyl(phenyl)carbamoyl)-2-oxopiperidine-1-carboxylate (20u, 162 mg, 
0.40 mmol) and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in mesitylene (8 mL) 
were reacted for 30 min according to general procedure F. Flash column 
chromatography [20‒30% EtOAc/PE] afforded a mixture of spirocycle 21u and lactam 
262b (106 mg, corresponding to 83 mg of pure 21u, 51%) as an off-white amorphous 
solid. A small sample of pure 21u was isolated for full characterisation, mp 162‒164 °C; 
Rf  (1:4 EtOAc:PE) = 0.10; max/cm-1 (thin film) 3062, 3031, 2978, 2935, 1768, 1718, 1609, 
1489, 1466, 1456; δH (400 MHz, CDCl3) 7.33‒7.22 (6H, m, H-2, H-9, H-10, H-11), 7.17 
(1H, td, J = 8.0, 1.0, H-4), 7.02 (1H, td, J = 8.0, 1.0, H-3), 6.69 (1H, br d, J = 8.0, H-5), 4.94 
(2H, d, J = 1.0, H-7), 3.95‒3.87 (2H, m, H-17), 2.47‒2.33 (2H, m, H-15a, H-16a), 2.23‒2.04 
(2H, m, H-15b, H-16b), 1.50 (9H, s, H-21); δC (100 MHz, CDCl3) 175.7 (C-13), 167.5 
(C-18), 152.9 (C-19), 143.0 (C-6), 135.3 (C-8), 131.9 (C-1), 128.8 (C-4), 128.8 (C-10), 127.5 
(C-11), 127.0 (C-9), 123.2 (C-2), 122.8 (C-3), 109.7 (C-5), 83.5 (C-20), 58.3 (C-14), 47.2 
(C-17), 43.8 (C-7), 32.1 (C-15), 27.9 (C-21), 19.5 (C-16); m/z (ESI) 429 [MNa]+; [HRMS 
(ESI): calcd for C24H26N2NaO4, 429.1785. Found: [MNa]+, 429.1791 (−1.3 ppm error)]. 
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tert-Butyl 1-benzyl-2,2'-dioxospiro[indoline-3,3'-pyrrolidine]-1'-carboxylate (21w) 
 
3
4
5
6
1
2
N
8
9
7
O
10
11N
12
O
13
14
15
16
17
O
O
18
19
 
 
tert-Butyl 3-(benzyl(phenyl)carbamoyl)-2-oxopyrrolidine-1-carboxylate (20w, 120mg, 
0.30 mmol) and copper(II) acetate monohydrate (6 mg, 0.03 mmol) in mesitylene (6 mL) 
were reacted for 30 min according to general procedure F. Flash column 
chromatography [20‒30% EtOAc/PE] afforded 21w (66 mg, 55%) as a colourless 
amorphous solid, mp 175‒177 °C; Rf (1:4 EtOAc:PE) = 0.20;  max/cm-1 (thin film) 3061, 
2962, 2931, 2872, 1783, 1749, 1718, 1612, 1490, 1467, 1456; δH (400 MHz, CDCl3) 7.34‒7.23 
(5H, m, H-15, H-16, H-17),  7.21 (1H, ddd, J = 7.5, 1.0, 0.5, H-2), 7.19 (1H, td, J = 7.5, 1.0, 
H-4), 7.04 (1H, td, J = 7.5, 1.0, H-3), 6.69 (1H, br d, J = 7.5, H-5), 5.02 (1H, d, J = 16.0, 
H-7a), 4.82 (1H, d, J = 16.0, H-7b), 4.21 (1H, ddd, J = 10.5, 8.0, 7.0, H-11a), 4.01 (1H, ddd, 
J = 10.5, 8.5, 5.0, H-11b), 2.70 (1H, ddd, J = 13.0, 8.0, 5.0, H-10a), 2.41 (1H, ddd, J = 13.0, 
8.5, 7.0, H-10b), 1.55 (9H, s, H-19); δC (100 MHz, CDCl3) 174.5 (C-8), 169.3 (C-12), 150.0 
(C-13), 143.4 (C-6), 135.0 (C-14), 129.3 (C-4), 128.9 (C-16), 128.8 (C-1), 127.6 (C-17), 127.0 
(C-15), 123.2 (C-3), 123.1 (C-2), 109.7 (C-5), 83.7 (C-18), 59.5 (C-9), 44.2 (C-11), 44.0 (C-7), 
28.2 (C-10), 28.0 (C-19); m/z (ESI) 415 [MNa]+; [HRMS (ESI): calcd for C23H24N2NaO4, 
415.1628. Found: [MNa]+, 415.1618 (2.5 ppm error)]; [Found C, 69.82%; H, 6.20%; N, 
6.81%. C23H24N2O4 requires C, 70.39%; H, 6.16%; N, 7.14%]. 
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1-Benzyl-1'-methylspiro[indoline-3,3'-pyrrolidine]-2,2'-dione (21x) 
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N-Benzyl-1-methyl-2-oxo-N-phenylpyrrolidine-3-carboxamide (20x, 123 mg, 
0.40 mmol) and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in mesitylene (8 mL) 
were reacted for 1 h according to general procedure F. Flash column chromatography 
[50‒75% EtOAc/PE] afforded 21x (71 mg, 58%) as an off-white amorphous solid, 
mp 151‒153 °C; Rf (EtOAc) = 0.50; max/cm-1 (thin film) 3059, 3031, 2932, 2885, 1714, 
1690, 1611, 1490, 1466, 1455; δH (400 MHz, CDCl3) 7.33‒7.21 (5H, m, H-15, H-16, H-17), 
7.19‒7.15 (2H, m, H-2, H-4), 7.03 (1H, ddd, J = 8.0, 7.0, 1.0, H-3), 6.69 (1H, dd, J = 8.0, 
1.0, H-5), 5.02 (1H, d, J = 16.0, H-7a), 4.84 (1H, d, J = 16.0 H-7b), 3.82 (1H, dd, J = 9.5, 8.5, 
6.0, H-11a), 3.62 (1H, ddd, J = 9.5, 8.5, 4.5, H-11b), 3.00 (3H, s, H-13), 2.76 (1H, ddd, 
J = 13.0, 8.5, 4.5, H-10a), 2.45 (1H, ddd, J = 13.0, 8.5, 6.0, H-10b); δC (100 MHz, CDCl3) 
175.9 (C-8), 170.4 (C-12), 143.5 (C-6), 135.3 (C-14), 129.9 (C-1), 128.9 (C-4), 128.8 (C-16), 
127.5 (C-17), 127.0 (C-15), 123.0 (C-3), 122.8 (C-2), 109.5 (C-5), 57.8 (C-9), 47.2 (C-11), 
43.9 (C-7), 30.5 (C-13), 29.3 (C-10); m/z (ESI) 307 [MH]+, 329 [MNa]+; [HRMS (ESI): calcd 
for C19H18N2NaO2, 329.1260. Found: [MNa]+, 329.1255 (1.6 ppm error)]. 
 
 
1-(4-Methoxybenzyl)-1'-methylspiro[indoline-3,3'-pyrrolidine]-2,2'-dione (21y) 
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N-(4-Methoxybenzyl)-1-methyl-2-oxo-N-phenylpyrrolidine-3-carboxamide (20y, 
135 mg, 0.40 mmol) and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in 
mesitylene (8 mL) were reacted for 1 h according to general procedure F. Flash column 
chromatography [50‒100% EtOAc/PE] afforded 21y (74 mg, 55%) as an off-white 
microcrystalline solid, mp 140‒142 °C; Rf (EtOAc) = 0.30; max/cm-1 (thin film) 3058, 
2997, 2935, 2837, 1712, 1692, 1612, 1586, 1514, 1489, 1466; δH (400 MHz, CDCl3) 7.26 (2H, 
d, J = 9.0, H-15), 7.17 (1H, td, J = 7.5, 1.5, H-4), 7.15 (1H, ddd, J = 7.5, 1.5, 0.5, H-2), 7.02 
(1H, td, J = 7.5, 1.0, H-3), 6.84 (2H, d, J = 9.0, H-16), 6.71 (1H, ddd, J = 7.5, 1.0, 0.5, H-5), 
4.95 (1H, d, J = 15.5, H-7a), 4.77 (1H, d, J = 15.5, H-7b), 3.81 (1H, ddd, J = 9.5, 8.5, 6.0, 
H-11a), 3.75 (3H, s, H-18), 3.61 (1H, ddd, J = 9.5, 8.5, 4.5, H-11b), 2.99 (3H, s, H-13), 2.74 
(1H, ddd, J = 13.0, 8.5, 4.5, H-10a), 2.43 (1H, ddd, J = 13.0, 8.5, 6.0, H-10b); δC (100 MHz, 
CDCl3) 175.8 (C-8), 170.5 (C-12), 158.9 (C-17), 143.5 (C-6), 130.0 (C-1), 128.8 (C-4), 128.4 
(C-15), 127.3 (C-14), 123.0 (C-3), 122.7 (C-2), 114.2 (C-16), 109.5 (C-5), 57.8 (C-9), 55.2 
(C-18), 47.2 (C-11), 43.3 (C-7), 30.5 (C-13), 29.3 (C-10); m/z (ESI) 337 [MH]+, 359 [MNa]+; 
[HRMS (ESI): calcd for C20H21N2O3, 337.1547. Found: [MH]+, 337.1547 (−0.0 ppm 
error)]. 
 
 
1,1'-Dimethylspiro[indoline-3,3'-pyrrolidine]-2,2'-dione (21z) 
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N,1-Dimethyl-2-oxo-N-phenylpyrrolidine-3-carboxamide (20z, 82 mg, 0.35 mmol) and 
copper(II) acetate monohydrate (7 mg, 0.035 mmol) in mesitylene (7 mL) were reacted 
for 1 h according to general procedure F. Flash column chromatography [EtOAc] 
afforded 21z (47 mg, 58%) as a colourless microcrystalline solid, mp 163‒165 °C; 
Rf (EtOAc) = 0.30; max/cm-1 (thin film) 3059, 2998, 2935, 2878, 1718, 1682, 1611, 1495, 
1471; δH (400 MHz, CDCl3) 7.31 (1H, td, J = 7.5, 1.0, H-4), 7.15 (1H, dd, J = 7.5, 1.0, H-2), 
7.07 (1H, td, J = 7.5, 1.0, H-3), 6.86 (1H, br d, J = 7.5, H-5), 3.79 (1H, ddd, J = 9.5, 8.5, 6.0, 
H-11a), 3.59 (1H, ddd, J = 9.5, 8.5, 4.5, H-11b), 3.22 (3H, s, H-7), 2.98 (3H, s, H-13), 2.68 
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(1H, ddd, J = 13.0, 8.5, 4.5, H-10a), 2.39 (1H, ddd, J = 13.0, 8.5, 6.0, H-10b); δC (100 MHz, 
CDCl3) 175.7 (C-8), 170.4 (C-12), 144.5 (C-6), 129.9 (C-1), 129.0 (C-4), 123.0 (C-3), 122.8 
(C-2), 108.5 (C-5), 57.8 (C-9), 47.2 (C-11), 30.5 (C-13), 29.5 (C-10), 26.5 (C-7); m/z (ESI) 
231, [MH]+, 253 [MNa]+; [HRMS (ESI): calcd for C13H14N2NaO2, 253.0947. Found: 
[MNa]+, 253.0948 (−0.3 ppm error)]; [Found C, 67.74%; H, 6.13%; N, 11.96%. 
C13H14N2O2 requires C, 67.81%; H, 6.13%; N, 12.17%]. 
 
 
5-Chloro-1,1'-dimethylspiro[indoline-3,3'-pyrrolidine]-2,2'-dione (21za) 
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N-(4-Chlorophenyl)-N,1-dimethyl-2-oxopyrrolidine-3-carboxamide (20za, 106 mg, 
0.40 mmol) and copper(II) acetate monohydrate (8 mg, 0.04 mmol) in mesitylene (8 mL) 
were reacted for 1 h according to general procedure F. Flash column chromatography 
[EtOAc] afforded 21za (69 mg, 66%) as an off-white powder, mp 171‒173 °C; 
Rf (EtOAc) = 0.30; max/cm-1 (thin film) 3064, 2941, 2888, 1718, 1691, 1610, 1491, 1468, 
1450; δH (400 MHz, CDCl3) 7.28 (1H, dd, J = 8.5, 2.0, H-4), 7.13 (1H, d, J = 2.0, H-2), 6.78 
(1H, d, J = 8.5, H-5), 3.78 (1H, ddd, J = 9.5, 8.5, 6.0, H-11a), 3.58 (1H, ddd, J = 9.5, 8.5, 4.5, 
H-11b), 3.20 (3H, s, H-7), 2.98 (3H, s, H-13), 2.68 (1H, ddd, J = 13.0, 8.5, 4.5, H-10a), 2.37 
(1H, ddd, J = 13.0, 8.5, 6.0, H-10b); δC (100 MHz, CDCl3) 175.2 (C-8), 169.8 (C-12), 143.1 
(C-6), 131.4 (C-1), 128.9 (C-4), 128.3 (C-3), 123.4 (C-2), 109.4 (C-5), 57.8 (C-9), 47.1 (C-11), 
30.6 (C-13), 29.3 (C-10), 26.7 (C-7); m/z (ESI) 287, 289 [MNa]+; [HRMS (ESI): calcd for 
C13H1335ClN2NaO2, 287.0558. Found: [MNa]+, 287.0548 (3.3 ppm error)]; [Found C, 
58.94%; H, 5.07%; N, 10.15%. C13H13ClN2O2 requires C, 58.99%; H, 4.95%; N, 10.58%]. 
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7.5 Towards the synthesis of spirotryprostatin A 
 
(S)-Ethyl 5-oxopyrrolidine-2-carboxylate (316) 
 
2
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The title compound was prepared based on the procedures by Kamimura247 and 
Williams.248 To a solution of (S)-pyroglutamic acid (315, 5.00 g, 38.8 mmol) in EtOH 
(70 mL) at 0 °C was added thionyl chloride (2.83 mL, 38.8 mmol) dropwise. The 
reaction was stirred at 0 °C for 10 min then allowed to warm to room temperature and 
stirred at this temperature for 1 h. After dilution with H2O (20 mL), NaHCO3 (12 g) was 
added slowly and the resulting suspension filtered. The filtrate was concentrated 
in vacuo to approx. half the original volume then extracted with CH2Cl2 (3 x 50 mL). 
The combined organic extracts were washed with brine (20 mL), dried (Na2SO4) and 
concentrated in vacuo to afford 316 (5.67 g, 93%) as colourless prisms, mp 52‒54 °C 
(lit288 53‒54 °C); Rf (EtOAc) = 0.30; []D20 +6.9 (c 1.00, MeOH) [lit289 []D +6.3 (c 1.00, 
EtOH)]; δH (400 MHz, CDCl3) 6.53 (1H, br s, NH), 4.23 (1H, dd, J = 8.5, 5.0, H-4), 4.21 
(2H, q, J = 7.0, H-6), 2.51‒2.41 (1H, m, H-3a), 2.41‒2.30 (2H, m, H-2), 2.25‒2.16 (1H, m, 
H-3b), 1.28 (3H, t, J = 7.0, H-7). Data consistent with the literature values.248,289 
 
 
(S)-1-tert-Butyl 2-ethyl 5-oxopyrrolidine-1,2-dicarboxylate (317) 
 
2
3
4
N
1
O
5
O
O
6
7
8 O
O
9
10
 
 
The title compound was prepared based on the procedure by Flynn.249  To a solution of 
(S)-ethyl 5-oxopyrrolidine-2-carboxylate (316, 5.57 g, 35.5 mmol) in CH2Cl2 (100 mL) 
was added N,N-dimethylaminopyridine (440 mg, 3.60 mmol), di-tert-butyl dicarbonate 
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(15.75 g, 72.2 mmol) and triethylamine (15.2 mL, 109 mmol). The reaction was stirred at 
room temperature for 12 h then concentrated in vacuo. Flash column chromatography 
[1:1 EtOAc:PE] afforded 317 (8.50 g, 93%) as off-white needles, mp 53‒54 °C (lit290 
53‒54 °C); Rf (1:1 EtOAc:PE) = 0.40; []D20 −37.5 (c 0.86, CH2Cl2) [lit290 []D −39.8 (c 0.5, 
MeOH); lit291 []D −34.9 (c 0.81, CHCl3)]; δH (400 MHz, CDCl3) 4.58 (1H, dd, J = 9.5, 3.0, 
H-4), 4.23 (2H, q, J = 7.0, H-6), 2.62 (1H, ddd, J = 17.5, 10.0, 9.5, H-2a), 2.48 (1H, ddd, J = 
17.5, 9.5, 3.5, H-2b), 2.36‒2.25 (1H, m, H-3a), 2.02 (1H, tdd, J = 9.5, 6.5, 3.5, H-3b), 1.48 
(9H, s, H-10), 1.28 (3H, t, J = 7.0, H-7); δC (100 MHz, CDCl3) 173.4 (C-1), 171.3 (C-5), 
149.2 (C-8), 83.5 (C-9), 61.6 (C-6), 58.9 (C-4), 31.1 (C-2), 27.8 (C-10), 21.5 (C-3), 14.1 (C-7). 
Data consistent with the literature values.290  
 
 
(S)-4-Benzyl 1-tert-butyl 2-ethyl 5-oxopyrrolidine-1,2,4-tricarboxylate (318) 
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(S)-1-tert-Butyl 2-ethyl 5-oxopyrrolidine-1,2-dicarboxylate (317, 8.28 g, 32.2 mmol), 
LiHMDS (1 M in THF, 67.7 mL, 67.7 mmol) and benzylchloroformate (4.60 mL, 
32.2 mmol) in THF (30 mL) were reacted according to general procedure D. Flash 
column chromatography [20‒33% EtOAc/PE] afforded 318 (9.13 g, 72%, 2:1 mixture of 
diastereoisomers) as a pale yellow oil, Rf (1:4 EtOAc:PE) = 0.10; max/cm-1 (thin film) 
3065, 3034, 2981, 2937, 2362, 2341, 1796, 1740, 1498, 1475, 1457; δH (400 MHz, CDCl3, 
minor diastereoisomer starred) 7.39‒7.28 (5H and 5H*, m, H-1, H-1*, H-2, H-2*, H-3, 
H-3*), 5.21 (2H, s, H-5), 5.18 (2H*, d, J = 3.5, H-5*), 4.64 (1H, dd, J = 9.5, 2.5, H-9), 
4.60‒4.56 (1H*, m, H-9*), 4.25‒4.07 (2H and 2H*, m, H-15, H-15*), 3.72 (1H, dd, J = 10.5, 
9.0, H-7), 3.60‒3.56 (1H*, m, H-7*), 2.73 (1H, ddd, J = 13.5, 10.5, 9.5, H-8a), 2.55‒2.51 
(2H*, m H-8a*, H-8b*), 2.24 (1H, ddd, J = 13.5, 9.0, 2.5, H-8b), 1.47 (9H and 9H*, s, H-13, 
H-13*), 1.27 (3H, t, J= 7.0, H-16), 1.23 (3H*, t, J = 7.0, H-16*); δC (100 MHz, CDCl3, minor 
diastereoisomer starred) 170.7 (C-14), 170.2 (C-14*), 167.8, 167.7 (C-6, C-10), 167.4, 167.1 
(C-6*, C-10*), 149.0 (C-11*), 148.9 (C-11), 135.12 (C-4*), 135.0 (C-4), 128.5 (C-2), 128.5 
(C-2*), 128.4 (C-1), 128.3 (C-1*), 128.2 (C-3), 128.1 (C-3*), 84.1 (C-12), 84.0 (C-12*), 67.6 
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(C-5), 61.9 (C-15), 61.7 (C-15*), 57.5 (C-9*), 57.1 (C-9), 48.7 (C-7*), 48.4 (C-7), 27.8 (C-13), 
25.3 (C-8), 24.6 (C-8*), 14.1 (C-16), 14.0 (C-16*); m/z (ESI) 414 [MNa]+; [HRMS (ESI): 
calcd for C20H25NNaO7, 414.1523. Found: [MNa]+, 414.1524 (−0.1 ppm error)].    
 
 
(S)-1-(tert-Butoxycarbonyl)-5-(ethoxycarbonyl)-2-oxopyrrolidine-3-carboxylic acid 
(319) 
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A solution of (S)-4-benzyl 1-tert-butyl 2-ethyl 5-oxopyrrolidine-1,2,4-tricarboxylate 
(318, 2.37 g, 6.07 mmol) in EtOAc (60 mL) was hydrogenolysed in the presence of 
10% Pd/C (290 mg) for 2 h according to general procedure E to afford the crude title 
compound (1.73 g, 7:3 mixture of diastereoisomers) as a colourless oil, 
Rf (1:1 EtOAc:PE) = 0.10; δH (400 MHz, CDCl3, minor diastereoisomer starred) 8.01 (1H, 
br s, OH), 4.66 (1H, dd, J = 9.5, 2.0, H-5), 4.60 (1H*, dd, J = 9.0, 5.0, H-5*), 4.25 (2H, q, 
J = 7.0, H-7), 3.69 (1H, dd, J = 11.0, 9.0, H-2), 3.60 (1H*, dd, J = 10.0, 6.0, H-2*), 2.67 (1H, 
ddd, J = 13.5, 11.0, 9.5, H-4a), 2.61 (1H*, ddd, J = 13.5, 10.0, 9.0, H-4a*), 2.50 (1H*, ddd, 
J = 13.5, 6.0, 5.0, H-4b*), 2.36 (1H, ddd, J = 13.5, 9.0, 2.0, H-4b), 1.50 (9H, s, H-11), 1.49 
(9H*, s, H-11*), 1.30 (3H, t, J = 7.0, H-8), 1.28 (3H, t, J = 7.0, H-8*). 
 
 
(S)-1-tert-Butyl 2-ethyl 4-((3-methoxyphenyl)(methyl)carbamoyl)-5-oxopyrrolidine-
1,2-dicarboxylate (320) 
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(S)-1-(tert-Butoxycarbonyl)-5-(ethoxycarbonyl)-2-oxopyrrolidine-3-carboxylic acid (319, 
453 mg), 3-methoxy-N-methylaniline (225 mg, 1.64 mmol), 2-chloro-1-
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methylpyridinium iodide (575 mg, 2.26 mmol) and triethylamine (1.05 mL, 7.52 mmol) 
in CH2Cl2 (10 mL) were reacted according to general procedure E. Flash column 
chromatography [20‒50% EtOAc/PE] afforded 320 (587 mg, 88% over 2 steps, 
4:1 mixture of diastereoisomers) as a pale yellow sticky oil, Rf (1:1 EtOAc:PE) = 0.40; 
max/cm-1 (thin film) 3071, 2980, 2938, 2839, 1791, 1747, 1722, 1659, 1601, 1498, 1456; 
δH (400 MHz, CDCl3, minor diastereoisomer starred) 7.30 (1H and 1H*, t, J = 8.0, H-4, 
H-4*), 6.95 (2H, v br s, H-5, H-7), 6.89 (1H and 1H*, dd, J = 8.0, 2.5, H-3, H-3*),  4.67 (1H, 
dd, J = 10.0, 2.5, H-12), 4.45 (1H*, dd, J = 9.0, 6.5, H-12*),  4.30‒4.22 (2H*, m, H-14*), 4.15 
(1H, dq, J = 11.0, 7.0, H-14a), 4.10 (1H, dq, J = 11.0, 7.0, H-14b), 3.82 (3H and 3H*, s, H-1, 
H-1*), 3.70 (1H, t, J = 9.0, H-10), 3.62 (1H*, dd, J = 9.0, 7.5, H-10*), 3.31 (3H, s, H-8),  3.29 
(3H*, s, H-8*), 2.84 (1H, dt, J = 13.5, 10.0, H-11a), 2.53 (1H*, ddd, J = 13.0, 7.5, 7.0, 
H-11a*),  2.33 (1H*, dt, J = 13.0, 9.0, H-11b*), 1.97 (1H, ddd, J = 13.5, 9.0, 2.5, H-11b), 1.47 
(9H and 9H*, s, H-19, H-19*), 1.30 (3H*, t, J = 7.0, H-15*), 1.18 (3H, t, J = 7.0, H-15); 
δC (100 MHz, CDCl3, minor diastereoisomer starred) 171.1 (C-13), 170.1 (C-13*), 169.7 
(C-16), 169.2 (C-16*), 167.8 (C-9), 167.2 (C-9*), 160.5 (C-2, C-2*), 149.0 (C-17*), 148.8 
(C-17), 144.1 (C-6*), 143.9 (C-6), 130.5 (C-4), 130.4 (C-4*), 119.3 (br, C-5, C-5* or C-7, 
C-7*), 114.2 (br, C-3, C-3*), 113.1 (C-5* or C-7*), 112.8 (C-5 or C-7), 83.7 (C-18), 83.6 
(C-18*), 61.6 (C-14*), 61.5 (C-14), 57.6 (C-12*), 57.4 (C-12), 55.4 (C-1, C-1*), 46.1 (C-10*), 
45.7 (C-10), 37.8 (C-8, C-8*), 27.7 (C-19, C-19*), 26.1 (C-11), 25.7 (C-11*), 14.0 (C-15*), 13.9 
(C-15); m/z (ESI) 443 [MNa]+; [HRMS (ESI): calcd for C21H28N2NaO7, 443.1789. Found: 
[MNa]+, 443.1797 (−1.8 ppm error)]. 
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(3S,5'S)-1'-tert-Butyl 5'-ethyl 6-methoxy-1-methyl-2,2'-dioxospiro[indoline-3,3'-
pyrrolidine]-1',5'-dicarboxylate (321p’), (3R,5'S)-1'-tert-butyl 5'-ethyl 6-methoxy-1-
methyl-2,2'-dioxospiro[indoline-3,3'-pyrrolidine]-1',5'-dicarboxylate (321p’’), (3S,5'S)-
1'-tert-butyl 5'-ethyl 4-methoxy-1-methyl-2,2'-dioxospiro[indoline-3,3'-pyrrolidine]-
1',5'-dicarboxylate (321o’) and (3R,5'S)-1'-tert-butyl 5'-ethyl 4-methoxy-1-methyl-2,2'-
dioxospiro[indoline-3,3'-pyrrolidine]-1',5'-dicarboxylate (321o’’) 
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(S)-1-tert-Butyl 2-ethyl 4-((3-methoxyphenyl)(methyl)carbamoyl)-5-oxopyrrolidine-1,2-
dicarboxylate (320, 162 mg, 0.40 mmol) and copper(II) acetate monohydrate (8 mg, 
0.04 mmol) in mesitylene (8 mL) were reacted for 45 min according to general 
procedure F Flash column chromatography [20‒33% EtOAc/PE] afforded an 
inseparable mixture of 321p’, 321p’’, 321o’, 321o’’, and lactam 317 (95 mg, corresponding 
to 32.5 mg of 321o, 20%; 21 mg of 321p, 13%; 14 mg of 321o*, 9%; 11.5 mg of 321p*, 7%) as 
a colourless oil, Rf (1:1 EtOAc:PE) = 0.40; max/cm-1 (thin film) 2980, 2938, 2843, 1792, 
1748, 1722, 1612, 1508, 1475; δH (400 MHz, CDCl3, minor diastereoisomers starred)  
7.31‒7.25 (1Ho, 1Ho*, m, Ho-4, Ho-4*), 7.17 (1Hp, d, J = 8.5, Hp-2), 7.05 (1Hp*, d, J = 8.5, 
Hp-2*), 6.61 (1Ho*, d, J = 8.5, Ho-3*), 6.61 (1Ho, d, J = 8.5, Ho‐ 3), 6.56 (1Hp*, dd, J = 8.5, 
2.0, Hp-3*), 6.55 (1Hp, dd, J = 8.5, 2.0, Hp-3), 6.51 (1Ho, 1Ho*, d, J = 8.0, Ho-5, Ho-5*), 6.43 
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(1Hp, d, J = 2.0, Hp-5), 6.42 (1Hp*, d, J = 2.0, Hp-5*), 4.99 (1Ho*, dd, J = 9.0, 8.0, Ho-11*), 
4.93 (1Ho, dd, J = 9.5, 6.0, Ho-11), 4.92 (1Hp, dd, J = 9.5, 5.0, Hp-11), 4.88 (1Hp*, dd, 
J = 9.5, 4.5, Hp-11*), 4.37‒4.25 (2Hp, 2Hp*, 2Ho and 2Ho*, m, Hp-17, Hp-17*, Ho-17, 
Ho-17*), 3.82 (3Ho, s, Ho-19), 3.81 (3Hp*, s, Hp-19*), 3.81 (3Hp, s, Hp-19), 3.79 (3Ho*, s, 
Ho-19*), 3.19 (3Hp, s, Hp-7), 3.17 (3Ho, s, Ho-7), 3.17 (3Ho*, s, Ho-7*), 3.16 (3Hp*, s, Hp-7*), 
2.98 (1Hp, dd, J = 14.0, 9.5, Hp-10a), 2.84 (1Ho, dd, J = 13.5, 9.5, Ho-10a), 2.77 (1Hp*, dd, 
J = 13.5, 4.5, Hp-10a*), 2.70 (1Ho*, dd, J = 13.0, 8.0, Ho-10a*), 2.68‒2.61 (1Ho*, 1Hp*, m, 
Ho-10b*, Hp-10b*), 2.84 (1Ho, dd, J = 13.5, 6.0, Ho-10b), 2.23 (1Hp, dd, J = 14.0, 5.0, 
Hp-10b), 1.52 (9Ho, s, Ho-15), 1.52 (9Hp*, s, Hp-15*), 1.51 (9Ho*, s, Ho-15*), 1.50 (9Hp, s, 
Hp-15), 1.35‒1.23 (3Hp, 3Hp*, 3Ho and 3Ho*, m, Hp-18, Hp-18*, Ho-18, Ho-18*); 
δC (100 MHz, CDCl3, minor diastereoisomers starred) 174.7, 174.4 (Cp-8, Co-8*), 173.8 
(Cp-8*), 173.6 (Co-8), 171.5 (Cp-16), 170.5 (Co-16*), 170.4 (Co-16), 169.9 (Cp-16*), 168.8 
(Cp-12), 168.6 (Cp-12*), 168.3 (Co-12), 168.2 (Co-12*), 161.2 (Cp-4*), 161.1 (Cp-4), 155.4 
(Co-2*), 155.0 (Co-2), 149.4 (Co-13), 149.3, 149.0 (Co-13*, Cp-13*), 148.9 (Cp-13), 145.7, 
145.6, 145.6 and 145.5 (Co-6, Cp-6, Co-6*, Cp-6*), 131.0 (Co-4*), 130.8 (Co-4), 124.5 (Cp-2), 
123.4 (Cp-2*), 120.3 (Cp-1*), 120.2 (Cp-1), 114.4 (Co-1), 113.0 (Co-1*), 107.1 (Cp-3), 106.9 
(Cp-3*), 106.2 (Co-3*), 106.0 (Co-3), 102.0 (Co-5), 101.8 (Co-5*), 96.7 (Cp-5*), 96.6 (Cp-5), 
84.2, 84.1 and 83.8 (Cp-14, Co-14*, Cp-14*), 83.8 (Co-14), 61.9, 61.8, 61.4 and 61.3 (Co-17, 
Cp-17, Co-17*, Cp-17*), 58.2, 58.0, 57.7, 57.6 (Co-9, Cp-9, Co-9*, Cp-9*), 57.4 (Co-11), 56.8, 
56.7 (Co-11*, Cp-11*), 56.5 (Cp-11), 55.5, 55.5 and 55.4 (Co-19, Cp-19, Co-19*,  Cp-19*), 31.5 
(Cp-10*), 31.3 (Cp-10), 29.4 (Co-10), 28.3 (Co-10*), 27.8, 27.7 and 27.7 (Co-15, Cp-15, Co-15*, 
Cp-15*), 26.8 (Co-7), 26.7 (Co-7*), 26.7 (Cp-7), 26.6 (Cp-7*), 14.1 and 14.0 (Co-18, Cp-18, 
Co-18*, Cp-18*); m/z (ESI) 441 [MNa]+; [HRMS (ESI): calcd for C21H26N2NaO7, 441.1632. 
Found: [MNa]+, 441.1632 (0.0 ppm error)]. 
 
 
(S)-1-tert-Butyl 2-ethyl 4-(methyl(phenyl)carbamoyl)-5-oxopyrrolidine-1,2-
dicarboxylate (324) 
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(S)-1-(tert-Butoxycarbonyl)-5-(ethoxycarbonyl)-2-oxopyrrolidine-3-carboxylic acid (319, 
467 mg), N-methylaniline (0.18 mL, 1.71 mmol), 2-chloro-1-methylpyridinium iodide 
(593 mg, 2.33 mmol) and triethylamine (1.08 mL, 7.75 mmol) in CH2Cl2 (10 mL) were 
reacted according to general procedure E. Flash column chromatography [20‒30% 
EtOAc/PE] afforded 324 (524 mg, 82% over 2 steps, 4:1 mixture of diastereoisomers) as 
a colourless oil, Rf (1:1 EtOAc:PE) = 0.40; max/cm-1 (thin film) 3063, 2981, 2937, 1792, 
1748, 1722, 1659, 1595, 1496, 1456; δH (400 MHz, CDCl3, minor diastereoisomer starred) 
7.44‒7.32 (5H and 5H*, m, H-1, H-1*, H-2, H-2*, H-3, H-3*), 4.65 (1H, dd, J = 10.0, 2.5, 
H-9), 4.43 (1H*, dd, J = 9.0, 7.0, H-9*), 4.30‒4.21 (2H*, m, H-11*), 4.13 (1H, dq, J = 11.0, 
7.0, H-11a), 4.08 (1H, dq, J = 11.0, 7.0, H-11b), 3.66 (1H, dd, J = 10.0, 9.0, H-7a), 3.58 
(1H*, dd, J = 9.5, 8.0, H-7*), 3.32 (3H, s, H-5), 3.30 (3H*, s, H-5*), 2.86 (1H, dt, J = 13.5, 
10.0, H-8a), 2.55 (1H*, dd, J = 13.0, 8.0, 7.0, H-8a*), 2.32 (1H*, dt, J = 13.0, 9.0, H-8b*), 
1.97 (1H, ddd, J = 13.5, 9.0, 2.5, H-8b), 1.47 (9H, 9H*, s, H-16, H-16*), 1.30 (3H*, t, J = 7.0, 
H-12*), 1.16 (3H, t, J = 7.0, H-12); δC (100 MHz, CDCl3, minor diastereoisomer starred) 
171.1 (C-10), 170.2 (C-10*), 169.7 (C-13), 169.2 (C-13*), 167.9 (C-6), 167.3 (C-6*), 149.1 
(C-14*), 148.9 (C-14) 143.1 (C-4*), 143.0 (C-4), 129.9 (C-2), 129.8 (C-2*), 128.3 (C-1), 128.2 
(C-1*), 127.4 (C-3, C-3*), 83.8 (C-15), 83.8 (C-15*), 61.6 (C-11*), 61.6 (C-11), 57.6 (C-9*), 
57.4 (C-9), 46.1 (C-7*), 45.7 (C-7), 38.0 (C-5, C-5*), 27.8 (C-16, C-16*), 26.1 (C-8), 25.7 
(C-8*), 14.1 (C-12*), 14.0 (C-12); m/z (ESI) 413 [MNa]+; [HRMS (ESI): calcd for 
C20H26N2NaO6, 413.1683. Found: [MNa]+, 413.1686 (−0.7 ppm error)]. 
 
 
(3R,5'S)-1'-tert-Butyl 5'-ethyl 1-methyl-2,2'-dioxospiro[indoline-3,3'-pyrrolidine]-1',5'-
dicarboxylate (325’) and (3S,5'S)-1'-tert-butyl 5'-ethyl 1-methyl-2,2'-
dioxospiro[indoline-3,3'-pyrrolidine]-1',5'-dicarboxylate (325’’)  
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(S)-1-tert-Butyl 2-ethyl 4-(methyl(phenyl)carbamoyl)-5-oxopyrrolidine-1,2-
dicarboxylate (324, 156 mg, 0.40 mmol) and copper(II) acetate monohydrate (8 mg, 
0.04 mmol) in mesitylene (8 mL) were reacted for 45 min according to general 
procedure F. Flash column chromatography [20‒33% EtOAc/PE] afforded an 
inseparable mixture of 325’, 325’’ and lactam 317 (90 mg, corresponding to 67.5 mg of 
325’ and 325’’, 44%, 5:3 dr; minor diastereoisomer was tentatively assigned as 325’’ due 
to a small NOE enhancement between H-2* and H-11*) as a pale yellow oil, 
Rf (1:1 EtOAc:PE) = 0.40; max/cm-1 (thin film) 3057, 2981, 2937, 1793, 1750, 1720, 1612, 
1494, 1473; δH (400 MHz, CDCl3, minor diastereoisomer starred) 7.34 (1H*, td, J = 7.5, 
1.0, H-4*),  7.33 (1H, dd, J = 7.5, 1.0, H-4), 7.29 (1H, dd, J = 7.5, 1.0, H-2), 7.17 (1H*, dd, 
J = 7.5, 1.0, H-2*), 7.08 (1H*, dd, J = 7.5, 1.0, H-3*), 7.08 (1H, dd, J = 7.5, 1.0, H-3), 6.86 
(1H, br d, J = 7.5, H-5*), 6.86 (1H, br d, J = 7.5, H-5*), 4.95 (1H, dd, J = 10.0, 5.0, H-11), 
4.91 (1H*, dd, J = 9.5, 4.5, H-11*), 4.38‒4.27 (2H, 2H*, m, H-17, H-17*), 3.22 (3H, s, H-7), 
3.19 (3H*, s, H-7*), 3.01 (1H, dd, J = 14.0, 10.0, H-10a), 2.80 (1H*, dd, J = 13.5, 4.5, 
H-10a*), 2.69 (1H*, dd, J = 13.5, 9.5, H-10b*), 2.28 (1H, dd, J = 14.0, 5.0, H-10b), 1.52 
(9H*, s, H-15*), 1.50 (9H, s, H-15), 1.34 (3H, t, J= 7.0, H-18), 1.33 (3H*, t, J= 7.0, H-18*); 
δC (100 MHz, CDCl3, minor diastereoisomer starred) 174.2 (C-8), 173.2 (C-8*), 171.5 
(C-16), 169.9 (C-16*), 168.5 (C-12), 168.3 (C-12*), 149.3 (C-13*), 148.9 (C-13), 144.4 (C-6*), 
144.2 (C-6), 129.7 (C-4*), 129.6 (C-4), 128.4 (C-1*), 128.3 (C-1), 123.8 (C-2), 123.4 (C-3), 
123.1 (C-3*), 122.7 (C-2*), 108.7 (C-5*), 108.6 (C-5), 84.3 (C-14), 84.2 (C-14*), 62.0 (C-17*), 
61.9 (C-17), 58.7 (C-9*), 58.5 (C-9), 56.8 (C-11*), 56.6 (C-11), 31.4 (C-10*), 31.2 (C-10), 27.7 
(C-15*), 27.7 (C-15), 26.7 (C-7), 26.6 (C-7*), 14.1, 14.0 (C-18, C-18*); m/z (ESI) 411 [MNa]+; 
[HRMS (ESI): calcd for C20H24N2NaO6, 411.1527. Found: [MNa]+, 411.1517 (2.2 ppm 
error)]. 
 
 
(S)-Methyl 5-oxopyrrolidine-2-carboxylate (326) 
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The title compound was prepared based on the procedures by Kamimura247 and 
Williams.248 To a solution of (S)-pyroglutamic acid (315, 5.00 g, 38.8 mmol) in MeOH 
(70 mL) at 0 °C was added thionyl chloride (2.83 mL, 38.8 mmol) dropwise. The 
reaction was stirred at 0 °C for 10 min then allowed to warm to room temperature and 
stirred at this temperature for 1 h. After dilution with H2O (20 mL), NaHCO3 (12 g) was 
added slowly and the resulting suspension filtered. The filtrate was concentrated 
in vacuo to approx. half the original volume then extracted with CH2Cl2 (3 x 50 mL). 
The combined organic extracts were washed with brine (20 mL), dried (Na2SO4) and 
concentrated in vacuo to afford 326 (3.85 g, 70%) as a colourless oil, Rf (EtOAc) = 0.20; 
[]D20 −2.9 (c 0.83, CH2Cl2) [lit292 []D −2.3 (c 1.0, CH2Cl2)]; δH (400 MHz, CDCl3) 6.59 
(1H, br s, NH), 4.25 (1H, dd, J = 9.0, 5.5, H-4), 3.76 (3H, s, H-6), 2.52‒2.17 (4H, m, H-2, 
H-3); δC (100 MHz, CDCl3) 177.9 (C-1), 172.4 (C-5), 55.3 (C-4), 52.5 (C-6), 29.2 (C-2), 24.7 
(C-3). Data consistent with the literature values.292,293 
 
 
(S)-5-(Hydroxymethyl)pyrrolidin-2-one (327)250 
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The title compound was prepared according to the procedure by Otsuka.250 To a 
solution of (S)-methyl 5-oxopyrrolidine-2-carboxylate (326, 3.84 g, 26.8 mmol) in EtOH 
(40 mL) at 0 °C was slowly added sodium borohydride (1.01 g, 27.3 mmol).  The 
reaction stirred at room temperature for 2 h before acidification with conc. aq. HCl 
(3 mL) and concentrated in vacuo. The residue was suspended in CHCl3 (20 mL), 
filtered through celite and the filtrate concentrated in vacuo. Flash column 
chromatography [5‒10% MeOH/CHCl3] afforded 327 (1.44 g, 46%) as colourless 
prisms, mp 65‒67 °C (lit294 68‒69 °C); Rf (1:9 MeOH:CHCl3) = 0.20; []D20 +39.1 (c 0.31, 
MeOH) [lit250 []D +34.5 (c 1.04, EtOH); lit295 []D +25 (c 0.35, MeOH)]; δH (400 MHz, 
CDCl3) 7.46 (1H, br s, NH), 4.55 (1H, t, J = 6.0, OH), 3.81‒3.74 (1H, m, H-4), 3.64 (1H, 
ddd, J = 11.5, 5.5, 3.0, H-5a), 3.43 (1H, dt, J = 11.5, 6.5, H-5b), 2.40‒2.26 (2H, m, H-2), 
2.14 (1H, dddd, J = 13.0, 9.0, 8.0, 7.0, H-3a), 1.77 (1H, dddd, J = 13.0, 9.5, 7.5, 5.5, H-3b); 
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δC (100 MHz, CDCl3) 179.4 (C-1), 65.7 (C-5), 56.5 (C-4), 30.3 (C-2), 22.5 (C-3). Data 
consistent with the literature values.250,294 
 
 
(S)-5-((tert-Butyldiphenylsilyloxy)methyl)pyrrolidin-2-one (328)251 
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The title compound was prepared according to the procedure by Zanardi.251 To a 
solution of (S)-5-(hydroxymethyl)pyrrolidin-2-one (327, 1.38 g, 12.0 mmol) in DMF 
(30 mL) was added imidazole (982 mg, 14.4 mmol) followed by 
tert-butyldiphenylsilylchloride (3.73 mL, 14.4 mmol). The reaction was stirred at room 
temperature for 16 h then quenched with aq. NH4Cl (80 mL) and extracted with EtOAc 
(2 x 40 mL). The combined organic extracts were washed with H2O (2 x 40 mL), dried 
(Na2SO4) and concentrated in vacuo. Flash column chromatography [EtOAc] afforded 
328 (3.81 g, 91%) as a colourless oil, Rf (EtOAc) = 0.50; []D20 +14.5 (c 0.565, CHCl3) [lit251 
[]D +15.4 (c 0.9, CHCl3)]; δH (400 MHz, CDCl3) 7.65‒7.62 (4H, m, H-9), 7.47‒7.37 (6H, 
m, H-10, H-11), 5.85 (1H, br s, NH), 3.84‒3.77 (1H, m, H-4), 3.62 (1H, dd, J = 10.5, 4.0, 
H-5a), 3.51 (1H, dd, J = 10.5, 7.5, H-5b), 2.35‒2.30 (2H, m, H-2), 2.18‒2.09 (1H, m, H-3a), 
1.76‒1.67 (1H, m, H-3b), 1.05 (9H, s, H-7); δC (100 MHz, CDCl3) 177.8 (C-1), 135.5 (C-9), 
132.9 (C-8), 129.9 (C-11), 127.8 (C-10), 67.5 (C-5), 55.6 (C-4), 29.7 (C-2), 26.8 (C-7), 22.7 
(C-3), 19.1 (C-6). Data consistent with the literature values.251 
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(S)-tert-Butyl 2-((tert-butyldiphenylsilyloxy)methyl)-5-oxopyrrolidine-1-carboxylate 
(329)251 
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The title compound was prepared according to the procedure by Zanardi.251 To a 
solution of (S)-5-((tert-butyldiphenylsilyloxy)methyl)pyrrolidin-2-one (328, 3.78 g, 
10.7 mmol) in MeCN (40 mL) was added di-tert-butyl dicarbonate (2.55 g, 11.8 mmol) 
and N,N-dimethylaminopyridine (130 mg, 1.07 mmol). The reaction was stirred at 
room temperature for 20 h, then concentrated in vacuo. Flash column chromatography 
[1:3 EtOAc:PE] afforded 329 (4.87, quant.) as a colourless oil which crystallised on 
standing, mp 107‒108 °C (lit296 106‒108 °C); Rf (1:1 EtOAc:PE) = 0.60; []D20 −38.7 
(c 0.995, CHCl3) [lit297 []D −38.4 (c 1.30, CHCl3)]; δH (400 MHz, CDCl3) 7.65‒7.59 (4H, 
m, H-9), 7.46‒7.35 (6H, m, H-10, H-11), 4.23‒4.18 (1H, m, H-4), 3.89 (1H, dd, J = 10.5, 
4.0, H-5a), 3.70 (1H, dd, J = 10.5, 2.5, H-5b), 2.79 (1H, dt, J = 17.5, 10.5, H-2a), 2.43 (1H, 
ddd, J = 17.5, 9.0, 3.0, H-2b), 2.20‒2.09 (2H, m, H-3), 1.43 (9H, s, H-14), 1.04 (9H, s, H-7); 
δC (100 MHz, CDCl3) 175.0 (C-1), 149.8 (C-12), 135.5 (C-9), 135.5 (C-9), 133.0 (C-8), 132.6 
(C-8), 129.8 (C-11), 129.8 (C-11), 127.8 (C-10), 127.8 (C-10), 82.7 (C-13), 64.9 (C-5), 58.8 
(C-4), 32.3 (C-2), 28.0 (C-14), 26.8 (C-7), 21.1 (C-3), 19.1 (C-6). Data consistent with the 
literature values.251,296 
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(5S)-3-Benzyl 1-tert-butyl 5-((tert-butyldiphenylsilyloxy)methyl)-2-oxopyrrolidine-
1,3-dicarboxylate (330) 
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(S)-tert-Butyl 2-((tert-butyldiphenylsilyloxy)methyl)-5-oxopyrrolidine-1-carboxylate 
(329, 4.65 g, 10.25 mmol), LiHMDS (1 M in THF, 21.5 mL, 21.5 mmol) and 
benzylchloroformate (1.46 mL, 10.25 mmol) in THF (20 mL) were reacted according to 
general procedure D. Flash column chromatography [1:9 EtOAc:PE] afforded 330 
(5.85 g, 91%, 10:1 mixture of diastereoisomers; major diastereoisomer was tentatively 
assigned as 330 due to a lack of NOE enhancement between H-2 and H-4) as a 
colourless oil, Rf (1:4 EtOAc:PE) = 0.40; []D20 −23.7 (c 1.10, CHCl3); max/cm-1 (thin film) 
3071, 3050, 3034, 2959, 2932, 2889, 2859, 1788, 1757, 1733, 1456; δH (400 MHz, CDCl3, 
major diastereoisomer quoted) 7.62‒7.56 (4H, m, H-9), 7.45‒7.30 (11H, m, H-10, H-11, 
H-18, H-19, H-20), 5.23 (2H, s, H-16), 4.27‒4.22 (1H, m, H-4), 3.94 (1H, dd, J = 11.0, 9.0, 
H-2), 3.91 (1H, dd, J = 10.5, 4.0, H-5a), 3.68 (1H, dd, J = 10.5, 2.5, H-5b), 2.59 (1H, ddd, 
J = 13.0, 11.0, 9.0, H-3a), 2.29 (1H, ddd, J = 13.0, 9.0, 1.0, H-3b), 1.44 (9H, s, H-14), 1.04 
(9H, s, H-7); δC (100 MHz, CDCl3, major diastereoisomer quoted) 169.1 (C-15), 169.0 
(C-1), 149.4 (C-12), 135.6 (C-17), 135.4 (C-9), 135.4 (C-9), 132.7 (C-8), 132.4 (C-8), 129.9 
(C-11), 129.9 (C-11), 128.5 (C-18), 128.2 (C-20), 128.0 (C-19), 127.8 (C-10), 127.8 (C-10), 
83.3 (C-13), 67.3 (C-16), 64.8 (C-5), 57.0 (C-4), 49.7 (C-2), 27.9 (C-14), 26.8 (C-7), 25.4 
(C-3), 19.1 (C-6); m/z (ESI) 610 [MNa]+; [HRMS (ESI): calcd for C34H41NNaO6Si, 
610.2595. Found: [MNa]+, 610.2596 (−0.2 ppm error)]. Enantiomer is reported in the 
literature.298 
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(5S)-1-(tert-Butoxycarbonyl)-5-((tert-butyldiphenylsilyloxy)methyl)-2-
oxopyrrolidine-3-carboxylic acid (331) 
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A solution of (5S)-3-benzyl 1-tert-butyl 5-((tert-butyldiphenylsilyloxy)methyl)-2-
oxopyrrolidine-1,3-dicarboxylate (330, 2.01 g, 3.43 mmol) in EtOAc (35 mL) was 
hydrogenolysed in the presence of 5% Pd/C (290 mg) for 18 h according to general 
procedure E to afford the crude title compound (1.76 g, 7:1 mixture of 
diastereoisomers) as a colourless oil. δH (400 MHz, CDCl3, major diastereoisomer 
quoted) 7.62‒7.56 (4H, m, H-9), 7.48‒7.36 (6H, m, H-10, H-11), 4.27‒4.23 (1H, m, H-4), 
3.98 (1H, dd, J = 11.0, 3.0, H-5a), 3.94 (1H, dd, J = 11.5, 9.5, H-2), 3.71 (1H, dd, J = 11.0, 
2.0, H-5b), 2.56‒2.40 (2H, m, H-3), 1.46 (9H, s, H-14), 1.04 (9H, s, H-7). Enantiomer is 
reported in the literature.298 
 
 
(5S)-tert-Butyl 5-((tert-butyldiphenylsilyloxy)methyl)-3-(methyl(phenyl)carbamoyl)-
2-oxopyrrolidine-1-carboxylate (332) 
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((5S)-1-(tert-Butoxycarbonyl)-5-((tert-butyldiphenylsilyloxy)methyl)-2-oxopyrrolidine-
3-carboxylic acid (331, 872 mg), N-methylaniline (0.21 mL, 1.93 mmol), 2-chloro-1-
methylpyridinium iodide (670 mg, 2.63 mmol) and triethylamine (1.22 mL, 8.76 mmol) 
in CH2Cl2 (15 mL) were reacted according to general procedure E. Flash column 
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chromatography [10‒20% EtOAc/PE] afforded 332 (903 mg, 88% over 2 steps, >20:1 dr; 
major diastereoisomer tentatively assigned as 332 due to a lack of NOE enhancement 
between H-2 and H-4) as a colourless sticky foam, Rf (1:4 EtOAc:PE) = 0.10; max/cm-1 
(thin film) 3070, 3052, 2959, 2932, 2858, 1785, 1746, 1716, 1655, 1595, 1567, 1496, 1472, 
1459; []D20 +48.6 (c 1.03, CHCl3); δH (400 MHz, CDCl3) 7.49‒7.22 (15H, m, H-9, H-10, 
H-11, H-18, H-19, H-20), 4.25‒4.20 (1H, m, H-4), 3.92 (1H, dd, J = 9.5, 10.0, H-2), 3.80 
(1H, dd, J = 10.5, 3.0, H-5a), 3.48 (1H, dd, J = 10.5, 2.0, H-5b), 3.33 (3H, s, H-16), 2.80 
(1H, dt, J = 12.5, 10.0, H-3a), 2.07‒2.00 (1H, ddd, J = 12.5, 9.5, 1.0, H-3b), 1.42 (9H, s, 
H-14), 0.71 (9H, s, H-7); δC (100 MHz, CDCl3) 170.9 (C-1), 169.3 (C-15), 149.4 (C-12), 
143.3 (C-17), 135.3 (C-9), 132.7 (C-8), 132.2 (C-8), 129.9 (one of C-11, C-18, C-19), 129.7 
(one of C-11, C-18, C-19), 128.1 (C-20), 127.7 (C-10), 127.7 (C-10), 127.5 (one of C-11, 
C-18, C-19), 82.9 (C-13), 64.9 (C-5), 57.2 (C-4), 47.3 (C-2), 38.3 (C-16), 27.9 (C-14), 26.6 
(C-7), 26.1 (C-3), 18.7 (C-6); m/z (ESI) 609 [MNa]+; [HRMS (ESI): calcd for 
C34H42N2NaO5Si, 609.2755. Found: [MNa]+, 609.2756 (−0.1 ppm error)]. 
 
 
(3R,5'S)-tert-Butyl 5'-((tert-butyldiphenylsilyloxy)methyl)-1-methyl-2,2'-
dioxospiro[indoline-3,3'-pyrrolidine]-1'-carboxylate (333’) and (3S,5'S)-tert-butyl 5'-
((tert-butyldiphenylsilyloxy)methyl)-1-methyl-2,2'-dioxospiro[indoline-3,3'-
pyrrolidine]-1'-carboxylate (333’’)  
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(5S)-tert-Butyl 5-((tert-butyldiphenylsilyloxy)methyl)-3-(methyl(phenyl)carbamoyl)-2-
oxopyrrolidine-1-carboxylate (332, 235 mg, 0.40 mmol) and copper(II) acetate 
monohydrate (8 mg, 0.04 mmol) in mesitylene (8 mL) were reacted for 30 min 
according to general procedure F. Flash column chromatography [1:4 EtOAc/PE] 
afforded 333’ (56 mg, 24%) as a yellow oil, as well as an inseparable mixture of 
Chapter 7 
 
 
244 
 
spirocycle 333’’ and lactam 329 (81 mg, corresponding to 58 mg of 333’’, 25%) as an off-
white sticky foam. 333’: Rf (1:4 EtOAc:PE) = 0.15; max/cm-1 (thin film) 3071, 3053, 2959, 
2933, 2889, 2858, 1786, 1749, 1718, 1614, 1494, 1471; []D20 −10.6 (c 0.78, CHCl3); 
δH (400 MHz, CDCl3) 7.66‒7.63 (4H, m, H-18), 7.47‒7.36 (6H, m, H-19, H-20), 7.31 (1H, 
td, J = 7.5, 1.0, H-4), 7.06 (1H, dd, J = 7.5, 1.0, H-2), 6.98 (1H, td, J = 7.5, 1.0, H-3), 6.85 
(1H, br d, J = 7.5, H-5), 4.59 (1H, dddd, J = 8.0, 7.0, 5.5, 2.5, H-11), 4.14 (1H, dd, J = 10.5, 
5.5, H-16a), 3.93 (1H, dd, J = 10.5, 2.5, H-16b), 3.20 (3H, s, H-7), 2.64 (1H, dd, J = 13.5, 
8.0, H-10a), 2.58 (1H, dd, J = 13.5, 7.0, H-10b), 1.44 (9H, s, H-15), 1.09 (9H, s, H-22); 
δC (100 MHz, CDCl3) 175.0 (C-8), 169.8 (C-12), 149.7 (C-13), 144.6 (C-6), 135.6 (C-18), 
135.5 (C-18), 133.0 (C-17), 132.9 (C-17), 129.9 (C-20), 129.9 (C-20), 129.2 (C-4), 128.8 
(C-1), 127.8 (C-19), 127.8 (C-19), 123.7 (C-2), 123.2 (C-3), 108.5 (C-5), 83.6 (C-14), 63.7 
(C-16), 58.9 (C-9), 56.2 (C-11), 30.2 (C-10), 27.9 (C-15), 26.9 (C-22), 26.6 (C-7), 19.4 (C-21); 
Stereochemistry assigned based on a lack of NOE enhancement between H-2 and H-11; 
m/z (ESI) 607 [MNa]+; [HRMS (ESI): calcd for C34H40N2NaO5Si, 607.2599. Found: 
[MNa]+, 607.2610 (−1.9 ppm error)]; 333’’: Rf (1:4 EtOAc:PE) = 0.20; max/cm-1 (thin film) 
3071, 3051, 2959, 2932, 2892, 2857, 1785, 1751, 1719, 1612, 1494, 1472; δH (400 MHz, 
CDCl3) 7.71‒7.68 (4H, m, H-18), 7.46‒7.35 (6H, m, H-19, H-20), 7.32 (1H, td, J = 7.5, 1.0, 
H-4), 7.18 (1H, ddd, J = 7.5, 1.0, 0.5, H-2), 7.07 (1H, td, J = 7.5, 1.0, H-3), 6.85 (1H, br d, 
J = 7.5, H-5), 4.44 (1H, tdd, J = 8.5, 5.0, 3.5, H-11), 4.27 (1H, dd, J = 9.5, 8.5, H-16a), 4.09 
(1H, dd, J = 9.5, 3.5, H-16b), 3.24 (3H, s, H-7), 2.94 (1H, dd, J = 14.0, 5.0, H-10a), 2.46 
(1H, dd, J = 14.0, 8.5, H-10b), 1.40 (9H, s, H-15), 1.08 (9H, s, H-22); δC (100 MHz, CDCl3) 
174.0 (C-8), 169.8 (C-12), 149.6 (C-13), 144.3 (C-6), 135.6 (C-18), 135.6 (C-18), 133.4 
(C-17), 133.2 (C-17), 130.1 (C-1), 129.7 (C-20), 129.3 (C-4), 127.7 (C-19), 123.0 (C-2), 122.6 
(C-3), 108.5 (C-5), 83.7 (C-14), 64.1 (C-16), 58.8 (C-9), 56.5 (C-11), 30.5 (C-10), 27.8 (C-15), 
26.8 (C-22), 26.7 (C-7), 19.3 (C-21); Stereochemistry assigned based on an NOE 
enhancement between H-2 and H-11; m/z (ESI) 607 [MNa]+; [HRMS (ESI): calcd for 
C34H40N2NaO5Si, 607.2599. Found: [MNa]+, 607.2593 (0.9 ppm error)]. 
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N-Benzyl-3-(tert-butyldiphenylsilyloxy)aniline (335a) 
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The title compound was prepared based on the procedure by Hennessy.252 To 
3-aminophenol (334, 2.18 g, 20.0 mmol), imidazole (1.77 g, 26.0 mmol) and 
tert-butyldiphenylsilyl chloride (5.72 mL, 22.0 mmol) was added DMF (8 mL) and the 
mixture was stirred at room temperature for 4 h. The reaction was diluted with H2O 
(10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic extracts were 
washed with H2O (5 x 10 mL) and brine (5 mL), then dried (MgSO4) and concentrated 
in vacuo to afford 3-(tert-butyldimethylsilyloxy)aniline (7.82 g). The crude residue was 
re-dissolved in MeOH (20 mL), and benzaldehyde (2.14 mL, 21.0 mmol) and acetic acid 
(3 drops) were added. The mixture was stirred at room temperature for 3 h. Sodium 
borohydride (760 mg, 20.0 mmol) was added in very small portions and the mixture 
stirred at room temperature for 1 h. The solvent was removed in vacuo, and the residue 
diluted with H2O (10 mL) and extracted with EtOAc (2 x 10 mL). The combined organic 
extracts were washed with brine (5 mL), dried (MgSO4) and concentrated in vacuo. 
Flash column chromatography [1:49 EtOAc:PE] afforded 335a (2.69 g, 31%) as a yellow 
oil, Rf (1:4 EtOAc:PE) = 0.70; max/cm-1 (thin film) 3419, 3069, 3049, 3028, 2999, 2957, 
2930, 2891, 2857, 1600, 1493, 1472, 1453; δH (400 MHz, CDCl3) 7.75‒7.72 (4H, m, H-15), 
7.45‒7.23 (11H, m, H-9, H-10, H-11, H-16, H-17), 6.89 (1H, t, J = 8.0, H-3), 6.21‒6.16 (2H, 
m, H-2, H-4), 6.12 (1H, t, J = 2.0, H-6), 4.11 (2H, s, H-7), 3.66 (1H, br s, NH), 1.10 (9H, s, 
H-13); δC (100 MHz, CDCl3) 156.7 (C-5), 149.2 (C-1), 139.3 (C-8), 135.5 (C-15), 133.2 
(C-14), 129.7 (C-17), 129.6 (C-3), 128.5 (C-10), 127.6 (C-16), 127.5 (C-9), 127.1 (C-11), 
109.2 (C-4), 106.3 (C-2), 104.3 (C-6), 48.2 (C-7), 26.5 (C-13), 19.4 (C-12); m/z (ESI) 438 
[MH]+; [HRMS (ESI): calcd for C29H32NOSi, 438.2248. Found: [MH]+, 438.2263 
(−3.4 ppm error)]. 
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N-Benzyl-3-(tert-butyldimethylsilyloxy)aniline (335b)252 
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The title compound was prepared according to the procedure by Hennessy.252 To 
3-aminophenol (334, 545 mg, 5.00 mmol), imidazole (442 mg, 6.50 mmol) and 
tert-butyldimethylsilyl chloride (831 mg, 5.50 mmol) was added DMF (3 mL) and the 
mixture was stirred at room temperature for 4 h. The reaction was diluted with H2O 
(5 mL) and extracted with EtOAc (3 x 5 mL). The combined organic extracts were 
washed with H2O (5 x 5 mL) and brine (5 mL), then dried (MgSO4) and concentrated in 
vacuo to afford 3-(tert-butyldimethylsilyloxy)aniline (1.01 g). The crude residue was 
re-dissolved in MeOH (5 mL), and benzaldehyde (0.48 mL, 4.71 mmol) and acetic acid 
(3 drops) were added. The mixture was stirred at room temperature for 3 h. Sodium 
borohydride (170 mg, 4.48 mmol) was added in very small portions and the mixture 
stirred at room temperature for 1 h. The solvent was removed in vacuo, and the residue 
diluted with H2O (5 mL) and extracted with EtOAc (2 x 5 mL). The combined organic 
extracts were washed with brine (5 mL), dried (MgSO4) and concentrated in vacuo. 
Flash column chromatography [1:49 EtOAc:PE] afforded 335b (793 mg, 51%) as a pale 
yellow oil, Rf (1:4 EtOAc:PE) = 0.70; δH (400 MHz, CDCl3) 7.42‒7.28 (5H, m, H-9, H-10, 
H-11), 7.05 (1H, t, J = 8.0, H-3), 6.30 (1H, ddd, J = 8.0, 2.0, 1.0, H-2), 6.26 (1H, ddd, 
J = 8.0, 2.0, 1.0, H-4), 6.17 (1H, t, J = 2.0, H-6), 4.33 (2H, s, H-7), 4.02 (1H, br s, NH), 1.00 
(9H, s, H-13), 0.19 (6H, s, H-14); δC (100 MHz, CDCl3) 156.7 (C-5), 149.4 (C-1), 139.4 
(C-8), 129.8 (C-3), 128.6 (C-10), 127.5 (C-9), 127.2 (C-11), 109.4 (C-4), 106.5 (C-2), 104.7 
(C-6), 48.3 (C-7), 25.7 (C-13), 18.2 (C-12), −4.5 (C-14); m/z (ESI) 314 [MH]+; [HRMS (ESI): 
calcd for C19H28NNOSi, 314.1935. Found: [MH]+, 314.1931 (1.2 ppm error)]. Data 
consistent with the literature values.252 
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3-(Benzylamino)phenol (335e) 
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To a solution of N-benzyl-3-(tert-butyldimethylsilyloxy)aniline (335b, 292 mg, 
0.93 mmol) in THF (5 mL) was added tetrabutylammonium fluoride (1 M in THF, 
1.03 mL, 1.03 mmol) and the reaction stirred at room temperature for 3 h. The mixture 
was diluted with H2O (5 mL) and extracted with EtOAc (3 x 5 mL). The combined 
organic extracts were washed with brine (5 mL), dried (MgSO4) and concentrated 
in vacuo. Flash column chromatography [1:4 EtOAc:PE] afforded 335e (185 mg, quant.) 
as a brown oil, Rf (1:4 EtOAc:PE) = 0.20; max/cm-1 (thin film) 3409, 3335, 3085, 3060, 
3029, 2927, 2852, 1602, 1511, 1496, 1471, 1452; δH (400 MHz, CDCl3) 7.38-7.33 (4H, m, 
H-9, H-10), 7.31‒7.27 (1H, m, H-11), 7.03 (1H, t, J = 8.0, H-3), 6.24 (1H, ddd, J = 8.0, 2.0, 
1.0, H-2), 6.19 (1H, ddd, J = 8.0, 2.0, 1.0, H-4), 6.12 (1H, t, J = 2.0, H-6), 4.30 (2H, s, H-7); 
δC (100 MHz, CDCl3) 156.7 (C-5), 149.7 (C-1), 139.2 (C-8), 130.2 (C-3), 128.6 (C-10), 127.5 
(C-9), 127.2 (C-11), 105.9 (C-2), 104.6 (C-4), 99.7 (C-6), 48.2 (C-7); m/z (ESI) 200 [MH]+; 
[HRMS (ESI): calcd for C13H14NO, 200.1070. Found: [MH]+, 200.1069 (0.5 ppm error)]. 
Data consistent with the literature values.299 
 
 
3-(Benzylamino)phenyl acetate (335c) 
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To a suspension of sodium hydride (60% in mineral oil, 38 mg, 0.92 mmol) in THF 
(3.5 mL) at 0 °C was added a solution of 3-(benzylamino)phenol (335e, 166 mg, 
0.83 mmol) in THF (1.5 mL) via syringe and the mixture stirred at 0 °C for 10 min. 
Acetic anhydride (0.083 mL, 0.88 mmol) was added and the mixture stirred at room 
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temperature for 1 h. The reaction was quenched with H2O (5 mL) and extracted with 
EtOAc (2 x 10 mL). The combined organic extracts were washed with brine (5 mL), 
dried (MgSO4) and concentrated in vacuo. Flash column chromatography 
[1:9 EtOAc:PE] afforded 335c (148 mg, 74%) as a colourless oil, Rf (1:4 EtOAc:PE) = 0.30; 
max/cm-1 (thin film) 3414, 3084, 3061, 3029, 2924, 2849, 1761, 1741, 1614, 1588, 1509, 
1495, 1452; δH (400 MHz, CDCl3) 7.38‒7.27 (5H, m, H-9, H-10, H-11), 7.16 (1H, t, J = 8.0, 
H-3), 6.50 (1H, ddd, J = 8.0, 2.0, 0.5, H-2), 6.44 (1H, ddd, J = 8.0, 2.0, 1.0, H-4), 6.36 (1H, t, 
J = 2.0, H-6), 4.31 (2H, br s, H-7), 4.12 (1H, br s, NH), 2.27 (3H, s, H-13); δC (100 MHz, 
CDCl3) 169.5 (C-12), 151.8 (C-5), 149.3 (C-1), 138.9 (C-8), 129.9 (C-3), 128.6 (C-10), 127.5 
(C-9), 127.3 (C-11), 110.5 (C-2), 110.3 (C-4), 105.7 (C-6), 48.2 (C-7), 21.2 (C-13); m/z (ESI) 
242 [MH]+; [HRMS (ESI): calcd for C15H16NO2, 242.1176. Found: [MH]+, 242.1181 
(−2.1 ppm error)]. 
 
 
tert-Butyl 3-(benzyl(3-(tert-butyldiphenylsilyloxy)phenyl)carbamoyl)-2-
oxopiperidine-1-carboxylate (20aa) 
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1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 513 mg), N-benzyl-3-
(tert-butyldiphenylsilyloxy)aniline (812 mg, 1.86 mmol), 2-chloro-1-methylpyridinium 
iodide (646 mg, 2.79 mmol) and triethylamine (1.2 mL, 9.30 mmol) in CH2Cl2 (15 mL) 
were reacted according to general procedure E. Flash column chromatography [20‒33% 
EtOAc/PE] afforded 20aa (1.04 g, 82% over 2 steps) as an off-white sticky foam, 
Rf (1:4 EtOAC:PE) = 0.20; max/cm-1 (thin film) 3070, 3030, 2958, 2933, 2894, 2859, 1769, 
1717, 1657, 1593, 1485, 1457; δH (400 MHz, CDCl3) 7.65‒7.62 (4H, m, H-24), 7.47‒7.32 
(6H, m, H-25, H-26), 7.21‒7.16 (3H, m, H-10, H-11), 7.11‒7.07 (2H, m, H-9), 7.00 (1H, t, 
J = 8.0, H-3), 6.74 (2H, v br s, H-2, H-4), 6.42 (1H, v br s, H-6), 4.84 (1H, br d, J = 14.0, 
H-7a), 4.52 (1H, v br s, H-7b), 3.57 (2H, dd, J = 7.5, 4.5, H-16), 3.29 (1H, dd, J = 10.0, 7.0, 
H-13), 2.02‒1.84 (2H, m, H-14a, H-15a), 1.60‒1.41 (2H, m, H-14b, H-15b), 1.50 (9H, s, 
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H-20), 1.06 (9H, s, H-22); δC (100 MHz, CDCl3) 170.0 (C-12), 168.0 (C-17), 156.3 (C-1), 
152.3 (C-18), 142.5 (C-5), 136.8 (C-8), 135.4 (C-24), 132.3 (C-23), 132.3 (C-23), 130.0 (C-3), 
130.0 (C-26), 128.5 (C-9), 128.2 (C-10), 127.8 (C-25), 127.8 (C-25), 127.1 (C-11), 119.9 (C-2 
or C-4), 83.0 (C-19), 52.9 (C-7), 48.7 (C-13), 46.4 (C-16), 27.9 (C-20), 26.4 (C-22), 25.3 
(C-14), 21.5 (C-15), 19.3 (C-21), some aromatic peaks not visible due to broadening; m/z 
(ESI) 685 [MNa]+; [HRMS (ESI): calcd for C40H46N2NaO5Si, 685.3068. Found: [MNa]+, 
685.3069 (−0.2 ppm error)]. 
 
 
tert-Butyl 3-(benzyl(3-(tert-butyldimethylsilyloxy)phenyl)carbamoyl)-2-
oxopiperidine-1-carboxylate (20ab) 
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1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 298 mg), N-benzyl-3-
(tert-butyldimethylsilyloxy)aniline (423 mg, 1.23 mmol), 2-chloro-1-methylpyridinium 
iodide (470 mg, 1.84 mmol) and triethylamine (0.85 mL, 6.14 mmol) in CH2Cl2 (5 mL) 
were reacted according to general procedure E. Flash column chromatography 
[1:3 EtOAc:PE] afforded 20ab (466 mg, 74% over 2 steps) as a colourless oil, 
Rf (1:2 EtOAc:PE) = 0.30; max/cm-1 (thin film) 3064, 3030, 2955, 2931, 2896, 2859, 1771, 
1718, 1659, 1592, 1485, 1459; δH (400 MHz, CDCl3) 7.28‒7.18 (5H, m, H-9, H-10, H-11), 
7.15 (1H, t, J = 8.0, H-3), 6.80 (1H, v br s, H-4 or H-6), 6.77 (1H, ddd, J = 8.0, 2.5, 1.0, 
H-2), 6.55 (1H, v br s, H-4 or H-6), 4.95 (1H, v br s, H-7a), 4.84 (1H, v br s, H-7b), 
3.63‒3.55 (2H, m, H-16), 3.47 (1H, dd, J = 10.5, 7.0, H-13), 2.25‒2.15 (1H, m, H-14a), 1.98 
(1H, ddd, J = 14.0, 9.5, 5.0, H-15a), 1.94‒1.84 (1H, m, H-14b), 1.64‒1.53 (1H, m, H-15b), 
1.50 (9H, s, H-20), 0.91 (9H, s, H-22), 0.07 (3H, s, H-23), 0.06 (3H, s, H-24); δC (100 MHz, 
CDCl3) 170.1 (C-12), 168.0 (C-17), 156.4 (C-1), 152.3 (C-18), 142.9 (C-5), 137.0 (C-8), 130.2 
(C-3), 128.6, 128.4 (C-9, C-10), 127.3 (C-11), 120.3 (C-2), 83.0 (C-19), 53.0 (C-7), 48.8 
(C-13), 46.4 (C-16), 27.9 (C-20), 25.6 (C-22), 25.4 (C-14), 21.5 (C-15), 18.1 (C-21), −4.6 
(C-23), −4.6 (C-24), some aromatic peaks not visible due to broadening; m/z (ESI) 561 
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[MNa]+; [HRMS (ESI): calcd for C30H42N2NaO5Si, 561.2755. Found: [MNa]+, 561.2750 
(0.9 ppm error)]. 
 
 
tert-Butyl 3-((3-acetoxyphenyl)(benzyl)carbamoyl)-2-oxopiperidine-1-carboxylate 
(20ac) 
 
2
1
6
5
4
3
O N
7 14
21 12
O
13
17
O
8
11
10
9
N
16
15
18
O
O
19
20
O
22
 
 
1-(tert-Butoxycarbonyl)-2-oxopiperidine-3-carboxylic acid (264b, 111 mg), 
3-(benzylamino)phenyl acetate (121 mg, 0.50 mmol), 2-chloro-1-methylpyridinium 
iodide (174 mg, 0.68 mmol) and triethylamine (0.32 mL, 2.28 mmol) in CH2Cl2 (5 mL) 
were reacted according to general procedure E. Flash column chromatography 
[2:3 EtOAc:PE] afforded 20ac (158 mg, 77% over 2 steps) as a colourless oil, 
Rf (1:1 EtOAc:PE) = 0.30; max/cm-1 (thin film) 3063, 3030, 2978, 2936, 1767, 1719, 1656, 
1601, 1486, 1456; δH (400 MHz, CDCl3) 7.29 (1H, t, J = 8.0, H-3), 7.28‒7.18 (5H, m, H-9, 
H-10, H-11), 7.06 (1H, v br s, H-4 or H-6), 7.04 (1H, dd, J = 8.0, 2.0, H-2), 6.95 (1H, v br s, 
H-4 or H-6), 5.00 (1H, d, J = 14.5, H-7a), 4.83 (1H, d, J = 14.5, H-7b), 3.63‒3.58 (2H, m, 
H-16), 3.46 (1H, dd, J = 10.5, 6.5, H-13), 2.25 (3H, s, H-22), 2.24‒2.14 (1H, m, H-14a), 
2.01‒1.85 (2H, m, H-14b, H-15a), 1.67‒1.57 (1H, m, H-15b), 1.49 (9H, s, H-20); 
δC (100 MHz, CDCl3) 170.1 (C-12), 168.9 (C-21), 168.2 (C-17), 152.0 (C-18), 151.0 (C-1), 
142.8 (C-5), 136.7 (C-8), 130.2 (C-3), 128.5, 128.4 (C-9, C-10), 127.3 (C-11), 121.6 (C-2), 
83.0 (C-19), 53.1 (C-7), 48.8 (C-13), 46.5 (C-16), 27.9 (C-20), 25.3 (C-14), 21.5 (C-15), 21.0 
(C-22), some aromatic peaks not visible due to broadening; m/z (ESI) 489 [MNa]+; 
[HRMS (ESI): calcd for C26H30N2NaO6, 489.1996. Found: [MNa]+, 489.1993 (0.7 ppm 
error)]. 
 
 
 
 
Chapter 7 
 
 
251 
 
tert-Butyl 3-(benzyl(3-hydroxyphenyl)carbamoyl)-2-oxopiperidine-1-carboxylate 
(20ae) 
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To a solution of tert-butyl 3-(benzyl(3-(tert-butyldimethylsilyloxy)phenyl)carbamoyl)-2-
oxopiperidine-1-carboxylate (20ab, 184 mg, 0.43 mmol) in THF (5 mL) was added 
tetrabutylammonium fluoride (1 M in THF, 0.38 mL, 0.38 mmol) and the reaction 
stirred at room temperature for 1.5 h. The mixture was diluted with H2O (5 mL) and 
extracted with EtOAc (3 x 5 mL). The combined organic extracts were washed with 
brine (5 mL), dried (MgSO4) and concentrated in vacuo. Flash column chromatography 
[2:3 EtOAc:PE] afforded 20ae (126 mg, 87%) as a colourless amorphous solid, 
mp 141‒142 °C; Rf (2:3 EtOAc:PE) = 0.10; max/cm-1 (thin film) 3390, 3065, 3031, 2979, 
2939, 1763, 1718, 1652, 1605, 1592, 1486, 1457; δH (400 MHz, CDCl3) 7.54 (1H, br s, OH), 
7.24‒7.15 (5H, m, H-9, H-10, H-11), 7.10 (1H, t, J = 8.0, H-3), 6.80 (1H, v br s, H-4 or 
H-6), 6.83 (1H, ddd, J = 8.0, 2.5, 1.0, H-2), 6.61 (1H, v br s, H-4 or H-6), 4.98 (1H, d, 
J = 15.0, H-7a), 4.80 (1H, d, J = 15.0, H-7b), 3.60 (2H, dd, J = 7.5, 4.5, H-16), 3.53 (1H, dd, 
J = 10.5, 6.5, H-13), 2.23‒2.12 (1H, m, H-14a), 1.98‒1.86 (2H, m, H-14b, H-15a), 1.63‒1.52 
(1H, m, H-15b), 1.48 (9H, s, H-20); δC (100 MHz, CDCl3) 170.4 (C-12), 168.8 (C-17), 157.4 
(C-1), 152.0 (C-18), 142.7 (C-5), 136.8 (C-8), 130.3 (C-3), 128.4, 128.3 (C-9, C-10), 127.2 
(C-11), 115.8 (C-2), 83.3 (C-19), 53.1 (C-7), 49.1 (C-13), 46.7 (C-16), 27.9 (C-20), 25.4 
(C-14), 21.5 (C-15), some aromatic peaks not visible due to broadening; m/z (ESI) 447 
[MNa]+; [HRMS (ESI): calcd for C24H28N2NaO5, 447.1890. Found: [MNa]+, 447.1871 
(4.5 ppm error)]. 
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tert-Butyl 3-(benzyl(3-(pivaloyloxy)phenyl)carbamoyl)-2-oxopiperidine-1-
carboxylate (20ad) 
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To a solution of tert-butyl 3-(benzyl(3-hydroxyphenyl)carbamoyl)-2-oxopiperidine-1-
carboxylate (20ae, 103 mg, 0.24 mmol) in CH2Cl2 (5 mL) was added 
N,N-dimethylaminopyridine (3 mg, 0.024 mmol), triethylamine (0.10 mL, 0.73 mmol) 
and trimethylacetyl chloride (0.06 mL, 0.48 mmol). The reaction was stirred at room 
temperature for 3 h then quenched with 10% HCl (2 mL) and the layers separated. The 
organic layer was washed with aq. NaHCO3 (5 mL) and brine (5 mL) then dried 
(Mg2SO4) and concentrated in vacuo. Flash column chromatography [1:2 EtOAc:PE] 
afforded 20ad (111 mg, 90%) as a colourless foam, Rf (2:3 EtOAc:PE) = 0.40; max/cm-1 
(thin film) 3064, 3030, 2976, 2935, 2875, 1753, 1718, 1656, 1601, 1482, 1457; δH (400 MHz, 
CDCl3) 7.29‒7.19 (6H, m, H-3, H-9, H-10, H-11), 7.01 (1H, ddd, J = 8.0, 2.0, 1.0, H-2), 6.70 
(1H, v br s), 6.90 (1H, v br s) (H-4, H-6), 4.98 (1H, br s, H-7a), 4.86 (1H, br s, H-7b), 
3.65‒3.60 (2H, m, H-16), 3.48 (1H, dd, J = 10.0, 7.0, H-13), 2.25‒2.15 (1H, m, H-14a), 
2.01‒1.84 (2H, m, H-14b, H-15a), 1.67‒1.55 (1H, m, H-15b), 1.50 (9H, s, H-20), 1.32 (9H, 
s, H-23); δC (100 MHz, CDCl3) 176.6 (C-21), 170.1 (C-12), 168.2 (C-17), 152.1 (C-18), 151.6 
(C-1), 142.8 (C-5), 136.7 (C-8), 130.1 (C-3), 128.6, 128.4 (C-9, C-10), 127.3 (C-11), 121.5 
(C-2), 83.0 (C-19), 53.1 (C-7), 48.9 (C-13), 46.5 (C-16), 39.1 (C-22), 27.9 (C-20), 27.0 (C-23), 
25.3 (C-14), 21.5 (C-15), some aromatic peaks not visible due to broadening; m/z (ESI) 
531 [MNa]+; [HRMS (ESI): calcd for C29H36N2NaO6, 531.2466. Found: [MNa]+, 531.2463 
(0.5 ppm error)]. 
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tert-Butyl 1-benzyl-6-(tert-butyldiphenylsilyloxy)-2,2'-dioxospiro[indoline-3,3'-
piperidine]-1'-carboxylate (21aap) and tert-butyl 1-benzyl-4-(tert-
butyldiphenylsilyloxy)-2,2'-dioxospiro[indoline-3,3'-piperidine]-1'-carboxylate 
(21aao) 
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tert-Butyl 3-(benzyl(3-(tert-butyldiphenylsilyloxy)phenyl)carbamoyl)-2-oxopiperidine-
1-carboxylate (20aa, 265 mg, 0.40 mmol) and copper(II) acetate monohydrate (8 mg, 
0.04 mmol) in mesitylene (8 mL) were reacted for 30 min according to general 
procedure F. Flash column chromatography [10‒20% EtOAc/PE] afforded 21aap 
(78 mg, 30%) as a colourless powder, and 21aao (49 mg, 19%) as an off-white 
amorphous solid. 21aap: mp 169‒170 °C; Rf (1:4 EtOAc:PE) = 0.20; max/cm-1 (thin film) 
3071, 3031, 2959, 2933, 2895, 2859, 1768, 1723, 1616, 1499, 1473, 1456; δH (400 MHz, 
CDCl3) 7.63‒7.59 (4H, m, H-26), 7.45‒7.39 (2H, m, H-28), 7.36‒7.30 (4H, m, H-27), 
7.21‒7.18 (3H, m, H-21, H-22), 7.05‒7.02 (2H, m, H-20), 7.02 (1H, d, J = 8.0, H-2), 6.42 
(1H, dd, J = 8.0, 2.0, H-3), 6.11 (1H, d, J = 2.0, H-5), 4.67 (1H, d, J = 15.5, H-7a), 4.57 (1H, 
d, J = 15.5, H-7b), 3.91‒3.78 (2H, m, H-12), 2.36 (1H, ddd, J = 13.5, 10.0, 3.5, H-10a),  
2.31‒2.21 (1H, m, H-11a), 2.15‒2.05 (1H, m, H-11b), 1.95 (1H, ddd, J = 13.5, 7.0, 3.5, 
H-10b), 1.48 (9H, s, H-16), 1.02 (9H, s, H-24); δC (100 MHz, CDCl3) 176.1 (C-8), 167.8 
(C-13), 156.3 (C-4), 152.8 (C-14), 143.8 (C-6), 135.4 (C-26), 135.2 (C-19), 132.6 (C-25), 
130.0, 130.0 (C-28), 128.6 (C-21), 127.8, 127.8 (C-27), 127.4 (C-22), 127.0 (C-20), 124.0 
(C-1), 123.7 (C-2), 113.5 (C-3), 102.3 (C-5), 83.4 (C-15), 57.9 (C-9), 47.2 (C-12), 43.8 (C-7), 
32.1 (C-10), 27.9 (C-16), 26.5 (C-24), 19.5, 19.4 (C-11, C-23); m/z (ESI) 683 [MNa]+; 
[HRMS (ESI): calcd for C40H44N2NaO5Si, 683.2912. Found: [MNa]+, 683.2912 (−0.1 ppm 
error)]; 21aao: mp 151‒153 °C;  Rf (1:4 EtOAc:PE) = 0.30; max/cm-1 (thin film) 3071, 3053, 
3031, 2957, 2932, 2897, 2859, 1770, 1715, 1698, 1608, 1494, 1468; δH (400 MHz, CDCl3) 
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7.75‒7.68 (4H, m, H-26), 7.47‒7.20 (11H, m, H-20, H-21, H-22, H-27, H-28), 6.65 (1H, t, 
J = 8.5, 8.0, H-4), 6.25 (1H, dd, J = 8.0, 0.5, H-5), 6.01 (1H, dd, J = 8.5, 0.5, H-3), 5.03 (1H, 
d, J = 16.0, H-7a), 4.67 (1H, d, J = 16.0, H-7b), 4.19‒4.13 (1H, m, H-12a), 3.77 (1H, td, 
J = 12.5, 4.0, H-12b), 3.00‒2.88 (1H, m, H-11a), 2.82 (1H, td, J = 13.0, 3.0, H-10a), 
2.17‒2.11 (1H, m, H-10b), 2.02‒1.95 (1H, m, H-11b), 1.47 (9H, s, H-16), 1.02 (9H, s, H-24); 
δC (100 MHz, CDCl3) 175.7 (C-8), 166.2 (C-13), 153.2 (C-14), 150.9 (C-2), 144.4 (C-6), 
135.7 (C-19), 135.4, 135.1 (C-26), 132.2, 130.9 (C-25), 130.0, 130.0 (C-28), 129.0 (C-4), 128.8 
(C-21), 128.0, 127.9 (C-27), 127.5 (C-22), 127.1 (C-20), 119.5 (C-1), 114.7 (C-3), 102.6 (C-5), 
83.1 (C-15), 57.0 (C-9), 47.2 (C-12), 43.9 (C-7), 29.6 (C-10), 27.9 (C-16), 26.1 (C-24), 19.0 
(C-23), 18.5 (C-11); m/z (ESI) 683 [MNa]+; [HRMS (ESI): calcd for C40H44N2NaO5Si, 
683.2912. Found: [MNa]+, 683.2889 (3.3 ppm error)]. 
 
 
tert-Butyl 1-benzyl-6-(tert-butyldimethylsilyloxy)-2,2'-dioxospiro[indoline-3,3'-
piperidine]-1'-carboxylate (21abp) and tert-butyl 1-benzyl-4-(tert-
butyldimethylsilyloxy)-2,2'-dioxospiro[indoline-3,3'-piperidine]-1'-carboxylate 
(21abo) 
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tert-Butyl 3-(benzyl(3-(tert-butyldimethylsilyloxy)phenyl)carbamoyl)-2-oxopiperidine-
1-carboxylate (20ab, 215 mg, 0.40 mmol) and copper(II) acetate monohydrate (8 mg, 
0.04 mmol) in mesitylene (8 mL) were reacted for 30 min according to general 
procedure F. Flash column chromatography [20‒33% EtOAc/PE] afforded a mixture of 
21abp and lactam  262b (54 mg, corresponding to 41 mg of pure 21abp, 19%; a small 
sample of pure 21abp was isolated for full characterisation) as an off-white amorphous 
solid, and 21abo (56 mg, 26%) as an off-white amorphous solid. 21abp: mp 136‒138 °C; 
Rf (1:4 EtOAc:PE) = 0.20; max/cm-1 (thin film) 3063, 3032, 2954, 2932, 2896, 2859, 1770, 
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1720, 1615, 1499, 1473, 1457; δH (400 MHz, CDCl3) 7.32‒7.20 (5H, m, H-20, H-21, H-22), 
7.12 (1H, d, J = 8.0, H-2), 6.43 (1H, dd, J = 8.0, 2.0, H-3), 6.13 (1H, d, J = 2.0, H-5), 4.92 
(1H, d, J = 16.0, H-7a), 4.85 (1H, d, J = 16.0, H-7b), 3.94‒3.81 (2H, m, H-12), 2.41 (1H, 
ddd, J = 13.5, 10.5, 3.5, H-10a), 2.35‒2.26 (1H, m, H-11a), 2.20‒2.09 (1H, m, H-11b), 2.01 
(1H, ddd, J = 13.5, 6.5, 3.5, H-10b), 1.49 (9H, s, H-16), 0.88 (9H, s, H-24), 0.03 (3H, s, 
H-25), 0.02 (3H, s, H-26); δC (100 MHz, CDCl3) 176.1 (C-8), 167.8 (C-13), 156.3 (C-4), 
152.7 (C-14), 143.9 (C-6), 135.2 (C-19), 128.8 (C-21), 127.5 (C-22), 127.0 (C-20), 124.3 
(C-1), 123.7 (C-2), 113.6 (C-3), 102.9 (C-5), 83.3 (C-15), 57.9 (C-9), 47.2 (C-12), 43.8 (C-7), 
32.1 (C-10), 27.9 (C-16), 25.5 (C-24), 19.5 (C-11), 18.1 (C-23), −4.7 (C-25, C-26); m/z (ESI) 
559 [MNa]+; [HRMS (ESI): calcd for C30H40N2NaO5Si, 559.2599. Found: [MNa]+, 
559.2597 (0.3 ppm error)]; 21abo: mp 159‒161 °C; Rf (1:4 EtOAc:PE) = 0.30; max/cm-1 
(thin film) 3063, 3032, 2957, 2931, 2896, 2858, 1771, 1714, 1696, 1606, 1495, 1468; 
δH (400 MHz, CDCl3) 7.32‒7.21 (5H, m, H-20, H-21, H-22), 7.02 (1H, t, J = 8.5, 8.0, H-4), 
6.50 (1H, dd, J = 8.5, 0.5, H-3), 6.31 (1H, dd, J = 8.0, 0.5, H-5), 4.91 (1H, d, J = 16.0, H-7a), 
4.81 (1H, d, J = 16.0, H-7b), 4.13‒4.06 (1H, m, H-12a), 3.69 (1H, td, J = 12.5, 4.0, H-12b), 
2.85-2.72 (1H, m, H-11a), 2.56 (1H, td, J = 13.0, 3.5, H-10a), 2.07‒2.00 (1H, m, H-10b), 
1.95 (1H, dtt, J = 11.5, 4.0, 3.5, H-11b), 1.50 (9H, s, H-16), 0.98 (9H, s, H-24), 0.29 (3H, s, 
H-25), 0.24 (3H, s, H-26); δC (100 MHz, CDCl3) 175.8 (C-8), 166.3 (C-13), 153.0 (C-14), 
151.2 (C-2), 144.6 (C-6), 135.6 (C-19), 129.5 (C-4), 128.7 (C-21), 127.4 (C-22), 126.9 (C-20), 
120.2 (C-1), 113.3 (C-3), 102.6 (C-5), 83.0 (C-15), 56.9 (C-9), 47.2 (C-12), 43.8 (C-7), 29.5 
(C-10), 27.9 (C-16), 25.8 (C-24), 18.9 (C-11), 18.2 (C-23), −3.8, −4.1 (C-25, C-26); m/z (ESI) 
559 [MNa]+; [HRMS (ESI): calcd for C30H40N2NaO5Si, 559.2599. Found: [MNa]+, 
559.2591 (1.5 ppm error)]. 
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tert-Butyl 6-acetoxy-1-benzyl-2,2'-dioxospiro[indoline-3,3'-piperidine]-1'-carboxylate 
(21acp) and tert-butyl 4-acetoxy-1-benzyl-2,2'-dioxospiro[indoline-3,3'-piperidine]-1'-
carboxylate (21aco) 
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tert-Butyl 3-((3-acetoxyphenyl)(benzyl)carbamoyl)-2-oxopiperidine-1-carboxylate (20ac, 
129 mg, 0.28 mmol) and copper(II) acetate monohydrate (6 mg, 0.03 mmol) in 
mesitylene (6 mL) were reacted for 30 min according to general procedure F. Flash 
column chromatography [20‒33% EtOAc/PE] afforded 21acp (19 mg, 15%) as an 
off-white amorphous solid, and 21aco (31 mg, 24%) as an off-white amorphous solid. 
21acp: mp 154‒156 °C; Rf (1:2 EtOAc:PE) = 0.20; max/cm-1 (thin film) 3064, 3032, 2978, 
2935, 1767, 1721, 1615, 1497, 1455; δH (400 MHz, CDCl3) 7.33‒7.23 (6H, m, H-2, H-20, 
H-21, H-22), 6.73 (1H, dd, J = 8.0, 2.0, H-3), 6.43 (1H, d, J = 2.0, H-5), 4.97 (1H, d, 
J = 16.0, H-7a), 4.83 (1H, d, J = 16.0, H-7b), 3.92‒3.86 (2H, m, H-12), 2.45‒2.31 (2H, m, 
H-10a, H-11a), 2.22 (3H, s, H-18), 2.19‒2.01 (2H, m, H-10b, H-11b), 1.49 (9H, s, H-16); 
δC (100 MHz, CDCl3) 175.8 (C-8), 169.2 (C-17), 167.2 (C-13), 152.7 (C-14), 151.1 (C-4), 
144.1 (C-6), 134.8 (C-19), 129.0 (C-1), 128.9 (C-21), 127.6 (C-22), 126.9 (C-20), 123.8 (C-2), 
115.5 (C-3), 104.0 (C-5), 83.6 (C-15), 58.0 (C-9), 47.2 (C-12), 43.9 (C-7), 32.0 (C-10), 
27.9 (C-16), 21.1 (C-18), 19.5 (C-11); m/z (ESI) 487 [MNa]+; [HRMS (ESI): calcd 
for C26H28N2NaO6, 487.1840. Found: [MNa]+, 487.1827 (2.5 ppm error)]; 
21aco: mp 155‒157 °C; Rf (1:2 EtOAc:PE) = 0.20; max/cm-1 (thin film) 3063, 3032, 2980, 
2935, 1771, 1718, 1621, 1470, 1455; δH (400 MHz, CDCl3) 7.32‒7.23 (5H, m, H-20, H-21, 
H-22), 7.16 (1H, dd, J = 8.5, 8.0, H-4), 6.86 (1H, d, J = 8.5, H-3), 6.54 (1H, d, J = 8.0, H-5), 
4.93 (1H, d, J = 16.0, H-7a), 4.82 (1H, d, J = 16.0, H-7b), 4.09 (1H, dt, J = 12.0, 4.0, H-12a), 
3.67 (1H, ddd, J = 12.0, 11.0, 4.0, H-12b), 2.66‒2.55 (1H, m, H-11a), 2.25 (3H, s, H-18), 
2.23‒2.19 (2H, m, H-10), 2.04‒1.95 (1H, m, H-11b), 1.50 (9H, s, H-16); δC (100 MHz, 
CDCl3) 175.4 (C-8), 167.9 (C-17), 166.4 (C-13), 152.9 (C-14), 146.0 (C-2), 144.5 (C-6), 135.1 
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(C-19), 129.7 (C-4), 128.8 (C-21), 127.6 (C-22), 127.0 (C-20), 122.6 (C-1), 117.0 (C-3), 107.0 
(C-5), 83.6 (C-15), 57.1 (C-9), 47.3 (C-12), 44.0 (C-7), 31.0 (C-10), 27.9 (C-16), 20.9 (C-18), 
19.7 (C-11); m/z (ESI) 487 [MNa]+; [HRMS (ESI): calcd for C26H28N2NaO6, 487.1840. 
Found: [MNa]+, 487.1837 (0.6 ppm error)]. 
 
 
tert-Butyl 1-benzyl-2,2'-dioxo-6-(pivaloyloxy)spiro[indoline-3,3'-piperidine]-1'-
carboxylate (21adp) and tert-butyl 1-benzyl-2,2'-dioxo-4-(pivaloyloxy)spiro[indoline-
3,3'-piperidine]-1'-carboxylate (21ado) 
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tert-Butyl 3-(benzyl(3-(pivaloyloxy)phenyl)carbamoyl)-2-oxopiperidine-1-carboxylate 
(20ad, 88 mg, 0.17 mmol) and copper(II) acetate monohydrate (3.5 mg, 0.018 mmol) in 
mesitylene (4 mL) were reacted for 30 min according to general procedure F. Flash 
column chromatography [15‒20% EtOAc/PE] afforded 21adp (13 mg, 15%) as an 
off-white amorphous solid, and a mixture of spirocycle 21ado and lactam 262b 
(25.5 mg, corresponding to 21.5 mg of pure 21ado, 25%; a small sample of pure 21ado 
was isolated for full characterisation) as an off-white amorphous solid. 21adp: 
mp 175‒176 °C; Rf (1:2 EtOAc:PE) = 0.40; max/cm-1 (thin film) 3064, 3032, 2977, 2934, 
2872, 1750, 1723, 1615, 1497, 1480, 1455; δH (400 MHz, CDCl3) 7.35‒7.23 (6H, m, H-2, 
H-21, H-22, H-23), 6.71 (1H, dd, J = 8.0, 2.0, H-3), 6.43 (1H, d, J = 2.0, H-5), 4.99 (1H, d, 
J = 16.0, H-7a), 4.85 (1H, d, J = 16.0, H-7b), 3.95‒3.85 (2H, m, H-12), 2.46‒2.30 (2H, m, 
H-10a, H-11a), 2.21‒2.03 (2H, m, H-10b, H-11b), 1.50 (9H, s, H-16), 1.30 (9H, s, H-19); 
δC (100 MHz, CDCl3) 176.8 (C-17), 175.9 (C-8), 167.3 (C-13), 152.8 (C-14), 151.7 (C-4), 
144.2 (C-6), 135.0 (C-20), 128.9 (C-22), 128.8 (C-1), 127.6 (C-23), 126.8 (C-21), 123.8 (C-2), 
115.5 (C-3), 103.8 (C-5), 83.6 (C-15), 58.0 (C-9), 47.2 (C-12), 43.8 (C-7), 39.1 (C-18), 32.0 
(C-10), 27.9 (C-16), 27.0 (C-19), 19.5 (C-11); m/z (ESI) 529 [MNa]+; [HRMS (ESI): calcd for 
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C29H35N2NaO6, 529.2309. Found: [MNa]+, 529.2298 (2.1 ppm error)]; 
21ado: mp 166‒168 °C; Rf (1:2 EtOAc:PE) = 0.50; max/cm-1 (thin film) 3063, 3032, 2977, 
2935, 2873, 1759, 1718, 1621, 1604, 1470, 1456; δH (400 MHz, CDCl3) 7.33‒7.24 (5H, m, 
H-20, H-21, H-22), 7.16 (1H, dd, J = 8.5, 8.0, H-4), 6.79 (1H, dd, J = 8.5, 0.5, H-3), 6.53 
(1H, dd, J = 8.0, 0.5, H-5), 4.94 (1H, d, J = 16.0, H-7a), 4.85 (1H, d, J = 16.0, H-7b), 
4.13‒4.06 (1H, m, H-12a), 3.68‒3.61 (1H, m, H-12b), 2.88‒2.75 (1H, m, H-11a), 2.31‒2.22 
(1H, m, H-10a), 2.15‒2.09 (1H, m, H-10b), 1.97‒1.89 (1H, m, H-11b), 1.50 (9H, s, H-16), 
1.33 (9H, s, H-23); δC (100 MHz, CDCl3) 175.9 (C-17), 175.0 (C-8), 166.0 (C-13), 153.0 
(C-14), 146.7 (C-2), 144.4 (C-6), 135.1 (C-19), 129.7 (C-4), 128.8 (C-21), 127.6 (C-22), 126.9 
(C-20), 122.1 (C-1), 116.9 (C-3), 106.6 (C-5), 83.4 (C-15), 56.9 (C-9), 47.2 (C-12), 43.9 (C-7), 
39.3 (C-18), 30.5 (C-10), 27.9 (C-16), 27.0 (C-23), 18.4 (C-11); m/z (ESI) 529 [MNa]+; 
[HRMS (ESI): calcd for C29H35N2NaO6, 529.2309. Found: [MNa]+, 529.2323 (−2.6 ppm 
error)]. 
 
 
(5S)-tert-Butyl 5-((tert-butyldiphenylsilyloxy)methyl)-3-((3-(tert-
butyldiphenylsilyloxy)phenyl)(methyl)carbamoyl)-2-oxopyrrolidine-1-carboxylate 
(336) 
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(5S)-1-(tert-Butoxycarbonyl)-5-((tert-butyldiphenylsilyloxy)methyl)-2-oxopyrrolidine-3-
carboxylic acid (331, 864 mg), N-benzyl-3-(tert-butyldiphenylsilyloxy)aniline (835 mg, 
1.91 mmol), 2-chloro-1-methylpyridinium iodide (664 mg, 2.60 mmol) and 
triethylamine (1.21 mL, 8.68 mmol) in CH2Cl2 (15 mL) were reacted according to 
general procedure E. Flash column chromatography [10‒20% EtOAc/PE] afforded 336 
(1.09 g, 68% over 2 steps, >20:1 dr; major diastereoisomer tentatively assigned based on 
a lack of NOE enhancement between H-2 and H-4) as an off-white sticky foam. 
Rf (1:4 EtOAc:PE) = 0.50; max/cm-1 (thin film) 3071, 3051, 3031, 2959, 2932, 2891, 2858, 
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1785, 1747, 1716, 1657, 1594, 1486, 1473; []D20 32.0 (c 1.03, CHCl3); δH (400 MHz, CDCl3) 
7.64‒7.60 (4H, m), 7.54‒7.46 (4H, m) (H-9, H-24), 7.45‒7.30 (12H, m, H-10, H-11, H-25, 
H-26), 7.21‒7.16 (3H, m, H-31, H-32), 7.09‒7.05 (2H, m, H-30), 6.90 (1H, t, J = 8.0, H-19), 
6.64 (1H, br s, H-18 or H-20), 4.91 (1H, br s, H-16a), 4.40 (1H, v br s, H-16b), 4.22 (1H, br 
d, J = 9.5, H-4), 3.88 (1H, dd, J= 10.0, 9.5, H-2), 3.79 (1H, dd, J = 10.5, 2.0, H-5a), 3.50 (1H, 
dd, J = 10.5, 2.0, H-5b), 2.73‒2.64 (1H, m, H-3a), 1.97 (1H, v br s, H-3b), 1.42 (9H, s, 
H-14), 1.07 (9H, s), 0.78 (9H, s) (H-7, H-28), some aromatic peaks not visible due to 
broadening; δC (100 MHz, CDCl3) 170.8, 169.4 (C-1, C-15), 156.3 (C-21), 149.4 (C-12), 
142.0 (C-17), 136.6 (C-29), 135.5, 135.5, 135.4, 135.4 (C-9, C-24), 132.8, 132.4, 132.3, 132.3 
(C-8, C-23), 130.0, 130.0, 129.8, 129.8 (C-11, C-26), 128.6 (C-30), 128.2 (C-31), 127.8, 127.7 
(C-10, C-25), 127.2 (C-32), 120.0 (C-18, C-20 or C-22), 82.8 (C-13), 64.9 (C-5), 57.2 (C-4), 
53.4 (C-16), 47.5 (C-2), 27.9 (C-14), 26.6, 26.5 (C-7, C-28), 26.2 (C-3), 19.4, 18.7 (C-6, C-27), 
some aromatic peaks not visible due to broadening; m/z (ESI) 939 [MNa]+; [HRMS 
(ESI): calcd for C56H64N2NaO6Si2, 939.4195. Found: [MNa]+, 939.4155 (4.3 ppm error)]. 
 
 
(3S,5'S)-tert-Butyl 1-benzyl-6-(tert-butyldiphenylsilyloxy)-5'-((tert-
butyldiphenylsilyloxy)methyl)-2,2'-dioxospiro[indoline-3,3'-pyrrolidine]-1'-
carboxylate (337p’’) 
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(5S)-tert-Butyl 5-((tert-butyldiphenylsilyloxy)methyl)-3-((3-(tert-
butyldiphenylsilyloxy)phenyl)(methyl)carbamoyl)-2-oxopyrrolidine-1-carboxylate 
(336, 267 mg, 0.29 mmol) and copper(II) acetate monohydrate (6 mg, 0.03 mmol) in 
mesitylene (6 mL) were reacted for 30 min according to general procedure F. Flash 
column chromatography [1:9 EtOAc/PE] afforded 337p’’ (44 mg, 16%) as a yellow oil, 
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as well as an inseparable mixture of other isomers, whose identity could not be firmly 
established, Rf (1:9 EtOAc:PE) = 0.30; max/cm-1 (thin film) 3071, 3050, 3027, 2958, 2931, 
2893, 2858, 1785, 1751, 1721, 1618, 1500, 1472, 1458; []D20 +3.7 (c 0.89, CHCl3); 
δH (400 MHz, CDCl3) 7.69‒7.66 (4H, m), 7.63‒7.60 (4H, m) (H-18, H-24), 7.45‒7.31 (12H, 
m, H-19, H-20, H-25, H-26), 7.22‒7.18 (3H, m, H-31, H-32), 7.10‒7.06 (2H, m, H-30), 6.78 
(1H, d, J = 8.0, H-2), 6.42 (1H, dd, J = 8.0, 2.0, H-3), 6.12 (1H, d, J = 2.0, H-5), 4.75 (1H, d, 
J = 15.5, H-7a), 4.51 (1H, d, J = 15.5, H-7b), 4.34 (1H, tdd, J = 8.5, 4.5, 3.5, H-11), 4.24 (1H, 
dd, J = 9.5, 8.5, H-16a), 4.06 (1H, dd, J = 9.5, 3.5, H-16b), 2.93 (1H, dd, J = 14.0, 8.5, 
H-10a), 2.91 (1H, dd, J = 14.0, 4.5, H-10b), 1.38 (9H, s, H-15), 1.06 (9H, s), 1.02 (9H, s) 
(H-22, H-28); δC (100 MHz, CDCl3) 174.7 (C-8), 170.2 (C-12), 156.6 (C-4), 149.5 (C-13), 
144.2 (C-6), 135.6, 135.5, 135.4, 135.4 (C-18, C-24), 135.0 (C-29), 133.5, 132.5, 132.5 (C-17, 
C-23), 130.0, 129.7 (C-20, C-26), 128.7 (C-31), 127.8, 127.7 (C-19, C-25), 127.4 (C-32), 127.1 
(C-30), 123.2 (C-2), 122.2 (C-1), 113.8 (C-3), 102.2 (C-5), 83.6 (C-14), 64.2 (C-16), 58.4 
(C-9), 56.5 (C-11), 44.0 (C-7), 30.7 (C-10), 27.8 (C-15), 26.8, 26.5 (C-22, C-28), 19.4, 19.3 
(C-21, C-27); Stereochemistry assigned based on an NOE enhancement between H-2 
and H-11; m/z (ESI) 937 [MNa]+; [HRMS (ESI): calcd for C56H62N2NaO6Si2, 937.4039. 
Found: [MNa]+, 937.4013 (2.7 ppm error)]. 
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a b s t r a c t
A one-pot oxidation/allylation/oxidation procedure has been developed for the conversion of primary
alcohols into b,c-unsaturated ketones. The methodology has been applied to a range of alcohols, and
in some cases, isomerisation to produce the corresponding a,b-unsaturated ketones has been carried out.
 2011 Elsevier Ltd. All rights reserved.
a,b- and b,c-Unsaturated ketones are important building blocks
in organic synthesis.1 As part of a natural product project, we
required a straightforward method of preparing b,c-unsaturated
ketones 5 (R = aryl, hetaryl, alkyl, etc.). Most of the available
procedures, such as the Barbier-type allylation of nitriles2 and
the Hosomi–Sakurai reaction of allyl silanes with acid chlorides,3
proceed from carboxylic acid derivatives,4 whereas we wished to
use alcohols 1 as simple starting materials.5,6 Given our interest
in tandem oxidation processes,7 the approach outlined in Scheme
1 appeared to present an attractive option. The idea was to oxidise
alcohols 1 to aldehydes 2 in the presence of an allylating reagent 3;
by using the oxidant in excess we hoped to achieve the in situ
oxidation of allylic alcohol 4 to produce the target b,c-unsaturated
ketones 5 in a one-pot process. In addition, we anticipated that it
would be straightforward to extend this sequence to produce
a,b-unsaturated ketones 6 given the numerous methods reported
for effecting this type of isomerisation.8
Preliminary studies were carried out to assess the viability of a
one-pot approach to b,c-unsaturated ketones using p-chlorobenzyl
alcohol (7), p-chlorobenzaldehyde (8) and secondary alcohol 9 as
test substrates (Scheme 2). The initial oxidation of p-chlorobenzyl
alcohol 7 was straightforward, as expected, with MnO2 and
Dess–Martin periodinane (DMP) giving the most reliable results.9
Many methods are available for the allylation of aldehydes and
0040-4039/$ - see front matter  2011 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tetlet.2011.03.033
⇑ Corresponding author. Tel.: +44 0 1904 322606; fax: +44 0 1904 324523.
E-mail addresses: richard.taylor@york.ac.uk, tet@york.ac.uk (R.J.K. Taylor).
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ketones,10 but in our hands with p-chlorobenzaldehyde (8), the use
of allyl stannane (3a) with catalytic Yb(OTf)3,11 or allyl triﬂuorob-
orate (3b) with boron triﬂuoride etherate12,13 or Montmorillonite
K10 (MK10)13 proved the most straightforward giving the allyl
alcohol 9 via a practically simple process at room temperature.
The ﬁnal step, the oxidation of the secondary benzylic alcohol 9,
proved more troublesome. No oxidation was observed using
MnO2 or TPAP/NMO, with DMP being most reliable for the forma-
tion of b,c-unsaturated ketone 10.14
Having studied the individual steps, we went on to examine
one-pot processes for the three-step sequence (Scheme 3). As can
be seen, with MnO2 as oxidant, it was possible to carry out a
tandem oxidation/allylation giving allylic alcohol 9 in low yield,
but further oxidation did not occur (as was expected after the
OH
Cl
O
Cl
8
OH
Cl
O
Cl
9 10
O
Cl
OH
Cl
M
8 9
(i) M = SnBu3 (3a); 
10 mol% Yb(OTf)3
MeCN, rt, 24 h, 84%
or
(ii) M = BF3K (3b); 
MK10
aq. CH2Cl2 , rt, 45 min, 88%
Ox.
Ox.
(i) MnO2, CH2Cl2 or MeCN
rt, 4 h, >86%
or
(ii) DMP, CH 2Cl2 ,  rt, 1 h
quant.
(i) MnO2, CH2Cl2  or MeCN, rt, 3 d
0%
or
(ii) DMP, CH 2Cl2 , rt, 3 h
quant.
7
Scheme 2.
OH
Cl
O
Cl
8 (only observable product)
OH
Cl
9  (36%) + 77
OH
Cl
7
O
Cl
10 (71%)
OH
Cl
7
i. DMP, CH2Cl2, rt, 1 h
BF3K 3bii.
MK10, rt, 1 h
iii. DMP, rt, 1 h
OH
Cl
OH
Cl
9 (12%) + 7 + 87
SnBu3 3a
MnO2 (5 eq)
10 mol% Yb(OTf) 3
MeCN, rt, 24 h
BF3K 3b
MnO2 (5 eq)
BF3.OEt2
CH2Cl2, rt, 24 h
BF3K 3b
DMP (2.5 eq)
BF3.OEt2
CH2Cl2, rt, 24 h
Scheme 3.
2512 C. L. Moody et al. / Tetrahedron Letters 52 (2011) 2511–2514
Appendix I 
 
 
263 
 
  
preliminary studies shown in Scheme 2). Concentrating on the use
of DMP as oxidant, the tandem process gave mainly aldehyde 8
with trace amounts of allylated adducts 9 and 10, at best. We,
therefore, developed a sequential process in which DMP oxidation
was followed by the addition of allyl triﬂuoroborate (3b) and
MK10, and ﬁnally additional DMP was added to ensure complete
oxidation. In this manner, the required a,b-unsaturated ketone
10 was obtained in a 71% yield by a one-pot procedure.
Having established a reliable one-pot procedure for the oxida-
tion/allylation/oxidation route to b,c-unsaturated ketone 10, we
went on to explore its scope (Table 1). As can be seen, the sequence
was successful with a range of electron-rich and electron-poor ben-
zylic alcohols (entries i–iv), with 2-naphthyl-methanol (entry v)
and with thiophene-2-methanol (entry vi). In addition to benzylic
and related systems, an allylic example proved successful (entry
vii), as did an unactivated alcohol (1,2:3,4-di-O-isopropylidene-
D-galactopyranose, entry viii). In all cases the yields were good to
excellent and the b,c-unsaturated ketones were usually stable for
a day or so, although isomerisation to give the corresponding
a,b-unsaturated ketones was observed on prolonged storage.
As mentioned earlier, if conjugated ketones are required, these
are easily obtained from the corresponding b,c-unsaturated
ketones. In our hands, DBU in diethyl ether16 gave the cleanest
isomerisation, with a,b-unsaturated ketones 25–27 being isolated
in almost quantitative yields, exclusively or predominantly as the
E-isomers (Scheme 4).
In summary, we have developed a one-pot oxidation/allylation/
oxidation procedure for the conversion of primary alcohols into
b,c-unsaturated ketones which involves DMP oxidation followed
by the addition of allyl triﬂuoroborate (3b) and Montmorillonite
K10 and ﬁnally additional DMP. The methodology has been applied
to a range of benzylic alcohols, as well as to an allylic and an
Table 1
One-pot oxidation/allylation/oxidation sequencea
Entry Substrate Product Isolated Yieldb (%)
i
OH
Cl
7
O
Cl
10
714a
ii
OH
MeO
11
O
MeO
12
924b
iii
OH
Br
13
O
Br
14
854a,c
iv
OH
O2N
15
O
O2N
16
964a
v
OH
17
O
18
754d
vi
19
S
OH O
20
S 76
4e
vii Ph
OH
21
Ph
O
22
674f
viii
23
O
OH
O
O
Me
Me
O
O
Me
Me 24
O
O
O
O
Me
Me
O
O
Me
Me
7515
a On a 0.25 mmol scale; (i) DMP (1.5–2.0 equiv), CH2Cl2, rt, 1 h; (ii) MK10, 3 (1.5–2.0 equiv), rt, 1 h; (iii) DMP (2.0–2.5 equiv), rt, 1 h.
b Quenched with sat. aq. NaHCO3 and sat. aq. Na2S2O3; puriﬁed by ﬂash column chromatography.
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unactivated carbohydrate example. In three examples, base-medi-
ated isomerisation to produce the corresponding a,b-unsaturated
ketones has been carried out. We are currently applying this
sequence to more complex systems as part of a natural product
programme.
Acknowledgements
The authors thank the EPSRC for Ph.D. project studentship fund-
ing (D.S.P., EP/03456X/1), and the University of York and Elsevier
for additional studentship funding (C.L.M.).
References and notes
1. Comprehensive Organic Functional Group Transformations II; Katritzky, A. R.,
Taylor, R. J. K., Eds.; Elsevier, 2005.
2. Lee, A. S.-Y.; Lin, L.-S. Tetrahedron Lett. 2000, 41, 8803.
3. Yadav, J. S.; Reddy, B. V. S.; Reddy, M. S.; Parimala, G. Synthesis 2003, 2390.
4. For other procedures, see: (a) Gohain, M.; Gogoi, B. J.; Prajapati, D.; Sandhu, J. S.
New J. Chem. 2003, 27, 1038; (b) Larock, R. C.; Lu, Y.-D. J. Org. Chem. 1993, 58,
2846; (c) Jones, P.; Knochel, P. J. Org. Chem. 1999, 64, 186; (d) Tada, M.;
Hiratsuka, M.; Goto, H. J. Org. Chem. 1990, 55, 4364; (e) Felpin, F.-X.; Bertrand,
M.-J.; Lebreton, J. Tetrahedron 2002, 58, 7381; (f) Jiang, D.; Peng, J.; Chen, Y. Org.
Lett. 2008, 10, 1695.
5. For an elegant ruthenium-catalysed procedure for converting alcohols into b,c-
unsaturated ketones, see: (a) Omura, S.; Fukuyama, T.; Horiguchi, J.; Murakami,
Y.; Ryu, I. J. Am. Chem. Soc. 2008, 130, 14094; (b) Shibahara, F.; Bower, J. F.;
Krische, M. J. J. Am. Chem. Soc. 2008, 130, 14120.
6. For other recent methods for the conversion of alcohols into homologated
allylic alcohols and b,c-unsaturated ketones, see: (a) Zhang, L.; Zha, Z.; Zhang,
Z.; Li, Y.; Wang, Z. Chem. Commun. 2010, 46, 7196; (b) Nomura, K.; Matsubara, S.
Synlett 2008, 1412.
7. Taylor, R. J. K.; Reid, M.; Foot, J.; Raw, S. A. Acc. Chem. Res. 2005, 38, 851. and
references cited therein.
8. Foster, C. E.; Mackie, P. R. Chapter 3.05 in Ref. 1.
9. All known compounds were characterised spectroscopically (comparison to
literature data) and by mp. comparison when available; novel compounds were
fully characterised.
10. For excellent reviews, see: (a) Denmark, S. E.; Almstead, N. G. In Modern
Carbonyl Chemistry; Otera, J., Ed.; Wiley-VCH: Weinheim, 2000. Chapter 10; (b)
Chemler, S. R.; Roush, W. R. InModern Carbonyl Chemistry; Otera, J., Ed.; Wiley-
VCH: Weinheim, 2000. Chapter 11; (c) Yamamoto, Y.; Asao, N. Chem. Rev. 1993,
93, 2207.
11. Aspinall, H. C.; Browning, A. F.; Greeves, N.; Ravenscroft, P. Tetrahedron Lett.
1994, 35, 4639.
12. Batey, R. A.; Thadani, A. N.; Smil, D. V. Tetrahedron Lett. 1999, 40, 4289.
13. Nowrouzi, F.; Thadani, A. N.; Batey, R. A. Org. Lett. 2009, 11, 2631.
14. Pyridinium chlorochromate was also successful in this oxidation reaction.
15. Representative experimental procedure: Galactopyranose derivative 24: To
1,2:3,4-di-O-isopropylidene-D-galactopyranose (23) (64 mg, 0.25 mmol) in
dry CH2Cl2 (5 mL) at rt under argon was added DMP (209 mg, 0.49 mmol)
and the mixture stirred for 1 h. Montmorillonite K10 (50 mg) was then added
followed by potassium allyl triﬂuoroborate (73 mg, 0.49 mmol) and the
mixture stirred for 1 h before adding a further portion of DMP (261 mg,
0.62 mmol). After stirring for a further 1 h, the reaction was quenched with sat.
aq NaHCO3 (5 mL) and sat. aq Na2S2O3 (5 mL) and allowed to stir for 1 h before
diluting with brine (10 mL) and CH2Cl2 (10 mL). The mixture was ﬁltered and
then the layers separated. The aqueous portion was further extracted with
CH2Cl2 (2  5 mL) and the combined organic extracts dried (Na2SO4) and
concentrated in vacuo. The residue was puriﬁed by silica gel chromatography
(0–5% acetone in CH2Cl2) to give the compound 24 (55 mg, 75%) as a colourless
micro-crystalline solid, mp 47–49 C; Rf (CH2Cl2) = 0.15; vmax/cm1 (thin ﬁlm)
2988, 2936, 1723 (C@O), 1383; [a]D 144 (c 0.4, CH2Cl2); dH (400 MHz, CDCl3)
5.97 (1H, ddt, J = 17.0, 10.5, 7.0, H-8), 5.64 (1H, d, J = 5.0, H-1), 5.20–5.08 (2H,
m, H-9), 4.63 (1H, dd, J = 8.0, 2.5, H-3), 4.56 (1H, dd, J = 8.0, 2.0, H-4), 4.35 (1H,
dd, J = 5.0, 2.5, H-2), 4.22 (1H, d, J = 2.0, H-5), 3.50 (1H, ddt, J = 18.5, 7.0, 1.5, H-
7a), 3.33 (1H, ddt, J = 18.5, 7.0, 1.5, H-7b), 1.49 (3H, s), 1.44 (3H, s), 1.33 (3H, s),
1.30 (3H, s); dC (100 MHz, CDCl3) 207.2 (C-6), 130.0 (C-8), 118.7 (C-9), 109.6,
109.0, 96.4 (C-1), 73.5 (C-5), 72.3 (C-4), 70.6 (C-3), 70.4 (C-2), 44.6 (C-7), 25.9,
25.8, 24.8, 24.2; m/z (ESI) 321 [M+Na]+; [HRMS (ESI): Calcd for C15H22NaO6,
321.1309. Found: [M+Na]+, 321.1317 (2.7 ppm error)]; [C15H22O6 requires C,
60.39; H, 7.43. Found C, 60.35; H, 7.35].
16. Chiu, P.; Wong, S. T. Synth. Commun. 1998, 28, 4513.
24
O
O
O
O
Me
Me
O
O
Me
Me 27
O
O
O
O
Me
Me
O
O
Me
Me
O
20
S
O
26
S
O
MeO
12
O
MeO
25
DBU, Et2O
24 h, 70%
DBU, Et2O
24 h, 96%
DBU, Et2O
24 h, 87%
E- only
E- only
E:Z > 20:1
Scheme 4.
2514 C. L. Moody et al. / Tetrahedron Letters 52 (2011) 2511–2514
Appendix II 
 
 
265 
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a b s t r a c t
A practical and efﬁcient entry to spirocyclic oxindoles from readily accessible anilide precursors, using
only catalytic amounts of an inexpensive copper salt together with air as the sole re-oxidant, is described.
In addition to providing access to a broad range of spiro-oxindole products, the utility of this method is
demonstrated in a formal synthesis of the natural product, horsﬁline.
 2012 Elsevier Ltd. All rights reserved.
The oxindole structure has long fascinated synthetic chemists,
partly due to the synthetic challenges that many oxindole-
containing targets present, and partly owing to the exciting biolog-
ical proﬁles they exhibit and their potential as pharmaceuticals.1
In terms of their structure, naturally-occurring oxindoles tend
to be appended with two substituents at the benzylic position
(i.e., 3,3-disubstituted), with a large proportion of these having
the side-chains tied together, thus giving rise to a spirocyclic junc-
tion.2 They can range from small members, such as horsﬁline (1),3
to the more imposing representatives, such as the polycyclic alka-
loid gelsemine (2),4 which has stimulated a number of total syn-
thesis programmes across the globe simply as a result of the
attraction of its formidable and striking structure (Fig. 1).5 More
importantly, many spiro-oxindole natural products display
remarkable biological properties: for example, strychnofoline (3)
displays useful antimitotic activity against cultures of mouse mel-
anoma,6 and has already succumbed to a creative total synthesis by
the Carreira laboratories.7 Most notably, the prominence of the
oxindole motif in naturally-occurring compounds of medicinal
value has spurred the development of a valuable collection of
fully synthetic clinical drugs and candidates thereof. This is well
exempliﬁed by satavaptan (4, SR-121463),8 an orally-active and
selective vasopressin V2 receptor antagonist, which belongs to a
new class of drugs developed for the treatment of hyponatraemia
and is currently in Phase III trials.
From the synthetic viewpoint, the transition metal catalysed
cyclisation of linear anilide precursors is a particularly efﬁcient
0040-4039/$ - see front matter  2012 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tetlet.2012.01.120
⇑ Corresponding author. Tel.: +44 (0) 1904 322 606; fax: +44 (0) 1904 324 523.
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Figure 1. Examples of spirocyclic oxindoles.
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strategy for the synthesis of 3,3-disubstituted oxindoles.9 Most of
these methods make use of palladium catalysis, namely in Heck
cyclisations,10 C–H activation processes,11 and enolate arylations,12
as well as others.13 Copper salts have also found utility as reagents
for cyclisations leading to oxindoles,14 however, it was in 2009 that
Kündig and Jia,15 as well as ourselves,16 reported a copper-medi-
ated cyclisation of unfunctionalised anilides to the 3,3-disubstituted
oxindole core via a formal double C–H activation approach
(Scheme 1). We subsequently disclosed an improved variant of this
reaction process,17 which utilised sub-stoichiometric amounts
(5 mol %) of a copper catalyst with no loss in reaction efﬁciency.
Herein we communicate a practical extension of this methodology
for the straightforward synthesis of spirocyclic oxindoles, which en-
ables the installation of a quaternary all-carbon centre via a direct
C–H, Ar-H functionalisation by means of copper catalysis without
the need for additional base.
In the current study, the use of just 10 mol % of the environ-
mentally benign and inexpensive copper(II) acetate monohydrate
as the catalyst and air as the stoichiometric re-oxidant enabled
us to rapidly establish the broad scope of this spirocyclisation
reaction (Table 1). The cyclisation precursors 5 were easily
prepared in just three straightforward synthetic steps from
protected lactams (see Supporting Information). All cyclisations
were carried out with mesitylene as the solvent at 170 C, thus
cutting down on reaction time (30–90 min). Comparable results
could also be achieved by running the reactions in reﬂuxing tol-
uene (120 C), although a longer reaction time was needed in or-
der to achieve full conversion (typically overnight). Oxygen in air
was all that was required to re-oxidise the copper catalyst. In
certain cases a small amount of substrate 5 was found to undergo
cleavage to the corresponding aniline and lactam/imide under the
reaction conditions, resulting in lower yields of the oxindole
products 6. This obstacle was eventually overcome by simply
bubbling air through the reﬂuxing reaction mixture, thus acceler-
ating the rate of copper re-oxidation and, ultimately, oxindole
cyclisation. In this way, the undesired cleavage of the starting
anilides 5 was minimised and the efﬁciency of the cyclisation
step improved.
In terms of substrate scope, anilides containing butyrolactam
unit 5a–d, appended with a range of substituents on the nitrogen
atoms and the benzene ring, as well as that incorporating the suc-
cinimide motif (5e), all provided the cyclic products 6a–e in good
to excellent yields (Table 1). The desired oxindoles 6f–i were also
successfully obtained with six-membered valerolactam-containing
anilides 5f–i as substrates. We were able to obtain a suitable crys-
tal of spirocyclic product 6i for X-ray crystallographic analysis and
conclusively established its identity (Fig. 2).18
Substitution on the benzene ring was next explored and prod-
ucts 6j–m were furnished in good yields. It is noteworthy that
access to aryl chlorides of type 6j allows for further palladium-
mediated manipulation to structurally more elaborate, and
potentially medicinally relevant, oxindoles. The result obtained
with the meta-methoxy-substituted example 5l was also intrigu-
ing: a mixture of regioisomers 6l and 6l0 was isolated,13f with the
major isomer 6l arising from radical addition to the position more
encumbered sterically, but potentially preferred electronically,
presumably due to the higher degree of stabilisation of the inter-
mediate cyclohexadienyl radical. Glutaramide- and caprolactam-
based anilides 5n and 5o also furnished spirocyclic oxindoles 6n
and 6o, respectively, in good yields. Of potential medicinal interest
are ß-lactam-containing oxindoles of type 6p,19 albeit the efﬁ-
ciency of the cyclisation of 5p was found to be somewhat lower.
Postulating that, mechanistically, this reaction proceeds via an
intermediate enol, the lower yield of cyclic product 6p could be
attributed to the high strain associated with the enol (or the resul-
tant radical species following oxidation of the enol), which con-
tains three adjacent sp2 centres within a four-membered ring. It
should be noted that, to the best of our knowledge, all the oxindole
products described here and accessed via the copper-catalysed
cyclisation method are novel compounds.
Having established the broad scope of this cyclisation method-
ology we sought to demonstrate its utility in the synthesis of the
natural product horsﬁline (1, Scheme 2).3 In this context, benzyl-
carboxylation of commercially available N-methylpyrrolidone (7)
afforded intermediate 8 which, upon hydrogenolysis and amide
coupling, swiftly furnished the linear cyclisation precursor 9 on
gram scale in excellent overall yield. Ready access to anilide 9
paved the way for the application of our copper(II)-mediated cyc-
lisation, which successfully provided the desired oxindole 10 in a
Table 1
Reaction scope investigation (yields are isolated)
N
O
N
O
a) air atmosphere
or
b) air bubbled through
N
OR
3
R2
R1
R2
R1
5 6
N
O
R3
Cu(OAc)2·H2O (10 mol%)
mesitylene ,170 ºC, 30-90 min
N
Me
O
N
O
R
N
Bn
O
Me
N
O
N
Me
O
Me
N
O
Cl
N
Me
O
N
O
R
N
Me
O
Me
N
O
O
6a (R = Me): 61%,a 76%c
6b (R = Boc): 76%a
6c: 58%,a 80%b 6d: 66%,a 76%b
6e: 70%a 6f (R = Me): 76%b
6g (R = Bn): 83%b
6h (R = PMB): 73b
N
Bn
O
BocN
O
N
Me
O
BocN
OCl
N
O
BocN
OMeO
OMeMeO
6i: 69%b
6j: 70%b
6k : 73%b
N
Me
O
NBoc
MeO
N
Me
O
NBoc
O
MeO
+
6l:6l' = 3.2:1
76%a
N
Me
O
BocN
O
OMe
N
Me
O
PMBN
O
O
N
Me
O
BocN
O
N
Me
O
Boc
NO
6m: 60%b
6n: 91%b
6o: 64%a 6p: 26%a
O
6l
6l'
a Reaction was carried out with the reﬂux condenser open to air.
b Reaction was carried out by vigorously bubbling compressed air through the
reﬂuxing reaction mixture.
c Reaction was carried out in toluene at 120 C for 15 h with the reﬂux condenser
open to air.
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71% yield and intercepted Trost’s intermediate for the formal syn-
thesis of horsﬁline (1).20
In summary, the copper(II)-mediated cyclisation methodology
enables entry to a large class of spirocyclic oxindoles via a direct
C–H, Ar-H functionalisation with high efﬁciency from easily acces-
sible starting materials with cheap reagents. This method allows
the installation of a quaternary carbon centre at the spirocycle
junction and constitutes an attractive approach for the preparation
of oxindole-based natural products and their analogues. The devel-
opment of a stereoselective variant of this process is currently
underway in our laboratories: preliminary studies have been car-
ried out using enantiopure additives but, to date, no signiﬁcant
enantioselectivity has been obtained.
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Scheme 2. Formal total synthesis of horsﬁline (1). Reagents and conditions: (a)
LDA, CbzCl, THF, 78 C, 1 h (48%); (b) H2, Pd/C, EtOAc, rt, 1 h (97%); (c) N-Dmb-4-
methoxyaniline, 2-chloro-1-methylpyridinium iodide, Et3N, CH2Cl2, 0 C to rt, 1 h
(97%); (d) Cu(OAc)2H2O (10 mol %), mesitylene, air bubbled through, 170 C,
90 min (71%). LDA = lithium di-iso-propylamide; Cbz = carboxybenzyl; THF = tetra-
hydrofuran; Dmb = 2,4-dimethoxybenzyl.
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Appendix III  
X-ray data for tert-butyl 3-(benzyl(phenyl)carbamoyl)-2-
oxopiperidine-1-carboxylate (20u) 
 
 
 
 
 
CCDC deposition number 857976 
 
Table 1 Crystal data and structure refinement for rjkt1102 
Identification code rjkt1102 
Empirical formula C24H26N2O4 
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Formula weight 406.47 
Temperature/K 110.00(10) 
Crystal system triclinic 
Space group P-1 
a/Å 9.1023(6) 
b/Å 10.7446(8) 
c/Å 11.3413(6) 
α/° 74.878(6) 
β/° 75.082(5) 
γ/° 81.943(6) 
Volume/Å3 1031.52(12) 
Z 2 
ρcalcmg/mm3 1.309 
m/mm-1 0.089 
F(000) 432 
Crystal size/mm3 0.199 × 0.1057 × 0.0813 
2Θ range for data collection 5.8 to 55.82° 
Index ranges -11 ≤ h ≤ 7, -14 ≤ k ≤ 13, -14 ≤ l ≤ 13 
Reflections collected 6258 
Independent reflections 4045[R(int) = 0.0179] 
Data/restraints/parameters 4045/0/274 
Goodness-of-fit on F2 1.093 
Final R indexes [I>=2σ (I)] R1 = 0.0423, wR2 = 0.0988 
Final R indexes [all data] R1 = 0.0503, wR2 = 0.1045 
Largest diff. peak/hole / e Å-3 0.236/-0.218 
Flack Parameter N/A 
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Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103) for rjkt1102. Ueq is defined as 1/3 of of the trace of the 
orthogonalised UIJ tensor. 
Atom x y z U(eq) 
C1 214.1(18) -1063.5(15) 7767.2(15) 17.8(3) 
C2 1992.1(18) -1153.0(15) 7408.1(15) 16.5(3) 
C3 2334.0(18) -1519.1(14) 6164.0(15) 16.3(3) 
C4 3704.8(18) -1705.6(15) 5333.4(16) 20.0(4) 
C5 3689(2) -2013.3(16) 4218.0(16) 23.4(4) 
C6 2321(2) -2122.2(16) 3938.9(16) 23.1(4) 
C7 922.1(19) -1921.8(15) 4760.8(15) 19.3(3) 
C8 964.8(18) -1619.7(14) 5864.1(15) 16.0(3) 
C9 -1884.0(18) -1275.6(16) 6799.8(16) 18.7(3) 
C10 -2534.9(17) -2581.2(15) 7249.5(15) 16.5(3) 
C11 -2786.2(18) -3204.9(17) 8518.8(15) 21.1(4) 
C12 -3375.3(19) -4404.9(17) 8948.0(16) 23.7(4) 
C13 -3738.4(19) -4995.2(17) 8118.9(16) 22.2(4) 
C14 -3497.2(18) -4381.7(16) 6854.6(16) 20.1(4) 
C15 -2891.0(17) -3187.6(16) 6422.8(15) 17.5(3) 
C16 2668(2) -2151.3(16) 8421.6(16) 21.8(4) 
C17 2502(2) -1634.1(16) 9581.1(16) 24.5(4) 
C18 3276(2) -386.5(16) 9233.9(16) 21.1(4) 
C19 2410.2(17) 239.4(15) 7217.7(15) 15.5(3) 
C20 2634.9(18) 1889.8(15) 8270.2(14) 16.3(3) 
C21 1455.2(19) 4032.9(15) 7456.0(15) 17.8(3) 
C22 766(2) 4411.6(18) 8691.1(17) 27.5(4) 
C23 2981(2) 4579.4(17) 6802.6(17) 27.0(4) 
C24 364(2) 4405.5(17) 6597.1(17) 25.1(4) 
N1 -271.5(15) -1343.3(13) 6825.1(12) 16.4(3) 
N2 2651.7(15) 576.4(12) 8245.9(12) 16.1(3) 
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O1 -608.6(13) -798.2(12) 8711.7(11) 26.3(3) 
O2 2457.8(14) 992.7(11) 6206.5(10) 21.1(3) 
O3 3430.0(13) 2243.0(11) 8801.9(11) 20.7(3) 
O4 1604.0(13) 2600(1) 7689.7(11) 20.2(3) 
  
Table 3 Anisotropic Displacement Parameters (Å2×103) for rjkt1102. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12 
C1 19.3(8) 14.9(8) 18.4(8) -3.0(6) -2.5(7) -4.1(7) 
C2 16.5(8) 15.1(8) 17.8(8) -3.2(6) -4.6(6) -0.9(6) 
C3 18.2(8) 10.8(7) 19.5(8) -2.6(6) -5.3(6) -0.2(6) 
C4 15.0(8) 16.3(8) 27.5(9) -4.3(7) -4.4(7) 0.8(6) 
C5 20.7(8) 20.6(8) 25.1(9) -8.1(7) 2.4(7) 1.4(7) 
C6 30.7(9) 19.3(8) 19.6(8) -8.0(7) -2.2(7) -2.6(7) 
C7 21.2(8) 17.3(8) 21.3(8) -5.3(7) -6.4(7) -3.6(7) 
C8 16.6(8) 10.0(7) 19.4(8) -2.0(6) -1.8(6) -2.1(6) 
C9 14.5(8) 20.1(8) 21.1(8) -4.5(7) -4.5(6) -0.5(7) 
C10 9.8(7) 18.7(8) 19.6(8) -3.0(7) -3.1(6) 0.4(6) 
C11 17.2(8) 28.3(9) 18.7(8) -6.4(7) -3.8(7) -4.4(7) 
C12 19.6(8) 30.7(10) 17.8(8) 3.7(7) -6.3(7) -6.4(7) 
C13 17.2(8) 20.2(8) 26.5(9) 1.3(7) -5.4(7) -4.9(7) 
C14 16.9(8) 21.7(8) 23.0(9) -5.6(7) -6.1(7) -2.2(7) 
C15 13.7(7) 21.2(8) 16.2(8) -2.0(6) -3.8(6) -0.7(7) 
C16 27.4(9) 14.4(8) 23.8(9) -1.0(7) -10.1(7) -0.9(7) 
C17 33.6(10) 19.2(9) 20.4(9) 2.0(7) -12.3(7) -2.0(8) 
C18 26.2(9) 19.0(8) 19.6(8) -2.8(7) -11.8(7) 2.0(7) 
C19 12.5(7) 16.1(8) 17.6(8) -3.7(6) -3.9(6) 0.1(6) 
C20 16.0(8) 18.0(8) 14.2(7) -3.1(6) -2.4(6) -2.0(6) 
C21 21.3(8) 11.3(7) 21.8(8) -5.0(6) -7.0(7) 1.3(6) 
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C22 32.2(10) 26.3(9) 25.4(9) -11.4(8) -6.9(8) 4.1(8) 
C23 26.1(9) 21.3(9) 30.3(10) 0.3(8) -6.4(8) -2.8(8) 
C24 28.3(9) 19.0(8) 32.5(10) -9.6(8) -16.0(8) 6.3(7) 
N1 15.1(7) 16.9(7) 18.0(7) -4.9(5) -3.3(5) -3.3(5) 
N2 19.1(7) 13.3(6) 16.1(7) -1.7(5) -7.2(5) 0.1(5) 
O1 22.5(6) 35.3(7) 22.7(6) -13.6(6) 0.2(5) -5.1(6) 
O2 29.9(7) 16.5(6) 17.2(6) -1.3(5) -8.5(5) -2.0(5) 
O3 23.3(6) 20.8(6) 21.4(6) -6.5(5) -9.8(5) -1.7(5) 
O4 21.8(6) 13.3(5) 29.2(6) -5.8(5) -12.8(5) 0.7(5) 
  
Table 4 Bond Lengths for rjkt1102. 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 C2 1.559(2)   C11 C12 1.385(2) 
C1 N1 1.369(2)   C12 C13 1.388(2) 
C1 O1 1.2149(19)   C13 C14 1.387(2) 
C2 C3 1.507(2)   C14 C15 1.386(2) 
C2 C16 1.545(2)   C16 C17 1.522(2) 
C2 C19 1.542(2)   C17 C18 1.515(2) 
C3 C4 1.381(2)   C18 N2 1.485(2) 
C3 C8 1.398(2)   C19 N2 1.383(2) 
C4 C5 1.392(2)   C19 O2 1.2133(19) 
C5 C6 1.389(3)   C20 N2 1.416(2) 
C6 C7 1.398(2)   C20 O3 1.2052(19) 
C7 C8 1.383(2)   C20 O4 1.3234(19) 
C8 N1 1.409(2)   C21 C22 1.515(2) 
C9 C10 1.511(2)   C21 C23 1.515(2) 
C9 N1 1.467(2)   C21 C24 1.510(2) 
C10 C11 1.394(2)   C21 O4 1.4853(18) 
C10 C15 1.394(2)         
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Table 5 Bond Angles for rjkt1102. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
N1 C1 C2 107.82(13)   C14 C13 C12 119.64(15) 
O1 C1 C2 126.74(15)   C15 C14 C13 120.09(16) 
O1 C1 N1 125.44(15)   C14 C15 C10 120.72(15) 
C3 C2 C1 101.77(12)   C17 C16 C2 111.33(13) 
C3 C2 C16 113.91(13)   C18 C17 C16 110.40(14) 
C3 C2 C19 110.27(12)   N2 C18 C17 110.27(13) 
C16 C2 C1 111.39(13)   N2 C19 C2 117.21(13) 
C19 C2 C1 104.71(12)   O2 C19 C2 119.43(14) 
C19 C2 C16 113.75(13)   O2 C19 N2 123.30(14) 
C4 C3 C2 130.81(15)   O3 C20 N2 122.25(15) 
C4 C3 C8 119.79(15)   O3 C20 O4 127.56(15) 
C8 C3 C2 109.36(13)   O4 C20 N2 110.13(13) 
C3 C4 C5 118.84(15)   C22 C21 C23 112.73(15) 
C6 C5 C4 120.71(15)   C24 C21 C22 111.23(14) 
C5 C6 C7 121.28(16)   C24 C21 C23 110.80(14) 
C8 C7 C6 117.02(15)   O4 C21 C22 108.81(13) 
C3 C8 N1 109.46(14)   O4 C21 C23 110.65(13) 
C7 C8 C3 122.36(15)   O4 C21 C24 102.09(12) 
C7 C8 N1 128.17(15)   C1 N1 C8 111.59(13) 
N1 C9 C10 113.04(13)   C1 N1 C9 123.34(13) 
C11 C10 C9 119.73(14)   C8 N1 C9 124.96(13) 
C15 C10 C9 121.57(14)   C19 N2 C18 121.67(13) 
C15 C10 C11 118.70(15)   C19 N2 C20 121.07(13) 
C12 C11 C10 120.57(15)   C20 N2 C18 115.88(13) 
C11 C12 C13 120.27(16)   C20 O4 C21 121.58(12) 
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Table 6 Torsion Angles for rjkt1102. 
A B C D Angle/˚ 
C1 C2 C3 C4 177.59(16) 
C1 C2 C3 C8 0.07(16) 
C1 C2 C16 C17 -74.53(17) 
C1 C2 C19 N2 92.15(16) 
C1 C2 C19 O2 -85.20(17) 
C2 C1 N1 C8 0.25(17) 
C2 C1 N1 C9 -176.09(13) 
C2 C3 C4 C5 -178.38(15) 
C2 C3 C8 C7 178.83(14) 
C2 C3 C8 N1 0.07(17) 
C2 C16 C17 C18 -57.89(19) 
C2 C19 N2 C18 31.0(2) 
C2 C19 N2 C20 -162.94(13) 
C3 C2 C16 C17 171.06(13) 
C3 C2 C19 N2 -159.08(13) 
C3 C2 C19 O2 23.6(2) 
C3 C4 C5 C6 0.5(2) 
C3 C8 N1 C1 -0.21(18) 
C3 C8 N1 C9 176.05(14) 
C4 C3 C8 C7 1.0(2) 
C4 C3 C8 N1 -177.76(14) 
C4 C5 C6 C7 0.3(3) 
C5 C6 C7 C8 -0.4(2) 
C6 C7 C8 C3 -0.2(2) 
C6 C7 C8 N1 178.28(15) 
C7 C8 N1 C1 -178.87(15) 
C7 C8 N1 C9 -2.6(2) 
C8 C3 C4 C5 -1.1(2) 
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C9 C10 C11 C12 -179.69(15) 
C9 C10 C15 C14 -179.56(14) 
C10 C9 N1 C1 -99.46(17) 
C10 C9 N1 C8 84.70(18) 
C10 C11 C12 C13 -0.7(3) 
C11 C10 C15 C14 0.6(2) 
C11 C12 C13 C14 0.5(3) 
C12 C13 C14 C15 0.3(2) 
C13 C14 C15 C10 -0.8(2) 
C15 C10 C11 C12 0.1(2) 
C16 C2 C3 C4 -62.4(2) 
C16 C2 C3 C8 120.07(15) 
C16 C2 C19 N2 -29.69(19) 
C16 C2 C19 O2 152.96(15) 
C16 C17 C18 N2 56.13(19) 
C17 C18 N2 C19 -44.2(2) 
C17 C18 N2 C20 149.06(14) 
C19 C2 C3 C4 66.9(2) 
C19 C2 C3 C8 -110.63(14) 
C19 C2 C16 C17 43.53(19) 
C22 C21 O4 C20 -71.80(18) 
C23 C21 O4 C20 52.58(19) 
C24 C21 O4 C20 170.54(14) 
N1 C1 C2 C3 -0.19(16) 
N1 C1 C2 C16 -121.95(14) 
N1 C1 C2 C19 114.68(14) 
N1 C9 C10 C11 71.24(19) 
N1 C9 C10 C15 -108.58(17) 
N2 C20 O4 C21 -173.42(13) 
O1 C1 C2 C3 179.60(16) 
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O1 C1 C2 C16 57.8(2) 
O1 C1 C2 C19 -65.5(2) 
O1 C1 N1 C8 -179.54(15) 
O1 C1 N1 C9 4.1(2) 
O2 C19 N2 C18 -151.73(15) 
O2 C19 N2 C20 14.3(2) 
O3 C20 N2 C18 19.8(2) 
O3 C20 N2 C19 -146.99(15) 
O3 C20 O4 C21 9.4(2) 
O4 C20 N2 C18 -157.50(13) 
O4 C20 N2 C19 35.70(19) 
  
Table 7 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters 
(Å2×103) for rjkt1102. 
Atom x y z U(eq) 
H4 4622 -1627 5516 24 
H5 4605 -2147 3654 28 
H6 2336 -2333 3191 28 
H7 4 -1989 4574 23 
H9A -1993 -897 5948 22 
H9B -2468 -711 7325 22 
H11 -2556 -2812 9082 25 
H12 -3528 -4817 9795 28 
H13 -4141 -5798 8409 27 
H14 -3743 -4772 6296 24 
H15 -2720 -2787 5572 21 
H16A 2150 -2940 8657 26 
H16B 3739 -2360 8079 26 
H17A 1429 -1480 9958 29 
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H17B 2956 -2271 10193 29 
H18A 3114 -42 9971 25 
H18B 4365 -556 8931 25 
H22A -144 3974 9106 41 
H22B 519 5329 8536 41 
H22C 1486 4171 9215 41 
H23A 3636 4377 7380 41 
H23B 2833 5501 6516 41 
H23C 3442 4207 6098 41 
H24A 819 4136 5831 38 
H24B 142 5327 6412 38 
H24C -564 3990 7002 38 
 
 
Crystal Data. C24H26N2O4, M =406.47, triclinic, a = 9.1023(6) Å, b = 
10.7446(8) Å, c = 11.3413(6) Å, α = 74.878(6)°, β = 75.082(5)°, γ = 81.943(6)°, U = 
1031.52(12) Å3, T = 110.00(10), space group P-1 (no. 2), Z = 2, μ(Mo Kα) = 0.089, 6258 
reflections measured, 4045 unique (Rint = 0.0179) which were used in all calculations. 
The final wR(F2) was 0.1045 (all data). 
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Abbreviations 
 
Å  Angstrom 
ABH  Aza-Baylis‒Hillman 
Ac  Acetyl 
approx. Approximately 
aq.  Aqueous 
Ar  Aryl/Aromatic 
BINAP  (1,1’-Binaphthalene-2,2’-diyl)bis(diphenylphosphine) 
Bn  Benzyl 
Boc  tert-Butoxycarbonyl 
br  Broad 
Cbz   Carboxybenzyl 
CbzCl   Carboxybenzyl chloride 
calcd  Calculated 
conc.  Concentrated 
cat.  Catalyst/catalytic 
COSY  Correlation spectroscopy 
CuTC  Copper(I) thiophene-2-carboxylate 
  Chemical shift 
Δ  Heat/reflux 
d  Doublet 
DABCO 1,4-Diazabicyclo[2.2.2]octane 
dba  Dibenzylideneacetone 
DBU  1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCB  o-Dichlorobenzene 
DCC  N,N’-Dicyclohexylcarbodiimide 
DCE  1,2-Dichloroethane 
DEPT  Distortionless enhancement by polarisation transfer 
DIBAL-H Diisobutylaluminium hydride 
DMAP  Dimethylaminopyridine 
Dmb  2,4-Dimethoxybenzyl 
DMF  Dimethylformamide 
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DMP  Dess‒Martin periodinane 
DMSO  Dimethyl sulfoxide 
dppb  Diphenylphosphinobutane 
dr  Diastereomeric ratio 
EDC  1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
ee  Enantiomeric excess 
ESI  Electrospray ionisation 
eq or eq. Equivalents 
Et  Ethyl 
Ether  Diethyl ether 
FCC  Flash column chromatography 
g  Gram(s) 
h  Hour(s) 
HFIP  Hexafluoro-isopropanol 
HMDS  Hexamethyldisilazane 
HRMS  High Resolution Mass Spectrometry 
HSQC  Heteronuclear Single Quantum Coherence 
HWE  Horner-Wadsworth-Emmons 
Hz  Hertz 
i  iso 
IBX  2-Iodoxybenzoic acid 
IPA  iso-Propylalcohol 
IR  Infrared 
J  Coupling constant in Hz 
KF-SiO2 10% w/w of finely ground KF and 90% w/w silica 
KHMDS Potassium hexamethyldisilazide 
L  Litres 
LDA  Lithium diisopropylamide 
LG  Leaving group 
lit.  Literature 
LHMDS Lithium hexamethyldisilazane 
m  Multiplet 
m  meta 
M  Molar 
M+  Molecular ion 
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m-CPBA meta-Chloroperbenzoic acid 
μ  Microwave irradiation 
Me  Methyl 
MeCN  Acetonitrile 
min  Minute(s) 
MK10  Montmorillonite K10 
mL  Millilitre 
mmol  Millimole 
mol. sieves Molecular sieves 
mp  Melting Point 
MS  Mass spectrometry  
L  Microlitre 
m/z  Mass to charge ratio 
n-BuLi  normal-Butyllithium  
NMO  N-Methylmorpholine-N-oxide 
NMR  Nuclear Magnetic Resonance 
NOE  Nuclear Overhauser Effect 
o  ortho 
[O]  Oxidant 
OAc  Acetate 
O/A/O/I Oxidation/allylation/oxidation/isomerisation 
OTf  Triflate/trifluoromethanesulfonate 
P  Undefined protecting group 
p  para 
PCC  Pyridinium chlorochromate 
PDC  Pyridinium dichromate 
PE  Petroleum Ether (that fraction which boils at 40-60 oC) 
Ph  Phenyl 
phen  1,10-phenanthroline 
PhMe  Toluene 
Piv  Pivaloyl 
PMB  p-Methoxybenzyl 
ppm  Parts per million 
Pr  Propyl 
Py  Pyridine 
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q  Quartet 
R  Undefined group 
Rf  Retention factor 
rt  Room temperature 
s  Singlet 
sat.  Saturated 
SM  Starting material 
t  Triplet 
t- or tert- Tertiary  
TBAF  Tetrabutylammonium fluoride 
TBS  tert-Butyldimethylsilyl 
TBDPS  tert-Butyldiphenylsilyl  
THF  Tetrahydrofuran 
TFA  Trifluoroacetic acid 
TLC  Thin layer chromatography 
TMS  Trimethylsilyl 
TPAP  Tetrapropylammonium perruthenate 
UV  Ultraviolet 
w/w  Weight to weight ratio 
X  Undefined halogen 
Z  Undefined electron withdrawing group 
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